0001558370-24-01146110-Q Scholar Rock Holding Corp 20240808202408080715260715260715260 0 0001558370-24-011461 10-Q 69 20240630 20240808 20240808 Scholar Rock Holding Corp 0001727196 2836 823750435 DE 1231 10-Q 34 001-38501 241186024 301 BINNEY STREET 3RD FLOOR CAMBRIDGE MA 02142 857-259-3860 301 BINNEY STREET 3RD FLOOR CAMBRIDGE MA 02142 10-Q 1 srrk-20240630x10q.htm 10-Q 0001727196--12-312024Q2false00799920687597949 5http://fasb.org/us-gaap/2024#PrimeRateMember0001727196us-gaap:CommonStockMember2024-04-012024-06-300001727196srrk:AtMarketOfferingMember2024-01-012024-06-300001727196us-gaap:CommonStockMember2023-01-012023-03-310001727196us-gaap:RetainedEarningsMember2024-06-300001727196us-gaap:AdditionalPaidInCapitalMember2024-06-300001727196us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001727196us-gaap:RetainedEarningsMember2024-03-310001727196us-gaap:AdditionalPaidInCapitalMember2024-03-310001727196us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001727196us-gaap:RetainedEarningsMember2023-12-310001727196us-gaap:AdditionalPaidInCapitalMember2023-12-310001727196us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001727196us-gaap:RetainedEarningsMember2023-06-300001727196us-gaap:AdditionalPaidInCapitalMember2023-06-300001727196us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001727196us-gaap:RetainedEarningsMember2023-03-310001727196us-gaap:AdditionalPaidInCapitalMember2023-03-310001727196us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001727196us-gaap:RetainedEarningsMember2022-12-310001727196us-gaap:AdditionalPaidInCapitalMember2022-12-310001727196us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001727196us-gaap:CommonStockMember2024-06-300001727196us-gaap:CommonStockMember2024-03-310001727196us-gaap:CommonStockMember2023-12-310001727196us-gaap:CommonStockMember2023-06-300001727196us-gaap:CommonStockMember2023-03-310001727196us-gaap:CommonStockMember2022-12-310001727196us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001727196us-gaap:EmployeeStockOptionMember2023-12-310001727196us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001727196us-gaap:RestrictedStockUnitsRSUMember2023-12-310001727196srrk:AggregateMembersrrk:AtMarketOfferingMember2024-01-012024-06-300001727196srrk:LoanAndSecurityAgreementMember2021-12-012021-12-310001727196us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001727196us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001727196us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001727196us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001727196us-gaap:RetainedEarningsMember2024-04-012024-06-300001727196us-gaap:RetainedEarningsMember2024-01-012024-03-310001727196us-gaap:RetainedEarningsMember2023-04-012023-06-300001727196us-gaap:RetainedEarningsMember2023-01-012023-03-310001727196srrk:LoanAndSecurityAgreementMember2024-05-170001727196srrk:TrancheThreeMembersrrk:LoanAndSecurityAgreementMember2024-05-170001727196srrk:TrancheFourMembersrrk:LoanAndSecurityAgreementMember2024-05-170001727196srrk:TrancheTwoMembersrrk:LoanAndSecurityAgreementMember2022-11-100001727196srrk:TrancheOneMembersrrk:LoanAndSecurityAgreementMember2022-11-100001727196srrk:LoanAndSecurityAgreementMember2022-11-100001727196srrk:LoanAndSecurityAgreementMember2020-10-160001727196srrk:BinneyStCambridgeMaMembersrrk:UponExpirationOfFirstExtensionTermMember2024-05-310001727196us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001727196us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001727196us-gaap:RestrictedStockUnitsRSUMember2024-06-300001727196us-gaap:EmployeeStockOptionMember2024-06-300001727196srt:MinimumMembersrrk:LoanAndSecurityAgreementMember2022-11-102022-11-100001727196srt:MaximumMembersrrk:LoanAndSecurityAgreementMember2022-11-102022-11-100001727196srrk:PreFundedWarrantMember2024-06-300001727196srrk:CommonWarrantMember2024-06-300001727196srrk:PreFundedWarrantMember2022-06-300001727196srrk:PreFundedWarrantMember2020-11-300001727196srrk:CommonWarrantMember2022-06-300001727196 2022-12-310001727196us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001727196us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001727196us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001727196us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001727196us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001727196us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001727196us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001727196us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001727196 2023-06-300001727196us-gaap:USTreasurySecuritiesMember2024-06-300001727196us-gaap:USTreasurySecuritiesMember2023-12-310001727196us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001727196us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001727196us-gaap:FairValueMeasurementsRecurringMember2023-12-310001727196us-gaap:FairValueMeasurementsRecurringMember2023-12-310001727196us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001727196us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001727196srrk:CommonWarrantMember2024-01-012024-06-300001727196us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001727196us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001727196srrk:CommonWarrantMember2023-01-012023-06-300001727196us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001727196us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001727196us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001727196us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001727196us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001727196us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001727196us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001727196us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001727196us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001727196 2024-04-012024-06-300001727196 2023-04-012023-06-300001727196us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001727196 2023-01-012023-03-310001727196 2023-01-012023-06-300001727196 2023-01-012023-12-310001727196us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001727196 2024-01-012024-03-310001727196us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001727196srrk:AggregateMembersrrk:PreFundedWarrantMember2024-01-012024-06-300001727196srrk:PreFundedWarrantMember2024-01-012024-06-300001727196srrk:CommonWarrantMember2024-01-012024-06-300001727196us-gaap:CommonStockMember2024-01-012024-03-310001727196us-gaap:CommonStockMember2023-04-012023-06-300001727196srt:MinimumMembersrrk:LoanAndSecurityAgreementMember2022-11-100001727196srt:MaximumMembersrrk:LoanAndSecurityAgreementMember2022-11-100001727196srrk:LoanAndSecurityAgreementMember2020-10-162020-10-160001727196srrk:AtMarketOfferingMember2022-11-300001727196srrk:LoanAndSecurityAgreementMember2024-05-172024-05-170001727196srrk:BinneyStCambridgeMaMember2024-05-310001727196srrk:BinneyStCambridgeMaMember2019-11-300001727196srrk:LoanAndSecurityAgreementMember2022-11-102022-11-100001727196srrk:BinneyStCambridgeMaMember2024-05-012024-05-310001727196srrk:BinneyStCambridgeMaMember2019-11-012019-11-300001727196 2024-06-300001727196 2023-12-310001727196srrk:JingMarantzMember2024-06-300001727196srrk:JingMarantzMember2024-04-012024-06-300001727196 2024-08-020001727196 2024-01-012024-06-30xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharessrrk:securityTable of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORMÂ 10-Qâ˜'QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹FOR THE QUARTERLY PERIOD ENDED June 30, 2024ORâ€‹â˜TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE NUMBER 001-38501_____SCHOLAR ROCK HOLDING CORPORATION(Exact name of registrant as specified in its charter)â€‹â€‹Delaware82-3750435(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)â€‹â€‹301 Binney Street, 3rd FloorCambridge, Massachusetts02142(Address of principal executive offices)(Zip Code)â€‹(857) 259 3860(Registrantâ€™s telephone number, including area code)â€‹Securities registered pursuant to Section 12(b) of the Exchange Act:â€‹â€‹â€‹â€‹Title of each classTrading symbol(s)Name of each exchange on which registeredCommon Stock, par value $0.001 per shareSRRKThe Nasdaq Global Select Marketâ€‹Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. Â Â YesÂ Â â˜Â Â Â Â NoÂ Â Â â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). Â Â YesÂ Â â˜'Â Â Â Â NoÂ Â Â â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act.LargeÂ acceleratedÂ filerâ˜AcceleratedÂ filerâ˜Â Â Â Â Non-accelerated filerâ˜'SmallerÂ reportingÂ companyâ˜'Â Â Â Â Â Â Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 13(a)Â of the Exchange Act. â˜Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). Â Â YesÂ Â â˜Â Â Â Â NoÂ Â â˜'The number of outstanding shares of the Registrantâ€™s Common Stock as of August 2, 2024 was 80,032,623.â€‹ Table of ContentsSPECIAL NOTEÂ REGARDING FORWARD-LOOKING STATEMENTSThis Quarterly Report on FormÂ 10-Q (â€œQuarterly Reportâ€), including the documents incorporated by reference, contains forward-looking statements within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of complying with those safe harbor provisions. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as â€œmayâ€, â€œwillâ€, â€œshouldâ€, â€œexpectsâ€, â€œintendsâ€, â€œplansâ€, â€œanticipatesâ€, â€œbelievesâ€, â€œestimatesâ€, â€œpredictsâ€, â€œpotentialâ€, â€œcontinueâ€ or the negative of these terms or other comparable terminology. Some of the risks and uncertainties that may cause our actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements include, among others, the following:â—the success, cost and timing of clinical trials for apitegromab (such as our Phase 3 SAPPHIRE clinical trial and our Phase 2 EMBRAZE clinical trial) and SRK-181, including the progress, completion, timing of results, and actual results of our clinical trials;â—the timing, scope, or likelihood of our ability to obtain and maintain regulatory approval from the U.S. Food and Drug Administration (â€œFDAâ€), the European Commission (â€œECâ€) and other regulatory authorities for apitegromab following completion of our Phase 3 SAPPHIRE clinical trial, and any related restrictions, limitations or warnings in the label of any approval for apitegromab;â—our success in identifying and executing a development program for our preclinical product candidates, including SRK-439 and identifying additional product candidates from our preclinical programs and research pipeline;â—our success in identifying and executing development programs for additional indications for apitegromab and SRK-181;â—the clinical utility of our product candidates and their potential advantages over other therapeutic options;â—our ability to obtain, generally or on terms acceptable to us, funding for our operations, including funding necessary to complete further development and, upon successful development, if approved, commercialization of apitegromab, SRK-181, SRK-439 or any of our future product candidates;â—our ability to retain our executives and highly skilled technical and managerial personnel, which could be affected due to any transition in management, or if we fail to recruit additional highly skilled personnel;â—our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and the duration of such protection and our ability to operate our business without infringing on the intellectual property rights of others;â—our ability, through third party manufacturers, to successfully manufacture our product candidates for clinical trials and for commercial use, if approved;â—our ability to successfully build a commercial infrastructure to launch and market apitegromab, or otherwise provide access to apitegromab, if and when it is approved or receives pricing or reimbursement approval;â—our ability to establish or maintain collaborations or strategic relationships; â—our expectations relating to the potential of our proprietary platform technology;â—the size and growth potential of the markets for our product candidates, and our ability to serve those markets, either alone or in combination with others;2 Table of Contentsâ—the impact of new laws and regulations or amendments to existing laws and regulations in the United States and foreign countries;â—risks associated with the impact of global economic and political developments on our business, including rising inflation and capital market disruptions, economic sanctions and economic slowdowns or recessions or public health pandemics;â—developments and projections relating to our competitors and our industry;â—our estimates and expectations regarding cash, cash reserves, and expense levels, future revenues, capital requirements and needs for additional financing, including our expected use of proceeds from our public offerings, and liquidity sources; â—our expectations regarding the period during which we qualify as a â€œsmaller reporting companyâ€ as defined by Rule 12b-2 of the Exchange Act; â—our expectations regarding our ability to continue as a going concern; andâ—other risks and uncertainties, including those listed under the caption PartÂ II, ItemÂ 1A â€œRisk Factorsâ€.The risks set forth above are not exhaustive. Other sections of this report may include additional factors that could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all risk factors, nor can we assess the impact of all risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. Investors should also refer to our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q for future periods and Current Reports on Form 8-K as we file them with the SEC, and to other materials we may furnish to the public from time to time through Current Reports on Form 8-K or otherwise, for a discussion of risks and uncertainties that may cause actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements. We expressly disclaim any responsibility to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events, or otherwise, and you should not rely upon these forward-looking statements after the date of this report.We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry data, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.â€‹3 Table of ContentsSCHOLAR ROCK HOLDING CORPORATIONTABLE OF CONTENTSâ€‹PagePARTÂ IÂ â€“ FINANCIAL INFORMATIONâ€‹ItemÂ 1. Financial Statements (Unaudited)5Consolidated Balance Sheets as of June 30, 2024 and December 31, 20235Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 6Consolidated Statements of Stockholdersâ€™ Equity for the Six Months Ended June 30, 2024 and 20237Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 20238Notes to Consolidated Financial Statements9ItemÂ 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations19ItemÂ 3. Quantitative and Qualitative Disclosures About Market Risk30ItemÂ 4. Controls and Procedures31â€‹â€‹PARTÂ II. OTHER INFORMATIONâ€‹ItemÂ 1. Legal Proceedings31ItemÂ 1A. Risk Factors32ItemÂ 2. Unregistered Sales of Equity Securities and Use of Proceeds80ItemÂ 3. Defaults Upon Senior Securities80ItemÂ 4. Mine Safety Disclosures80ItemÂ 5. Other Information80ItemÂ 6. Exhibits81SIGNATURES82â€‹â€‹â€‹4 Table of Contentsâ€‹PART I. FINANCIAL INFORMATIONItem 1. Financial StatementsSCHOLAR ROCK HOLDING

CORPORATIONCONSOLIDATED BALANCE SHEETS(Unaudited)(In thousands, except share and per share data)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â JuneÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â Â Â Â 2024â€‹2023AssetsÂ â€‹Â Â Â â€‹Â Â Current assets:Â â€‹Â Â Â â€‹Â Â Cash and cash equivalentsâ€‹$ 93,372â€‹$ 101,855Marketable securitiesâ€‹Â 97,122â€‹Â 178,083Prepaid expenses and other current assetsâ€‹Â 8,643â€‹Â 8,256Total current assetsâ€‹Â 199,137â€‹Â 288,194Property and equipment, netâ€‹Â 3,549â€‹Â 4,600Operating lease right-of-use assetâ€‹â€‹ 17,975â€‹â€‹ 11,417Restricted cashâ€‹Â 2,407â€‹Â 2,407Other long-term assetsâ€‹Â 3,797â€‹Â 4,417Total assetsâ€‹$ 226,865â€‹$ 311,035Liabilities and Stockholdersâ€™ Equityâ€‹Â Â Â Â â€‹Â Â Â Current liabilities:â€‹Â Â Â â€‹Â Â Â Accounts payableâ€‹$ 3,315â€‹$ 3,465Accrued expensesâ€‹Â 21,886â€‹Â 20,449Operating lease liabilityâ€‹â€‹ 6,198â€‹â€‹ 7,408Short-term debtâ€‹â€‹ 1,588â€‹â€‹ 1,334Other current liabilitiesâ€‹â€‹ â€”â€‹â€‹ 85Total current liabilitiesâ€‹Â 32,987â€‹Â 32,741Long-term portion of operating lease liabilityâ€‹â€‹ 11,773â€‹â€‹ 4,392Long-term debtâ€‹â€‹ 48,485â€‹â€‹ 48,684Total liabilitiesâ€‹Â 93,245â€‹Â 85,817Commitments and contingencies (NoteÂ 9)â€‹Â Â Â â€‹Â Â Â Stockholdersâ€™ equity:â€‹â€‹â€‹â€‹Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at JuneÂ 30,Â 2024 and DecemberÂ 31,Â 2023â€‹â€‹ â€”â€‹â€‹ â€”Common stock, $0.001 par value; 300,000,000 shares authorized; 79,992,068 and 75,979,495 shares issued and outstanding as of June 30,Â 2024 and DecemberÂ 31,Â 2023, respectivelyâ€‹Â 80â€‹Â 76Additional paid-in capitalâ€‹Â 925,376â€‹Â 901,471Accumulated other comprehensive income (loss)â€‹Â (54)â€‹Â 92Accumulated deficitâ€‹Â (791,782)â€‹Â (676,421)Total stockholdersâ€™ equityâ€‹Â 133,620â€‹Â 225,218Total liabilities and stockholdersâ€™ equityâ€‹$ 226,865â€‹$ 311,035â€‹The accompanying notes are an integral part of these consolidated financial statements.5 Table of ContentsSCHOLAR ROCK HOLDING CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited)(In thousands, except share and per share data)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended JuneÂ 30,Â â€‹Six Months Ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Operating expenses:â€‹Â â€‹â€‹Â Â Â â€‹Â â€‹â€‹Â â€‹Research and developmentâ€‹$ 42,373â€‹$ 26,867â€‹$ 85,466â€‹$ 56,602General and administrativeâ€‹Â 17,125â€‹Â 12,215â€‹Â 32,451â€‹â€‹ 22,989Total operating expensesâ€‹Â 59,498â€‹Â 39,082â€‹Â 117,917â€‹Â 79,591Loss from operationsâ€‹Â (59,498)â€‹Â (39,082)â€‹Â (117,917)â€‹Â (79,591)Other income (expense), netâ€‹Â 990â€‹Â 1,157â€‹Â 2,556â€‹Â 2,287Net lossâ€‹$ (58,508)â€‹$ (37,925)â€‹$ (115,361)â€‹$ (77,304)Net loss per share, basic and dilutedâ€‹$ (0.60)â€‹$ (0.47)â€‹$ (1.20)â€‹$ (0.97)Weighted average common shares outstanding, basic and dilutedâ€‹Â 96,813,116â€‹Â 80,117,983â€‹Â 96,352,858â€‹Â 79,865,424â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Comprehensive loss:â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹Net lossâ€‹$ (58,508)â€‹$ (37,925)â€‹$ (115,361)â€‹$ (77,304)Other comprehensive income (loss):â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹Unrealized gain (loss) on marketable securitiesâ€‹Â (4)â€‹Â 266â€‹Â (146)â€‹Â 821Total other comprehensive income (loss)â€‹Â (4)â€‹Â 266â€‹Â (146)â€‹Â 821Comprehensive lossâ€‹$ (58,512)â€‹$ (37,659)â€‹$ (115,507)â€‹$ (76,483)â€‹The accompanying notes are an integral part of these consolidated financial statements.â€‹â€‹6 Table of ContentSCHOLAR ROCK HOLDING CORPORATIONCONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (Unaudited)(In thousands, except share data)â€‹Â Â â€‹â€‹â€‹â€‹Accumulatedâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Additionalâ€‹Otherâ€‹â€‹â€‹â€‹Totalâ€‹â€‹CommonStockâ€‹Paidâ€'inâ€‹Comprehensiveâ€‹Accumulatedâ€‹Stockholdersâ€™â€‹Â Â SharesÂ Â AmountÂ Â CapitalÂ Â Income (Loss)Â Â DeficitÂ Â EquityBalance at DecemberÂ 31,Â 2023â€‹ 75,979,495â€‹$ 76â€‹$ 901,471â€‹$ 92â€‹$ (676,421)â€‹$ 225,218Unrealized loss on marketable securitiesâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (142)â€‹â€‹ â€”â€‹â€‹ (142)Exercise of stock optionsâ€‹ 47,293â€‹â€‹ â€”â€‹â€‹ 280â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 280Issuance of common shares upon RSU vestingâ€‹ 360,373â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Exercise of pre-funded and common warrantsâ€‹ 3,357,493â€‹â€‹ 4â€‹â€‹ 6,102â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 6,106Equity-based compensation expenseâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ 8,164â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 8,164Net lossâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (56,853)â€‹â€‹ (56,853)Balance at MarchÂ 31,Â 2024â€‹ 79,744,654â€‹$ 80â€‹$ 916,017â€‹$ (50)â€‹$ (733,274)â€‹$ 182,773Unrealized loss on marketable securitiesâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (4)â€‹â€‹ â€”â€‹â€‹ (4)Exercise of stock optionsâ€‹ 6,617â€‹â€‹ â€”â€‹â€‹ 47â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 47Issuance of common shares upon RSU vestingâ€‹ 240,797â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Equity-based compensation expenseâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ 9,312â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 9,312Net lossâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (58,508)â€‹â€‹ (58,508)Balance at JuneÂ 30,Â 2024â€‹ 79,992,068â€‹$ 80â€‹$ 925,376â€‹$ (54)â€‹$ (791,782)â€‹$ 133,620â€‹Â Â â€‹â€‹â€‹â€‹Accumulatedâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Additionalâ€‹Otherâ€‹â€‹â€‹â€‹Totalâ€‹â€‹CommonStockâ€‹Paidâ€'inâ€‹Comprehensiveâ€‹Accumulatedâ€‹Stockholdersâ€™â€‹Â Â SharesÂ Â AmountÂ Â CapitalÂ Â LossÂ Â DeficitÂ Â EquityBalance at DecemberÂ 31,Â 2022â€‹ 51,672,579â€‹$ 52â€‹$ 771,699â€‹$ (884)â€‹$ (510,632)â€‹$ 260,235Unrealized gain on marketable securitiesâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 555â€‹â€‹ â€”â€‹â€‹ 555Sale of common shares, net of issuance costsâ€‹ 68,696â€‹â€‹ â€”â€‹â€‹ 827â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 827Exercise of stock optionsâ€‹ 28,706â€‹â€‹ â€”â€‹â€‹ 243â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 243Issuance of common shares upon RSU vestingâ€‹ 219,378â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Equity-based compensation expenseâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ 6,170â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 6,170Otherâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ 2â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 2Net lossâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (39,379)â€‹â€‹ (39,379)Balance at MarchÂ 31,Â 2023â€‹ 51,989,359â€‹$ 52â€‹$ 778,941â€‹$ (329)â€‹$ (550,011)â€‹$ 228,653Unrealized gain on marketable securitiesâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 266â€‹â€‹ â€”â€‹â€‹ 266Sale of common shares, net of issuance costsâ€‹ 550,594â€‹â€‹ 1â€‹â€‹ 4,395â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 4,396Exercise of stock optionsâ€‹ 53,333â€‹â€‹ â€”â€‹â€‹ 292â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 292Issuance of common shares upon RSU vestingâ€‹ 273,035â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Exercise of pre-funded warrantsâ€‹ 2,293,466â€‹â€‹ 2â€‹â€‹ (2)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Equity-based compensation expenseâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ 6,818â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 6,818Otherâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ 1â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 1Net lossâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (37,925)â€‹â€‹ (37,925)Balance at JuneÂ 30,Â 2023â€‹ 55,159,787â€‹$ 55â€‹$ 790,445â€‹$ (63)â€‹$ (587,936)â€‹$ 202,501The accompanying notes are an integral part of these consolidated financial statements.â€‹7 Table of ContentsSCHOLAR ROCK HOLDING CORPORATIONCONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)(In thousands)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended â€‹â€‹JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Cash flows from operating activities:â€‹Â â€‹â€‹Â Â â€‹â€‹Â Â Net lossâ€‹$ (115,361)â€‹$ (77,304)Adjustments to reconcile net loss to net cash used in operating activities:â€‹Â â€‹â€‹Â â€‹Depreciation and amortizationâ€‹Â 1,096â€‹Â 1,464Amortization of debt discount and debt issuance costsâ€‹â€‹ 135â€‹â€‹ 157Equity-based compensationâ€‹Â 17,476â€‹Â 12,988Amortization/accretion of investment securitiesâ€‹â€‹ (3,236)â€‹â€‹ (2,563)Non-cash operating lease expenseâ€‹â€‹ 2,893â€‹â€‹ 3,658Change in operating assets and liabilities:â€‹Â â€‹â€‹Â â€‹Prepaid expenses and other current assetsâ€‹Â (526)â€‹Â 1,571Other assetsâ€‹â€‹ 620â€‹â€‹ 117Accounts payableâ€‹Â (150)â€‹Â (950)Accrued expensesâ€‹Â 1,456â€‹Â (10,516)Operating lease liabilitiesâ€‹â€‹ (3,280)â€‹â€‹ (4,144)Other liabilitiesâ€‹â€‹ (104)â€‹â€‹ (82)Net cash used in operating activitiesâ€‹Â (98,981)â€‹â€‹ (75,604)Cash flows from investing activities:â€‹Â â€‹â€‹Â â€‹Purchases of property and equipmentâ€‹Â (45)â€‹â€‹ (71)Proceeds from sale of property and equipmentâ€‹â€‹ â€”â€‹â€‹ 13Purchases of marketable securitiesâ€‹â€‹ (68,449)â€‹â€‹ (105,200)Maturities of marketable securitiesâ€‹Â 152,500â€‹â€‹ 180,000Net cash provided by investing activitiesâ€‹Â 84,006â€‹Â 74,742Cash flows from financing activities:â€‹Â â€‹â€‹Â â€‹Proceeds from sale of common shares, net of issuance costsâ€‹â€‹ â€”â€‹â€‹ 5,223Proceeds from pre-funded and common warrant exercisesâ€‹â€‹ 6,106â€‹â€‹ â€”Debt modification paymentâ€‹ (80)â€‹â€‹ â€”Proceeds from stock option exercisesâ€‹â€‹ 466â€‹â€‹ 539Otherâ€‹â€‹ â€”â€‹â€‹ 3Net cash provided by financing activitiesâ€‹Â 6,492â€‹Â 5,765Net (decrease)/increase in cash, cash equivalents and restricted cashâ€‹Â (8,483)â€‹Â 4,903Cash, cash equivalents and restricted cash, beginning of periodâ€‹Â 104,262â€‹â€‹ 105,773Cash, cash equivalents and restricted cash, end of periodâ€‹$ 95,779â€‹$ 110,676Supplemental disclosure for non-cash items:â€‹Â â€‹â€‹Â â€‹Operating lease liability adjustment from rent modificationâ€‹$ 9,451â€‹$ â€”Supplemental cash flow information:â€‹â€‹â€‹â€‹â€‹â€‹Cash paid for interestâ€‹$ 3,330â€‹$ 3,090â€‹The accompanying notes are an integral part of these consolidated financial statements.â€‹â€‹8 Table of ContentsSCHOLAR ROCK HOLDING CORPORATIONNotesÂ to Consolidated Financial Statements(Unaudited)1. Nature of the Business Scholar Rock Holding Corporation (the â€œCompanyâ€) is a late-stage biopharmaceutical company focused on the discovery, development, and delivery of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. As a global leader in transforming growth factor beta (â€œTGFÎ²â€) superfamily biology, the Companyâ€™s novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. By targeting the signaling proteins at the cellular level and acting in the disease microenvironment, the Company believes that it may avoid the historical dose-limiting safety challenges associated with inhibiting growth factors for therapeutic effect.The Companyâ€™s first product candidate, apitegromab, is a highly selective, fully human, monoclonal antibody, with a unique mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of spinal muscular atrophy (â€œSMAâ€). The Company is conducting SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with nonambulatory Type 2 and Type 3 SMA. In 2023, the Company completed enrollment for the Phase 3 SAPPHIRE trial. In 2024, the Company announced data from the Phase 2 TOPAZ trial extension period which showed patient outcomes at 48 months of treatment with apitegromab. The FDA granted Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation to apitegromab for the treatment of SMA in May 2021, August 2020 and March 2018, respectively. The European Medicines Agency (â€œEMAâ€) granted Priority Medicine (â€œPRIMEâ€) designation in March 2021 and the EC granted Orphan Medicinal Product designation in December 2018 to apitegromab for the treatment of SMA.In October 2023, the Company announced plans to expand into cardiometabolic disorders and advance its anti-myostatin program with SRK-439, a novel, fully human anti-myostatin monoclonal antibody, for evaluation in cardiometabolic disorders, including obesity, towards a potential investigational new drug (â€œINDâ€) submission in 2025. To inform the development of SRK-439, in May 2024 the Company initiated the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab to preserve muscle mass in individuals living with obesity and on background therapy of a GLP-1 receptor agonist (â€œGLP-1 RAâ€), with data expected in the second quarter of 2025. The Companyâ€™s second product candidate, SRK-181, a highly selective inhibitor of the activation of latent TGFÎ² is being developed for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies (referred to together as anti-PD-(L)1 antibody therapies). SRK-181 is being evaluated in the Companyâ€™s Phase 1 DRAGON proof-of-concept clinical trial in patients with locally advanced or metastatic solid tumors that exhibit resistance to anti-PD-(L)1 antibody therapies. The Phase 1 DRAGON trial completed enrollment in December 2023 and continues to treat patients who remain on study. This two-part clinical trial consists of a dose escalation portion (Part A) and a dose expansion evaluating SRK-181 in combination with an approved anti-PD- (L)1 antibody therapy (Part B). Part B includes the following active cohorts: urothelial carcinoma, cutaneous melanoma, non-small cell lung cancer, clear cell renal cell carcinoma, and head and neck squamous cell carcinoma. Safety, efficacy and biomarker data were presented in November 2023 at the Society for Immunotherapy of Cancer 38th Annual Meeting and in June 2024 at the American Society of Clinical Oncology (â€œASCOâ€) annual meeting. Additionally, the Company continues to create a pipeline of product candidates to deliver novel therapies to underserved patients suffering from a wide range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. The Company was originally formed in May 2012. Its principal offices are in Cambridge, Massachusetts.Since its inception, the Companyâ€™s operations have focused on research and development of monoclonal antibodies that selectively inhibit activation of growth factors for therapeutic effect, as well as establishing the Companyâ€™s intellectual property portfolio and performing research and development activities. The Company has primarily financed its 9 Table of Contentsoperations through various equity financings, as well as research and development collaboration agreements and the Companyâ€™s debt facility (Note 10).Revenue generation activities have been limited to two collaborations, both containing research services and the issuance of a license. The first agreement, executed in 2013, was with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson and was terminated in July 2022. The second agreement (the â€œGilead Collaboration Agreementâ€), with Gilead Sciences, Inc. (â€œGileadâ€), was in effect between December 2018 and January 2022. No revenues have been recorded from the sale of any commercial product.The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Companyâ€™s product candidates. The Company has incurred recurring losses since its inception, including net losses of $115.4 million and $77.3 million for the six months ended June 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of $791.8 million as of June 30, 2024. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. The Company has evaluated whether there are certain events, considered in the aggregate, which raise substantial doubt about the Companyâ€™s ability to continue as a going concern beyond one year after the date that the consolidated financial statements are issued. Based on current operating plans, the Company does not expect to have sufficient cash, cash equivalents and marketable securities to fund its operating expenses and capital requirements beyond one year from the issuance of these consolidated financial statements without receiving additional external financing, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.The Company will require additional funding through a combination of contribution from revenues, equity offerings, debt financings or other capital sources, such as collaborations with other companies, strategic alliances or licensing arrangements to finance its future operations. The Company may not be able to obtain such funding on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any such funding may adversely affect the holdings or rights of the Companyâ€™s stockholders. If the Company is unable to obtain sufficient capital, the Company may be forced to delay or reduce the scale of some of its operations.â€‹2. Summary of Significant Accounting PoliciesSummary of Significant Accounting PoliciesThe significant accounting policies used in preparation of the unaudited consolidated financial statements are described in the Companyâ€™s audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Companyâ€™s Annual Report on Form 10-K. There have been no material changes to the significant accounting policies previously disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. â€‹Cash, Cash Equivalents and Restricted Cashâ€‹The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As of JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Cash and cash equivalentsâ€‹$ 93,372â€‹$ 108,064Restricted cashâ€‹Â 2,407â€‹Â 2,612â€‹â€‹$ 95,779â€‹$ 110,676â€‹10 Table of ContentsUnaudited Interim Financial InformationThe consolidated financial statements of the Company included herein have been prepared pursuant to the rulesÂ and regulations of the Securities and Exchange Commission (the â€œSECâ€). The unaudited consolidated financial statements include the accounts of Scholar Rock Holding Corporation and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the fullÂ year or any other interim period.Use of EstimatesThe preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.Recently Adopted Accounting PronouncementsIn June 2016, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update 2016-13, Financial Instrumentsâ€”Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (â€œASU 2016-13â€). The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under previous GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. In November 2019, the FASB deferred the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. Therefore, the new standard was effective for the Company on January 1, 2023. The Company established processes and internal controls to comply with the new credit loss standard and related disclosure requirements.

The Companyâ€™s investment policy has primary objectives of preservation of capital and maintenance of liquidity. As a result, the Company typically invests in money market funds, U.S. treasury obligations and government agency securities. The Company believes that such funds are subject to minimal credit risk. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these investments. The adoption of this standard did not have a material impact on the Companyâ€™s consolidated financial position and results of operations.Recently Issued Accounting PronouncementsIn November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2017-07â€). The standard requires disclosure of incremental segment information on an annual and interim basis and allows for multiple measures of a segmentâ€™s profit or loss provided that one of those measures is consistent with GAAP. The amendments in this update do not change how a public company identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments, but rather requires public entities to provide in interim periods all disclosures about a reporting segmentâ€™s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for interim periods starting on January 1, 2025. The option for early adoption is permitted, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures in future years as a result of the adoption of ASU 2023-07.11 Table of ContentsIn December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which enhances the transparency of income tax disclosures to provide information to investors to better assess how a companyâ€™s operations and related tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This requires public entities to disclose additional categories in the rate reconciliation regarding federal and state income taxes, and provide more details surrounding reconciling items if a quantitative threshold is met. The effective date for public companies is for annual periods starting on January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures will be in future years as a result of the adoption of ASU 2023-09.3. Fair Value of Financial Assets and LiabilitiesThe following tables summarize the assets and liabilities measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023 (in thousands):â€‹FairÂ ValueÂ MeasurementsÂ at JuneÂ 30,Â 2024â€‹Â Â Â TotalÂ Â Â Â LevelÂ 1Â Â Â Â LevelÂ 2Â Â Â Â LevelÂ 3Assets:â€‹â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â Money market funds, included in cash and cash equivalentsâ€‹$ 79,688â€‹$ 79,688â€‹$ â€”â€‹$ â€”U.S. treasury obligations, included in cash and cash equivalentsâ€‹â€‹ 9,331â€‹â€‹ 9,331â€‹â€‹ â€”â€‹â€‹ â€”Marketable securities:â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â U.S. treasury obligations and government agency securitiesâ€‹â€‹ 97,122â€‹â€‹ 97,122â€‹â€‹ â€”â€‹â€‹ â€”Total assetsâ€‹$ 186,141â€‹$ 186,141â€‹$ â€”â€‹$ â€”â€‹FairÂ ValueÂ MeasurementsÂ at DecemberÂ 31,Â 2023â€‹Â Â Â Â TotalÂ Â Â Â LevelÂ 1Â Â Â Â LevelÂ 2Â Â Â Â LevelÂ 3Assets:â€‹â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â Money market funds, included in cash and cash equivalentsâ€‹$ 61,764â€‹$ 61,764â€‹$ â€”â€‹$ â€”U.S. treasury obligations, included in cash and cash equivalentsâ€‹â€‹ 30,765â€‹â€‹ 30,765â€‹â€‹ â€”â€‹â€‹ â€”Marketable securities:â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â U.S. treasury obligations and government agency securitiesâ€‹Â 178,083â€‹â€‹ 178,083â€‹â€‹ â€”â€‹â€‹ â€”Total assetsâ€‹$ 270,612â€‹$ 270,612â€‹$ â€”â€‹$ â€”â€‹Cash, cash equivalents and marketable securities are Level 1 assets and include investments in money market funds and U.S. treasury obligations and government agency securities that are valued using quoted market prices. Accordingly, money market funds and government funds are categorized as Level 1 as of June 30, 2024 and December 31, 2023. There were no transfers of assets between fair value measurement levels during the six months ended June 30, 2024 or 2023.The carrying amounts reflected in the balance sheets for prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values at June 30, 2024 and December 31, 2023, due to their short-term nature. The Company believes the terms of its debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company's debt approximates its fair value based on Level 3 of the fair value hierarchy.12 Table of Contents4. Marketable SecuritiesThe following table summarizes the Companyâ€™s investments as of June 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Grossâ€‹â€‹â€‹Amortizedâ€‹Unrealizedâ€‹Estimatedâ€‹Â Â Â Â CostÂ Â Â Â GainsÂ Â Â Â LossesÂ Â Â Â FairÂ ValueMarketable securities available-for-sale:â€‹â€‹Â Â â€‹â€‹â€‹â€‹â€‹â€‹Â Â â€‹â€‹Â Â U.S. treasury obligations and government agency securitiesâ€‹$ 97,176â€‹$ 1â€‹$ (55)â€‹$ 97,122Total available-for-sale securitiesâ€‹$ 97,176â€‹$ 1â€‹$ (55)â€‹$ 97,122â€‹The following table summarizes the Companyâ€™s investments as of December 31, 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Grossâ€‹â€‹â€‹Amortizedâ€‹Unrealizedâ€‹Estimatedâ€‹Â Â Â Â CostÂ Â Â Â GainsÂ Â Â Â LossesÂ Â Â Â FairÂ ValueMarketable securities available-for-sale:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹U.S. treasury obligations and government agency securitiesâ€‹$ 177,991â€‹$ 93â€‹$ (1)â€‹$ 178,083Total available-for-sale securitiesâ€‹$ 177,991â€‹$ 93â€‹$ (1)â€‹$ 178,083â€‹The aggregate fair value of marketable securities with unrealized losses was $81.3Â million and $11.9Â million at June 30, 2024 and December 31, 2023, respectively.Â At June 30, 2024 and December 31, 2023, 47 investments andÂ threeÂ investments, respectively, were in an unrealized loss position. All such investments have been in an unrealized loss position for less than aÂ year and these losses are considered temporary. The Company has the ability and intent to hold these investments until a recovery of their amortized cost, which may not occur until maturity.â€‹The Company believes that U.S. treasury obligations and government agency securities are subject to minimal credit risk. As a result, the Company did not record any charges for credit-related impairments for its available-for-sale securities for the six months ended June 30, 2024.â€‹â€‹5. Prepaid Expenses and other AssetsAs of June 30, 2024 and December 31, 2023, prepaid expenses and other assets consist of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹AsÂ ofâ€‹â€‹JuneÂ 30,Â â€‹Â Â Â Â DecemberÂ 31,Â â€‹Â Â Â Â 2024â€‹2023Prepaid external research and development expensesâ€‹$ 3,392â€‹$ 4,059Prepaid otherâ€‹â€‹ 2,906â€‹â€‹ 2,486Receivablesâ€‹â€‹ 1,288â€‹â€‹ 1,076Prepaid insuranceâ€‹â€‹ 1,057â€‹â€‹ 635â€‹â€‹$ 8,643â€‹$ 8,256â€‹As of June 30, 2024 and December 31, 2023, other long-term assets consist of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹AsÂ ofâ€‹â€‹JuneÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â Â Â Â 2024â€‹2023Prepaid external research and development expensesâ€‹$ 3,399â€‹$ 4,074Prepaid otherâ€‹â€‹ 375â€‹â€‹ 312Prepaid insuranceâ€‹â€‹ 23â€‹â€‹ 31â€‹â€‹$ 3,797â€‹$ 4,417â€‹13 Table of Contents6. Accrued ExpensesAs of June 30, 2024 and December 31, 2023, accrued expenses consist of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹AsÂ ofâ€‹â€‹JuneÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â Â Â Â 2024â€‹2023Accrued external research and development expenseâ€‹$ 9,339â€‹$ 6,825Accrued payroll and related expensesâ€‹â€‹ 7,352â€‹â€‹ 10,591Accrued professional and consulting expenseâ€‹â€‹ 4,254â€‹â€‹ 2,267Accrued otherâ€‹â€‹ 941â€‹â€‹ 766â€‹â€‹$ 21,886â€‹$ 20,449â€‹â€‹â€‹â€‹â€‹â€‹7. Common Stockâ€‹In June 2024, the stockholders approved an amendment to our amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000. The Company has had a sales agreement in place during various time periods with Jefferies LLC with respect to an at-the-market (â€œATMâ€) offering program. Under this program, the Company is able to offer and sell, from time to time at its sole discretion, shares of its common stock through Jefferies as its sales agent. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. The current ATM agreement, established in November 2022, allows for the sale of shares of common stock having an aggregate offering price of up to $100 million. As of June 30, 2024, the Company has sold 619,290 shares, generating net proceeds of $5.2 million, under the ATM program. No sales were made under the ATM program during the six months ended June 30, 2024. The Company has issued pre-funded warrants, as well as warrants as part of its financing activities. Both the pre-funded warrants and warrants meet the conditions for equity classification and are recorded as a component of stockholdersâ€™ equity within additional paid-in capital. In June 2022 and November 2020, the Company issued 25,510,205 and 2,179,487 pre-funded warrants, respectively. During the six months ended June 30, 2024, 2,526,833 of the Companyâ€™s pre-funded warrants were exercised. As of June 30, 2024, the Company has 17,008,164 pre-funded warrants outstanding. In June 2022, the Company also issued 10,459,181 warrants with an exercise price of $7.35. During the six months ended June 30, 2024, 830,660 of the Companyâ€™s warrants were exercised. As of June 30, 2024, the Company has 9,157,496 warrants outstanding.â€‹8. Equity-Based CompensationThe Company recorded equity-based compensation expense related to all equity-based awards, which was allocated as follows in the consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Six Months Ended â€‹â€‹JuneÂ 30,Â â€‹JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Research and development expenseâ€‹$ 4,050â€‹$ 2,838â€‹$ 7,581â€‹$ 5,483General and administrative expenseâ€‹Â 5,261â€‹Â 3,980â€‹Â 9,895â€‹Â 7,505â€‹â€‹$ 9,311â€‹$ 6,818â€‹$ 17,476â€‹$ 12,988â€‹â€‹14 Table of ContentsThe following table summarizes the Companyâ€™s unrecognized equity-based compensation expense as of June 30, 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of June 30, 2024â€‹â€‹Unrecognized Expense (in thousands)Â Â Â Weighted Average Remaining Period of Recognition (years)Restricted Stock Units$ 35,116â€‹ 2.8Stock Optionsâ€‹ 42,470â€‹ 2.6â€‹$ 77,586â€‹â€‹â€‹Restricted Stock UnitsThe following table summarizes the Companyâ€™s restricted stock unit activity for the current year:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weightedâ€‹â€‹â€‹AverageÂ Grantâ€‹Â Â Â Â NumberÂ ofÂ UnitsÂ Â Â Â Date Fair ValueRestricted stock units as of DecemberÂ 31,Â 2023Â 2,089,552â€‹$ 11.92GrantedÂ 1,647,159â€‹$ 14.98VestedÂ (601,170)â€‹$ 12.16ForfeitedÂ (150,878)â€‹$ 12.38Restricted stock units as of JuneÂ 30,Â 2024Â 2,984,663â€‹$ 13.54â€‹The total fair value of restricted stock units vested during the six months ended June 30, 2024 was $8.2 million.Stock OptionsThe following table summarizes the Companyâ€™s stock option activity for the current year:â€‹Weightedâ€‹â€‹â€‹â€‹â€‹â€‹Weightedâ€‹Averageâ€‹â€‹â€‹â€‹â€‹NumberÂ ofÂ â€‹Averageâ€‹Remainingâ€‹Aggregateâ€‹Â Â PriceÂ Â Â Contractual TermÂ Â Â Intrinsic Valueâ€‹â€‹â€‹â€‹â€‹(inÂ years)â€‹(inÂ thousands)Outstanding as of DecemberÂ 31,Â 2023Â 7,300,953â€‹$ 15.00â€‹ 7.90â€‹$ 52,299GrantedÂ 2,196,217â€‹$ 14.98â€‹â€‹â€‹â€‹Exercisedâ€‹ (53,910)â€‹$ 6.09â€‹â€‹â€‹â€‹CancelledÂ (275,708)â€‹$ 17.91â€‹â€‹â€‹â€‹Outstanding as of JuneÂ 30,Â 2024Â 9,167,552â€‹$ 14.96â€‹ 7.86â€‹$ 3,529Options exercisable as of JuneÂ 30,Â 2024Â 4,473,458â€‹$ 16.82â€‹ 6.75â€‹$ 2,506â€‹Using the Black-Scholes option pricing model, the weighted average fair value of options granted during the six months ended June 30, 2024 was $11.50. The following weighted average assumptions were used in determining the fair value of options granted in the six months ended June 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended â€‹â€‹JuneÂ 30,Â â€‹â€‹2024Â Â Â Â 2023â€‹Risk-free interest rate4.18 %Â Â 3.84 %Expected dividend yield0.0%Â Â 0.0%Expected term (years to liquidity)5.98 â€‹6.13 â€‹Expected volatility91.35 %Â Â 90.51 %â€‹â€‹â€‹15 Table of Contents9. Commitments and ContingenciesOperating Lease In November 2019, the Company entered into a lease of office and laboratory space at 301 Binney Street in Cambridge, Massachusetts to be used as its new corporate headquarters (the â€œLeaseâ€). The expiration date of the Lease was originally in August 2025 and included an option to extend the term by two years. The base rent under the original Lease was $6.9 million per year, subject to an annual increase of 3.5%, and the Company was subject to a free-rent period through mid-August 2020. Variable lease payments include the Companyâ€™s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The Lease included incentives of $14.1 million in the form of an allowance for tenant improvements related to the design and build out of the space. In connection with the Lease, the Company has secured a letter of credit for $2.3 million which renews automatically each year. The Lease commencement date, for accounting purposes, was reached in September 2020. â€‹In May 2024, the Company entered into the First Amendment (the â€œLease Amendmentâ€) to the Lease to extend the term for approximately two years, commencing on August 19, 2025 (the â€œFirst Extension Termâ€) with the base rent to start at approximately $6.2 million per year, followed by a 3% annual increase. Pursuant to the Lease Amendment, the Company also has an option to extend the term of the Lease by five years, upon the expiration of the First Extension Term.â€‹Other information related to the Lease is as follows (in thousands, except lease term and discount rate):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For Three Months Ended â€‹For Six Months Ended â€‹â€‹Â Â Â JuneÂ 30,Â Â Â Â Â JuneÂ 30,Â â€‹â€‹â€‹â€‹2024â€‹2024Â Â Â Â Lease Cost:â€‹â€‹â€‹â€‹â€‹â€‹Operating lease costâ€‹$ 1,751â€‹$ 3,576â€‹Variable lease costâ€‹â€‹ 363â€‹â€‹ 723â€‹Total lease costâ€‹$ 2,114â€‹$ 4,299â€‹â€‹â€‹â€‹â€‹For Six Months Ended â€‹â€‹JuneÂ 30,Â â€‹â€‹2024Â Â Â Â Â Other information:â€‹â€‹Operating cash flows used for operating leases$ 3,963â€‹Weighted average remaining lease termâ€‹ 3.2â€‹Weighted average incremental borrowing rateâ€‹ 13.1%â€‹â€‹Legal Proceedingsâ€‹The Company, from time to time, may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the six months ended June 30, 2024 and 2023. â€‹10. DebtOn October 16, 2020 (the â€œClosing Dateâ€) the Company entered into a Loan and Security Agreement with Oxford Finance LLC (â€œOxfordâ€) and Silicon Valley Bank (â€œSVBâ€) for $50.0 million (the â€œLoan and Security Agreementâ€). Tranche 1 of $25.0 million was funded on the Closing Date. The Company had an additional $25.0 million in loan proceeds available under Tranche 2 which was funded in December 2021, in conjunction with the Company entering into the First Amendment to Loan and Security Agreement with Oxford and SVB. The Loan and Security Agreement was to mature on May 1, 2025 and required interest-only payments through November 2022, with principal payments to commence in December 2022. Pursuant to the Loan and Security Agreement, the Company was required to maintain cash in an SVB account equal to the lesser ofÂ 100%Â of the Companyâ€™s consolidated cash orÂ 105%Â of the dollar amount of the outstanding debt. 16 Table of Contentsâ€‹On November 10, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (â€œAmendment 2â€) to increase the Companyâ€™s borrowing capacity under the Loan and Security Agreement to an amount up to $100.0 million, comprised of the original $50.0 million loan which remains outstanding and two additional $25.0 million tranches. The first $25.0 million tranche available under Amendment 2, was available at the Companyâ€™s discretion through December 2023 upon achievement of certain development and business performance milestones. The Company did not exercise this tranche. The second $25.0 million tranche available under Amendment 2, may be available upon the Companyâ€™s request, at Oxford and SVBâ€™s discretion. Amendment 2 also extended the interest-only payment period for an additional 24 months through November 2024, with principal payments to commence in December 2024. The maturity of the loan was extended to November 2027. â€‹Effective upon Amendment 2, the interest rate on the unpaid principal is the greater of the Wall Street Journal prime rate plus 4.60% or 9.35% per annum. Prepayment is permitted and may include a pre-payment fee ranging from 0% - 3% (of the principal amount being prepaid), depending on when the prepayment is made. The Company is also required to make a final payment equal to 2% of the original principal amount. â€‹In conjunction with Amendment 2, the Company was required to pay $0.9 million for the accrued portion of the final payment on the previous outstanding balance.â€‹On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (â€œFDICâ€) as receiver. Afterward, the FDIC transferred all deposits of the former Silicon Valley Bank to Silicon Valley Bridge Bank, N.A., as operated by the FDIC. On March 27, 2023, Silicon Valley Bridge Bank was closed by the Office of the Comptroller of the Currency, and the FDIC was appointed as receiver. First Citizens Bank then entered into an agreement with the FDIC to purchase out of FDIC receivership substantially all loans and certain other assets and assume all customer deposits and certain other liabilities of Silicon Valley Bridge Bank. On March 27, 2023, Silicon Valley Bridge Bank and its U.S. branches began operating as Silicon Valley Bank, a division of First Citizens Bank.â€‹On April 18, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement to amend certain provisions relating to the Companyâ€™s operating accounts.â€‹On May 17, 2024, the Company entered into the Fourth Amendment to the Loan and Security Agreement (â€œLoan Amendment No. 4â€). The Company currently has $50.0 million outstanding under the Loan and Security Agreement, which was drawn down in two equal tranches. The third $25.0 million tranche is available at the Companyâ€™s discretion through December 2024, upon achievement of certain clinical and business milestones, which were amended under Loan Amendment No. 4. The fourth $25.0 million tranche may be available through June 1, 2025 (or through December 1, 2025 upon achievement of certain business milestones) upon the Companyâ€™s request, at Oxford and SVBâ€™s discretion. Amendment No. 4 also extends the interest-only payment period for an additional six months through May 2025, with principal payments to commence in June 2025, or for an additional six months through November 2025 upon achievement of certain business performance milestones, with principal payments to commence in December 2025.â€‹11. Net Loss per ShareThe Company calculates basic net loss per share by dividing net loss by the weighted average number of common shares outstanding, excluding restricted common stock. The weighted average number of common shares used in the basic and diluted net loss per share calculation includes the pre-funded warrants issued in connection with the Companyâ€™s November 2020 and June 2022 follow-on offerings as the pre-funded warrants are exercisable at any time for nominal cash consideration. As of June 30, 2024, 10,681,528 pre-funded warrants have been exercised and 17,008,164 pre-funded warrants remain outstanding. The Company has generated a net loss in all periods presented, so the

basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.â€‹17 Table of ContentsThe following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Restricted stock unitsâ€‹ 2,984,663â€‹ 2,047,026Stock optionsâ€‹ 9,167,552â€‹ 7,835,195Warrantsâ€‹ 9,157,496â€‹ 10,459,181â€‹â€‹ 21,309,711â€‹ 20,341,402â€‹â€‹â€‹18 Table of ContentsItem 2.Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsThe following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report, and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods.The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report, including those risks identified under PartÂ II, ItemÂ 1A. Risk Factors.We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rulesÂ of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.OverviewWe are a late-stage biopharmaceutical company focused on the discovery, development, and delivery of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. As a global leader in TGFÎ² superfamily biology, our novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. By targeting the signaling proteins at the cellular level and acting in the disease microenvironment, we believe we may avoid the historical dose-limiting safety challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path.Based on this proprietary and scalable technology platform, we are building a growing portfolio of novel product candidates with the aim of transforming the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis and iron-restricted anemia. We have discovered and progressed the development of:â—Apitegromab, an investigational, fully human monoclonal antibody that inhibits myostatin activation by selectively binding the pro- and latent forms of myostatin in skeletal muscle and is being developed for the treatment of SMA. We also believe apitegromab could have potential in the treatment of other neuromuscular disorders where the inhibition of myostatin may be beneficial. â—SRK-439, a novel, preclinical, investigational myostatin inhibitor that has high in vitro affinity for pro- and latent myostatin and maintains myostatin specificity and is being developed for the treatment of cardiometabolic disorders.â—SRK-181, an inhibitor of the activation of latent TGFÎ²1, that is being developed for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.â—Potent and selective inhibitors of the activation of TGFÎ² for the treatment of fibrotic diseases. We are advancing multiple antibody profiles toward product candidate selection including antibodies that selectively inhibit the activation of latent TGFÎ²1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFÎ²1 presented by cells of the immune system.19 Table of Contentsâ—Additional discovery and early preclinical programs related to the selective modulation of growth factor signaling including bone morphogenic protein 6 and other growth factors.Our first product candidate, apitegromab, is a highly selective, fully human, monoclonal antibody with a unique mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. We areÂ conducting SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with nonambulatory Type 2 and Type 3 SMA (which is estimated to represent the majority of the current prevalent SMA patient population in the U.S. and Europe).Â We completed enrollment of SAPPHIRE in 2023, with the top-line data readout expected in the fourth quarter of 2024. If successful and if apitegromab is approved, we expect to initiate a commercial product launch in 2025.Â Apitegromab was evaluated in our Phase 2 TOPAZ proof-of-concept clinical trial for the treatment of patients with Type 2 and Type 3 SMA.Â Positive 12-month top-line results were initially announced in April 2021. We have subsequently presented data from the TOPAZ trial over 24-months (2022), 36-months (2023) and 48-months (2024). At 48-months over 90% of TOPAZ patients with nonambulatory Type 2 and 3 SMA receiving an SMN therapy remained on apitegromab treatment and showed sustained clinical benefit, a continued favorable safety profile with no new safety findings. Additionally, we have a long-term extension study, ONYX, for patients from both the TOPAZ and SAPPHIRE studies, who are receiving apitegromab in conjunction with an approved SMN therapy. The FDA granted Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation to apitegromab for the treatment of SMA in May 2021, August 2020 and March 2018, respectively. The EMA granted PRIME designation in March 2021 and the EC granted Orphan Medicinal Product designation in December 2018 to apitegromab for the treatment of SMA.In October 2023, we announced an expansion of our therapeutic focus into cardiometabolic disorders by advancing our anti-myostatin program with SRK-439, a novel, fully human anti-myostatin monoclonal antibody, for evaluation in cardiometabolic disorders, including obesity. We are developing SRK-439 towards a potential IND submission in 2025. In June 2024, new preclinical data that support the potential of SRK-439 to increase lean mass and contribute to a favorable body composition following withdrawal from GLP-1 RA treatment were presented at the American Diabetes Associationâ€™s 84th Scientific Sessions. To inform the development of SRK-439, in May 2024 we initiated the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab to preserve muscle mass in individuals living with obesity and on background therapy of a GLP-1 RA, with data expected in the second quarter of 2025. â€‹We believe that apitegromab has the potential to be the first muscle-targeted therapy which is aimed at improving motor function in patients with SMA who are receiving an SMN therapy. We have identified multiple other diseases for which the selective inhibition of the activation of myostatin may offer therapeutic benefit, including additional patient populations in SMA (such as patients under the age of two with SMA and ambulatory patients with SMA) and indications for other neuromuscular disorders beyond SMA.â€‹Our second product candidate, SRK-181, a highly selective inhibitor of the activation of latent TGFÎ², is being developed for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies (referred to together as anti-PD-(L)1 antibody therapies). SRK-181 is being evaluated in our Phase 1 DRAGON proof-of-concept clinical trial in patients with locally advanced or metastatic solid tumors that exhibit resistance to anti-PD-(L)1 antibody therapies. We completed enrollment of the DRAGON trial in December 2023 and continue to treat patients who remain on study. This two-part clinical trial consists of a dose escalation portion (Part A) and a dose expansion portion evaluating SRK-181 in combination with an approved anti-PD-(L)1 antibody therapy (Part B).Â Part B commenced in 2021 and includes the following active cohorts: urothelial carcinoma, cutaneous melanoma, non-small cell lung cancer, clear cell renal cell carcinoma (â€œccRCCâ€), and head and neck squamous cell carcinoma. Safety, efficacy and biomarker data were presented in November 2023 at the Society for Immunotherapy of Cancer (â€œSITCâ€) 38thÂ Annual Meeting and in June 2024 at the ASCO annual meeting. The data showed encouraging responses in heavily pretreated and anti-PD-(L)1 resistant patients across multiple tumor types. We believe that the DRAGON trial achieved its study objectives by showing objective, durable clinical responses in patients with ccRCC resistant to PD-1 therapy above what is expected from continuing PD-1 alone. We anticipate that emerging data from the DRAGON trial will be presented at medical meetings in the future.â€‹20 Table of ContentsUsing our innovative approach and proprietary platform, we are creating a pipeline of novel product candidates that selectively modulate the activation of growth factors implicated in a variety of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Our proprietary platform is designed to generate highly selective antibodies that target the growth factorâ€™s latent precursor form prior to its activation within the disease microenvironment, or tissue where it is localized.Â Our structural insights and unique antibody discovery capabilities can also be applied to other protein classes beyond growth factors, with an aim of generating differentiated candidates targeting cell surface receptors such as immune cell receptors or G-protein coupled receptors, where selectivity remains challenging.â€‹Since inception, we have incurred significant operating losses. Our net losses were $115.4 million for the six months ended June 30, 2024. As of June 30, 2024, we had an accumulated deficit of $791.8 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future in performing our ongoing activities, as we:â—continue development activities for apitegromab, including the conduct of our Phase 3 SAPPHIRE pivotal clinical trial in SMA, ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies and the associated drug supply;â—continue research and development activities for SRK-181, including the conduct of our Phase 1 DRAGON proof-of-concept clinical trial;â—continue research and development activities for our cardiometabolic program, including EMBRAZE, our Phase 2 proof-of-concept trial with apitegromab and advancing SRK-439 towards a potential IND submission in 2025;â—continue to discover, validate and develop additional product candidates through the use of our proprietary platform;â—maintain, expand and protect our intellectual property portfolio;â—hire additional research, development, commercial and other business personnel; andâ—continue to build the infrastructure to support our operations as a public company.â€‹To date, we have not generated any revenue from product sales. If we successfully complete clinical development and obtain regulatory approval for apitegromab, SRK-181, SRK-439 or any of our future product candidates, we may generate revenue in the future from product sales. In addition, if we obtain regulatory approval for apitegromab, SRK-181, SRK-439 or any of our future product candidates, we expect to incur significant expenses related to developing our commercialization capabilities to support product sales, marketing and distribution activities. Based on current operating plans and excluding any contribution from revenues or external financing, we may not have sufficient cash, cash equivalents and marketable securities to fund our operating expenses and capital requirements beyond one year from the issuance date of the interim consolidated financial statements in this Quarterly Report on Form 10-Q, and therefore, we have concluded that there is substantial doubt about our ability to continue as a going concern. See the section entitled â€œLiquidity and Capital Resourcesâ€ for more information.Financial Operations OverviewOperating ExpensesResearch and DevelopmentResearch and development expenses consist primarily of costs incurred for our research and development activities, including our product candidate discovery efforts, preclinical studies, manufacturing, and clinical trials under our research programs, which include:â—employee-related expenses, including salaries, benefits and equity-based compensation expense for our research and development personnel;â—expenses incurred under agreements with third parties that conduct research and development and preclinical activities on our behalf;21 Table of Contentsâ—expenses incurred under agreements related to our clinical trials, including the costs for investigative sites and contract research organizations (â€œCROsâ€), that conduct our clinical trials;â—manufacturing process-development, manufacturing of clinical supplies and technology-transfer expenses;â—consulting and professional fees related to research and development activities;â—costs of purchasing laboratory supplies and non-capital equipment used in our internal research and development activities;â—costs related to compliance with clinical regulatory requirements; andâ—facility costs and other allocated expenses, which include expenses for rent and maintenance of facilities, insurance, depreciation and other supplies.â€‹Research and development costs are expensed as incurred. Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks. Nonrefundable advance payments for research and development goods and services to be received in the future from third parties are deferred and capitalized. The capitalized amounts are expensed as the related services are performed.A significant portion of our research and development costs have been external costs, which we track on a program-by-program basis after a clinical product candidate has been identified. However, we do not allocate our internal research and development expenses, consisting primarily of employee-related costs, depreciation and other indirect costs, on a program-by-program basis as they are deployed across multiple projects.Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, as well as the associated clinical trial material requirements. We expect research and development costs for our product candidates to continue to be substantial for the foreseeable future as the development programs progress. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans. The successful development of apitegromab, SRK-181, SRK-439 and any future product candidates is uncertain. Accordingly, at this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of apitegromab, SRK-181, SRK-439 and any future product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from the sale of our product candidates, if approved. This is due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:â—the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities;â—establishing an appropriate safety profile;â—successful enrollment in and completion of clinical trials;â—whether our product candidates show safety and efficacy in our clinical trials;â—receipt of marketing approvals from applicable regulatory authorities, if any;â—establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;â—obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;â—significant and changing government regulation;â—commercializing the product candidates, if and when approved, whether alone or in collaboration with others; and22 Table of Contentsâ—continued acceptable safety profile of the products following any regulatory approval.A change in the outcome of any of these variables with respect to the development of apitegromab, SRK-181, SRK-439 or any of our future product candidates could significantly change the costs and timing associated with the development of that product candidate.General and AdministrativeGeneral and administrative expenses consist primarily of employee-related expenses, including salaries, benefits and equity-based compensation expenses for personnel in executive, finance, business development, investor relations, legal, information technology, human resources and commercial functions. Other significant general and administrative expenses include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters and fees for accounting, consulting services, and corporate expenses.Other Income (Expense), NetOther income (expense), net consists primarily of interest income earned on our cash, cash equivalents and marketable securities, partially offset by interest expense incurred on our debt facility, including amortization of debt discount and debt issuance costs.Results of OperationsComparison of the Three Months Ended June 30, 2024 and 2023The following table summarizes our results of operations for the three months ended June 30, 2024 and 2023 (in thousands, exceptÂ percentages):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

increase in other early development candidates, including pre-clinical costs and manufacturing development for SRK-439 and unallocated costs.â€‹â—$5.2 million increase in internal research and development costs, which was primarily driven by an increase in employee compensation and benefits, including salaries, bonus, and non-cash equity-based compensation expense related to increased headcount, as well as an increase in temporary support expense.Total research and development expenses are expected to continue to be substantial, driven by employee compensation costs and development costs associated with our clinical stage programs as we continue to advance our product candidates, including apitegromab through our Phase 3 SAPPHIRE clinical trial in SMA and ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies and costs associated with supporting our cardiometabolic program, including EMBRAZE, our Phase 2 proof-of-concept trial of apitegromab and our preclinical program, SRK-439. Additionally, we will continue to invest in our pipeline. We expect costs of our SRK-181 program to decrease, as we completed enrollment of the Phase 1 DRAGON clinical trial in December 2023.General and AdministrativeGeneral and administrative expense was $17.1 million and $12.2 million for the three months ended June 30, 2024 and 2023, respectively, an increase of $4.9 million or 40.2%. The increase was primarily associated with employee-related costs including salaries, benefits and non-cash equity-based compensation expense related to increased headcount, in addition to an increase in consulting and professional services. We expect general and administrative expense to increase as we continue to invest in commercial readiness activities.24 Table of ContentsOther Income (Expense), NetThe change in other income (expense), net was primarily attributable to an increase in interest income earned due to higher interest rates, partially offset by an increase in interest expense related to the Loan and Security Agreement, also due to higher interest rates.Comparison of the Six Months Ended June 30, 2024 and 2023The following table summarizes our results of operations for the six months ended June 30, 2024 and 2023 (in thousands, exceptÂ percentages):â€‹Six Months Ended JuneÂ 30,Â â€‹ChangeÂ â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â $Â Â Â Â %Â Operating expenses:â€‹Research and developmentâ€‹$ 85,466â€‹$ 56,602â€‹$ 28,864â€‹ 51.0%General and administrativeâ€‹Â 32,451â€‹Â 22,989â€‹Â 9,462â€‹ 41.2%Total operating expensesâ€‹Â 117,917â€‹Â 79,591â€‹Â 38,326â€‹ 48.2%Loss from operationsâ€‹Â (117,917)â€‹Â (79,591)â€‹Â (38,326)â€‹ 48.2%Other income (expense), netâ€‹Â 2,556â€‹Â 2,287â€‹Â 269â€‹ 11.8%Net lossâ€‹$ (115,361)â€‹$ (77,304)â€‹$ (38,057)â€‹ 49.2%â€‹â€‹Operating ExpensesResearch and DevelopmentResearch and development expense was $85.5 million and $56.6 million for the six months ended June 30, 2024 and 2023, respectively, an increase of $28.9 million or 51.0%. The following table summarizes our research and development expense for the six months ended June 30, 2024 and 2023 (in thousands, exceptÂ percentages): â€‹Six Months Ended JuneÂ 30,Â â€‹ChangeÂ â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â $Â Â Â Â %Â External costs by program:â€‹Apitegromabâ€‹$ 35,330â€‹$ 18,202â€‹$ 17,128â€‹ 94.1%SRK-181â€‹â€‹ 6,005â€‹â€‹ 7,666â€‹â€‹ (1,661)â€‹ (21.7)%Other early programs and unallocated costsâ€‹Â 4,943â€‹Â 2,066â€‹Â 2,877â€‹ 139.3%Total external costsâ€‹Â 46,278â€‹Â 27,934â€‹Â 18,344â€‹ 65.7%Internal costs:â€‹Â â€‹â€‹Â â€‹â€‹Â â€‹â€‹Â Â â€‹Employee compensation and benefitsâ€‹Â 30,426â€‹â€‹ 20,634â€‹Â 9,792â€‹ 47.5%Facility and otherâ€‹Â 8,762â€‹â€‹ 8,034â€‹Â 728â€‹ 9.1%Total internal costsâ€‹Â 39,188â€‹Â 28,668â€‹Â 10,520â€‹ 36.7%Total research and development expenseâ€‹$ 85,466â€‹$ 56,602â€‹$ 28,864â€‹ 51.0%â€‹The increase in research and development expense was primarily attributable to the following:â—An increase in our external research and development costs of $18.3 million, which primarily consisted of:o$17.1 million increase in costs associated with apitegromab primarily due to clinical trial costs, particularly the conduct of ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies and EMBRAZE, our Phase 2 proof-of-concept study (including purchases of GLP-1 drug), as well as an increase in clinical drug supply manufacturing to support lifecycle management initiatives; o$1.7 million decrease in costs associated with SRK-181 mostly due to purchases of pembrolizumab in 2023 which were used in the Phase 1 DRAGON clinical trial; and25 Table of Contentso$2.9 million increase in other early development candidates, including pre-clinical costs and manufacturing development for SRK-439 and unallocated costs.â€‹â—$10.5 million increase in internal research and development costs, which was primarily driven by an increase in employee compensation and benefits, including salaries, bonus, payroll taxes and non-cash equity-based compensation expense related to increased headcount, as well as an increase in temporary support expense.Total research and development expenses are expected to continue to be substantial, driven by employee compensation costs and development costs associated with our clinical stage programs as we continue to advance our product candidates, including apitegromab through our Phase 3 SAPPHIRE clinical trial in SMA and ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies and costs associated with supporting our cardiometabolic program, including EMBRAZE, our Phase 2 proof-of-concept trial of apitegromab and our preclinical program, SRK-439. Additionally, we will continue to invest in our pipeline. We expect costs of our SRK-181 program to decrease, as we completed enrollment of the Phase 1 DRAGON clinical trial in December 2023.General and AdministrativeGeneral and administrative expense was $32.5 million and $23.0 million for the six months ended June 30, 2024 and 2023, respectively, an increase of $9.5 million or 41.2%. The increase was primarily associated with employee-related costs including salaries, benefits and non-cash equity-based compensation expense related to increased headcount, in addition to an increase in consulting and professional services. We expect general and administrative expense to increase as we continue to invest in commercial readiness activities.Other Income (Expense), NetThe change in other income (expense), net was primarily attributable to an increase in interest income earned due to higher interest rates, partially offset by an increase in interest expense related to the Loan and Security Agreement, also due to higher interest rates.Liquidity and Capital ResourcesSources of LiquiditySince our inception, we have not generated any product revenue and have incurred significant operating losses and negative cash flows from our operations. We have funded our operations to date primarily with proceeds from the sale of our convertible preferred stock and units in private placements before our initial public offering (â€œIPOâ€), and sale of our common stock through our IPO in 2018, to Gilead in an exempt private placement, through multiple secondary public offerings and through ATM sales, as well as payments from our research collaborations and the Loan and Security Agreement entered into in October 2020 and subsequently amended (see Note 10).The following table provides information regarding our total cash, cash equivalents and marketable securities at June 30, 2024 and December 31, 2023 (in thousands):â€‹JuneÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹â€‹2024â€‹2023Cash and cash equivalentsâ€‹$ 93,372â€‹$ 101,855Marketable securitiesâ€‹Â 97,122â€‹Â 178,083Total cash, cash equivalents and marketable securitiesâ€‹$ 190,494â€‹$ 279,938â€‹During the six months ended June 30, 2024, our cash, cash equivalents and marketable securities balance decreased by $89.4 million. The change was primarily due to cash used to operate our business, including payments related to, among other things, research and development and general and administrative expenses as we continued to invest in our product candidates and supported our internal research and development efforts and made interest payments on our debt, partially offset by proceeds from the exercises of warrants and stock options.â€‹26 Table of ContentsOur current ATM program, established in November 2022, allows for the sale of shares of our common stock having an aggregate offering price of up to $100 million. As of June 30, 2024, the Company has sold 619,290 shares, generating net proceeds of $5.2 million, under the ATM program. No sales were made under the ATM program during the six months ended June 30, 2024. In October 2021, we sold 500,000 shares of our common stock through a sale in our prior ATM program (in place between March 2021 and June 2022)Â and received $13.1 million in net proceeds, after deducting commissions and fees. â€‹On October 11, 2023, we entered into an underwriting agreement with J.P. Morgan Securities LLC and Piper Sandler & Co., as representatives of the several underwriters named therein, relating to the issuance and sale of an aggregate of 12,408,760 shares of our common stock at $6.85 per share. Pursuant to the underwriting agreement, we also granted the underwriters a 30-day option to purchase up to 1,861,314 additional shares in an amount equal to 15% of the securities offered in the public offering (the â€œOption Sharesâ€) of common stock. The underwriters exercised in full their option to purchase the Option Shares on October 12, 2023. Total proceeds of the transaction, including the Option Shares were approximately $92.4 million, net of underwriting discounts and estimated offering expenses. The offering closed on October 16, 2023.â€‹In JuneÂ 2022, we entered into a securities purchase agreement relating to the issuance and sale of an aggregate of 16,326,530 shares of our common stock, pre-funded warrants to purchase 25,510,205 shares of our common stock and associated common warrants to purchase 10,459,181 shares of our common stock. Gross proceeds from the transaction were $205.0 million. Upon the offering closing, we received $195.3 million in net proceeds, after deducting placement agent fees and expenses and offering expenses.â€‹In October 2020, we entered into an underwriting agreement relating to the issuance and sale of an aggregate of 3,717,948 shares of our common stock at $39.00 per share and pre-funded warrants to purchase 2,179,487 shares of our common stock. The offering closed in November 2020, and we received $215.9 million in net proceeds, after deducting underwriting discounts and commissions and offering expenses.â€‹In October 2020, we entered into the Loan and Security Agreement with Oxford and SVB, which was amended in November 2022, for $100 million of which $25.0 million from Tranche 1 was received in October 2020 and $25.0 million from Tranche 2 was received in December 2021 (Note 10).â€‹In June and July 2019, we sold 3,450,000 shares of our common stock through an underwritten public offering. As a result of the offering, we received aggregate net proceeds, after underwriting discounts and commissions and other offering expenses, of $48.3 million. â€‹In December 2018, we entered into the Gilead Collaboration Agreement pursuant to which we conducted research and preclinical development activities relating to the diagnosis, treatment, cure, mitigation or prevention of diseases, disorders or conditions, other than in the field of oncology in accordance with a pre-determined research plan. Pursuant to the Gilead Collaboration Agreement, Gilead made non-refundable payments of $80.0 million, including an upfront payment and an equity investment. In December 2019, we achieved a $25.0 million preclinical milestone for the successful demonstration of efficacy in preclinical in vivo proof-of-concept studies, and subsequently received the associated payment in January 2020. Revenue was recognized during the period January 2019 through December 2021, as research and development services were provided. All revenue related to the Gilead Collaboration Agreement had been fully recognized by January 31, 2022, upon the termination of Gileadâ€™s option exercise period.â€‹During the six months ended June 30, 2024, 2,526,833 of the Companyâ€™s pre-funded warrants were exercised. As of June 30, 2024, the Company had 17,008,164 pre-funded warrants outstanding.â€‹During the six months ended June 30, 2024, 830,660 of the Companyâ€™s common warrants were exercised. As of June 30, 2024, the Company had 9,157,496 common warrants outstanding.â€‹27 Table of ContentsCash FlowsThe following table provides information regarding our cash flows for the six months ended June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Net cash used in operating activitiesâ€‹$ (98,981)â€‹$ (75,604)Net cash provided by investing activitiesâ€‹Â 84,006â€‹Â 74,742Net cash provided by financing activitiesâ€‹Â 6,492â€‹Â 5,765Net (decrease)/increase in cash, cash equivalents and restricted cashâ€‹$ (8,483)â€‹$ 4,903â€‹Net Cash Used in Operating ActivitiesNet cash used in operating activities was $99.0 million for the six months ended June 30, 2024, and consisted of our net loss of $115.4 million and changes in our assets and liabilities of $2.0 million, partially offset by non-cash adjustments of $18.4 million. The non-cash adjustments are primarily from equity-based compensation. â€‹Net cash used in operating activities was $75.6 million for the six months ended June 30, 2023, and consisted of our net loss of $77.3 million, changes in our assets and liabilities of $14.0 million, partially offset by non-cash adjustments of $15.7 million. The changes in our assets and liabilities includes a $10.5 million change in accrued expenses, mostly related to external research and development expenses. The non-cash adjustments are primarily from equity-based compensation.â€‹Net Cash Provided by Investing ActivitiesNet cash provided by investing activities was $84.0 million for the six months ended June 30, 2024 compared to net cash provided by investing activities of $74.7 million for the six months ended June 30, 2023. Net cash provided by investing activities for both periods was primarily associated with transactions involving our marketable securities.Net Cash Provided by Financing ActivitiesNet cash provided by financing activities was $6.5 million for the six months ended June 30, 2024 compared to $5.8 million for the six months ended June 30, 2023. Net cash provided by financing activities for the six months ended June 30, 2024 was primarily attributable to proceeds from the exercise of warrants. Net cash provided by financing activities for the six months ended June 30, 2023 was primarily attributable to proceeds from the sale of common stock through our ATM. Funding RequirementsWe expect our expenses to be substantial as we continue the research and development of apitegromab in SMA. In addition, if we seek marketing approval for apitegromab, or any of our future product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We expect to continue to incur costs related to SRK-181 as we continue to treat patients who remain on the Phase 1 DRAGON clinical trial. We expect to incur costs to support our cardiometabolic program, including EMBRAZE, our Phase 2 proof-of-concept trial of apitegromab and our preclinical program, SRK-439. Additionally, we will support the development of our pipeline and any other preclinical programs. Furthermore, we expect to continue to incur costs associated with operating as a public company.We expect that our existing cash, cash equivalents marketable securities will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2025. However, we will require additional capital in order to complete clinical development and commercialization for each of our current programs. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:28 Table of Contentsâ—the costs and timing of developing our product candidates and future product candidates, including costs associated with apitegromab in our Phase 3 SAPPHIRE clinical trial in SMA and ONYX, ourÂ long-term extension studyÂ in SMA for patients from both the TOPAZ and SAPPHIRE studies, our Phase 2 proof-of-concept trial for apitegromab in our cardiometabolic program, our Phase 1 DRAGON clinical trial for SRK-181, and the costs and timing of conducting future preclinical studies and clinical trials for SRK-439 or any other product candidates;â—the costs of future manufacturing of apitegromab, SRK-181, SRK-439 and any other future product candidates;â—the scope, progress, results and costs of discovery, preclinical development, laboratory testing and clinical trials for other potential product candidates we may develop, if any;â—the costs of identifying and developing, or in-licensing or acquiring, additional product candidates and technologies;â—the costs, timing and outcome of regulatory review of our product candidates;â—our ability to establish and maintain collaborations on favorable terms, if at all;â—the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements, license agreements, or other agreements we might have at such time;â—the costs of seeking marketing approvals for our product candidates that successfully complete clinical trials, if any;â—the costs and timing of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;â—the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;â—the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;â—our headcount growth and associated costs as we expand our business operations and research and development activities; â—the costs of supporting our infrastructure and facilities, including equipment and physical infrastructure to support our research and development;â—the costs of operating as a public company; andâ—the impact of adverse global economic conditions on our business, which may exacerbate the magnitude of the factors discussed above.â€‹Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takesÂ years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.In accordance with Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entityâ€™s Ability to Continue as a Going Concern (Subtopic 205-40), we are required to evaluate whether there are conditions and events, considered in the aggregate, which raise substantial doubt about our ability to continue as a going concern from the issuance date of our consolidated financial statements. We have incurred losses since our inception, and as of June 30, 2024 we had an accumulated deficit of $791.8 million. During the six months ended June 30, 2024, we recorded a net loss of $115.4 million. In addition, during the six months ended June 30, 2024 our cash, cash equivalents and marketable securities balance decreased by $89.4 million, resulting in a cash, cash equivalents and marketable securities balance of $190.5 million as of June 30, 2024. Based on current operating plans, we may not have sufficient cash, cash equivalents and marketable securities to fund our operating expenses and capital requirements beyond one year from the issuance of these consolidated financial statements without receiving additional external financing and, therefore, we have concluded that there is substantial doubt about our ability to continue as a going concern. The financial statements do not 29 Table of Contentsinclude any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability to continue as a going concern. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, common stockholder ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect the rights of a common stockholder. Additional debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have

to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Market volatility or other factors could also adversely impact our ability to access capital as and when needed. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.Critical Accounting EstimatesThis managementâ€™s discussion and analysis is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates. Our actual results may differ from these estimates under different assumptions or conditions.There have been no material changes to our critical accounting estimates from those described in Part II, Item 7. â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ included in our Annual Report on Form 10-K for the year ended December 31, 2023.Off-Balance Sheet ArrangementsWe did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.Recent Accounting PronouncementsWe have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this Quarterly Report, they will not have a material impact on our financial statements or do not otherwise apply to our operations.Item 3.Â Quantitative and Qualitative Disclosures About Market RiskWe are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required under this item. 30 Table of ContentsItem 4.Â Controls and ProceduresManagementâ€™s Evaluation of our Disclosure Controls and ProceduresWe maintain â€œdisclosure controls and procedures,â€ as defined in RulesÂ 13a-15(e)Â and 15d-15(e)Â under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1)Â recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commissionâ€™s rulesÂ and forms and (2)Â accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.Our management, with the participation of our chief executive officer (principal executive officer) and chief financial officer (principal financial and accounting officer) has evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2024, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date. We continue to review and document our disclosure controls and procedures, including our internal controls and procedures for financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.Changes in Internal Controls Over Financial ReportingNo change in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the six months ended June 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.â€‹PartÂ II. OTHER INFORMATIONItemÂ 1. Legal Proceedings From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Quarterly Report, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.â€‹â€‹â€‹â€‹â€‹â€‹31 Table of ContentsItemÂ 1A. Risk Factors Careful consideration should be given to the following risk factors, together with all other information set forth in this Quarterly Report, including our consolidated financial statements and related notes, and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ and in other documents that we file with the Securities and Exchange Commission (the â€œSECâ€), in evaluating Scholar Rock Holding Corporation and our subsidiaries (collectively, the â€œCompanyâ€, â€œweâ€, or â€œourâ€) and our business, before investing in our common stock. Investing in our common stock involves a high degree of risk. If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The market price of our common stock could decline if one or more of these risks or uncertainties were to occur, which may cause you to lose all or part of the money you paid to buy our common stock. The risk factors described below disclose both material and other risks, and are not intended to be exhaustive and are not the only risks facing the Company. New risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations. Certain statements below are forward-looking statements. See â€œSpecial Note Regarding Forward-Looking Statementsâ€ in this Quarterly Report.Summary of the Material Risks Associated with Our BusinessOur business is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled â€œRisk Factors.â€ These risks include, but are not limited to, the following:Risks Related to Product Development, Regulatory Approval and Commercializationâ—Product development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of apitegromab, SRK-181, SRK-439, or any future product candidates. Many of the factors that cause, or lead to, a delay in the initiation or completion of clinical trials may also ultimately lead to the denial of regulatory approval or limit market acceptance of our product candidates.â—The results of preclinical studies and early-stage clinical trials may not be predictive of future results. Success of a product candidate in an early-stage clinical trial may not be replicated in later-stage clinical trials.â—Interim, initial and preliminary results from our clinical trials that we announce or publish from time to time may change (e.g. from positive safety or efficacy results to poor or negative safety or efficacy results) as more patient data become available and are subject to additional audit, validation and verification procedures that could result in material changes in the final data.â—We rely on third parties to conduct our clinical trials and to conduct certain aspects of our preclinical studies. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with legal and regulatory requirements, we may be delayed or unable to receive regulatory approval of or commercialize apitegromab, SRK-181, SRK-439 or any future product candidates, and our business could be materially harmed.â—We have never commercialized a product and will need to build and scale our business for potential commercialization of apitegromab, including building our compliance, medical affairs and commercial organizations, which, if we are not able to do so successfully could negatively impact our business, including the potential for a successful commercialization of apitegromab.â—The regulatory approval process for our product candidates in the U.S., EU and other jurisdictions will be lengthy, time-consuming and inherently unpredictable and we may fail to receive or be delayed in receiving regulatory approval of apitegromab, SRK-181, SRK-439 and future product candidates.â—We have received Orphan Drug designation from the FDA for apitegromab for the treatment of SMA and the EC granted Orphan Medicinal Product designation to apitegromab for the treatment of SMA. We may seek Orphan Drug designation from regulatory authorities in other jurisdictions for apitegromab and Orphan Drug 32 Table of Contentsdesignation from the FDA, EC or regulatory authorities in other jurisdictions for our other product candidates. In any of these instances, we may not receive the requested designation or we may be unable to realize the benefits associated with Orphan Drug designation, including the potential for market exclusivity. â—Preclinical development is uncertain. Our preclinical programs, such as SRK-439, may experience delays or may never advance to clinical trials, which would adversely affect our ability to develop our product pipeline and receive regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.Risks Related to Our Business and Operationsâ—Because we rely on a limited number of third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials, and, if approved, commercial materials, may become limited or interrupted or may not be of satisfactory quantity or quality.â—Our reliance on third parties, such as manufacturers, may subject us to risks relating to manufacturing scale-up and may cause us to undertake substantial obligations, including financial obligations.â—We will need to continue to grow our organization in certain areas, including our personnel, systems and relationships with third parties, in order to develop our drug candidates and we may experience difficulties in managing this growth.â—Our executives and highly skilled technical and managerial personnel are critical to our business. If we have transition in management, lose key personnel, or if we fail to recruit additional highly skilled personnel, our ability to further develop apitegromab, SRK-181, SRK-439 and identify and develop new or next generation product candidates may be impaired.â—Failure to comply with health care privacy and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operation results and business.Risks Related to Intellectual Propertyâ—Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.â—Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. Third-party claims of intellectual property infringement may prevent or delay our product discovery, development, and commercialization efforts.Risks Related to Our Financial Condition and Capital Requirementsâ—We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.â—We will require additional capital to fund our operations and if we fail to obtain necessary capital, we will not be able to complete the development and commercialization of apitegromab, SRK-181, SRK-439 and any future product candidates.â—Based on current operating plans, we may not have sufficient cash, cash equivalents and marketable securities to fund our operating expenses and capital requirements beyond one year from the issuance of these consolidated financial statements, without receiving additional external financing and, therefore, we may not be able to continue as a going concern.33 Table of ContentsRisks Related to Our Common Stockâ—The price of our stock is volatile, and you could lose all or part of your investment.Risks Related to Product Development, Regulatory Approval and CommercializationProduct development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of apitegromab, SRK-181, SRK-439, or any future product candidates. Many of the factors that cause, or lead to, a delay in the initiation or completion of clinical trials may also ultimately lead to the denial of regulatory approval or limit market acceptance of our product candidates.Before obtaining regulatory approvals for the commercial sale of any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain, a clinical trial can fail at any stage of development. We may experience delays in initiating, progressing or completing our clinical trials. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful. Clinical trials may fail to meet their primary or secondary endpoints, raise safety concerns or generate mixed results. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Clinical data may not be sufficient to apply for and obtain regulatory approval on the timelines we expect or at all. Other decisions or actions of regulatory agencies may affect our plans, progress or results.We also may experience numerous unforeseen events during, or as a result of, any clinical trials in process or any future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize apitegromab, SRK-181, SRK-439, or any future product candidates, including:â—delay or inability to reach agreement with the FDA or comparable foreign regulatory authorities on acceptable clinical trial design, conduct or statistical analysis plan;â—regulators, Institutional Review Boards (â€œIRBsâ€) or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;â—we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;â—failure by our collaborators to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial;â—collaborators may provide insufficient funding for a clinical trial program, delay or stop a clinical trial, abandon a product candidate or clinical trial program, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;â—clinical trials of any product candidates may fail to show safety and effectiveness, or produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs;â—the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower or more challenging than we anticipate or subjects may drop out of these clinical trials or fail to return for post treatment follow-up at a higher rate than we anticipate;â—challenges in identifying or recruiting sufficient study sites or investigators for clinical trials;â—our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; 34 Table of Contentsâ—clinical study sites or clinical investigators may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;â—we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;â—limitations on our or our CROsâ€™ ability to access and verify clinical trial data captured at clinical study sites through monitoring and source document verification;â—the cost of clinical trials of a product candidate may be greater than we anticipate;â—the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate to initiate or complete a given clinical trial;â—our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate the trials, or reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates;â—our product candidates may have undesirable side effects or other unexpected characteristics when used in a new disease indication or with products in a different class which may raise safety, efficacy or other concerns about our product candidate as a potential therapy in that new disease indication or other indications or its use with products in a different class;â—our failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidate and/or data emerging from other molecules in the same class as our product candidate;â—the FDA, EMA or other regulatory authorities may require us to submit additional data, such as long-term toxicology studies, or change or impose other requirements before permitting us to initiate a clinical trial;â—evolution in the standard of care or changes in applicable governmental regulations or policies during the development of a product candidate that require amendments to ongoing clinical trials and/or the conduct of additional preclinical studies or clinical trials; andâ—lack of adequate funding to complete a clinical trial.Many of the factors that cause, or lead to, a delay in the initiation or completion of clinical trials may also ultimately lead to the denial of regulatory approval or limit market acceptance of our product candidates. For example, we anticipate some of our future trials to, in part, utilize an open-label trial design, and our ongoing Phase 1 DRAGON clinical trial for SRK-181 in cancer immunotherapy and our ongoing ONYX long-term extension study for apitegromab in patients from both the TOPAZ and SAPPHIRE trials, utilize an open-label trial design. An open-label trial is one where both the patient and investigator know whether the patient is receiving the test article or either an existing approved drug or placebo. Open-label trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label studies are aware that they are receiving treatment. Open-label trials may be subject to a patient bias, for example, if patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Open-label trials also may be subject to an investigator bias where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The potential sources of bias in clinical trials as a result of open-label design may not be adequately mitigated and may cause any of our trials that utilize such design to fail and additional trials may be necessary to support future marketing applications. In addition, other types of trials (including randomized, double-blind, parallel arm studies), particularly if smaller in size or if limited to one study, are also subject to potential sources of bias and limitations that may exaggerate any therapeutic effect or falsely identify a positive efficacy signal, or conversely, fail to detect an efficacy signal when in fact there may actually be a positive therapeutic effect. Furthermore, we are

conducting clinical trials with apitegromab in SMA, but by using apitegromab in a Phase 2 obesity clinical trial, we may become aware of safety information associated with apitegromab 35 Table of Contentsthat we did not observe when we used apitegromab in our clinical trials in SMA. We, the FDA, the competent authorities and/or ethics committees of the EU Member States or other applicable regulatory authorities for their jurisdictions, or an IRB for their site(s) may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects.Our product development costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly.Our clinical development strategy depends on the continued use and availability of certain third-party approved drug therapies. Apitegromab and SRK-181 are our two clinical-stage product candidates. Patients in our Phase 3 SAPPHIRE clinical trial, and ONYX, our long-term extension study for patients from both the TOPAZ and SAPPHIRE studies, are receiving apitegromab in conjunction with an approved SMN therapy. These patients are reliant on the continued use and availability of such therapies. If access to an approved SMN therapy such as nusinersen or risdiplam becomes limited or is unavailable, we may be forced to pause or stop our SAPPHIRE or ONYX long-term extension trials, or the medical condition of patients may be affected which could negatively affect the efficacy and safety results for apitegromab in the trials or reduce the amount of data or confound the data from these trials. In May 2024, we initiated the Phase 2 EMBRAZE proof-of-concept trial of apitegromab in combination with approved GLP-1 RAs in obesity. This study will rely upon the continued availability of such GLP-1 RA. Access to approved GLP-1 RAs are limited for use in clinical trials and may continue to be limited for such use. If GLP-1 RAs become more limited or unavailable, we may be unable to enroll, or may be delayed in enrolling patients, or may be forced to stop our Phase 2 study. While we have obtained substantial supply of an approved GLP-1 RA for use in this Phase 2 study, we cannot assure you that we will be able to obtain adequate supply for future studies of our product candidate in obesity. Patients in Part B of our ongoing Phase 1 DRAGON clinical trial of SRK-181 in patients with locally advanced or metastatic solid tumors that exhibit resistance to anti-PD-(L)1 antibody therapies are receiving SRK-181 in conjunction with an approved anti-PD-(L)1 therapy such as pembrolizumab. If access to the approved anti-PD-(L)1 therapy becomes limited or is unavailable, we may be forced to pause or stop our Phase 1 DRAGON clinical trial, or the medical condition of patients may be affected which could negatively affect the efficacy and safety results for SRK-181 in the trial. Any delay or suspension of our clinical trials would significantly and delay our clinical development programs and harm our business, financial condition and results of operations.The results or success of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of future results or replicated in later preclinical studies or clinical trials of our product candidates in the same indications or other indications.The results or success of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of future results or replicated in later preclinical studies or later-stage clinical trials. Preclinical studies and early-stage clinical trials are primarily designed to study PK and PD, understand the side effects of product candidates, and evaluate various doses and dosing schedules. Our current or future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later-stages of clinical trials may fail to show desired pharmacological properties or produce positive safety and efficacy results despite having progressed through preclinical studies and early-stage clinical trials. We completed a Phase 1 clinical trial for apitegromab in healthy adult volunteers and we completed the treatment period of our Phase 2 TOPAZ clinical trial for the treatment of patients with Type 2 and Type 3 SMA. In 2024, we announced data from the Phase 2 TOPAZ trial extension period which showed patient outcomes at 48 months of treatment with apitegromab. These data show that continued treatment with apitegromab over the extended period was associated with sustained clinical benefit, a continued favorable safety profile with no new safety findings, and a retention rate of over 90% in patients with nonambulatory Types 2 and 3 SMA receiving SMN therapy. In January 2022, we initiated our Phase 3 SAPPHIRE clinical trial of apitegromab for the 36 Table of Contentstreatment of patients with Type 2 and Type 3 SMA and in September 2023, we announced completion of trial enrollment. We expect the top-line data readout for the SAPPHIRE trial in the fourth quarter of 2024. We also announced in October 2023 our plans to expand into cardiometabolic disorders based on preclinical data with SRK-439, and we initiated the Phase 2 EMBRAZE proof-of-concept trial of apitegromab in combination with a GLP-1 receptor agonist in obesity in May 2024 with data readout expected in the second quarter of 2025. We cannot assure you that the Phase 3 SAPPHIRE clinical trial or any other future clinical trials of apitegromab, such as our Phase 2 clinical trial in obesity, or of SRK-439 will show positive results. Additionally, product candidates evaluated in one disease indication may interact in unforeseen or harmful ways in a patient population with a different disease indication than was previously studied. For example, we are evaluating apitegromab in SMA, and have initiated a Phase 2 clinical trial of apitegromab in obesity. Apitegromab may interact in unforeseen or different ways in the obesity population than in the SMA patient population. There can be no assurance that any of our current or planned clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There can also be no assurance that any of our future clinical trials will show similar results to our earlier clinical trials or support further development or registration of any of our product candidates. Interim, initial, or preliminary results from our clinical trials that we announce or publish from time to time may change (e.g. from positive safety or efficacy results to poor or negative safety or efficacy results) as more patient data become available and are subject to additional audit, validation and verification procedures that could result in material changes in the final data.From time to time, we may publish interim, initial, or preliminary data, including interim top-line results or initial or preliminary results from our clinical trials. Any interim, initial or preliminary data and other results from our clinical trials may materially change as more patient data become available. Preliminary, initial, interim or top-line results also remain subject to audit, validation and verification procedures that may result in the final data being materially different from the interim, initial or preliminary data we previously published. As a result, interim, initial or preliminary data may not be predictive of final results and should be viewed with caution until the final data are available. We may also arrive at different conclusions, or considerations may qualify such results, once we have received and fully evaluated additional data. For example, clinical data from our Phase 1 DRAGON trial in cancer immunotherapy, including preliminary safety, efficacy and biomarker data were presented in November 2023 at the SITC 38th Annual Meeting and in June 2024 at the ASCO 2024 annual meeting, and we will continue to present data from our Phase 1 DRAGON trial while the trial is ongoing. Tumor response data is based on assessments by site investigators. Central reads for the tumor responses are also being conducted, with a comprehensive review of the central reads to be performed once completed within and/or across the cohorts. Differences between preliminary, initial or interim data and final data could adversely affect our business.There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical development even after achieving promising results in earlier studies, and we cannot be certain that we will not face similar setbacks. Many drugs have failed to replicate efficacy and safety results in larger or more complex later stage trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain regulatory approval. If we fail to produce positive results in our ongoing and planned preclinical studies and clinical trials in apitegromab, SRK-181, SRK-439 or if a regulatory authority interprets and analyzes the results as not positive, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, may be materially adversely affected.If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including: â—the patient eligibility and exclusion criteria defined in the protocol;37 Table of Contentsâ—the size of the patient population required for analysis of the trialâ€™s primary endpoints; â—the willingness or availability of patients to participate in our trials;â—the number and location of participating trial sites;â—the proximity of patients to trial sites and any limitations on travel or access to trial sites;â—the design of the trial;â—our ability to recruit clinical trial investigators with the appropriate competencies and experience;â—cliniciansâ€™ and patientsâ€™ perceptions as to the potential advantages and risks of the product candidate being studied in relation to other therapies;â—our ability to obtain and maintain patient consents; andâ—the risk that patients enrolled in clinical trials will drop-out of the trials before completion of their involvement in the study.For example, we are initially developing apitegromab for the treatment of SMA, a rare disease, affecting an estimated 20,000 patients in the U.S. and Europe. As a result, we may encounter difficulties enrolling patients in our clinical trials for apitegromab due, in part, to the small size of this patient population. In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. Additionally, patients may opt out of participation in clinical trials in favor of treatment with FDA-approved therapies, or therapies approved in the EU or other foreign jurisdictions. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our future clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.We rely on third parties to conduct our clinical trials and certain aspects of our preclinical studies. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with legal and regulatory requirements, we may be delayed or unable to receive regulatory approval of or commercialize apitegromab, SRK-181, SRK-439, or any future product candidates, and our business could be materially harmed.We depend upon third parties to conduct certain aspects of our preclinical studies and to conduct our clinical trials, under agreements with universities, medical institutions, CROs, strategic partners and others. We often have to negotiate budgets and contracts with such third parties, and if we are unsuccessful or if the negotiations take longer than anticipated, this could result in delays to our development timelines and increased costs.We rely especially heavily on third parties over the course of our clinical trials, and, as a result, have limited control over the clinical investigators and limited visibility into their day-to-day activities, including with respect to their individual employment policies or compliance with the approved clinical protocol. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with Good Clinical Practice (â€œGCPâ€) requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable 38 Table of Contentsand the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP requirements. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in civil monetary penalties, adverse publicity and civil and criminal sanctions. The FDA and National Institutes of Health have signaled the governmentâ€™s willingness to begin enforcing these registration and reporting requirements against non-compliant clinical trial sponsors. Our failure or any failure by these third parties to comply with these regulations would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.Any third parties conducting aspects of our preclinical studies or clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to our preclinical studies and clinical trials. The third party CROs and clinical trial sites that conduct our clinical trials have experienced staffing shortages and the inability of a CRO or clinical trial site to maintain appropriate levels of competent staffing to support the demands of our clinical trials could negatively impact the execution of our clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines if they need to be replaced or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons, our development timelines, including clinical development timelines, may be extended, delayed or terminated and we may not be able to complete development of, receive regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.39 Table of ContentsWe have never commercialized a product and will need to build and scale our business for potential commercialization of apitegromab, including building our compliance, medical affairs and commercial organizations, which, if we are not able to do so successfully could negatively impact our business, including the potential for a successful commercialization of apitegromab.Although we are preparing our commercialization capabilities in anticipation of a potential approval and commercial launch of apitegromab, we have no prior sales or distribution experience and limited capabilities for marketing and market access. We expect to invest significant financial and management resources over time to establish compliance, medical affairs and commercial organizations for the marketing, sales and distribution of apitegromab, if approved, and other capabilities and infrastructure to support commercial operations. If we are unable to establish these commercial capabilities and infrastructure in a timely manner or to enter into agreements with third parties to market, sell, and/or distribute apitegromab if approved, we may be unable to complete a successful commercial launch. To the extent we enter into agreements with third parties, the revenue we receive may depend upon the efforts of such third parties, over which we may have limited or no control, and our revenue from product sales may be lower than if we had commercialized the products ourselves. We also face competition in our search for third parties to assist us with the distribution, sales and marketing of our products.Furthermore, we intend to commercialize apitegromab globally, if approved. In order to do so, we must build, on a territory-by-territory basis, marketing, sales, distribution, managerial and other capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so.The regulatory approval process for our product candidates in the U.S., EU and other jurisdictions will be lengthy, time-consuming and inherently unpredictable and we may fail to receive or be delayed in receiving regulatory approval of apitegromab, SRK-181, SRK-439 and future product candidates.The research, testing, manufacturing, labeling, approval, sale, import, export, marketing, promotion and distribution of drug products, including biologics, are subject to extensive regulation by the FDA in the U.S. and other regulatory authorities outside the U.S. We are not permitted to market any biological product in the U.S. until we receive a biologics license from the FDA. We have not previously submitted a Biologics License Application (â€œBLAâ€) to the FDA or similar marketing application to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, pure and potent for each desired indication. FDA approval of a new biologic or drug generally requires dispositive data from two (and in some cases, one) adequate and well-controlled pivotal Phase 3 clinical trials of the biologic or drug in the relevant patient population. The FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials or our analysis or interpretation of data from preclinical studies or clinical trials, the results of our clinical trials may not meet the level of statistical significance or amount of data required for approval, or we may be unable to demonstrate that our product candidatesâ€™ clinical and other benefits outweigh their safety risks. A BLA must also include significant information regarding the chemistry, manufacturing, and controls for the product, and

the manufacturing facilities must complete a successful pre-license inspection as well as certain key clinical sites conducting our clinical trials. The FDA, EMA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies.The FDA may seek independent advice from a panel of experts, referred to as an Advisory Committee, on complex or novel issues that may be presented in an application, including issues related to the adequacy of the safety and efficacy data to support approval. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to receive approval of any product candidates that we develop based on the completed clinical trials.Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions at which such trials are being conducted, or the FDA, the competent authorities and/or ethics committees of the EU Member States or other regulatory authorities, or recommended for suspension or termination by the DSMB for such trial, due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, competent authorities of the EU Member States or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or 40 Table of Contentsdelays in the completion of, any clinical trial of our product candidates, the prospects for regulatory approval and commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing any clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.We have received Orphan Drug designation from the FDA for apitegromab for the treatment of SMA and the EC granted Orphan Medicinal Product designation to apitegromab for the treatment of SMA. We may seek Orphan Drug designation from regulatory authorities in other jurisdictions for apitegromab and Orphan Drug designation from the FDA, EC or regulatory authorities in other jurisdictions for our other product candidates. In any of these instances, we may not receive the requested designation or we may be unable to realize the benefits associated with Orphan Drug designation, including the potential for market exclusivity. We have received Orphan Drug designation from the FDA for apitegromab for the treatment of SMA, and following the EMAâ€™s Committee for Orphan Medicinal Productsâ€™ positive opinion, the EC designated apitegromab as an orphan medicinal product for the treatment of SMA. Even if we receive orphan drug exclusivity, the benefit of that exclusivity may be limited if we seek approval for an indication broader than the orphan-designated indication or could be revoked under certain circumstances, for example if the FDA later determines that the request for designation was materially defective or that we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we receive orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition during the exclusivity period because different drugs with different active moieties can be approved for the same condition, and the same product can be approved for different uses. Also, in the U.S., even after an orphan drug is approved and receives orphan drug exclusivity, the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug, including because it has been shown to be clinically superior to the drug with exclusivity because it is safer, more effective or makes a major contribution to patient care. In the EU, a marketing authorization may be granted to a similar medicinal product to an authorized orphan product for the same orphan indication if:â—the second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior; orâ—the holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application; orâ—the holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.â—See the sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled, â€œBusiness â€" Government Regulation â€" US Biological Product Development â€" Orphan Drug Designationâ€ and â€œBusiness â€" Government Regulation â€" European Union Drug Development â€" European Union Orphan Designation and Exclusivity.â€We have received Rare Pediatric Disease designation for apitegromab for the treatment of SMA. However, a marketing application for apitegromab, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher. We have received Rare Pediatric Disease designation for apitegromab for the treatment of SMA. Designation of a biologic as a product for a rare pediatric disease does not guarantee that a BLA for such biologic will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Under the Federal Food, Drug, and Cosmetic Act, we will need to request a rare pediatric disease priority review voucher in our original BLA for apitegromab. The FDA may determine that a BLA for apitegromab, if approved, does not meet the eligibility criteria for a rare pediatric disease priority review voucher, including for the following reasons:â—SMA no longer meets the definition of a rare pediatric disease;41 Table of Contentsâ—apitegromab contains an active ingredient (including any ester or salt of the active ingredient) that has been previously approved in an application;â—the BLA is not deemed eligible for priority review;â—the BLA does not rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population; orâ—the BLA seeks approval for a different adult indication than the rare pediatric disease for which apitegromab is designated.The authority for the FDA to award rare pediatric disease priority review vouchers for biologics after September 30, 2024 is currently limited to biologics that receive Rare Pediatric Disease designation on or prior to September 30, 2024, and the FDA may only award rare pediatric disease priority review vouchers through September 30, 2026. If the BLA for apitegromab is not approved on or prior to September 30, 2026 for any reason, it will not be eligible for a priority review voucher. However, it is possible the authority for the FDA to award rare pediatric disease priority review vouchers will be further extended by Congress. We have received Fast Track designation from the FDA and PRIME designation from the EMA for apitegromab for the treatment of SMA. We may seek Fast Track designation or Breakthrough Therapy designation from the FDA or PRIME designation from the EMA for certain of our current and future product candidates, and we may not be successful in receiving such designations, or if received, such designation may not actually lead to a faster development or regulatory review or approval process.We may seek Fast Track designation, Breakthrough Therapy designation or PRIME designation for certain of our product candidates.In May 2021, the FDA granted Fast Track designation for apitegromab for the treatment of SMA. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure that the FDA would decide to grant it. Although the FDA has granted Fast Track designation for apitegromab in SMA, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the products no longer meet the conditions for qualification and rescind the breakthrough designation. See the sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled, â€œBusiness â€" Government Regulation â€" US Biological Product Development â€" Expedited Development and Review Programs.â€In March 2021, the EMA granted PRIME designation to apitegromab for the treatment of SMA. PRIME is a scheme provided by the EMA to enhance support for the development of medicines that target an unmet medical need. The receipt of PRIME designation for apitegromab for the treatment of SMA may not result in a faster development process, review or approval compared to products considered for approval under conventional regulatory agency procedures and does not assure ultimate approval by the EMA.See the section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled, â€œBusiness â€" Government Regulation â€" European Union Drug Development â€" European Union Expedited Review and Development.â€42 Table of ContentsReceiving and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in receiving or maintaining regulatory approval of our product candidates in other jurisdictions.Receiving and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to receive or maintain regulatory approval in any other jurisdiction, but a failure or delay in receiving regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in other jurisdictions. Even if the FDA grants marketing approval of a product candidate, the EC, the competent authorities of EU Member States or comparable regulatory authorities in foreign jurisdictions may not approve the manufacturing, marketing and promotion of the product candidate in other countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S., including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the U.S. have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Receiving foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.If any of our product candidates are approved, they will be subject to ongoing regulatory requirements, including requirements related to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, import, export, conduct of post-marketing studies and submission of safety, efficacy and other post-marketing information. In addition, we will be subject to continued compliance with current Good Manufacturing Practice (â€œcGMPâ€) and GCP requirements for any clinical trials that we conduct post-approval.Manufacturers and manufacturersâ€™ facilities are required to comply with extensive FDA, EU and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to periodic review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA or other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved uses for which the product may be marketed or contain requirements for potentially costly post-market testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:43 Table of Contentsâ—restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;â—fines, warning letters, untitled letters or holds on clinical trials;â—refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;â—product seizure or detention or refusal to permit the import or export of our product candidates; andâ—permanent injunctions and consent decrees, including the imposition of civil or criminal penalties.The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Products may be promoted only for their approved indications and in a manner consistent with their FDA-approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of unapproved uses and a company that is found to have improperly promoted unapproved uses may be subject to significant liability. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. In addition, the U.S. Supreme Courtâ€™s July 2024 decision to overturn established case law giving deference to regulatory agenciesâ€™ interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDAâ€™s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may face enforcement action and our business may be harmed.Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.If apitegromab, SRK-181, SRK-439 or any future product candidate we develop receives marketing approval, whether as a single agent or in conjunction with other therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. For example, doctors may deem it sufficient to treat patients with SMA with an SMN therapy such as nusinersen or risdiplam, and therefore will not be willing to utilize apitegromab in conjunction with such SMN therapy. If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including:â—efficacy and potential advantages compared to alternative treatments;â—the amount, scope and nature of the clinical data (and other forms of data) available;â—the ability to offer our products, if approved, for sale at competitive prices;â—convenience and ease of administration compared to alternative treatments;â—the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;â—the strength of marketing and distribution support;â—the ability to obtain sufficient third-party coverage and adequate reimbursement; andâ—the prevalence and severity of any side effects.44 Table of ContentsCompeting therapies may exist or could emerge that adversely affect the amount of revenue we are able to generate from the sale of apitegromab, if approved, or any of our future product candidates, if successfully developed and approved. The biopharmaceutical industry is highly competitive. There are many public and private companies, universities, governmental agencies and other research organizations actively engaged in the research and development of products that may be similar to our product candidates or address similar markets. If we are successful in developing apitegromab, it is probable that the number of companies seeking to develop products and therapies similar to our products candidates or targeting similar indications will increase. Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and human resources than we do, and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and the commercialization of those treatments. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. We expect competition in the indications we are pursuing will focus on efficacy, safety, convenience, availability, and price. The commercial opportunity for apitegromab, if approved, could be reduced or eliminated if our competitors develop and commercialize products that are perceived to be safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than apitegromab. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.Preclinical development is uncertain. Our preclinical programs, such as SRK-439, may experience delays or may never advance to clinical trials, which would adversely affect our ability to develop our product pipeline and receive regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.Before we can commence clinical trials for any product candidate, we must complete extensive preclinical studies that support our planned INDs in the U.S., or similar applications in other jurisdictions. We cannot be certain of the timely completion or outcome of our preclinical studies or of the timing of any planned IND submission to the FDA or similar applications in other jurisdictions, and cannot predict if the FDA, EMA or other regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical studies will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for the clinical development of our preclinical programs, such as our potential IND for SRK-439, on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA, the competent authorities and/or ethics committees in the EU Member States or other regulatory authorities allowing clinical trials to begin.Conducting preclinical testing can be a lengthy, time-consuming and expensive process. The time required for

such testing may vary substantially according to the type, complexity and novelty of the program, and can be several years or more per program. Delays associated with programs for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. We also may be affected by delays associated with the preclinical testing and studies of certain programs that are the responsibility of our collaborators or our potential future collaborators over which we have limited or no control. The commencement and rate of completion of preclinical studies for a product candidate may be delayed by many factors, including, for example, challenges in reaching consensus with regulatory agencies regarding the scope of the necessary preclinical study program and/or appropriate preclinical study designs.Risks Related to Our Business and OperationsBecause we rely on a limited number of third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials, and, if approved, commercial materials, may become limited or interrupted or may not be of satisfactory quantity or quality.We rely on a limited number of third-party contract manufacturers to manufacture all of our clinical trial product supplies and, if approved, all of our commercial product supplies, including all of our drug substance, drug product, labeling, and packaging. We do not own our own manufacturing facilities for producing any clinical trial or commercial product supplies. There can be no assurance that our preclinical, clinical development, and, if approved, commercial product supplies will not be limited or interrupted due to impacts to our third-party contract manufacturers. For example, 45 Table of Contentswe rely on a single source supplier for the manufacture of apitegromab and SRK-181. Any replacement of our current drug substance contract manufacturer or drug product contract manufacturer would require significant resources, lead time and expertise because there may be a limited number of qualified replacements. In addition, our ability to procure sufficient supplies for the development of apitegromab, SRK-181, SRK-439 or future product candidates could be impacted by factors outside of our control such as current macroeconomic and geopolitical events and the changing rates of inflation and interest rates. We have no direct control over our contract manufacturersâ€™ ability to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, all of our third-party contract manufacturers supply and/or manufacture materials or products for other companies, which exposes our third-party contract manufacturers to regulatory risks for the production of such materials and products. As a result, failure to satisfy the regulatory requirements for the production of those materials and products may affect the regulatory clearance of our contract manufacturersâ€™ facilities generally.The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMP. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on the original manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we must change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.We expect to continue to rely on third-party manufacturers for commercial supplies of drug substance, drug product, and packaged and labeled product for apitegromab, if we receive regulatory approval. We will also rely on our contract manufacturers to manufacture sufficient quantities of apitegromab to produce validation batches. We do not have long-term supply agreements in place with any of our contract manufacturers, and each batch of our product candidates is individually contracted through a purchase order governed by master service and quality agreements. If our existing contract manufacturers for our product candidates are not willing to enter into long-term supply agreements, or are not willing or are unable to supply product candidate supplies to us, we could be required to engage new contract manufacturers who would need to scale up the manufacturing process before we would be able to use the product candidate supplies they manufacture, which could result in delays to our clinical trials or future commercialization plans, if we are successful and gain approval.To the extent that we have existing, or in the future enter into, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third-partyâ€™s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including:â—an inability to initiate or continue clinical trials for apitegromab, SRK-181, SRK-439 or of future product candidates under development;â—delay in submitting regulatory applications, or receiving regulatory approvals, for apitegromab, SRK-181, SRK-439 or future product candidates;â—loss of the cooperation of an existing or future collaborator;46 Table of Contentsâ—subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;â—requirements to cease distribution or to recall batches of apitegromab, SRK-181, SRK-439 or future product candidates; andâ—in the event of approval to market and commercialize apitegromab, SRK-181, SRK-439 or a future product candidate, an inability to meet commercial demands for our products.In addition, we contract with fill and finishing providers which we believe have the appropriate expertise, facilities and scale to meet our needs. Failure to maintain compliance with cGMP can result in a contractor receiving FDA sanctions, which can impact our ability to operate or lead to delays in any clinical development programs. We believe that our current fill and finish contractors are operating in accordance with cGMP, but we can give no assurance that the FDA, EMA, competent authorities of the EU Member States or other regulatory agencies will not conclude that a lack of compliance exists. In addition, any delay in contracting for fill and finish services, or failure of the contract manufacturer to perform the services as needed, may delay any clinical trials, registration and commercial launches, which could negatively affect our business.Our reliance on third parties, such as manufacturers, may subject us to risks relating to manufacturing scale-up and may cause us to undertake substantial obligations, including financial obligations.In order to continue to conduct later-stage clinical trials, or, if approved, produce commercial product, we will need to manufacture such product candidate in large quantities. In particular, we expect to rely on our contract manufacturers to scale our manufacturing processes for future clinical trials of apitegromab, and if our development efforts are successful and if apitegromab is approved, for commercial supply of apitegromab. We, or any manufacturing partners, may be unable to successfully increase the manufacturing capacity for apitegromab in a timely or cost-effective manner to meet our supply requirements. In addition, quality-control issues may arise during scale-up activities. If we, or any manufacturing partners, are unable to successfully scale-up the manufacture of our product candidates in sufficient quality and quantity, the development, testing, clinical trials, and if approved, commercial supply, of that product candidate may be delayed or infeasible, and regulatory approval, commercial launch or commercial supply of any resulting product may be delayed or not received, which could significantly harm our business.We will need to continue to grow our organization in certain areas, including our personnel, systems and relationships with third parties, in order to develop our product candidates, and we may experience difficulties in managing this growth.As our clinical development plans and commercialization strategies continue to develop and expand, we expect we will need to hire additional managerial, clinical development, scientific, regulatory, commercial, and administrative personnel. Our ability to compete in the highly competitive biotechnology industry depends upon our ability to attract and retain highly qualified specialized personnel. As apitegromab approaches commercialization, we will also need to hire sales, marketing and other commercial personnel. Future growth would impose significant added responsibilities on members of management, including:â—identifying, recruiting, integrating, maintaining and motivating additional employees;â—managing our development efforts effectively, including the clinical and regulatory review process for apitegromab, SRK-181, SRK-439, and any future product candidates, while complying with our contractual obligations to contractors and other third parties; andâ—improving our operational, financial and management controls, reporting systems and procedures.Our future financial performance and our ability to commercialize apitegromab, SRK-181, SRK-439 and future product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.47 Table of ContentsWe currently rely, and for the foreseeable future will continue to rely, in substantial part on third parties, advisors and consultants to provide certain services, including CROs, contract manufacturers and companies focused on antibody development and discovery activities. There can be no assurance that the services of third parties, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality, accuracy or quantity of the services provided is compromised for any reason, our preclinical studies and clinical trials may be extended, delayed or terminated, and we may not be able to receive, or may be substantially delayed in receiving, regulatory approval of apitegromab, SRK-181, SRK-439 or future product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.We may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition for a limited number of qualified personnel in the biopharmaceutical space, especially those engaged in oncology and immuno-oncology and cardiometabolic fields. In this highly competitive market, there may be increased costs to attract and retain qualified personnel. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high quality candidates than what we have to offer. If we are not able to offer competitive compensation or appealing opportunities for high quality candidates, we may not be able to attract or retain qualified candidates and personnel. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize apitegromab, SRK-181, SRK-439 or any future product candidates and, accordingly, may not achieve our research, development and commercialization goals.Our executives and highly skilled technical and managerial personnel are critical to our business. If we have transition in management, lose key personnel, or if we fail to recruit additional highly skilled personnel, our ability to further develop apitegromab, SRK-181 and SRK-439 and identify and develop new or next generation product candidates may be impaired.Our performance substantially depends on the performance of our management team. Any transition or loss of the services of any of our executives or highly skilled technical and managerial personnel could have a disruptive impact on our ability to implement our strategy and impede the achievement of our research, development and commercialization objectives. In addition, these transitions or departures could, cause us to incur increased operating expenses, divert senior management resources in searching for replacements, or otherwise have a material adverse effect on our business, internal controls, financial condition and results of operations. Management transition inherently causes some loss of institutional knowledge, which can negatively affect strategy and operational execution during this phase. If we have additional changes to our executives or highly skilled technical and managerial personnel, we may be unable to successfully manage and grow our business, and our results of operations, execution of corporate goals, internal controls and financial condition could suffer as a result. The unplanned loss of the services of our executives or other personnel also could harm our reputation.Our internal computer systems, or those used by our contract research organizations, or other contractors or consultants, may fail or suffer security breaches, incidents or compromises.We have outsourced significant parts of our IT and business infrastructure to third-party providers, and we currently use these providers to perform business critical IT and business services for us. Despite the implementation of security measures, our computer systems, whether they are managed by us directly or by the third parties with whom we contract, and those of our existing and future CROs, and other contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. Our increased reliance on personnel working from home may increase our cyber security risk, create data accessibility concerns, and make us more susceptible to workforce and communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other agencies and contractors. For example, the loss of preclinical or clinical data could result in delays in our 48 Table of Contentsregulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of apitegromab, SRK-181 and SRK-439 and to conduct preclinical studies and clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of apitegromab, SRK-181, SRK-439 and future product candidates could be delayed.As a company that uses IT systems, our systems may be subject to cyber-attacks, incidents or compromises. Due to the nature of some of these attacks, there is a risk that they may remain undetected for a period of time. While we have invested in the protection of data and information technology, our efforts may not prevent service interruptions or security breaches (e.g., ransomware attacks). We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business, or reputational losses, including regulatory fines, that may result from an interruption or breach of our systems.Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws and regulations of the FDA, EU Member States, EMA and other similar foreign regulatory bodies; provide true, complete and accurate information to the FDA, EMA and other similar foreign regulatory bodies; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we receive FDA approval of apitegromab, SRK-181, SRK-439 or any future product candidates and begin commercializing those products in the U.S., our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by our employees, independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of civil, criminal and administrative penalties, damages, monetary fines, individual imprisonment, disgorgement, possible exclusion from participation in government healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and the curtailment of our operations, any of which could adversely affect our ability to operate our business, financial condition and results of operations.Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations. Changes in statutes, regulations or the interpretation of existing statutes or regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; (iv) additional record-keeping requirements; or (v) changes to our pricing arrangements, or coverage of or reimbursement for our products. If any such changes were to be imposed, they could adversely affect the profitability and operation of our business. See the sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled, â€œBusiness â€” Government Regulation â€” Current and Future Healthcare Reform Legislationâ€ and â€œBusiness â€” Government Regulation â€” Coverage and Reimbursement.â€It is possible that the ACA, as currently enacted or as it may be amended or otherwise modified in the future, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare or other healthcare funding, more rigorous coverage criteria, or new payment methodologies or otherwise affect the prices 49 Table of Contentswe may obtain for any of our product candidates for which we may receive regulatory approval. Any reduction in reimbursement from Medicare or other government programs may result in a

similar reduction in payments from commercial payors. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be modified or invalidated. The continuing health care reform initiatives efforts of the government, insurance companies, managed care organizations and other payers of health care services to contain or reduce costs of health care may adversely affect the demand for any product candidates for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability; and the level of taxes that we are required to pay.Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.Healthcare providers, physicians and third-party payors in the U.S. and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information received in the course of patient recruitment for clinical trials. See the section in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled â€œBusiness â€“ Government Regulation â€“ Other Healthcare Laws.â€ It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical manufacturer to incur significant legal expenses and divert managementâ€™s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.Failure to comply with health care privacy and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.We, our CROs, and any potential collaborators may be subject to strict and changing federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security) and policies and contractual obligations related to data privacy and security. In the U.S., numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our CROs and collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 (â€œHIPAAâ€), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009. Depending on the facts and circumstances, we could be subject to civil, criminal, and administrative penalties if we knowingly obtain, use, or 50 Table of Contentsdisclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individualsâ€™ privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.We have conducted our Phase 2 TOPAZ clinical trial of apitegromab in the European Economic Area (â€œEEAâ€), are conducting our Phase 3 SAPPHIRE clinical trial and ONYX, our long-term extension clinical trial of apitegromab, in the EEA and the UK, and may conduct future clinical trials in the EEA or the UK and therefore may be subject to additional privacy laws. The EU General Data Protection Regulation (the â€œEU GDPRâ€) imposes a broad range of strict requirements on companies subject to the EU GDPR, including requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside the EEA or the UK, including to the U.S., providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individualsâ€™ requests to exercise their rights in respect of their personal information, where required reporting security breaches involving personal data to the competent national data protection authority and affected individuals, where required, appointing data protection officers, where required conducting data protection impact assessments, and record-keeping. The EU GDPR imposes penalties in the event of non-compliance, including fines of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to 20,000,000 Euros or up to 4% of our total worldwide annual turnover for more serious offenses. The EU GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the EU GDPR. The EU GDPR ceased to apply in the UK after the UKâ€™s exit from the EU on January 31, 2020, but the UK incorporated the EU GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law (â€œ the UK GDPRâ€). The UK GDPR and the UK Data Protection Act 2018 set out the UKâ€™s data protection regime, which is independent from but currently still aligned to the EUâ€™s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to Â£17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the EUâ€™s GDPR, the UK is recognized as providing adequate protection under the EU GDPR (â€œUK Adequacy Decisionâ€) and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Likewise, personal data transfers from the UK to the EEA remain free flowing. The UK Government has introduced a Data Protection and Digital Information Bill (â€œUK Billâ€) into the UK legislative process. The aim of the UK Bill is to reform the UKâ€™s data protection regime following Brexit. If passed, the final version of the UK Bill may have the effect of further altering the similarities between the UK and EEA data protection regime and threaten the UK Adequacy Decision from the EC. This may lead to additional compliance costs and could increase our overall risk. The respective provisions and enforcement of the EU GDPR and UK GDPR may further diverge in the future and create additional regulatory challenges and uncertainties.Adequate safeguards must be implemented to enable the transfer of personal data outside of the EEA or the UK in compliance with European and UK data protection laws. The EC has issued forms of standard contractual clauses (â€œSCCsâ€) for data transfers from controllers or processors in the EEA (or otherwise subject to the EU GDPR) to controllers or processors established outside the EEA (and not subject to the EU GDPR). The UK is not subject to the ECâ€™s SCCs but has published its own standard clauses, the International Data Transfer Agreement, which enables transfers from the UK. We will be required to implement these new safeguards when conducting restricted data transfers under the EU GDPR and UK GDPR and doing so will require significant effort and cost. Where relying on the SCCs or 51 Table of ContentsUK IDTA for data transfers, we may also be required to carry out transfer impact assessments to assess whether the recipient is subject to local laws which allow public authority access to personal data.In July 2023, the EC adopted its adequacy decision for the EU-U.S. Data Privacy Framework (â€œFrameworkâ€). On the basis of the new adequacy decision, personal data can flow safely from the EU to U.S. companies participating in the Framework, without having to put in place additional data protection safeguards. There has been an extension to the Framework to cover UK transfers to the United States. The long term validity of the Framework remains uncertain as the Framework could be challenged like its predecessor frameworks.The EU GDPR and UK GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the EU GDPR and UK GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the EU GDPR and UK GDPR, including as implemented by individual countries. Given the new law, we face uncertainty as to the exact interpretation of the new requirements and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the law. Compliance with the EU GDPR and UK GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. EU Member States have adopted implementing national laws to implement the EU GDPR which may partially deviate from the EU GDPR and the competent authorities in the EU Member States may interpret EU GDPR obligations slightly differently from country to country, so that we do not expect to operate in a uniform legal landscape in the EU. Also, as it relates to processing and transfer of genetic data, the EU GDPR specifically allows national laws to impose additional and more specific requirements or restrictions, and European laws have historically differed quite substantially in this field, leading to additional uncertainty.We expect that we will continue to face uncertainty as to whether our efforts to comply with our obligations under European privacy laws will be sufficient. If we are investigated by a European or UK data protection authority, we may face fines and other penalties. Any such investigation or charges by European or UK data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or pharmaceutical partners. We may also experience hesitancy, reluctance, or refusal by European or multi-national clients or pharmaceutical partners to continue to use our products and solutions due to the potential risk exposure as a result of the current (and, in particular, future) data protection obligations imposed on them by certain data protection authorities in interpretation of current law, including the EU GDPR and UK GDPR. Such clients or pharmaceutical partners may also view any alternative approaches to compliance as being too costly, too burdensome, too legally uncertain, or otherwise objectionable and therefore decide not to do business with us. Any of the foregoing could materially harm our business, prospects, financial condition and results of operations.In addition, many states in which we operate have laws that protect the privacy and security of sensitive and personal information. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. Where state laws are more protective than HIPAA, we must comply with the state laws we are subject to, in addition to HIPAA. In certain cases, it may be necessary to modify our planned operations and procedures to comply with these more stringent state laws. Further, in some cases where we process sensitive and personal information of individuals from numerous states, we may find it necessary to comply with the most stringent state laws applicable to any of the information. For example, Californiaâ€™s California Consumer Privacy Act (â€œCCPAâ€), creates comprehensive individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. While there are currently exceptions for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA, as amended by the California Privacy Rights Act, and other enacted or proposed comprehensive state consumer privacy legislation may impact our business activities. We continue to monitor the impact that the state consumer privacy and protection laws, like the CCPA, may have on our business activities. See the section in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled â€œBusiness â€“ Government Regulation â€“ European General Data Protection Regulation and â€œBusiness â€“ Government Regulation â€“ Other Healthcare and Privacy Laws.â€52 Table of ContentsArtificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data.The potential use of new and evolving technologies, such as artificial intelligence, in our offerings to employees may result in additional spending and present risks and challenges that can impact our business including by posing security and other risks to our confidential information, proprietary information and personal information, and as a result we may be exposed to reputational harm, legal liability, and regulatory investigations and fines.We may build and integrate artificial intelligence into our offerings, and this innovation may present risks and challenges that could affect its adoption, and therefore our business. If we enable or offer solutions that draw controversy due to perceived or actual negative societal impact, we may experience brand or reputational harm, competitive harm or legal liability. The use of certain artificial intelligence technology can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement, for example where third party data sources are used to train artificial intelligence models, or the output of artificial intelligence systems reproduce or incorporate third party intellectual property rights, in each case without the right to do so. Additionally, we expect to see increasing government and supranational regulation related to artificial intelligence use and ethics, which may also significantly increase the burden and cost of research, development and compliance in this area. For example, the EUâ€™s Artificial Intelligence Act (â€œAI Actâ€) â€“ the worldâ€™s first comprehensive AI law â€“ is anticipated to enter into force in Summer 2024 and, with some exceptions, become effective 24 months thereafter. This legislation imposes tiered obligations on providers and deployers of artificial intelligence systems which are put onto the EU market, or where the output is intended for use in the EU market, depending on the risk classification of the AI system, and encourages providers and deployers of artificial intelligence systems to account for EU fundamental rights in their development and use of these systems. If we develop or use AI systems that are governed by the AI Act, it may necessitate ensuring higher standards of data quality, transparency, and human oversight, and if the AI systems are considered high risk, we would be required to implement substantive risk and quality management systems and post-market monitoring systems and adhere to specific and burdensome and costly ethical, accountability, and administrative requirements. Other jurisdictions, including the United States and UK, are also taking steps to regulate AI systems. The rapid evolution of artificial intelligence will require the application of significant resources to design, develop, test and maintain our service offerings to help ensure that artificial intelligence is implemented in accordance with applicable law and regulation and in a socially responsible, safe and ethical manner and to minimize any real or perceived unintended harmful impacts. Our vendors may in turn incorporate artificial intelligence tools into their own offerings, and the providers of these artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business. A risk of our proprietary intellectual property rights being compromised through the use of artificial intelligence could arise through third party vendors using our data to train their models and/or to generate output for other users of their systems. There is also a risk (as with any hosted service) of security incidents occurring that could lead to unauthorized access to our data. In the event that personal data (including special category data relating to patients) were to be compromised, we may also face action from regulators and affected data subjects, and damage to our reputation.53 Table of ContentsAdditional laws and regulations governing international operations, including certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, could negatively impact or restrict our operations.If we further expand our operations outside of the U.S., we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act (â€œFCPAâ€) prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper

payments to government officials and have led to FCPA enforcement actions.Various laws, regulations and executive orders also restrict the use and dissemination outside of the U.S., or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the U.S., it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the U.S., which could limit our growth potential and increase our development costs.The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPAâ€™s accounting provisions.If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.Although we maintain workersâ€™ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities, and as a result, may be subject to lengthy and expensive litigation 54 Table of Contentsand excessive damages and we may not have, or be able to obtain, sufficient capital to pay such amounts. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.We face an inherent risk of product liability as a result of testing apitegromab, SRK-181, SRK-439 and any of our future product candidates in clinical trials and will face an even greater risk if we commercialize any products, if approved. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:â—inability to bring a product candidate to the market;â—decreased demand for our products;â—injury to our reputation;â—withdrawal of clinical trial participants and inability to continue clinical trials;â—initiation of investigations by regulators;â—costs to defend the related litigation;â—diversion of managementâ€™s time and our resources;â—substantial monetary awards to trial participants;â—product recalls, withdrawals or labeling, marketing or promotional restrictions;â—loss of revenue;â—exhaustion of any available insurance and our capital resources;â—the inability to commercialize any product candidate, if approved; andâ—decline in our share price.Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. We may be unable to obtain, or may obtain on unfavorable terms, additional clinical trial insurance in amounts adequate to cover any liabilities from any of our clinical trials. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.55 Table of ContentsInadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agenciesâ€™ operations, could prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.Our current laboratory operations are concentrated in one location, and we or the third parties upon whom we depend, including our clinical trial sites and the manufacturing facilities of our third-party contract manufacturers, may experience business interruptions and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster, including earthquakes, outbreak of disease or other natural disasters.Our office and laboratory facilities are located in Cambridge, Massachusetts. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, the facilities at any clinical trial site, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of apitegromab, SRK-181, SRK-439 and future product candidates or interruption of our business operations. If a natural disaster, outbreak of disease, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities, our clinical trial sites or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time.Global events, including global health concerns could also result in social, economic, and labor instability in the countries in which we operate or where the third parties with whom we engage, including our clinical trial sites and manufacturing facilities of our third-party contract manufacturers, operate. Unforeseen global events, such as increasing rates of inflation and interest, could adversely impact our business. For example, we are conducting SAPPHIRE, our Phase 3 clinical trial and, ONYX, our long-term extension clinical trial of apitegromab in the U.S. and EU, and regional instability caused by the 2022 Russian invasion of Ukraine could adversely affect the conduct of our clinical trials. Such conflicts could lead to sanctions, embargoes, supply shortages, regional instability, geopolitical shifts, cyberattacks, other retaliatory actions, and adverse effects on macroeconomic conditions, currency exchange rates, and financial markets, which could adversely impact our operations and financial results, as well as those of third parties with whom we conduct business.The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at our facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, the manufacturing facilities of our third-party contract manufacturers, or the sites where we conduct clinical trials or preclinical studies, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, our research and development programs may be harmed. Any business 56 Table of Contentsinterruption may have a material and adverse effect on our business, financial condition, results of operations and prospects.Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.The success of our product candidates, apitegromab and SRK-181, and future product candidates such as SRK-439, if approved, depends on the availability of coverage and adequate reimbursement from third-party payors. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, apitegromab, SRK-181, SRK-439 or future product candidates or assure that coverage and reimbursement will be available for any product that we may develop. See the sections in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled â€œBusinessâ€ Government Regulation â€” Coverage and Reimbursementâ€ and â€œBusinessâ€”Government Regulationâ€”Current and Future Healthcare Reform Legislation.â€Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid or national payor bodies (such as in European countries), and commercial payors is critical to new product acceptance.Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payorâ€™s determination that use of a product is:â—a covered benefit under its health plan;â—safe, effective and medically necessary;â—appropriate for the specific patient;â—cost-effective; andâ—neither experimental nor investigational.In the U.S., no uniform policy of coverage and reimbursement for products exists among third party payors, Coverage and reimbursement for products can differ significantly from payor to payor. One payorâ€™s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. Coverage and reimbursement for products may vary widely across national payors from country to country.Payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain and maintain coverage and reimbursement for any product, we may need to conduct expensive evidence generation studies in order to demonstrate the medical necessity and cost-effectiveness of such a product, in addition to the costs required to obtain regulatory approvals. If payors do not consider a product to be cost-effective compared to current standards of care, they may not cover the product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to cover its costs or make a profit. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of product candidates. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.57 Table of ContentsPayment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. Additional state and federal healthcare reform measures are expected to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures.Moreover, increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European Member States.We intend to seek approval to market our product candidates in both the U.S. and in selected foreign jurisdictions. If we receive approval in one or more foreign jurisdictions for apitegromab, SRK-181, SRK-439 or future product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of medicinal products is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after receiving marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future health care reform measures.Much like the federal Anti-Kickback Statute prohibition in the U.S., the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-inducement, advertising and anti-bribery laws of EU Member States. Infringement of these laws could result in substantial fines and imprisonment.Payments made to physicians in certain EU Member States must be disclosed publicly. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physicianâ€™s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.In addition, in most foreign countries, including several EU Member States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced Member States, can further reduce prices. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price 58 Table of Contentscontrols or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of any of our product candidates in those countries would be negatively affected.We may seek to enter into collaborations in the future with third parties, including for apitegromab, SRK-181, SRK-439 or potential product candidates. If

we are unable to enter into such collaborations, or if these collaborations are not successful, our business could be adversely affected. A part of our strategy is to evaluate and, as deemed appropriate, enter into additional collaborations or partnerships in the future when strategically attractive, including potentially with biotechnology or pharmaceutical companies. We have limited capabilities for product development and only recently have begun to build our capabilities to prepare for potential commercialization. Accordingly, we may enter into collaborations with other companies to provide us with important technologies, capabilities and funding for our programs and underlying technology. Any future collaboration we enter into may pose a number of risks, including the following: â—collaborators may have significant discretion or decision-making authority in determining the efforts and resources that they will apply to the collaboration or that we are required to apply to the collaboration;â—collaborators may not perform their obligations as expected or in a manner satisfactory to us;â—we may commit to certain preclinical or clinical development or commercialization efforts as part of the collaboration that we are unable to meet or our collaborators may not be satisfied with our preclinical or clinical development or commercialization efforts;â—collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaboratorsâ€™ strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities;â—collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;â—collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;â—product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;â—collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;â—collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;59 Table of Contentsâ—disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;â—collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;â—collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;â—if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us;â—collaborations may be terminated by the collaborator, and, if terminated, we may be blocked to advance the program due to collaborator patents that are not licensed to us; andâ—collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.If our future collaborations do not result in the successful discovery, development and commercialization of product candidates or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this Quarterly Report on Form 10-Q also apply to the activities of potential therapeutic collaborators. Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the biotechnology or pharmaceutical industry, including within the business and financial communities, could be adversely affected. We face significant competition in seeking appropriate partners for our product candidates, and the negotiation process is time-consuming and complex. In order for us to successfully partner our product candidates, potential partners must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaboratorâ€™s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaboratorâ€™s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations or do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates, bring them to market and generate revenue from sales of drugs or continue to develop our technology, and our business may be materially and adversely affected. Even if we are successful in our efforts to establish new strategic collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. Any delay in entering into new strategic collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.60 Table of ContentsRisks Related to Our Intellectual PropertyOur success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected. The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. Unforeseen global events, and sanctions or actions relating to such events, could affect our ability to file, prosecute, maintain, and/or defend patents and applications in those markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the U.S. and/or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. For example, Russia issued a decree in March of 2022, stating that patent owners who reside in a country â€œunfriendlyâ€ to Russia are not entitled to compensation in the event of patent infringement. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property and/or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, a competitorâ€™s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights, or will design around the claims of patents that we have had issued that cover our products. In addition, periodic maintenance fees on any issued patent are due to be paid to the U.S. Patent Office (â€œUSPTOâ€) and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during 61 Table of Contentsthe patent application process and following the issuance of a patent. While an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Moreover, complications due to global pandemics may result in inadvertent lapse due to, for example, unexpected closures of the USPTO or foreign patent offices, delays in delivery of notifications relating to deadlines, or failure to timely and/or properly obtain signatures on necessary documents. Additionally, due to the ongoing conflict in Ukraine, there remain uncertainties as to any potential impact on patent protection and/or enforcement in the region, including, for example, payments to the Russian Patent Office and other entities. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:â—it is possible that our pending patent applications will not result in issued patents;â—we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions;â—the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates;â—it is possible that there are prior public disclosures that could invalidate our or our licensorsâ€™ patents, as the case may be, or parts of our or their patents;â—our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties;â—we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights;â—the laws of foreign countries may not protect our or our licensorsâ€™, as the case may be, proprietary rights to the same extent as the laws of the U.S.;â—the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors;â—it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;â—others may be able to make or use compounds or cells that are similar to the biological compositions of our product candidates but that are not covered by the claims of our patents;â—others may independently develop similar or alternative technologies or duplicate any of our technologies;â—it is possible that others may circumvent our owned or in-licensed patents;â—the active biological ingredients in our current product candidates will eventually become commercially available in biosimilar drug products, and no patent protection may be available with regard to formulation or method of use;62 Table of Contentsâ—we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents;â—we may not develop additional proprietary technologies for which we can obtain patent protection;â—it is possible that product candidates or diagnostic tests we develop may be covered by third partiesâ€™ patents or other exclusive rights; â—it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours; and/orâ—the patents of others may have an adverse effect on our business.Our current patents covering our proprietary technologies and our product candidates are expected to expire beginning in 2034, without taking into account any possible patent term adjustments or extensions. Our earliest patents may expire before, or soon after, our first product achieves marketing approval in the U.S. or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a material adverse effect on our business, results of operations, financial condition and prospects. We own pending patent applications covering our proprietary technologies or our product candidates that if issued as patents are expected to expire from 2034 through 2045, without taking into account any possible patent term adjustments or extensions. However, we cannot be assured that the USPTO or relevant foreign patent offices will grant any of these patent applications.We depend on intellectual property licensed from third parties. Failure to comply with our obligations under any of these licenses or termination of any of these licenses could result in the loss of significant rights, which would harm our business.We are dependent on patents, know-how and proprietary technology, including intellectual property rights licensed from others. We may be a party to license agreements pursuant to which we in-license key patents and patent applications for our product candidates. These licenses impose various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate the license. Any termination of licenses by third parties could result in our loss of significant intellectual property rights and could harm our ability to commercialize our product candidates.We may have limited control over the maintenance and prosecution of these in-licensed patents and patent applications, activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the licensorsâ€™ infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves.Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:â—the scope of rights granted under the license agreement and other interpretation related issues;â—whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;â—our right to sublicense patent and other rights to third parties under collaborative development relationships; andâ—the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.63 Table of ContentsIf disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.Because our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights.Our product candidates may also require specific formulations to work effectively and efficiently, and these rights may be held by others. We may develop products containing our compounds and pre-existing pharmaceutical compounds. We may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates. These diagnostic test or tests may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify

as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institutionâ€™s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.The licensing or acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.Changes in patent law in the U.S. and in ex-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act (the â€œAmerica Invents Actâ€), enacted in 2013, the U.S. moved from a â€œfirst to inventâ€ to a â€œfirst to fileâ€ system. Under a â€œfirst to fileâ€ system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. 64 Table of Contentspatent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO only recently developed new regulations and procedures in connection with the America Invents Act, and many of the substantive changes to patent law, including the â€œfirst to fileâ€ provisions, only became effective in March 2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. Recent U.S. Supreme Court rulings have also narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. As a consequence, issued patents may be found to contain invalid claims according to the newly revised eligibility and validity standards. Additionally, some of our owned or in-licensed patents may be subject to challenge and subsequent invalidation or significant narrowing of claim scope in proceedings before the USPTO, or during litigation, under the revised criteria which could also make it more difficult to obtain patents.Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the case Amgen Inc. v. Sanofi, the Federal Circuit held that a well characterized antigen is insufficient to satisfy the written description requirement of certain claims directed to a genus of antibodies that are solely defined by function. While the validity of a subset of patents at issue was subsequently upheld by a district court jury, uncertainty remains as to the legal question pertaining to the written description requirement under 35 USC Â§112 as it relates to functional antibodies. In the case of Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. We cannot predict how these decisions or any future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Similarly, any adverse changes in the patent laws of other jurisdictions could have a material adverse effect on our business and financial condition. For example, Russia issued a decree in March of 2022, stating that patent owners who reside in a country â€œunfriendlyâ€ to Russia are not entitled to compensation in the event of patent infringement.Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post-grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods.If a third-party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:â—infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our managementâ€™s attention from our core business;65 Table of Contentsâ—substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third-partyâ€™s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent ownerâ€™s attorneysâ€™ fees;â—a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do;â—if a license is available from a third-party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products; andâ—redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting clinical trials and other development activities in the U.S. is protected under the Safe Harbor exemption as set forth in 35 U.S.C. Â§ 271. If and when apitegromab, SRK-181, or another one of our product candidates is approved by the FDA, that certain third-party may then seek to enforce its patent by filing a patent infringement lawsuit against us. While we are not aware of any claims of such a patent that could otherwise materially adversely affect commercialization of our product candidates, we may be incorrect in this belief, or we may not be able to prove it in a litigation. In this regard, patents issued in the U.S. by law enjoy a presumption of validity that can be rebutted only with evidence that is â€œclear and convincing,â€ a heightened standard of proof. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms, or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneysâ€™ fees for willful infringement, obtain one or more licenses from third parties, and/or pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain 66 Table of Contentslicenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.We may also choose to challenge the patentability of claims in a third-partyâ€™s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-exam, inter partes review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge the grant of a third-partyâ€™s patent in opposition proceedings in the European Patent Office (â€œEPOâ€) or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office, then we may be exposed to litigation by a third-party alleging that the patent may be infringed by our product candidates or proprietary technologies.Additionally, the Unified Patent/Unified Patent Court system in Europe became fully operational in June 2023.â—The new court may be associated with greater degrees of uncertainty in litigation, with respect to both planning and outcome. â—The opt-out selection afforded during the transition may have a direct impact on future litigation and may result in loss of certain flexibility with regard to choice of forum and other litigation strategy considerations.We may incur substantial costs as a result of litigation or other proceedings relating to our patents or the patents of our licensors, and we may be unable to protect our rights to our products and technology. Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims against a third party(ies), which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. There is also the risk that, even if the validity of our patents or the patents of our licensors is upheld, the court will refuse to stop the third-party on the ground that such third-partyâ€™s activities do not infringe our owned or in-licensed patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. In some situations, we or our licensor, may not be able to detect infringement against our owned or in-licensed patents, as the case may be, which may be especially difficult for manufacturing processes or formulation patents. Even if we or our licensors detect infringement by a third-party of our owned or in-licensed patents, we or our licensors, as the case may be, may choose not to pursue litigation against or settlement with the third-party. If we, or our licensors, later sue such third-party for patent infringement, the third-party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us or our licensors to enforce our owned or in-licensed patents, as the case may be, against such third-party.Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.If we or one of our licensing partners initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or 67 Table of Contentsunenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include inter parties review, ex parte re-examination, post-grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). For example, EP3368069 and EP2981822 are currently subject to opposition proceedings. Such proceedings are expensive and could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.In addition, because some patent applications in the U.S. may be maintained in secrecy until the patents are issued, because patent applications in PCT member jurisdictions are typically not published until 18 months after the earliest filing, and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and in-licensed issued patents or our pending applications, or that we or, if applicable, a licensor were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products, compositions, methods of use, or technology similar to ours. Any such patent application may have priority over our owned and in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to those owned by or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the U.S. If we or one of our licensors is a party to an interference proceeding involving a U.S. patent application on inventions owned by or in-licensed to us, we may incur substantial costs, divert managementâ€™s time and expend other resources, even if we are successful.For applications filed under pre-AIA, interference proceedings declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a

decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the U.S.We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.We have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Indeed, Russia issued a decree in March of 2022, stating that patent owners who reside in a country â€œunfriendlyâ€ to Russia are not entitled to compensation in the event of patent infringement. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the U.S. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to 68 Table of Contentsbiopharmaceutical products and/or methods of medical treatment, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.As another example, in Europe, a new unitary patent system became effective in June 2023, which may significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (â€œUPCâ€). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Subject to current transitional provisions, European patents have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC are potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.Patent terms may result in inadequate protection for our product candidates, and we may be unable to obtain patent term extensions and data exclusivity for our product candidates, resulting in material harm to our business.Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited. Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, also known as the Hatch Waxman Amendments. The Hatch Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. The patent term restoration period is generally one-half of the time between the effective date of the IND or the date of patent grant (whichever is later) and the date of submission of the BLA, plus the time between the date of submission of the BLA and the date of FDA approval of the product. The patent holder must apply for restoration within 60 days of approval. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. We may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. Given the amount of time required for the development, testing and regulatory review of new product candidates, the patents protecting our product candidates might expire before or shortly after such candidates are commercialized. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours, which could materially harm our business, financial condition, results of operations, and prospects.If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.In addition to patent protection, we rely heavily upon know-how and trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third parties, to protect our 69 Table of Contentsconfidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third-party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.In addition, courts outside the U.S. are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the partyâ€™s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. We have also adopted policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets.Third parties may assert that our employees or consultants have wrongfully used, disclosed, or misappropriated their confidential information or trade secrets.As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, and although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.70 Table of ContentsIf our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.Risks Related to Our Financial Condition and Capital RequirementsWe have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.We are a biopharmaceutical company formed in 2012 and our operations to date have been focused on research and development of monoclonal antibodies that selectively inhibit activation of growth factors for therapeutic effect. We have not yet demonstrated the ability to progress any of our product candidates through clinical trials, we have no products approved for commercial sale and we have not generated any revenue from product sales to date. We continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. For the six months ended June 30, 2024 and 2023, we reported a net loss of $115.4 million and $77.3 million, respectively. We have incurred losses since our inception, and as of June 30, 2024, we had an accumulated deficit of $791.8 million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, apitegromab, SRK-181, SRK-439, and any future product candidates.To become and remain profitable, we or any current or potential future collaborators must develop and eventually commercialize products with significant market potential and favorable pricing. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, receiving marketing approval for product candidates, manufacturing, marketing and selling products for which we may receive marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholdersâ€™ equity and working capital.We will require additional capital to fund our operations and if we fail to obtain necessary capital, we will not be able to complete the development and commercialization of apitegromab, SRK-181, SRK-439 and any future product candidates.Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts of cash to conduct further research and development, including clinical trials for apitegromab and SRK-181 and preclinical studies and clinical trials for SRK-439 and any future product candidates, to seek regulatory approvals for our product candidates and to launch and commercialize any products for which we receive regulatory approval. As of June 30, 2024, we had approximately $190.5 million in cash, cash equivalents and marketable securities. Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities as of June 30, 2024, will be sufficient to fund our operating expenses and capital expenditure requirements into the second half of 2025. However, our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and we will in any event require additional capital in order to complete clinical 71 Table of Contentsdevelopment of any of our current programs. Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. Additionally, any program setbacks or delays due to changes in federal or state laws or clinical site or clinical vendor policies as a result of the impacts of current macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates could impact our programs and increase our expenditures. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:â—the initiation, progress, timing, completion, costs and results of clinical trials for apitegromab and SRK-181 and preclinical studies and clinical trials for SRK-439 and any future product candidates;â—the clinical development plans we establish for our product candidates;â—the number and characteristics of product candidates that we identify and develop;â—the terms of any collaboration, strategic alliance, or licensing agreements we are currently party to or may choose to enter into in the future;â—the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA, and other comparable foreign regulatory authorities;â—the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;â—the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;â—the effect of competing technological and market developments;â—the cost and timing of developing research cell lines and development and completion of commercial scale outsourced manufacturing activities; â—the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those of our manufacturers, suppliers, or other vendors resulting from pandemics or similar public health crisis or macroeconomic conditions; andâ—the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own.We do not have any committed external source of funds or other support for our development efforts. Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholdersâ€™ rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also could be required to seek collaborators for apitegromab, SRK-181, SRK-439 or any future product candidate at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of apitegromab, SRK-181, SRK-439 or one or more of our future product

candidates or other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.72 Table of ContentsBased on current operating plans, we may not have sufficient cash, cash equivalents and marketable securities to fund our operating expenses and capital requirements beyond one year from the issuance of these consolidated financial statements, without receiving additional external financing and, therefore, we may not be able to continue as a going concern.Since inception, we have incurred significant net losses and may continue to incur net losses in the future. As of June 30, 2024, we had an accumulated deficit of $791.8 million. During the six months ended June 30, 2024, we recorded a net loss of $115.4 million. In addition, during the six months ended June 30, 2024 we used $99.0 million in operating activities resulting in a cash, cash equivalents and marketable securities balance of $190.5 million as of June 30, 2024. Based on current operating plans, we may not have sufficient cash, cash equivalents and marketable securities to fund our operating expenses and capital requirements beyond one year from the issuance of these consolidated financial statements without receiving additional external financing. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to grant rights to develop and market our product candidates that we would otherwise prefer to develop and market ourselves or agree to terms less favorable than what we would otherwise prefer. We may also be required to delay, limit, reduce or terminate our product development or future commercialization.If we do not obtain additional capital from external sources, we will not have sufficient working capital to fund our planned operations beyond one year of the issuance of these consolidated financial statements and may not be able to continue as a going concern.Changes in tax law could adversely affect our business and financial condition.The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. For example, under Section 174 of the Code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development in the U.S. will be capitalized and amortized, which may have an adverse effect on our cash flow. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. It cannot be predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our shareholdersâ€™ tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation.As of December 31, 2023, we had net operating loss carryforwards for federal and state income tax purposes of $403.2 million and $402.8 million, respectively, which begin to expire in 2032, except for our post 2017 federal net operating loss carryforwards of $352.7 million which do not expire. As of December 31, 2023, we also had available tax credit carryforwards for federal and state income tax purposes of $40.8 million and $6.1 million, respectively, which begin to expire in 2034 and 2024, respectively. Additionally, for taxable years beginning after December 31, 2017 the deductibility of the indefinite lived federal net operating losses is limited to 80% of our taxable income in any future taxable year. Under Section 382 of the Internal Revenue Code of 1986, as amended (the â€œCodeâ€), changes in our ownership may limit the amount of our net operating loss carryforwards and tax credit carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50% within a three-year period. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit carryforwards before they expire. Private placements and other transactions that have occurred since our inception, as well as our IPO, may trigger such an ownership change pursuant to Section 382 of the Code. Any such limitation, whether as the result of our IPO, 73 Table of Contentsprior private placements, sales of our common stock by our existing stockholders or additional sales of our common stock by us, could have a material adverse effect on our results of operations in future years. Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Since then, additional financial institutions have experienced similar failures and have been placed into receivership. Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program. Additionally, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the Company, the financial institutions with which the Company has credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which the Company has financial or business relationships, but could also include factors involving financial markets or the financial services industry generally. The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following:â—delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;â—delayed or lost access to, or reductions in borrowings available under our existing debt facility; orâ—potential or actual breach of contractual obligations that require the Company to maintain certain financial accounts at specific financial institutions.In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.74 Table of ContentsIn addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by our suppliers, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, a supplier could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on us, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. Any supplier bankruptcy or insolvency, or any breach or default by a supplier, or the loss of any significant supplier relationships, could result in material losses to us and may have a material adverse impact on our business.Our current investment policy focuses on preservation of capital. However, we could recognize losses on securities held in our investment portfolio, particularly if interest rates increase or economic and market conditions deteriorate. As of June 30, 2024, the fair value of our cash equivalents and investments in our marketable debt securities portfolio was approximately $186.1 million and consisted primarily of investments in money market funds and U.S. treasury obligations and government agency securities. Factors beyond our control can significantly influence the fair value of securities in our portfolio and can cause potential adverse changes to the fair value of these securities. For example, fixed-rate securities acquired by us are generally subject to decreases in market value when interest rates rise. Additional factors include, but are not limited to, rating agency downgrades of the securities or our own analysis of the value of the security, defaults by the issuer with respect to the underlying securities, and continued instability in the credit markets. Any of the foregoing factors could cause other-than-temporary impairment in future periods and result in realized losses. The process for determining whether impairment is other-than-temporary usually requires difficult, subjective judgments about the future financial performance of the issuer and any collateral underlying the security in order to assess the probability of receiving all contractual principal and interest payments on the security.At June 30, 2024, we had $0.1 million in net unrealized losses in our marketable securities available-for-sale portfolio, and unrealized losses in our securities portfolio may increase in the future due to the aforementioned economic factors. While our goal is to hold each security until maturity, that may not be possible in light of our policy to preserve capital and liquidity and because investment in securities with unrealized losses has a diminished utility as a source of liquidity prior to maturity. Selling securities with an unrealized loss would result in the realization of such losses, which could have an adverse effect on our financial condition and results of operations.Risks Related to Our Common StockThe price of our stock is volatile, and you could lose all or part of your investment.Similar to the trading prices of the common stock of other biopharmaceutical companies, the trading price of our common stock is subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this â€œRisk Factorsâ€ section and elsewhere in this Quarterly Report on Form 10-Q, these factors include:â—announcements of significant acquisitions, strategic collaborations or partnerships, joint ventures or capital commitments by us, our collaborators or our competitors;â—actual or anticipated variations in quarterly operating results or our cash position;â—our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;â—changes in accounting practices; andâ—significant lawsuits, including patent or stockholder litigation.In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a companyâ€™s securities. This type of litigation, if 75 Table of Contentsinstituted, could result in substantial costs and a diversion of managementâ€™s attention and resources, which would harm our business, operating results or financial condition.We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, our ability to pay cash dividends is currently restricted by the terms of our debt facility with Oxford and SVB, and future debt or other financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.Our Board members, management, and their affiliates, own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. As of June 30, 2024, our executive officers, directors and their affiliates beneficially hold, in the aggregate, approximately 14% of our outstanding voting stock. These stockholders, acting together, are able to significantly influence all matters requiring stockholder approval. For example, these stockholders are able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.We are and expect to continue to be a â€œsmaller reporting companyâ€ as defined in the Exchange Act, and have elected and expect to continue to elect to take advantage of certain of the scaled disclosures available to smaller reporting companies, including reduced disclosure obligations regarding executive compensation.While we are no longer an â€œemerging growth companyâ€, we are and expect to continue to be a â€œsmaller reporting companyâ€ as defined in the Exchange Act, and have elected and expect to continue to elect to take advantage of certain of the scaled disclosures available to smaller reporting companies, including reduced disclosure obligations regarding executive compensation. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to audit our internal control over financial reporting for so long as we report less than $100 million in annual revenues for the most recent fiscal year and may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock price may be more volatile. We will remain a smaller reporting company until our public float exceeds $250 million or our annual revenues exceed $100 million with a public float greater than $700 million.â€‹We expect to continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. â€‹As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. These rules and regulations have significantly increased our legal and financial compliance costs and we anticipate that these activities will become more time-consuming and costly over time now that we no longer qualify as an emerging growth company.Pursuant to Section 404 of the Sarbanes-Oxley Act, we will be required to furnish a report by our management on our internal control over financial reporting. Our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act until the date we report at least $100 million in annual revenues and have a public float of at least $75 million for the most recent fiscal year or have a public float of at least $700 million for the most recent fiscal year. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need 76 Table of Contentsto continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction to the trading price of our common stock in the financial markets due to a loss of confidence in the reliability of our financial statements. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are a â€œsmaller reporting companyâ€, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. We will qualify as a â€œsmaller

reporting companyâ€ if the market value of our common stock held by non-affiliates is below $250 million (or $700 million if our annual revenue is less than $100 million) as of June 30 in any given year. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our managementâ€™s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation.We have broad discretion in the use of our existing cash, cash equivalents and marketable securities and may not use them effectively. Our management has broad discretion in the application of our existing cash, cash equivalents and marketable securities. Because of the number and variability of factors that will determine our use of our existing cash and cash equivalents, their ultimate use may vary substantially from their currently intended use. Our management might not apply our existing cash and cash equivalents in ways that ultimately increase the value of your investment. The failure by our management to apply these funds effectively could harm our business. Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:â—a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;â—a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;77 Table of Contentsâ—a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors;â—advance notice requirements for stockholder proposals and nominations for election to our board of directors;â—a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;â—a requirement of approval of not less than two thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our amended and restated certificate of incorporation; andâ—the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock.In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.We may be subject to securities litigation, which is expensive and could divert management attention.The market price of our common stock may be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our managementâ€™s attention from other business concerns, which could seriously harm our business.Our amended and restated bylaws contain certain exclusive forum provisions requiring that substantially all disputes between us and our stockholders be resolved in certain judicial forums, which could limit our stockholdersâ€™ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our bylaws, any action to interpret, apply, enforce, or determine the validity of our amended and restated certificate of incorporation or bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. In addition, our amended and restated bylaws contain a provision by virtue of which, unless we consent in writing to the selection of an alternative forum, the U.S. District Court for the District of Massachusetts will be the exclusive forum for any complaint asserting a cause of action arising under the Securities Act. 78 Table of ContentsIn addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions, however, stockholders cannot and will not be deemed to have waived compliance with federal securities laws and the rules and regulations thereunder. We have chosen the U.S. District Court for the District of Massachusetts as the exclusive forum for such causes of action because our principal executive offices are located in Cambridge, Massachusetts. Some companies that have adopted similar federal district court forum selection provisions are currently subject to a suit in the Court of Chancery of the State of Delaware brought by stockholders who assert that the federal district court forum selection provision is not enforceable. While the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are â€œfacially validâ€ under Delaware law, there is uncertainty as to whether other courts will enforce our federal forum selection provision, and we may incur additional costs of litigation should such enforceability be challenged. If the federal forum selection provision is otherwise found inapplicable to, or unenforceable in respect of, one or more of the specified actions or proceedings, we may incur additional costs, which could have an adverse effect on our business, financial condition or results of operations. We recognize that the federal district court forum selection clause may impose additional litigation costs on stockholders who assert the provision is not enforceable and may impose more general additional litigation costs in pursuing any such claims, particularly if the stockholders do not reside in or near the Commonwealth of Massachusetts. Additionally, the choice of forum provision may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.We have issued a substantial number of warrants and equity awards from our equity plans which are exercisable into shares of our common stock which could result in substantial dilution to the ownership interests of our existing stockholders.As of June 30, 2024, approximately 9,157,496 shares of our common stock were reserved for issuance upon exercise or conversion of outstanding warrants. Additionally, 12,152,215 shares of our common stock were reserved for issuance upon exercise of outstanding stock options and vested restricted stock units. The exercise or conversion of these securities will result in a significant increase in the number of outstanding shares and substantially dilute the ownership interests of our existing stockholders. The shares underlying the equity awards from our equity plans are registered on a Form S-8 registration statement. As a result, upon vesting these shares can be freely exercised and sold in the public market upon issuance, subject to volume limitations applicable to affiliates. The exercise of options and the subsequent sale of the underlying common stock could cause a decline in our stock price. As of June 30, 2024, we also have 17,008,164 shares of our common stock reserved for issuance upon exercise of pre-funded warrants, which are already included in our calculation of our weighted average common shares outstanding. Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.The sales of a substantial number of the shares and/or the exercise and sale of a substantial number of the pre-funded warrants in the public market or the perception that these sales might occur could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. In addition, the sale of substantial amounts of our common stock could adversely impact the price of our common stock. The sale, or the availability for sale, of a large number of shares of our common stock in the public market could cause the price of our common stock to decline. As of June 30, 2024, 10,681,528 of the 27,689,692 pre-funded warrants have been exercised.The sale or issuance of our common stock to, or through, Jefferies may cause significant dilution and the sale of the shares of common stock acquired by Jefferies, or the perception that such sales may occur, could cause the price of our common stock to fall.On November 14, 2022, we entered into a sales agreement with Jefferies LLC (â€œJefferiesâ€), pursuant to which we may offer and sell our common stock, subject to certain limitations in the sales agreement and compliance with applicable law, at any time throughout the term of the sales agreement. The number of shares that are sold by Jefferies after 79 Table of Contentsdelivering a placement notice will fluctuate based on the market price of the common stock during the sales period and limits we set with Jefferies. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued. Sales to, or through, Jefferies by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.From January 1, 2024 through June 30, 2024, we did not sell any shares of common stock through the Jefferies sales agreement.â€‹ItemÂ 2. Unregistered Sales of Equity SecuritiesRecent Sales of Unregistered SecuritiesNone.Issuer Purchases of Equity SecuritiesNone.ItemÂ 3. Defaults Upon Senior SecuritiesNone.ItemÂ 4. Mine Safety DisclosuresNone.ItemÂ 5. Other InformationTrading PlansDuring the three months ended June 30, 2024, certain of our officers adopted contracts, instructions or written plans for the purchase or sale of our securities as noted below: Name and TitleType of Trading ArrangementAction Taken (Date of Action)Duration or End DateAggregate Number of Securities to be SoldDescription of Trading ArrangementJing Marantz, Chief Medical OfficerTrading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c)Adoption (April 19, 2024)August 11, 2025120,000Sale of the Company's common stock pursuant to the terms of the planâ€‹Other than as disclosed above, no other officer or director adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended June 30, 2024.â€‹â€‹80 Table of ContentsItemÂ 6. Exhibits EXHIBITÂ INDEXIncorporated by Reference to:ExhibitNumberÂ DescriptionFormFile No.ExhibitÂ No.Filing Date3.1â€‹Amended and Restated Certificate of Incorporation of the RegistrantS-1/A333-2244933.2May 8, 20183.2â€‹Amendment to Amended and Restated Certificate of Incorporation of the RegistrantS-1/A333-2244933.1.1 May 14, 20183.3â€‹Amendment to Amended and Restated Certificate of Incorporation of the Registrant8-K001-385013.1June 28, 20243.4â€‹Amended and Restated By-laws of the RegistrantS-1/A333-2244933.4May 8, 201810.1*â€‹First Amendment to Lease Agreement, dated May 13, 2024, by and between Scholar Rock, Inc. and BMR-Rogers Street LLC â€‹â€‹â€‹â€‹10.2*â€ â€‹Fourth Amendment to Loan and Security Agreement, dated May 17, 2024, by and among the Registrant, Scholar Rock, Inc., Oxford Finance LLC and Silicon Valley Bank â€‹â€‹â€‹â€‹31.1*Â Certification of Principal Executive Officer Pursuant to RuleÂ 13a-14(a)Â or RuleÂ 15d-14(a)Â of the Securities Exchange Act of 1934â€‹â€‹â€‹â€‹31.2*Â Certification of Principal Financial Officer Pursuant to RuleÂ 13a-14(a)Â or RuleÂ 15d-14(a)Â of the Securities Exchange Act of 1934â€‹â€‹â€‹â€‹32.1**Â Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. SectionÂ 1350, as Adopted Pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002â€‹â€‹â€‹â€‹101.INSâ€‹XBRL Instance Documentâ€‹â€‹â€‹â€‹101.SCHÂ XBRL Taxonomy Extension Schema Documentâ€‹â€‹â€‹â€‹101.CALÂ XBRL Taxonomy Extension Calculation Linkbase Document â€‹â€‹â€‹â€‹101.DEFÂ XBRL Taxonomy Extension Definition Linkbase Documentâ€‹â€‹â€‹â€‹101.LABÂ XBRL Taxonomy Extension Label Linkbase Documentâ€‹â€‹â€‹â€‹101.PREÂ XBRL Taxonomy Extension Presentation Linkbase Documentâ€‹â€‹â€‹â€‹104Â Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)â€‹â€‹â€‹â€‹â€‹*Â Â Â Â Â Â Â Â Filed herewith**Â Â Â Â Â Furnished herewithâ€ Â Â Â Â Â Â Â Portions of this exhibit (indicated by asterisks) were omitted in accordance with the rules of the Securities and Exchange Commission.â€‹â€‹â€‹81 Table of Contentsâ€‹SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.Â SCHOLAR ROCK HOLDING CORPORATIONÂ Â Â â€‹Date: August 8, 2024By:/s/ Jay T. BackstromÂ Â Jay T. BackstromPresident and Chief Executive Officer(Principal Executive Officer)â€‹Date: August 8, 2024By:/s/ Edward H. MylesÂ Â Edward H. MylesChief Operating Officer & Chief Financial Officer(Principal Financial and Accounting Officer)â€‹â€‹â€‹â€‹82 EX-10.1 2 srrk-20240630xex10d1.htm EX-10.1 Exhibit 10.1FIRST AMENDMENT TO LEASETHIS FIRST AMENDMENT TO LEASE (this â€œAmendmentâ€) is entered into as of this13day of May, 2024, by and between BMR-ROGERS STREET LLC, a Delaware limitedliability company (â€œLandlord,â€), and SCHOLAR ROCK, INC., a Delaware corporation (â€œTenantâ€).RECITALSA.WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of November 5, 2019 (as the same may have been amended, supplemented or modified from time to time, the â€œExisting Leaseâ€), whereby Tenant leases certain premises (the â€œPremisesâ€) from Landlord at 301 Binney Street in Cambridge, Massachusetts (the â€œBuildingâ€);B.WHEREAS, Landlord and Tenant desire to extend the Term of the Existing Lease;andC.WHEREAS, Landlord and Tenant desire to modify and amend the Existing Leaseonly in the respects and on the conditions hereinafter stated.AGREEMENTNOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows:1.Definitions. For purposes of this Amendment, capitalized terms shall have the meanings ascribed to them in the Existing Lease unless otherwise defined herein. The Existing Lease, as amended by this Amendment, is referred to collectively herein as the â€œLease.â€ From and after the date hereof, the term â€œLease,â€ as used in the Existing Lease, shall mean the Existing Lease, as amended by this Amendment.2.First Extension Term; Term Expiration Date. The Term is hereby extended for two(2) years and thirteen (13) days commencing on August 19, 2025 (the â€œFirst Extension Term Commencement Dateâ€). The Term Expiration Date is hereby amended to be August 31, 2027. The period of time from the First Extension Term Commencement Date through the new Term Expiration Date shall be referred to herein as the â€œFirst Extension Term.â€ The term â€œTermâ€ as used in the Lease shall refer to the Term under the Existing Lease as extended by the First Extension Term.3.Option. The parties acknowledge and agree that that extension of the Lease pursuant to this Amendment does not constitute the exercise of the extension Option under Section 42 of the Existing Lease. The parties further agree to amend the â€œOption,â€ as defined in Section 42 of the Existing Lease as follows:â€‹â€‹BioMed Realty form dated 10/04/23â€‹â€‹â€‹a.The first paragraph of Section 42 of the Existing Lease shall be amended by deleting the words â€œtwo (2) yearsâ€ and replacing them with â€œfive (5) yearsâ€.b.The first sentence of Section 42.1 of the Existing Lease shall be amended by deleting the words â€œthe greater of (a) one hundred three percent (103%) of the then- current Base Rent, and (b)â€ and by deleting the words â€œthe greater of: (i) three percent (3%) or (ii)â€.c.The first sentence of Section 42.3 of the Existing Lease shall be amended by deleting the words â€œfifteen (15) monthsâ€ and replacing them with â€œtwelve (12) monthsâ€.For the avoidance of doubt, the Option (as amended by this Section 3) shall continue to be subject to the terms and conditions of Section 42 of the Existing Lease.4.Base Rent During First Extension Term. Monthly and annual installments of Base Rent for the Premises during the First Extension Term shall be as set forth in the table below.â€‹â€‹â€‹â€‹DatesRentable Square Feet of the Premisesâ€‹Annual Fixed Rent per Rentable Square Footâ€‹â€Annual Fixed Rent per yearâ€‹Annual Fixed Rent per monthAugust 1, 2025â€“ August 18,2025â€‹51,408â€‹$154.92 annuallyâ€‹--*â€‹--**August 19,2025 â€“ August31, 2025â€‹51,408â€‹$120.00 annuallyâ€‹--**â€‹--**September 1,2025 â€“ August31, 2026â€‹51,408â€‹$120.00 annuallyâ€‹$6,168,960.00â€‹$514,080.00September 1,2026 â€“ August31, 2027â€‹51,408â€‹$123.60 annuallyâ€‹$6,354,028.80â€‹$529,502.40**$ 385,350.07 is the Base rent due for eighteen (18) day stub period from August 1, 2025 to August 18, 2025, and $215,581.92 in Base Rent due for thirteen (13) day stub period from August 19, 2025 through August 31, 2025. The total amount due for August 2025 shall be $600,931.99.5.Additional Rent. Tenantâ€™s obligation to pay Additional Rent, including, without limitation, Tenantâ€™s Adjusted Share of Operating Expenses, the Property Management Fee, costsâ€‹â€‹2â€‹of utilities for the Premises, and any parking fees with respect to the Premises, shall continue through the First Extension Term in accordance with and to the extent provided in the Lease.6.Condition of Premises. Tenant acknowledges that (a) it is in possession of and is fully familiar with the condition of the Premises and, notwithstanding anything contained in the Lease to the contrary, agrees to take the same in its condition â€œas isâ€ as of the date hereof, subject to Landlordâ€™s repair and maintenance obligations expressly provided in the Lease, and (b) Landlord shall have no obligation to alter, repair or otherwise prepare the Premises for

Tenantâ€™s continued occupancy for the First Extension Term or to pay for any improvements to the Premises, except as may be expressly provided in the Lease.7.Broker. Landlord and Tenant each represents and warrants to the other that it has had no dealings with any real estate broker or agent in connection with the negotiation of this Amendment other than CBRE (â€œLandlordâ€™s Brokerâ€) and Jones Lang LaSalle (â€œTenantâ€™s Brokerâ€) and that it knows of no other real estate broker or agent that is or might be entitled to a commission in connection with this Lease. Landlord shall compensate Landlordâ€™s Broker and Tenantâ€™s Broker in relation to this Amendment pursuant to separate agreements between Landlord and Landlordâ€™s Broker and Landlord and Tenantâ€™s Broker respectively, in each case conditioned and contingent on the full execution and delivery of this Amendment and satisfaction of any other contingencies set forth in that separate agreement. Tenant agrees to indemnify the Landlord Indemnitees for any and all cost or liability for compensation claimed by any broker or agent, other than Tenantâ€™s Broker, employed or engaged by Tenant or claiming to have been employed or engaged by Tenant.8.No Default. Tenant represents, warrants and covenants that, to the best of Tenantâ€™s knowledge, Landlord and Tenant are not in default of any of their respective obligations under the Existing Lease and no event has occurred that, with the passage of time or the giving of notice (or both) would constitute a default by either Landlord or Tenant thereunder. Landlord represents, warrants and covenants that, to the best of Landlordâ€™s knowledge, Landlord and Tenant are not in default of any of their respective obligations under the Existing Lease and no event has occurred that, with the passage of time or the giving of notice (or both) would constitute a default by either Landlord or Tenant thereunder.9.Notices. Tenant confirms that, notwithstanding anything in the Lease to the contrary, notices delivered to Tenant pursuant to the Lease should be sent to:Scholar Rock, Inc. 301 Binney StreetCambridge, MA 02142Attn: Jeremy Crossin, Erin Moore with a copy to:Scholar Rock, Inc. 301 Binney StreetCambridge, MA 02142â€‹â€‹3â€‹Attn: Legal10.Effect of Amendment. Except as modified by this Amendment, the Existing Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed. In the event of any conflict between the terms contained in this Amendment and the Existing Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties.11.Successors and Assigns. Each of the covenants, conditions and agreements contained in this Amendment shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs, legatees, devisees, executors, administrators and permitted successors and assigns and sublessees. Nothing in this section shall in any way alter the provisions of the Lease restricting assignment or subletting.12.Miscellaneous. This Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of the paragraphs and subparagraphs in this Amendment are inserted and included solely for convenience and shall not be considered or given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.13.Authority. Tenant warrants and represents that the individual or individuals signing this Amendment have the power, authority and legal capacity to sign this Amendment on behalf of Tenant.14.Counterparts; Facsimile and PDF Signatures. This Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document. A facsimile or portable document format (PDF) signature on this Amendment shall be equivalent to, and have the same force and effect as, an original signature.15.Landlordâ€™s Lender. The Landlord, Tenant and Deutsche Bank AG, a German Bank, authorized by the New York Department of Financial Services, Goldman Sachs Bank USA, a New York state chartered bank, and JPMorgan Chase Bank, N.A., a banking association chartered under the laws of the United States (collectively, the â€œLenderâ€) are parties to that certain Subordination Agreement, Acknowledgement of Lease Assignment, Attornment and Non-Disturbance Agreement, dated as of May 9, 2022 (the â€œSNDAâ€). Landlord represents that the Lenderâ€™s approval of this Amendment is not required under the loan agreement between Landlord and Lender.16.The parties agree to execute and record an amendment to the Notice of Lease, recorded with the Middlesex South Registry of Deeds in Book 73898, Page 351 to reflect the changes to the terms of the Lease to the extent set forth in such Notice of Lease.[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]â€‹â€‹4â€‹IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment as a sealed Massachusetts instrument as of the date and year first above written.LANDLORD:BMR-ROGERS STREET LLC,a Delaware limited liability companyâ€‹â€‹By:/s/ Colleen Oâ€™ConnorName: Colleen O'Connorâ€‹ â€‹ Title: SVP, Leasing, East Coast & U.K. Marketsâ€‹ â€‹â€‹TENANT:SCHOLAR ROCK, INC.,a Delaware corporationâ€‹â€‹By:/s/ Edward MylesName: Edward Mylesâ€‹ â€‹Title: COO & CFOâ€‹ EX-10.2 3 srrk-20240630xex10d2.htm EX-10.2 Exhibit 10.2CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.â€‹â€‹â€‹â€‹FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENTâ€‹THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this â€œAmendmentâ€) isentered into as of May 1 , 2024, by and among OXFORD FINANCE LLC, a Delaware limited liability company with 7 an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (â€œOxfordâ€), as collateral agent (in such capacity, â€œCollateral Agentâ€), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender, and SILICON VALLEY BANK, a division of First-Citizens Bank & Trust Company with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (â€œBankâ€ or â€œSVBâ€) (each a â€œLenderâ€ and collectively, the â€œLendersâ€), SCHOLAR ROCK HOLDING CORPORATION, a Delaware corporation (â€œParentâ€), and SCHOLAR ROCK, INC., a Delaware corporation (together with Parent, individually and collectively, jointly and severally, â€œBorrowerâ€) with an office located at 301 Binney Street, 3rd Floor, Cambridge, MA 02142.â€‹A.WHEREAS, Collateral Agent, Borrower and the Lenders have entered into that certain Loan and Security Agreement dated as of October 16, 2020, as amended by that certain First Amendment to Loan and Security Agreement dated as of November 16, 2021, as amended by that certain Second Amendment to Loan and Security Agreement dated as of November 10, 2022 and as amended by that certain Third Amendment to Loan and Security Agreement dated as of April 18, 2023 (as amended herein and as further amended, supplemented or otherwise modified from time to time, the â€œLoan Agreementâ€) pursuant to which the Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; andâ€‹B.WHEREAS, Borrower, the Lenders party to this Amendment (constituting the Required Lenders) and Collateral Agent desire to amend such provisions as provided herein and subject to the terms and conditions set forth herein.â€‹Agreementâ€‹NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, the Lenders and Collateral Agent hereby agree as follows:â€‹1.Definitions. Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.â€‹2.Amendments to Loan Agreement.â€‹2.1Section 2.2(b) (Repayment). Section 2.2(b) of the Loan Agreement is hereby amended and restated as follows:â€‹â€œ(b)Repayment. Borrower shall make monthly payments in arrears of interest only commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lenderâ€™s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to (x) thirty (30) months if the Amortization Date is June 1, 2025 and (y) twenty-four (24) months if the Amortization Date is December 1, 2025. All unpaid principal and accrued and unpaidâ€‹CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).â€‹â€‹2.2Section 2.5(e) (Fees). Section 2.5(e) of the Loan Agreement is hereby amended and restated as follows:â€‹â€œ(e) Good Faith Deposit. Prior to the Effective Date, Borrower has paid to Collateral Agent a deposit of One Hundred Thousand Dollars ($100,000.00) (â€œGood Faith Depositâ€), to initiate Collateral Agentâ€™s and Lendersâ€™ due diligence review and documentation process. Prior to the Fourth Amendment Effective Date, Borrower has paid to Collateral Agent a deposit of Fifty Thousand Dollars ($50,000.00) (â€œFourth Amendment Good Faith Depositâ€), to initiate Collateral Agentâ€™s and Lendersâ€™ due diligence review and documentation process in connection with the Fourth Amendment. The Good Faith Deposit and the Fourth Amendment Good Faith Deposit have been, or will be, used to pay Lendersâ€™ Expenses due on the Effective Date or the Fourth Amendment Effective Date, as applicable; provided, however, (i) Borrower shall be responsible for the entire amount of Lendersâ€™ Expenses payable under Section 2.5(e) hereof, and (ii) Collateral Agent agrees to deposit, within five (5) Business Days after the Fourth Amendment Effective Date, the portion (if any) of the Fourth Amendment Good Faith Deposit that will not be used to pay Lendersâ€™ Expenses that have accrued on or prior to the Fourth Amendment Effective Date into a deposit account of Borrower maintained with Bank or Bankâ€™s Affiliates to which Borrower has full access and which cash in such deposit account Borrower can use for any purposes not expressly prohibited by the Loan Agreement, and Collateral Agent shall provide Borrower written notice of any such deposit within one (1) Business Day of when such deposit is made.â€‹2.3Section 2.5(g) (Fees). New Section 2.5(g) is hereby added to the end of Section 2.5 of the Loan Agreement as follows:â€‹â€œ(g) Â Interest-Only Extension Milestone Fees. The First Interest-Only Extension Milestone Fee, due and payable to the Lenders in accordance with their respective Pro Rata Shares, on the Fourth Amendment Effective Date. The Second Interest-Only Extension Milestone Fee, shall be due and payable (if ever) when and if the Amortization Date Extension Condition Satisfaction occurs, and, if ever due and payable, to be shared between the Lenders in accordance with their respective Pro Rata Shares.â€‹2.4Section 6.6 (Operating Accounts). Section 6.6 of the Loan Agreement is hereby amended and restated as follows:â€‹â€œ(a) Borrower shall at all times have on deposit in operating, depository and securities Collateral Accounts maintained with Bank or Bankâ€™s Affiliates, in Collateral Accounts which are subject to a Control Agreement in favor of Collateral Agent, cash in an amount equal to the lesser of (i) one hundred percent (100.0%) of the Dollar value of all of Borrowerâ€™s consolidated cash, including any Subsidiariesâ€™, in the aggregate, at all financial institutions, and (ii) one hundred five percent (105.0%) of the Dollar amount of the then-outstanding Obligations. Bank may, upon consultation with Collateral Agent and the Required Lenders, restrict withdrawals or transfers by or on behalf of Borrower that would violate this Section 6.6(a), regardless of whether an Event of Default exists. In addition, Borrower and its Subsidiaries shall, within thirty (30) days after the Fourth Amendment Effective Date and at all times thereafter, have on deposit in operating, depository and securities Collateral Accounts maintained with Bank or Bankâ€™s Affiliates cash and investments in an aggregate amount of not less than twenty-five percent (25.0%) of the Dollar value of all of Borrowerâ€™s and its Subsidiariesâ€™ cash and investments (including Cash Equivalents); provided, however, notwithstanding the foregoing, if Borrower achieves the Second Interest-Only Extension Milestone, then Borrower and its Subsidiaries shall, within thirty (30) days after the date that Borrower achieves the Second Interest-Only Extension Milestone and at all times thereafter, have on deposit in operating, depository and securities Collateral Accounts maintained with Bank or Bankâ€™s Affiliates cash and investments in an aggregate amount of not less than sixty percent (60.0%) of the Dollar value of all of Borrowerâ€™s and its Subsidiariesâ€™ cash and investments (including Cash Equivalents).â€‹(b)Borrower shall provide Collateral Agent five (5) daysâ€™ prior written notice before Borrower or any of its Subsidiaries establishes any Collateral Account at or with anyâ€‹CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.Person other than Bank or its Affiliates. In addition, for each Collateral Account that Borrower or any of its Subsidiaries (other than any Collateral Account of the MSC Subsidiary), at any time opens or maintains, Borrower or such Subsidiary shall cause the applicable bank or financial institution at or with which such Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Collateral Agentâ€™s Lien in such Collateral Account in accordance with the terms hereunder prior to the establishment of such Collateral Account, which Control Agreement may not be terminated without prior written consent of Collateral Agent. The provisions of the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrowerâ€™s, or any of its Subsidiariesâ€™, employees and identified to Collateral Agent by Borrower as such in the Perfection Certificates.â€‹(c)Neither Borrower nor any of its Subsidiaries shall maintain any Collateral Accounts except Collateral Accounts maintained in accordance with Sections 6.6(a) and (b).â€‹â€‹2.5Section 10 (Notices). The address information for Goodwin Procter LLP (but not the address information for Borrower, which remains unchanged) in Section 10 of the Loan Agreement hereby is amended and restated in its entirety as follows:â€‹GOODWIN PROCTER LLP520 Broadway, Suite 500 SantaMonica, CA 90401 Attn: Kristopher J. RingEmail: KRing@goodwinlaw.comâ€‹â€‹2.6Section 13 (Definitions). The following terms and such definitions in Section 13.1 of the Loan Agreement hereby are amended and restated in their entirety as follows:â€‹â€œâ€œAmortization Dateâ€ is June 1, 2025; provided, however, if Borrower achieves the Second Interest-Only Extension Milestone on or prior to May 1, 2025, then the Amortization Date with respect to all Term Loans shall automatically be extended to December 1, 2025 (any such extension, the â€œAmortization Date Extension Condition Satisfactionâ€).â€‹â€‹â€œâ€œKey Personâ€ is each of Borrowerâ€™s (i) President and Chief Executive Officer, who is Jay Backstrom, M.D., MPH as of the Fourth Amendment Effective Date, (ii) Chief Financial Officer, who is Ted Myles as of the Fourth Amendment Effective Date and (iii) Chief Medical Officer, who is Jing Marantz, M.D. as of the Fourth Amendment Effective Date.â€‹â€‹â€œâ€œObligationsâ€ are all of Borrowerâ€™s obligations to pay when due any debts, principal, interest, Lendersâ€™ Expenses, the Prepayment Fee (if any), the Second Amendment Accrued Final Payment, the Final Payment, the First Interest-Only Extension Milestone Fee, the Second Interest-Only Extension Milestone Fee and other amounts Borrower owes the Lenders now or later, in connection with, related to, following, or arising from, out of or under, this Agreement or, the other Loan Documents, or otherwise, including, without limitation, all obligations relating to letters of credit (including reimbursement obligations for drawn and undrawn letters of credit), cash management services, and foreign exchange contracts, if any, and including interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts, liabilities, or obligations of Borrower assigned to the Lenders and/or Collateral Agent, and the performance of Borrowerâ€™s duties under the Loan Documents.â€‹â€œâ€œTerm D Draw Periodâ€ is the period commencing on the date of the occurrence of the Term D Milestone and ending on the earliest of (i) December 31, 2024 and (ii) the occurrence of an Event of Default; provided, however, that the Term D Draw Period shall not commence if on the date of the occurrence of the Term D Milestone an Event of Default has occurred and is continuing.â€‹â€‹CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.â€‹â€‹â€œâ€œTerm D Milestoneâ€ is Borrowerâ€™s delivery to Collateral Agent and the Lenders of evidence, satisfactory to Collateral Agent and the Lenders in their sole but reasonable discretion, of Borrowerâ€™s receipt of (i) [***] and (ii) unrestricted (other than from (a) Collateral Agentâ€™s Liens and control agreements and (b) bankersâ€™ Liens described in clause (h) in the defined term Permitted Liens) net cash proceeds after the Fourth Amendment Effective Date of not less than One Hundred Fifty Million Dollars ($150,000,000.00) from the issuance and sale of its equity securities in a single equity financing transaction (or subsequent closings from such single equity financing that are completed within thirty-five days (35) days following the initial closing of such single equity financing transaction) and net cash proceeds from any pre-funded warrants with respect to any warrantholder or any of its Affiliates received within thirty-five days (35) days following the initial closing of such single equity financing transaction.â€‹â€‹2.7Section 13 (Definitions). The following terms and such definitions are hereby added to Section13.1 of the Loan Agreement as follows:â€‹â€œâ€œAmortization Date Extension Condition Satisfactionâ€ is defined in the definition of â€œAmortization Dateâ€.â€‹â€‹â€œâ€œFirst Interest-Only Extension Milestone Feeâ€ is a fee, due and payable to the Lenders in accordance with their respective Pro Rata Shares, in an aggregate amount equal to Thirty Thousand Dollars ($30,000.00) on the Fourth Amendment Effective Date.â€‹â€‹â€œâ€œFourth Amendmentâ€ means that certain Fourth Amendment to Loan and Security Agreement, dated as of the Fourth Amendment Effective Date, by and among Borrower, Parent, Oxford as a lender and Collateral Agent, SVB as a lender and the other Lenders party thereto.â€‹â€‹â€œâ€œFourth Amendment Effective Dateâ€ is May 17, 2024.â€‹â€‹â€œâ€œFourth Amendment Good Faith Depositâ€ is defined in Section 2.5(e).â€‹â€‹â€œâ€œSecond Interest-Only Extension Milestoneâ€ is Borrowerâ€™s delivery to Collateral Agent and the Lenders of evidence, satisfactory to Collateral Agent and the Lenders in their sole but reasonable discretion, of Borrowerâ€™s receipt of unrestricted net cash proceeds after the Fourth Amendment Effective Date of at least One Hundred Fifty Million Dollars ($150,000,000.00) from the issuance and sale of its equity securities in a single equity financing transaction (or subsequent closings from such single equity financing that are completed within thirty-five days (35) days following the initial closing of such single equity financing transaction) and net cash proceeds from any pre-funded warrants with

respect to any warrantholder or any of its Affiliates received within thirty-five days (35) days following the initial closing of such single equity financing transaction.â€â€‹â€œâ€œSecond Interest-Only Extension Milestone Feeâ€ is a fee, due and payable to the Lenders in accordance with their respective Pro Rata Shares, in an aggregate amount equal to Forty Thousand Dollars ($40,000.00) within five (5) Business Days of written confirmation from Collateral Agent to Borrower that the Amortization Date Extension Condition Satisfaction has occurred.â€2.8Silicon Valley Bank. The references in the Loan Agreement to â€œSilicon Valley Bank, a division of First- Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank))â€ in the Introduction, Section 10, Section 12.11, Schedule 1.1 and the Exhibits are hereby replaced with â€œSilicon Valley Bank, a division of FirstCitizens Bank & Trust Companyâ€.â€‹2.9Schedule 1.1 (Lenders and Commitments). Schedule 1.1 of the Loan Agreement is hereby amended and restated as set forth on Exhibit A to this Amendment.â€‹2.10Compliance Certificate. The Compliance Certificate attached as Exhibit C to the Loan Agreement is hereby amended and restated as set forth on Exhibit B to this Amendment.â€‹CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.2.11Amortization Tables. The Amortization Tables previously attached to the Disbursement Letters for the Term A Loans, Term B Loans and Term C Loan are replaced by the Amortization Tables attached as Exhibit C to this Amendment.â€‹3.Limitation of Amendment.â€‹3.1The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which the Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.â€‹3.2This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents are hereby ratified and confirmed and shall remain in full force and effect.â€‹4.Representations and Warranties.To induce Collateral Agent and the Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and the Lenders as follows:â€‹4.1Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct in all material respects as of such date) and (b) no Event of Default has occurred and is continuing;â€‹4.2Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;â€‹4.3The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;â€‹4.4The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not contravene(i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;â€‹4.5The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made (or will be obtained or made on the date hereof);â€‹4.6This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws relating to or affecting creditorsâ€™ rights and general equitable principles.â€‹5.Release by Borrower.â€‹CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.5.1FOR GOOD AND VALUABLE CONSIDERATION, Borrower hereby forever relieves, releases, and discharges Collateral Agent and each Lender and their respective present or former employees, officers, directors, agents, representatives, attorneys, and each of them, from any and all claims, debts, liabilities, demands, obligations, promises, acts, agreements, costs and expenses, actions and causes of action, of every type, kind, nature, description or character whatsoever, whether known or unknown, suspected or unsuspected, absolute or contingent, arising out of or in any manner whatsoever connected with or related to facts, circumstances, issues, controversies or claims existing or arising from the beginning of time through and including the date of execution of this Amendment solely to the extent such claims arise out of or are in any manner whatsoever connected with or related to the Loan Documents, the Recitals hereto, any instruments, agreements or documents executed in connection with any of the foregoing or the origination, negotiation, administration, servicing and/or enforcement of any of the foregoing (collectively â€œReleased Claimsâ€).â€‹5.2By entering into this release, Borrower recognizes that no facts or representations are ever absolutely certain and it may hereafter discover facts in addition to or different from those which it presently knows or believes to be true, but that it is the intention of Borrower hereby to fully, finally and forever settle and release all matters, disputes and differences, known or unknown, suspected or unsuspected in relation to the Released Claims; accordingly, if Borrower should subsequently discover that any fact that it relied upon in entering into this release was untrue, or that any understanding of the facts was incorrect, Borrower shall not be entitled to set aside this release by reason thereof, regardless of any claim of mistake of fact or law or any other circumstances whatsoever. Borrower acknowledges that it is not relying upon and has not relied upon any representation or statement made by Collateral Agent or the Lenders with respect to the facts underlying this release or with regard to any of such partyâ€™s rights or asserted rights.â€‹5.3This release may be pleaded as a full and complete defense and/or as a cross-complaint or counterclaim against any action, suit, or other proceeding that may be instituted, prosecuted or attempted in breach of this release. Borrower acknowledges that the release contained herein constitutes a material inducement to Collateral Agent and the Lenders to enter into this Amendment, and that Collateral Agent and the Lenders would not have done so but for Collateral Agentâ€™s and the Lendersâ€™ expectation that such release is valid and enforceable in all events.â€‹6.Loan Document. Borrower, the Lenders and Collateral Agent agree that this Amendment shall be a Loan Document. Except as expressly set forth herein, the Loan Agreement and the other Loan Documents shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.â€‹7.Effectiveness. This Amendment shall be deemed effective as of the date hereof upon (a) the due execution and delivery of this Amendment by the parties hereto, (b) Collateral Agentâ€™s receipt of the First Interest-Only Extension Milestone Fee referenced in Section 2.5(g) of the Loan Agreement (as amended by this Amendment) in an aggregate amount of Thirty Thousand Dollars ($30,000.00) to be shared between the Lenders in accordance with their respective Pro Rata Shares, and (c) all such other agreements, documents and deliverables requested in writing by Collateral Agent in its reasonable discretion prior to the date hereof (including such agreements, documents and deliverables as detailed in the closing checklist provided in connection with this Amendment).â€‹8.Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument. Delivery by electronic transmission (e.g. â€œ.pdfâ€) of an executed counterpart of this Amendment shall be effective as a manually executed counterpart signature thereof.â€‹9.Governing Law. This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York.â€‹CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.â€‹[Balance of Page Intentionally Left Blank]â€‹CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as of the date first set forth above.â€‹BORROWER:â€‹SCHOLAR ROCK HOLDING CORPORATIONâ€‹â€‹By /s/ Jay Backstromâ€‹ â€‹ Name: Jay BackstromTitle: President and Chief Executive Officerâ€‹â€‹SCHOLAR ROCK, INC.â€‹â€‹By /s/ Jay Backstromâ€‹ â€‹ Name: Jay BackstromTitle: President and Chief Executive Officerâ€‹â€‹â€‹â

INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.â€‹â€‹â€‹Oxford Finance & SVB Amortization TableScholar Rock Tranche 1 Totalâ€‹â€‹Start Date:11/10/2022â€‹Disclaimer:Interest Rate:13.10000%29 IO + 30 PITHIS IS A STANDARD AMORTIZATION SCHEDULE. IT IS NOT INTENDED TO BE USED FOR PAYOFF PURPOSES.Term:59â€‹â€‹Payment:Variesâ€‹â€‹Exit Fee:$1,000,000.002.00%â€‹Amount:50,000,000.00â€‹THIS AMORTIZATION SCHEDULEInterim Interest Days:21â€‹REPRESENTS A FLOATING INTEREST RATEInterim Interest:â€‹â€‹LOAN. INTEREST RATE CHARGED MAYâ€‹â€‹â€‹DIFFER FROM RATE PER THIS SCHEDULEâ€‹â€‹â€‹BASED ON THE TERMS OF THE LOANâ€‹â€‹â€‹AGREEMENTâ€‹â€‹PMTPaymentBeginningMonthlyInterestPrincipalEndingNo.Date:Balance:Paymentâ€‹â€‹Balanceâ€‹12/1/22â€‹Interim Interest Due:â€‹$50,000,000.0011/1/23$50,000,000.00$564,027.78$564,027.78$0.00$50,000,000.0022/1/23$50,000,000.00$564,027.78$564,027.78$0.00$50,000,000.0033/1/23$50,000,000.00$509,444 IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.â€‹â€‹â€‹Oxford Finance & SVB Amortization TableScholar Rock Tranche 1 Totalâ€‹â€‹284/1/25$50,000,000.00$564,027.78$564,027.78$0.00$50,000,000.00295/1/25$50,000,000.00$545,833.33$545,833.33$0.00$50,000,000.00306/1/25$50,000,000.00$2,230,694.44$56 Payment$1,000,000.00$1,000,000.00$0.00â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Totals$75,641,342.59$25,641,342.59$50,000,000.00â€‹â€‹â€‹â€‹CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.â€‹â€‹â€‹Oxford Finance & SVB Amortization TableScholar Rock Tranche 1 Totalâ€‹â€‹Start Date:11/10/2022â€‹Disclaimer:Interest Rate:13.10000%35 IO + 24 PITHIS IS A STANDARD AMORTIZATION SCHEDULE. IT IS NOT INTENDED TO BE USED FOR PAYOFF PURPOSES.Term:59â€‹â€‹Payment:Variesâ€‹â€‹Exit Fee:$1,000,000.002.00%â€‹Amount:50,000,000.00â€‹THIS AMORTIZATION SCHEDULEInterim Interest Days:21â€‹REPRESENTS A FLOATING INTEREST RATEInterim Interest:â€‹â€‹LOAN. INTEREST RATE CHARGED MAYâ€‹â€‹â€‹DIFFER FROM RATE PER THIS SCHEDULEâ€‹â€‹â€‹BASED ON THE TERMS OF THE LOANâ€‹â€‹â€‹AGREEMENTâ€‹â€‹PMTPaymentBeginningMonthlyInterestPrincipalEndingNo.Date:Balance:Paymentâ€‹â€‹Balanceâ€‹12/1/22â€‹Interim Interest Due:â€‹$50,000,000.0011/1/23$50,000,000.00$564,027.78$564,027.78$0.00$50,000,000.0022/1/23$50,000,000.00$564,027.78$564,027.78$0.00$50,000,000.0033/1/23$50,000,000.00$509,444 IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK â€œ[***]â€.â€‹â€‹â€‹Oxford Finance & SVB Amortization TableScholar Rock Tranche 1 Totalâ€‹â€‹PMTPaymentBeginningMonthlyInterestPrincipalEndingNo.Date:Balance:Paymentâ€‹â€‹Balance284/1/25$50,000,000.00$564,027.78$564,027.78$0.00$50,000,000.00295/1/25$50,000 Payment$1,000,000.00$1,000,000.00$0.00â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Totals$77,301,585.65$27,301,585.65$50,000,000.00â€‹ EX-31.1 4 srrk-20240630xex31d1.htm EX-31.1 Exhibit 31.1CertificationsI, Jay T. Backstrom, certify that:1.Â Â Â Â Â Â Â Â Â Â Â I have reviewed this Quarterly Report on Form 10-Q of Scholar Rock Holding Corporation;2.Â Â Â Â Â Â Â Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Â Â Â Â Â Â Â Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.Â Â Â Â Â Â Â Â Â Â Â The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Â Â Â Â Â Â Â Â Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Â Â Â Â Â Â Â Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Â Â Â Â Â Â Â Â Â Â Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Â Â Â Â Â Â Â Â Â Â Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.Â Â Â Â Â Â Â Â Â Â Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)Â Â Â Â Â Â Â Â Â Â Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Â Â Â Â Â Â Â Â Â Â Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹â€‹Date: August 8, 2024/s/ Jay T. Backstromâ€‹Jay T. Backstromâ€‹President and Chief Executive Officer(Principal Executive Officer)â€‹ EX-31.2 5 srrk-20240630xex31d2.htm EX-31.2 Exhibit 31.2CertificationsI, Edward H. Myles, certify that:1.Â Â Â Â Â Â Â Â Â Â Â I have reviewed this Quarterly Report on Form 10-Q of Scholar Rock Holding Corporation;2.Â Â Â Â Â Â Â Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Â Â Â Â Â Â Â Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.Â Â Â Â Â Â Â Â Â Â Â The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Â Â Â Â Â Â Â Â Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Â Â Â Â Â Â Â Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Â Â Â Â Â Â Â Â Â Â Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Â Â Â Â Â Â Â Â Â Â Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.Â Â Â Â Â Â Â Â Â Â Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)Â Â Â Â Â Â Â Â Â Â Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Â Â Â Â Â Â Â Â Â Â Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹â€‹Date: August 8, 2024/s/ Edward H. Mylesâ€‹Edward H. Mylesâ€‹Chief Operating Officer & Chief Financial Officer(Principal Financial and Accounting Officer)â€‹ EX-32.1 6 srrk-20240630xex32d1.htm EX-32.1 Exhibit 32.1CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report on Form 10-Q of Scholar Rock Holding Corporation (the â€œCompanyâ€) for the period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to his or her knowledge, that:(1)the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be â€œfiledâ€ for any purpose whatsoever.Date: August 8, 2024/s/ Jay T. Backstromâ€‹Jay T. Backstromâ€‹President and Chief Executive Officerâ€‹â€‹â€‹Date: August 8, 2024/s/ Edward H. Mylesâ€‹Edward H. Mylesâ€‹Chief Operating Officer & Chief Financial Officerâ€‹ GRAPHIC 7 srrk-20240630xex10d1002.jpg GRAPHIC begin 644 srrk-20240630xex10d1002.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @,# P,$ P,$ P,%!0@%!0$%"P@(!P@- Q$,# @/#_VP!# H $P@# L*"PL- #A(0$1)0&1#8J%A,#3!9&"-9)A:" B;!(6<:!:"T!)UH,&T"!=#2,!# #VP!# $#P$!3!8!&!0"&!(B(!AAP$B(2(D!%Q88 GRAPHIC 8 srrk-20240630xex10d1003.jpg GRAPHIC begin 644 srrk-20240630xex10d1003.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @,# P,$ P,$ P,%!0@%!0$%"P@(!P@- end GRAPHIC 9 srrk-20240630xex10d1006.jpg GRAPHIC begin 644 srrk-20240630xex10d1006.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# end GRAPHIC 10 srrk-20240630xex10d1007.jpg GRAPHIC begin 644 srrk-20240630xex10d1007.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @,# P,$ P,$ P,%!0@%!0$%"P@(!P@- Q$,# @/#_VP!# H $P@# L*"PL- #A(0$1)0&1#8J%A,#3!9&"-9)A:" B;!(6<:!:"T!)UH,&T"!=#2,!# #VP!# $#P$!3!8!&!0"&!(B(!AAP$B(2(D!%Q88

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end GRAPHIC 11 srrk-20240630xex10d2001.jpg GRAPHIC begin 644 srrk-20240630xex10d2001.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!04%!3_P 1" ! 2 # 2(A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#\JJ*** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** 8* "BBB@ HHHH **** "BBB@ HHHH __9 end GRAPHIC 12 srrk-20240630xex10d2002.jpg GRAPHIC begin 644 srrk-20240630xex10d2002.jpg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end GRAPHIC 13 srrk-20240630xex10d2004.jpg GRAPHIC begin 644 srrk-20240630xex10d2004.jpg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end EX-101.SCH 14 srrk-20240630.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Fair Value of Financial Assets and Liabilities - (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Marketable Securities - Summary of Investments (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Prepaid Expenses and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Equity-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Nature of the Business (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Common Stock - (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Equity-Based Compensation - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Equity-Based Compensation - Unrecognized Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Equity-Based Compensation - Restricted stock (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - Equity-Based Compensation - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 99940805 - Disclosure - Equity-Based Compensation - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Net Loss per Share - Antidilutive (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Nature of the Business link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Fair Value of Financial Assets and Liabilities link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Prepaid Expenses and Other Assets link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Prepaid Expenses and Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 srrk-20240630_cal.xml EX-101.CAL EX-101.DEF 16 srrk-20240630_def.xml EX-101.DEF EX-101.LAB 17 srrk-20240630_lab.xml EX-101.LAB Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Statement Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Marketable securities Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Restricted Cash, Noncurrent Restricted cash Other Assets, Noncurrent Other long-term assets Total other long-term assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Accrued expenses Operating Lease, Liability, Current Operating lease liability Short-Term Debt Short-term debt Other Liabilities, Current Other current liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Long-term portion of operating lease liability Long-Term Debt, Excluding Current Maturities Long-term debt Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Note 9) Equity, Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023 Common Stock, Value, Issued Common stock, $0.001 par value; 300,000,000 shares authorized; 79,992,068 and 75,979,495 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) Retained Earnings (Accumulated Deficit) Accumulated deficit Equity, Attributable to Parent Balance at end Balance at beginning Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) Other income (expense), net Net loss Net loss Earnings Per Share, Basic Net loss per share, basic (in dollars per share) Earnings Per Share, Diluted Net loss per share, diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding, diluted (in shares) Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive income (loss): OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Unrealized gain (loss) on marketable securities Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Retained Earnings [Member] Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (decrease) in Stockholders' Equity Shares, Outstanding Balance at end (in shares) Balance at beginning (in shares) Stock Issued During Period, Value, New Issues Sale of common shares, net of issuance costs Stock Issued During Period, Shares, New Issues Sale of common shares, net of issuance costs (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercised (in shares) Exercise of stock options (in shares) Stock Issued During Period, Value, Restricted Stock Award, Gross Issuance of common shares upon RSU vesting Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of common shares upon RSU vesting (in shares) Equity impact of shares issued during period on exercise of warrants. Stock Issued During Period, Value, Exercise Of Warrants Exercise of pre-funded and common warrants Number of shares issued during period on exercise of warrants. Stock Issued During Period, Shares, Exercise Of Warrants Exercise of pre-funded and common warrants (in shares) APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Equity-based compensation expense Stock Issued During Period, Value, Other Other CONSOLIDATED STATEMENT OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Amortization of Debt Issuance Costs Amortization of debt discount and debt issuance costs Share-Based Payment Arrangement, Noncash Expense Equity-based compensation Accretion (Amortization) of Discounts and Premiums, Investments Amortization/accretion of investment securities Operating Lease, Right-of-Use Asset, Periodic Reduction Non-cash operating lease expense Increase (Decrease) in Operating Capital [Abstract] Change in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Noncurrent Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Operating Lease Liability Operating lease liabilities Increase (Decrease) in Other Noncurrent Liabilities Other liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from sale of property and equipment Payments to Acquire Marketable Securities Purchases of marketable securities Proceeds from Sale and Maturity of Marketable Securities Maturities of marketable securities Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from sale of common shares, net of issuance costs Proceeds from Warrant Exercises Proceeds from pre-funded and common warrant exercises Payments of Debt Restructuring Costs Debt modification payment Proceeds from Stock Options Exercised Proceeds from stock option exercises Proceeds from (Payments for) Other Financing Activities Other Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease)/increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, beginning of period Total Investing and Financing Items [Abstract] Supplemental disclosure of non-cash items: Effect on cash flow during the period of non-cash operating lease liability, adjustment from rent modification. Operating Lease Liability, Adjustment From Rent Modification Operating lease liability, adjustment from rent modification Supplemental Cash Flow Information [Abstract] Supplemental cash flow information: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Nature of the Business Business Description and Basis of Presentation [Text Block] Nature of the Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value of Financial Assets and Liabilities Fair Value Disclosures [Text Block] Fair Value of Financial Assets and Liabilities Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Marketable Securities Prepaid Expense and Other Assets Other Assets Disclosure [Text Block] Prepaid Expenses and Other Assets Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Common Stock. The entire disclosure of common stock. Common Stock [Text Block] Common Stock Equity-Based Compensation Share-Based Payment Arrangement [Text Block] Equity-Based Compensation Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Debt Debt Disclosure [Text Block] Debt Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Restricted Cash Disclosure of accounting policy for unaudited interim financial information. Unaudited Interim Financial Information [Policy Text Block] Unaudited Interim Financial Information Use of Estimates, Policy [Policy Text Block] Use of Estimates New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted and Recently Issued Accounting Pronouncements Restrictions on Cash and Cash Equivalents [Table Text Block] Reconciliation of cash, cash equivalents and restricted cash Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of summary of the assets and liabilities measured at fair value on a recurring basis Marketable Securities [Table Text Block] Summary of investments Schedule of Other Current Assets [Table Text Block] Schedule of prepaid expenses and other current assets Schedule of Other Assets, Noncurrent [Table Text Block] Schedule of other long-term assets Schedule of Accrued Liabilities [Table Text Block] Summary of accrued expenses Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Equity-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of allocation of equity-based compensation Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Summary of unrecognized equity-based compensation expense Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Summary of stock activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of stock option activity Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted average assumptions in fair value Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Leased assets Lease, Cost [Table Text Block] Summary of lease costs Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Summary of anti-dilutive securities Restricted Cash and Cash Equivalents [Abstract] Cash and cash equivalents and restricted cash Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Money Market Funds [Member] Money market funds US Treasury Securities [Member] U.S. Treasury obligations Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial assets and financial liabilities measured at fair value on a recurring basis: Assets, Fair Value Disclosure [Abstract] Assets: Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Marketable Securities [Abstract] Marketable securities: Investments, Fair Value Disclosure U.S. Treasury obligations and government agency securities Assets, Fair Value Disclosure Total assets Transfer Of Assets Between Fair Value Measurement Levels. Transfer Of Assets Between Fair Value Measurement Levels Transfer of assets between fair value measurement levels. Debt Securities, Available-for-Sale [Table] Financial Instrument [Axis] Financial Instruments [Domain] Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Marketable securities available-for-sale Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Debt Securities, Available-for-Sale Estimated Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Aggregate fair value of marketable securities with unrealized gains (losses) position for less than a year Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Number of investments in an unrealized loss position for less than a year Prepaid Expense and Other Assets, Current [Abstract] Prepaid expenses and other current assets The amount of prepaid external research and development expense as of the balance sheet date. Used to reflect the current portion of the asset (due within one year or within the normal operating cycle if longer). Prepaid External Research And Development Expense, Current Prepaid external research and development expense Other Prepaid Expense, Current Prepaid other Nontrade Receivables, Current Receivables Prepaid Insurance Prepaid insurance Other Assets, Noncurrent Disclosure [Abstract] Other long-term assets The amount of prepaid external research and development expense as of the balance sheet date. Used to reflect the noncurrent portion of the asset (due after one year or outside the normal operating cycle if longer). Prepaid External Research And Development Expense, Noncurrent Prepaid external research and development expense Prepaid Expense Other, Noncurrent Prepaid other Amount of asset related to consideration paid in advance for insurance that provides economic benefits after a future period of one year or the normal operating cycle, if longer. Prepaid Insurance, Noncurrent Prepaid insurance The amount of accrued external research and development expense as of the balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued External Research And Development Expense Accrued external research and development expense Employee-related Liabilities, Current Accrued payroll and related expenses Accrued Professional Fees, Current Accrued professional and consulting expense Other Accrued Liabilities, Current Accrued other Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Sale of Stock [Axis] Sale of Stock [Domain] Represents information relating to At the market offering. At Market Offering [Member] ATM Offering Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Warrant [Member] Warrants Represents the information pertaining to the pre-funded warrants. Pre Funded Warrant [Member] Pre-funded warrants Represents the information pertaining to the common warrants. Common Warrant [Member] Warrants, non pre-funded Scenario [Axis] Scenario [Domain] Information reported for the aggregate, since inception. Aggregate [Member] Aggregate Subsidiary, Sale of Stock [Line Items] Equity Maximum aggregate offering price. Maximum Aggregate Offering Price Maximum aggregate offering price Proceeds from Issuance of Private Placement Sale of shares Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrant to purchase (in shares) Class of Warrant or Right, Outstanding Outstanding warrants (in shares) Class of Warrant or Right, Exercise Price of Warrants or Rights Warrant exercise price (in dollars per share) Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Research and Development Expense [Member] Research and development expense General and Administrative Expense [Member] General and administrative expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Equity-based compensation Share-Based Payment Arrangement, Expense Equity-based compensation expense Restricted Stock Units (RSUs) [Member] Restricted stock units Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized Expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted Average Remaining Period of Recognition Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of Shares/Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Outstanding, end (in shares) Outstanding, beginning (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Outstanding, end (in dollars per share) Outstanding, beginning (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Fair value of non-option awards vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Units Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding, end (in shares) Outstanding, beginning (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Options exercisable, end (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding, end (in dollars per share) Outstanding, beginning (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options exercisable, end (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value, end Aggregate intrinsic value, beginning Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate intrinsic value, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Assumptions used in determining the fair value of options Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (years to liquidity) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Name of Property [Axis] Name of Property [Domain] Related to property located on Binney Street in Cambridge, Massachusetts. Binney St Cambridge MA [Member] 301 Binney St, Cambridge MA Represents information pertaining to the scenario after expiration of first extension term Upon Expiration Of First Extension Term [Member] First extension Lessee, Operating Lease, Existence of Option to Extend [true false] Option to extend the term Lessee, Operating Lease, Renewal Term Renewal term Amount of base rent for initial period under the lease. Lessee Operating Lease Base Rent Base rent The annual upward lease adjustment percentage. Annual Lease Adjustment Percent Annual upward adjustment (as a percent) Incentive to Lessee Incentive to lease Letters of Credit Outstanding, Amount Letter of credit Lease, Cost [Abstract] Lease Cost: Operating Lease, Cost Operating lease cost Variable Lease, Cost Variable lease cost Lease, Cost Total lease cost Operating Lease, Payments Operating cash flows used for operating leases Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term Operating Lease, Weighted Average Discount Rate, Percent Weighted average incremental borrowing rate Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents the Loan and Security Agreement. Loan and Security Agreement [Member] Loan and Security Agreement Tranche one of the debt agreement Tranche One [Member] Tranche One Tranche two of the debt agreement Tranche Two [Member] Tranche Two Represents information pertaining to tranche three. Tranche Three [Member] Tranche Three Represents information pertaining to tranche four. Tranche Four [Member] Tranche Four Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Debt Instrument [Line Items] Debt Line of Credit Facility, Maximum Borrowing Capacity Line of credit maximum Proceeds from Issuance of Debt Proceeds from credit facility The interest only period. Interest Only, Period Interest only period Debt Instrument, Basis Spread on Variable Rate Variable rate (as a percent) Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Prepayment penalty as a percent Prepayment Penalty, Percent Prepayment penalty (as a percent) Represents the final payment fee, as a percent of the aggregate advances on the debt. Debt Instrument, Final Payment Fee Final payment fee (as a percent) Repayments of Debt Repayments of debt Dollar value of company's consolidated cash as a percent, as required by the agreement. Percentage Of Dollar Value of Consolidated Cash Percentage of dollar value of company's consolidated cash The amount of cash required in a lender's account as a percentage of outstanding obligation requirement as per the agreement. Percentage of Outstanding Obligation Amount of cash required in a lender's account as a percentage of outstanding obligation (as a percent) Long-Term Debt Long-term portion of loan Additional period of only interest payments in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Line of Credit Facility, Interest Only Payments, Additional Period Interest additional period Additional extension period for repayment of principal amounts in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Line of Credit Facility, Repayment Of Principal, Extension Period Extension period Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities excluded from the calculation of net loss per share Information pertaining to Jing Marantz. Jing Marantz [Member] EX-101.PRE 18 srrk-20240630_pre.xml EX-101.PRE XML 20 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 02, 2024 Document and Entity Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Securities Act File Number 001-38501 Â Entity Registrant Name SCHOLAR ROCK HOLDING CORP Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 82-3750435 Â Entity Address, Address Line One 301 Binney Street, 3rd Floor Â Entity Address, City or Town Cambridge Â Entity Address, State or Province MA Â Entity Address, Postal Zip Code 02142 Â City Area Code 857 Â Local Phone Number 259 3860 Â Title of 12(b) Security Common Stock Â Trading Symbol SRRK Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 80,032,623 Entity Central Index Key 0001727196 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name:

dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 21 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 93,372 $ 101,855 Marketable securities 97,122 178,083 Prepaid expenses and other current assets 8,643 8,256 Total current assets 199,137 288,194 Property and equipment, net 3,549 4,600 Operating lease right-of-use asset 17,975 11,417 Restricted cash 2,407 2,407 Other long-term assets 3,797 4,417 Total assets 226,865 311,035 Current liabilities: Â Â Accounts payable 3,315 3,465 Accrued expenses 21,886 20,449 Operating lease liability 6,198 7,408 Short-term debt 1,588 1,334 Other current liabilities Â 85 Total current liabilities 32,987 32,741 Long-term portion of operating lease liability 11,773 4,392 Long-term debt 48,485 48,684 Total liabilities 93,245 85,817 Commitments and contingencies (Note 9) Stockholders' equity: Â Â Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023 Common stock, $0.001 par value; 300,000,000 shares authorized; 79,992,068 and 75,979,495 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 80 76 Additional paid-in capital 925,376 901,471 Accumulated other comprehensive income (loss) (54) 92 Accumulated deficit (791,782) (676,421) Total stockholders' equity 133,620 225,218 Total liabilities and stockholders' equity $ 226,865 $ 311,035 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -

Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 CONSOLIDATED BALANCE SHEETS Â Â Preferred stock, par value $ 0.001 $ 0.001 Preferred stock, shares authorized 10,000,000 10,000,000 Preferred stock, shares outstanding 0 0 Common stock, par value $ 0.001 $ 0.001 Common stock, shares authorized 300,000,000 Â Common stock, shares issued 79,992,068 75,979,495 Common stock, shares outstanding 79,992,068 75,979,495 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Operating expenses: Â Â Â Â Research and development $ 42,373 $ 26,867 $ 85,466 $ 56,602 General and administrative 17,125 12,215 32,451 22,989 Total operating expenses 59,498 39,082 117,917 79,591 Loss from operations (59,498) (39,082) (117,917) (79,591) Other income (expense), net 990 1,157 2,556 2,287 Net loss $ (58,508) $ (37,925) $ (115,361) $ (77,304) Net loss per share, basic (in dollars per share) $ (0.60) $ (0.47) $ (1.20) $ (0.97) Net loss per share, diluted (in dollars per share) $ (0.60) $ (0.47) $ (1.20) $ (0.97) Weighted average common shares outstanding, basic (in shares) 96,813,116 80,117,983 96,352,858 79,865,424 Weighted average common shares outstanding, diluted (in shares) 96,813,116 80,117,983 96,352,858 79,865,424 Comprehensive loss: Â Â Â Â Net loss $ (58,508) $ (37,925) $ (115,361) $ (77,304) Other comprehensive income (loss): Â Â Â Â Unrealized gain (loss) on marketable securities (4) 266 (146) 821 Total other comprehensive income (loss) (4) 266 (146) 821 Comprehensive loss $ (58,512) $ (37,659) $ (115,507) $ (76,483) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3:

http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 24 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Total Balance at beginning at Dec. 31, 2022 $ 52 $ 771,699 $ (884) $ (510,632) $ 260,235 Balance at beginning (in shares) at Dec. 31, 2022 51,672,579 Â Â Â Â Â Increase (decrease) in Stockholders' Equity Â Â Â Â Â Unrealized gain (loss) on marketable securities Â Â 555 Â 555 Sale of common shares, net of issuance costs Â 827 Â Â 827 Sale of common shares, net of issuance costs (in shares) 68,696 Â Â Â Â Exercise of stock options Â 243 Â Â 243 Exercise of stock options (in shares) 28,706 Â Â Â Â Issuance of common shares upon RSU vesting (in shares) 219,378 Â Â Â Â Equity-based compensation expense Â 6,170 Â Â 6,170 Other Â 2 Â Â 2 Net Income (Loss) Â Â Â (39,379) (39,379) Balance at end at Mar. 31, 2023 $ 52 778,941 (329) (550,011) 228,653 Balance at end (in shares) at Mar. 31, 2023 51,989,359 Â Â Â Â Balance at beginning at Dec. 31, 2022 $ 52 771,699 (884) (510,632) 260,235 Balance at beginning (in shares) at Dec. 31, 2022 51,672,579 Â Â Â Â Increase (decrease) in Stockholders' Equity Â Â Â Â Â Unrealized gain (loss) on marketable securities Â Â Â Â 821 Net Income (Loss) Â Â Â Â (77,304) Balance at end at Jun. 30, 2023 $ 55 790,445 (63) (587,936) 202,501 Balance at end (in shares) at Jun. 30, 2023 55,159,787 Â Â Â Â Balance at beginning at Mar. 31, 2023 $ 52 778,941 (329) (550,011) 228,653 Balance at beginning (in shares) at Mar. 31, 2023 51,989,359 Â Â Â Â Increase (decrease) in Stockholders' Equity Â Â Â Â Â Unrealized gain (loss) on marketable securities Â Â 266 Â 266 Sale of common shares, net of issuance costs $ 1 4,395 Â Â 4,396 Sale of common shares, net of issuance costs (in shares) 550,594 Â Â Â Â Exercise of stock options Â 292 Â Â 292 Exercise of stock options (in shares) 53,333 Â Â Â Â Issuance of common shares upon RSU vesting (in shares) 273,035 Â Â Â Â Exercise of pre-funded and common warrants $ 2 (2) Â Â Â Â Exercise of pre-funded and common warrants (in shares) 2,293,466 Â Â Â Â Equity-based compensation expense Â 6,818 Â Â 6,818 Other Â 1 Â Â 1 Net Income (Loss) Â Â Â (37,925) (37,925) Balance at end at Jun. 30, 2023 $ 55 790,445 (63) (587,936) 202,501 Balance at end (in shares) at Jun. 30, 2023 55,159,787 Â Â Â Â Balance at beginning at Dec. 31, 2023 $ 76 901,471 92 (676,421) 225,218 Balance at beginning (in shares) at Dec. 31, 2023 75,979,495 Â Â Â Â Increase (decrease) in Stockholders' Equity Â Â Â Â Â Unrealized gain (loss) on marketable securities Â Â (142) Â (142) Exercise of stock options Â 280 Â Â 280 Exercise of stock options (in shares) 47,293 Â Â

Â Â Issuance of common shares upon RSU vesting (in shares) 360,373 Â Â Â Â Exercise of pre-funded and common warrants $ 4 6,102 Â Â 6,106 Exercise of pre-funded and common warrants (in shares) 3,357,493 Â Â Â Â Equity-based compensation expense Â 8,164 Â Â 8,164 Net Income (Loss) Â Â Â (56,853) (56,853) Balance at end at Mar. 31, 2024 $ 80 916,017 (50) (733,274) 182,773 Balance at end (in shares) at Mar. 31, 2024 79,744,654 Â Â Â Â Balance at beginning at Dec. 31, 2023 $ 76 901,471 92 (676,421) 225,218 Balance at beginning (in shares) at Dec. 31, 2023 75,979,495 Â Â Â Â Increase (decrease) in Stockholders' Equity Â Â Â Â Â Unrealized gain (loss) on marketable securities Â Â Â Â (146) Net Income (Loss) Â Â Â Â (115,361) Balance at end at Jun. 30, 2024 $ 80 925,376 (54) (791,782) 133,620 Balance at end (in shares) at Jun. 30, 2024 79,992,068 Â Â Â Â Balance at beginning at Mar. 31, 2024 $ 80 916,017 (50) (733,274) 182,773 Balance at beginning (in shares) at Mar. 31, 2024 79,744,654 Â Â Â Â Increase (decrease) in Stockholders' Equity Â Â Â Â Â Unrealized gain (loss) on marketable securities Â Â (4) Â (4) Exercise of stock options Â 47 Â Â 47 Exercise of stock options (in shares) 6,617 Â Â Â Â Issuance of common shares upon RSU vesting (in shares) 240,797 Â Â Â Â Equity-based compensation expense Â 9,312 Â Â 9,312 Net Income (Loss) Â Â Â (58,508) (58,508) Balance at end at Jun. 30, 2024 $ 80 $ 925,376 $ (54) $ (791,782) $ 133,620 Balance at end (in shares) at Jun. 30, 2024 79,992,068 Â Â Â Â X - DefinitionNumber of shares issued during period on exercise of warrants. + ReferencesNo definition available. + Details Name: srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants Namespace Prefix: srrk_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of shares issued during period on exercise of warrants. + ReferencesNo definition available. + Details Name: srrk_StockIssuedDuringPeriodValueExerciseOfWarrants Namespace Prefix: srrk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 25 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (115,361) $ (77,304) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 1,096 1,464 Amortization of debt discount and debt issuance costs 135 157 Equity-based compensation 17,476 12,988 Amortization/accretion of investment securities (3,236) (2,563) Non-cash operating lease expense 2,893 3,658 Change in operating assets and liabilities: Â Â Prepaid expenses and other current assets (526) 1,571 Other assets 620 117 Accounts payable (150) (950) Accrued expenses 1,456 (10,516) Operating lease liabilities (3,280) (4,144) Other liabilities (104) (82) Net cash used in operating activities (98,981) (75,604) Cash flows from investing activities: Â Â Purchases of property and equipment (45) (71) Proceeds from sale of property and equipment Â 13 Purchases of marketable securities (68,449) (105,200) Maturities of marketable securities 152,500 180,000 Net cash provided by investing activities 84,006 74,742 Cash flows from financing activities: Â Â Proceeds from sale of common shares, net of issuance costs Â 5,223 Proceeds from pre-funded and common warrant exercises 6,106 Â Debt modification payment (80) Â Proceeds from stock option exercises 466 539 Other Â 3 Net cash provided by financing activities 6,492 5,765 Net (decrease)/increase in cash, cash equivalents and restricted cash (8,483) 4,903 Cash, cash equivalents and restricted cash, beginning of period 104,262 105,773 Cash, cash equivalents and restricted cash, end of period 95,779 110,676 Supplemental disclosure of non-cash items: Â Â Operating lease liability, adjustment from rent modification 9,451 Â Supplemental cash flow information: Â Â Cash paid for interest $ 3,330 $ 3,090 X - DefinitionEffect on cash flow during the period of non-cash operating lease liability, adjustment from rent modification. + ReferencesNo definition available. + Details Name: srrk_OperatingLeaseLiabilityAdjustmentFromRentModification Namespace Prefix: srrk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent operating liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X -

DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtRestructuringCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Nature of the Business 6 Months Ended Jun. 30, 2024 Nature of the Business Â Nature of the Business 1. Nature of the Business Scholar Rock Holding Corporation (the â€œCompanyâ€) is a late-stage biopharmaceutical company focused on the discovery, development, and delivery of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. As a global leader in transforming growth factor beta (â€œTGFÎ²â€) superfamily biology, the Companyâ€™s novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. By targeting the signaling proteins at the cellular level and acting in the disease microenvironment, the Company believes that it may avoid the historical dose-limiting safety challenges associated with inhibiting growth factors for therapeutic effect.The Companyâ€™s first product candidate, apitegromab, is a highly selective, fully human, monoclonal antibody, with a unique mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of spinal muscular atrophy (â€œSMAâ€). The Company is conducting SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with nonambulatory Type 2 and Type 3 SMA. In 2023, the Company completed enrollment for the Phase 3 SAPPHIRE trial. In 2024, the Company announced data from the Phase 2 TOPAZ trial extension period which showed patient outcomes at 48 months of treatment with apitegromab. The FDA granted Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation to apitegromab for the treatment of SMA in May 2021, August 2020 and March 2018, respectively. The European Medicines Agency (â€œEMAâ€) granted Priority Medicine (â€œPRIMEâ€) designation in March 2021 and the EC granted Orphan Medicinal Product designation in December 2018 to apitegromab for the treatment of SMA.In October 2023, the Company announced plans to expand into cardiometabolic disorders and advance its anti-myostatin program with SRK-439, a novel, fully human anti-myostatin monoclonal antibody, for evaluation in cardiometabolic disorders, including obesity, towards a potential investigational new drug (â€œINDâ€) submission in 2025. To inform the development of SRK-439, in May 2024 the Company initiated the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab to preserve muscle mass in individuals living with obesity and on background therapy of a GLP-1 receptor agonist (â€œGLP-1 RAâ€), with data expected in the second quarter of 2025. The Companyâ€™s second product candidate, SRK-181, a highly selective inhibitor of the activation of latent TGFÎ² is being developed for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies (referred to together as anti-PD-(L)1 antibody therapies). SRK-181 is being evaluated in the Companyâ€™s Phase 1 DRAGON proof-of-concept clinical trial in patients with locally advanced or metastatic solid tumors that exhibit resistance to anti-PD-(L)1 antibody therapies. The Phase 1 DRAGON trial completed enrollment in December 2023 and continues to treat patients who remain on study. This two-part clinical trial consists of a dose escalation portion (Part A) and a dose expansion evaluating SRK-181 in combination with an approved anti-PD- (L)1 antibody therapy (Part B). Part B includes the following active cohorts: urothelial carcinoma, cutaneous melanoma, non-small cell lung cancer, clear cell renal cell carcinoma, and head and neck squamous cell carcinoma. Safety, efficacy and biomarker data were presented in November 2023 at the Society for Immunotherapy of Cancer 38th Annual Meeting and in June 2024 at the American Society of Clinical Oncology (â€œASCOâ€) annual meeting. Additionally, the Company continues to create a pipeline of product candidates to deliver novel therapies to underserved patients suffering from a wide range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. The Company was originally formed in May 2012. Its principal offices are in Cambridge, Massachusetts.Since its inception, the Companyâ€™s operations have focused on research and development of monoclonal antibodies that selectively inhibit activation of growth factors for therapeutic effect, as well as establishing the Companyâ€™s intellectual property portfolio and performing research and development activities. The Company has primarily financed its operations through various equity financings, as well as research and development collaboration agreements and the Companyâ€™s debt facility (Note 10).Revenue generation activities have been limited to two collaborations, both containing research services and the issuance of a license. The first agreement, executed in 2013, was with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson and was terminated in July 2022. The second agreement (the â€œGilead Collaboration Agreementâ€), with Gilead Sciences, Inc. (â€œGileadâ€), was in effect between December 2018 and January 2022. No revenues have been recorded from the sale of any commercial product.The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug

candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Companyâ€™s product candidates. The Company has incurred recurring losses since its inception, including net losses of $115.4 million and $77.3 million for the six months ended June 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of $791.8 million as of June 30, 2024. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. The Company has evaluated whether there are certain events, considered in the aggregate, which raise substantial doubt about the Companyâ€™s ability to continue as a going concern beyond one year after the date that the consolidated financial statements are issued. Based on current operating plans, the Company does not expect to have sufficient cash, cash equivalents and marketable securities to fund its operating expenses and capital requirements beyond one year from the issuance of these consolidated financial statements without receiving additional external financing, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.The Company will require additional funding through a combination of contribution from revenues, equity offerings, debt financings or other capital sources, such as collaborations with other companies, strategic alliances or licensing arrangements to finance its future operations. The Company may not be able to obtain such funding on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any such funding may adversely affect the holdings or rights of the Companyâ€™s stockholders. If the Company is unable to obtain sufficient capital, the Company may be forced to delay or reduce the scale of some of its operations. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Policies Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting PoliciesSummary of Significant Accounting PoliciesThe significant accounting policies used in preparation of the unaudited consolidated financial statements are described in the Companyâ€™s audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Companyâ€™s Annual Report on Form 10-K. There have been no material changes to the significant accounting policies previously disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. â€‹Cash, Cash Equivalents and Restricted Cashâ€‹The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As of JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Cash and cash equivalentsâ€‹$ 93,372â€‹$ 108,064Restricted cashâ€‹Â 2,407â€‹Â 2,612â€‹â€‹$ 95,779â€‹$ 110,676â€‹Unaudited Interim Financial InformationThe consolidated financial statements of the Company included herein have been prepared pursuant to the rulesÂ and regulations of the Securities and Exchange Commission (the â€œSECâ€). The unaudited consolidated financial statements include the accounts of Scholar Rock Holding Corporation and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the fullÂ year or any other interim period.Use of EstimatesThe preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.Recently Adopted Accounting PronouncementsIn June 2016, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update 2016-13, Financial Instrumentsâ€”Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (â€œASU 2016-13â€). The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under previous GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. In November 2019, the FASB deferred the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. Therefore, the new standard was effective for the Company on January 1, 2023. The Company established processes and internal controls to comply with the new credit loss standard and related disclosure requirements. The Companyâ€™s investment policy has primary objectives of preservation of capital and maintenance of liquidity. As a result, the Company typically invests in money market funds, U.S. treasury obligations and government agency securities. The Company believes that such funds are subject to minimal credit risk. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these investments. The adoption of this standard did not have a material impact on the Companyâ€™s consolidated financial position and results of operations.Recently Issued Accounting PronouncementsIn November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2017-07â€). The standard requires disclosure of incremental segment information on an annual and interim basis and allows for multiple measures of a segmentâ€™s profit or loss provided that one of those measures is consistent with GAAP. The amendments in this update do not change how a public company identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments, but rather requires public entities to provide in interim periods all disclosures about a reporting segmentâ€™s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for interim periods starting on January 1, 2025. The option for early adoption is permitted, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures in future years as a result of the adoption of ASU 2023-07.In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which enhances the transparency of income tax disclosures to provide information to investors to better assess how a companyâ€™s operations and related tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This requires public entities to disclose additional categories in the rate reconciliation regarding federal and state income taxes, and provide more details surrounding reconciling items if a quantitative threshold is met. The effective date for public companies is for annual periods starting on January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures will be in future years as a result of the adoption of ASU 2023-09. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value of Financial Assets and Liabilities 6 Months Ended Jun. 30, 2024 Fair Value of Financial Assets and Liabilities Â Fair Value of Financial Assets and Liabilities 3. Fair Value of Financial Assets and LiabilitiesThe following tables summarize the assets and liabilities measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Prepaid Expenses and Other Assets 6 Months Ended Jun. 30, 2024 Prepaid Expense and Other Assets Â Prepaid Expenses and Other Assets 5. Prepaid Expenses and other AssetsAs of June 30, 2024 and December 31, 2023, prepaid expenses and other assets consist of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹AsÂ ofâ€‹â€‹JuneÂ 30,Â â€‹Â Â Â Â DecemberÂ 31,Â â€‹Â Â Â Â 2024â€‹2023Prepaid external research and development expensesâ€‹$ 3,392â€‹$ 4,059Prepaid otherâ€‹â€‹ 2,906â€‹â€‹ 2,486Receivablesâ€‹â€‹ 1,288â€‹â€‹ 1,076Prepaid insuranceâ€‹â€‹ 1,057â€‹â€‹ 635â€‹â€‹$ 8,643â€‹$ 8,256â€‹As of June 30, 2024 and December 31, 2023, other long-term assets consist of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹AsÂ ofâ€‹â€‹JuneÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â Â Â Â 2024â€‹2023Prepaid external research and development expensesâ€‹$ 3,399â€‹$ 4,074Prepaid otherâ€‹â€‹ 375â€‹â€‹ 312Prepaid insuranceâ€‹â€‹ 23â€‹â€‹ 31â€‹â€‹$ 3,797â€‹$ 4,417â€‹ X - DefinitionThe entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets. + ReferencesNo definition available. + Details Name: us-gaap_OtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses 6 Months Ended Jun. 30, 2024 Accrued Expenses Â Accrued Expenses 6. Accrued ExpensesAs of June 30, 2024 and December 31, 2023, accrued expenses consist of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹AsÂ ofâ€‹â€‹JuneÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹Â Â Â Â 2024â€‹2023Accrued external research and development expenseâ€‹$ 9,339â€‹$ 6,825Accrued payroll and related expensesâ€‹â€‹ 7,352â€‹â€‹ 10,591Accrued professional and consulting expenseâ€‹â€‹ 4,254â€‹â€‹ 2,267Accrued otherâ€‹â€‹ 941â€‹â€‹ 766â€‹â€‹$ 21,886â€‹$ 20,449â€‹ X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock 6 Months Ended Jun. 30, 2024 Common Stock. Â Common Stock 7. Common Stockâ€‹In June 2024, the stockholders approved an amendment to our amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000. The Company has had a sales agreement in place during various time periods with Jefferies LLC with respect to an at-the-market (â€œATMâ€) offering program. Under this program, the Company is able to offer and sell, from time to time at its sole discretion, shares of its common stock through Jefferies as its sales agent. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. The current ATM agreement, established in November 2022, allows for the sale of shares of common stock having an aggregate offering price of up to $100 million. As of June 30, 2024, the Company has sold 619,290 shares, generating net proceeds of $5.2 million, under the ATM program. No sales were made under the ATM program during the six months ended June 30, 2024. The Company has issued pre-funded warrants, as well as warrants as part of its financing activities. Both the pre-funded warrants and warrants meet the conditions for equity classification and are recorded as a component of stockholdersâ€™ equity within additional paid-in capital. In June 2022 and November 2020, the Company issued 25,510,205 and 2,179,487 pre-funded warrants, respectively. During the six months ended June 30, 2024, 2,526,833 of the Companyâ€™s pre-funded warrants were exercised. As of June 30, 2024, the Company has 17,008,164 pre-funded warrants outstanding. In June 2022, the Company also issued 10,459,181 warrants with an exercise price of $7.35. During the six months ended June 30, 2024, 830,660 of the Companyâ€™s warrants were exercised. As of June 30, 2024, the Company has 9,157,496 warrants outstanding. X - DefinitionThe entire disclosure of common stock. + ReferencesNo definition available. + Details Name: srrk_CommonStockTextBlock Namespace Prefix: srrk_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation 6 Months Ended Jun. 30, 2024 Equity-Based Compensation Â Equity-Based Compensation 8. Equity-Based CompensationThe Company recorded equity-based compensation expense related to all equity-based awards, which was allocated as follows in the consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Six Months Ended â€‹â€‹JuneÂ 30,Â â€‹JuneÂ 30,Â â€‹Â Â 2024Â Â Â 2023Â Â 2024Â Â Â 2023Research and development expenseâ€‹$ 4,050â€‹$ 2,838â€‹$ 7,581â€‹$ 5,483General and administrative expenseâ€‹Â 5,261â€‹Â 3,980â€‹Â 9,895â€‹Â 7,505â€‹â€‹$ 9,311â€‹$ 6,818â€‹$ 17,476â€‹$ 12,988â€‹â€‹The following table summarizes the Companyâ€™s unrecognized equity-based compensation expense as of June 30, 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of June 30, 2024â€‹â€‹Unrecognized Expense (in thousands)Â Â Â Â Weighted Average Remaining Period of Recognition (years)Restricted Stock Units$ 35,116â€‹ 2.8Stock Optionsâ€‹ 42,470â€‹ 2.6â€‹$ 77,586â€‹â€‹â€‹Restricted Stock UnitsThe following table summarizes the Companyâ€™s restricted stock unit activity for the current year:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weightedâ€‹â€‹â€‹Average Grantâ€‹Â Â Â Â NumberÂ ofÂ UnitsÂ Â Â Date Fair ValueRestricted stock units as of DecemberÂ 31,Â 2023Â 2,089,552â€‹$ 11.92GrantedÂ 1,647,159â€‹$ 14.98VestedÂ (601,170)â€‹$ 12.16ForfeitedÂ (150,878)â€‹$ 12.38Restricted stock units as of JuneÂ 30,Â 2024Â 2,984,663â€‹$ 13.54â€‹The total fair value of restricted stock units vested during the six months ended June 30, 2024 was $8.2 million.Stock OptionsThe following table summarizes the Companyâ€™s stock option activity for the current year:â€‹Weightedâ€‹â€‹â€‹â€‹â€‹â€‹Weightedâ€‹Averageâ€‹â€‹â€‹â€‹NumberÂ ofÂ â€‹Averageâ€‹Remainingâ€‹Aggregateâ€‹Â Â PriceÂ Â Â Contractual TermÂ Â Â Intrinsic Valueâ€‹â€‹â€‹â€‹â€‹â€‹(inÂ years)â€‹(inÂ thousands)Outstanding as of DecemberÂ 31,Â 2023Â 7,300,953â€‹$ 15.00â€‹ 7.90â€‹$ 52,299GrantedÂ 2,196,217â€‹$ 14.98â€‹â€‹â€‹â€‹Exercisedâ€‹ (53,910)â€‹$ 6.09â€‹â€‹â€‹â€‹CancelledÂ (275,708)â€‹$ 17.91â€‹â€‹â€‹â€‹Outstanding as of JuneÂ 30,Â 2024Â 9,167,552â€‹$ 14.96â€‹ 7.86â€‹$ 3,529Options exercisable as of JuneÂ 30,Â 2024Â 4,473,458â€‹$ 16.82â€‹ 6.75â€‹$ 2,506â€‹Using the Black-Scholes option pricing model, the weighted average fair value of options granted during the six months ended June 30, 2024 was $11.50. The following weighted average assumptions were used in determining the fair value of options granted in the six months ended June 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended â€‹â€‹JuneÂ 30,Â â€‹â€‹2024Â Â Â 2023â€‹Risk-free interest rate4.18 %Â 3.84 %Expected dividend yield0.0%Â Â 0.0%Expected term (years to liquidity)5.98 â€‹6.13 â€‹Expected volatility91.35 %Â 90.51 %â€‹ X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies. Â Commitments and Contingencies 9. Commitments and ContingenciesOperating Lease In November 2019, the Company entered into a lease of office and laboratory space at 301 Binney Street in Cambridge, Massachusetts to be used as its new corporate headquarters (the â€œLeaseâ€). The expiration date of the Lease was originally in August 2025 and included an option to extend the term by two years. The base rent under the original Lease was $6.9 million per year, subject to an annual increase of 3.5%, and the Company was subject to a free-rent period through mid-August 2020. Variable lease payments include the Companyâ€™s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The Lease included incentives of $14.1 million in the form of an allowance for tenant improvements related to the design and build out of the space. In connection with the Lease, the Company has secured a letter of credit for $2.3 million which renews automatically each year. The Lease commencement date, for accounting purposes, was reached in September 2020. â€‹In May 2024, the Company entered into the First Amendment (the â€œLease Amendmentâ€) to the Lease to extend the term for approximately two years, commencing on August 19, 2025 (the â€œFirst Extension Termâ€) with the base rent to start at approximately $6.2 million per year, followed by a 3% annual increase. Pursuant to the Lease Amendment, the Company also has an option to extend the term of the Lease by five years, upon the expiration of the First Extension Term.â€‹Other information related to the Lease is as follows (in thousands, except lease term and discount rate):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For Three Months Ended â€‹For Six Months Ended â€‹â€‹Â Â Â Â JuneÂ 30,Â Â Â Â Â JuneÂ 30,Â â€‹â€‹â€‹2024â€‹2024Â Â Â Â Â Â Lease Cost:â€‹â€‹â€‹â€‹â€‹â€‹Operating lease costâ€‹$ 1,751â€‹$ 3,576â€‹Variable lease costâ€‹â€‹ 363â€‹â€‹ 723â€‹Total lease costâ€‹$ 2,114â€‹$ 4,299â€‹â€‹â€‹â€‹â€‹â€‹For Six Months Ended â€‹â€‹JuneÂ 30,Â â€‹â€‹2024Â Â Â Â Â Â Other information:â€‹â€‹â€‹Operating cash flows used for operating leases$ 3,963â€‹Weighted average remaining lease termâ€‹ 3.2â€‹Weighted average incremental borrowing rateâ€‹ 13.1%â€‹â€‹Legal Proceedingsâ€‹The Company, from time to time, may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the six months ended June 30, 2024 and 2023. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt 6 Months Ended Jun. 30, 2024 Debt Â Debt 10. DebtOn October 16, 2020 (the â€œClosing Dateâ€) the Company entered into a Loan and Security Agreement with Oxford Finance LLC (â€œOxfordâ€) and Silicon Valley Bank (â€œSVBâ€) for $50.0 million (the â€œLoan and Security Agreementâ€). Tranche 1 of $25.0 million was funded on the Closing Date. The Company had an additional $25.0 million in loan proceeds available under Tranche 2 which was funded in December 2021, in conjunction with the Company entering into the First Amendment to Loan and Security Agreement with Oxford and SVB. The Loan and Security Agreement was to mature on May 1, 2025 and required interest-only payments through November 2022, with principal payments to commence in December 2022. Pursuant to the Loan and Security Agreement, the Company was required to maintain cash in an SVB account equal to the lesser ofÂ 100%Â of the Companyâ€™s consolidated cash orÂ 105%Â of the dollar amount of the outstanding debt. â€‹On November 10, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (â€œAmendment 2â€) to increase the Companyâ€™s borrowing capacity under the Loan and Security Agreement to an amount up to $100.0 million, comprised of the original $50.0 million loan which remains outstanding and two additional $25.0 million tranches. The first $25.0 million tranche available under Amendment 2, was available at the Companyâ€™s discretion through December 2023 upon achievement of certain development and business performance milestones. The Company did not exercise this tranche. The second $25.0 million tranche available under Amendment 2, may be available upon the Companyâ€™s request, at Oxford and SVBâ€™s discretion. Amendment 2 also extended the interest-only payment period for an additional 24 months through November 2024, with principal payments to commence in December 2024. The maturity of the loan was extended to November 2027. â€‹Effective upon Amendment 2, the interest rate on the unpaid principal is the greater of the Wall Street Journal prime rate plus 4.60% or 9.35% per annum. Prepayment is permitted and may include a pre-payment fee ranging from 0% - 3% (of the principal amount being prepaid), depending on when the prepayment is made. The Company is also required to make a final payment equal to 2% of the original principal amount. â€‹In conjunction with Amendment 2, the Company was required to pay $0.9 million for the accrued portion of the final payment on the previous outstanding balance.â€‹On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (â€œFDICâ€) as receiver. Afterward, the FDIC transferred all deposits of the former Silicon Valley Bank to Silicon Valley Bridge Bank, N.A., as operated by the FDIC. On March 27, 2023, Silicon Valley Bridge Bank was closed by the Office of the Comptroller of the Currency, and the FDIC was appointed as receiver. First Citizens Bank then entered into an agreement with the FDIC to purchase out of FDIC receivership substantially all loans and certain other assets and assume all customer deposits and certain other liabilities of Silicon Valley Bridge Bank. On March 27, 2023, Silicon Valley Bridge Bank and its U.S. branches began operating as Silicon Valley Bank, a division of First Citizens Bank.â€‹On April 18, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement to amend certain provisions relating to the Companyâ€™s operating accounts.â€‹On May 17, 2024, the Company entered into the Fourth Amendment to the Loan and Security Agreement (â€œLoan Amendment No. 4â€). The Company currently has $50.0 million outstanding under the Loan and Security Agreement, which was drawn down in two equal tranches. The third $25.0 million tranche is available at the Companyâ€™s discretion through December 2024, upon achievement of certain clinical and business milestones, which were amended under Loan Amendment No. 4. The fourth $25.0 million tranche may be available through June 1, 2025 (or through December 1, 2025 upon achievement of certain business milestones) upon the Companyâ€™s request, at Oxford and SVBâ€™s discretion. Amendment No. 4 also extends the interest-only payment period for an additional six months through May 2025, with principal payments to commence in June 2025, or for an additional six months through November 2025 upon achievement of certain business performance milestones, with principal payments to commence in December 2025. X - ReferencesNo definition available. + Details Name:

us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss per Share 6 Months Ended Jun. 30, 2024 Net Loss per Share Â Net Loss per Share 11. Net Loss per ShareThe Company calculates basic net loss per share by dividing net loss by the weighted average number of common shares outstanding, excluding restricted common stock. The weighted average number of common shares used in the basic and diluted net loss per share calculation includes the pre-funded warrants issued in connection with the Companyâ€™s November 2020 and June 2022 follow-on offerings as the pre-funded warrants are exercisable at any time for nominal cash consideration. As of June 30, 2024, 10,681,528 pre-funded warrants have been exercised and 17,008,164 pre-funded warrants remain outstanding. The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.â€‹The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended JuneÂ 30,Â â€‹Â Â Â Â Â 2024Â Â Â Â Â 2023Restricted stock unitsâ€‹ 2,984,663â€‹ 2,047,026Stock optionsâ€‹ 9,167,552â€‹ 7,835,195Warrantsâ€‹ 9,157,496â€‹ 10,459,181â€‹â€‹ 21,309,711â€‹ 20,341,402â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Net Income (Loss) $ (58,508) $ (56,853) $ (37,925) $ (39,379) $ (115,361) $ (77,304) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 38 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended 6 Months Ended Jun. 30, 2024 shares Jun. 30, 2024 shares Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â Trading PlansDuring the three months ended June 30, 2024, certain of our officers adopted contracts, instructions or written plans for the purchase or sale of our securities as noted below: Name and TitleType of Trading ArrangementAction Taken (Date of Action)Duration or End DateAggregate Number of Securities to be SoldDescription of Trading ArrangementJing Marantz, Chief Medical OfficerTrading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c)Adoption (April 19, 2024)August 11, 2025120,000Sale of the Company's common stock pursuant to the terms of the planâ€‹Other than as disclosed above, no other officer or director adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended June 30, 2024. Jing Marantz [Member] Â Â Trading Arrangements, by Individual Â Â Name Jing Marantz Â Title Chief Medical Officer Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date April 19, 2024 Â Aggregate Available 120,000 120,000 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name:

ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd_IndividualAxis=srrk_JingMarantzMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Policies Â Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents and Restricted Cashâ€‹The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As of JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Cash and cash equivalentsâ€‹$ 93,372â€‹$ 108,064Restricted cashâ€‹Â 2,407â€‹Â 2,612â€‹â€‹$ 95,779â€‹$ 110,676 Unaudited Interim Financial Information Unaudited Interim Financial InformationThe consolidated financial statements of the Company included herein have been prepared pursuant to the rulesÂ and regulations of the Securities and Exchange Commission (the â€œSECâ€). The unaudited consolidated financial statements include the accounts of Scholar Rock Holding Corporation and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the fullÂ year or any other interim period. Use of Estimates Use of EstimatesThe preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates. Recently Adopted and Recently Issued Accounting Pronouncements Recently Adopted Accounting PronouncementsIn June 2016, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update 2016-13, Financial Instrumentsâ€”Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (â€œASU 2016-13â€). The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under previous GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. In November 2019, the FASB deferred the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. Therefore, the new standard was effective for the Company on January 1, 2023. The Company established processes and internal controls to comply with the new credit loss standard and related disclosure requirements. The Companyâ€™s investment policy has primary objectives of preservation of capital and maintenance of liquidity. As a result, the Company typically invests in money market funds, U.S. treasury obligations and government agency securities. The Company believes that such funds are subject to minimal credit risk. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these investments. The adoption of this standard did not have a material impact on the Companyâ€™s consolidated financial position and results of operations.Recently Issued Accounting PronouncementsIn November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2017-07â€). The standard requires disclosure of incremental segment information on an annual and interim basis and allows for multiple measures of a segmentâ€™s profit or loss provided that one of those measures is consistent with GAAP. The amendments in this update do not change how a public company identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments, but rather requires public entities to provide in interim periods all disclosures about a reporting segmentâ€™s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for interim periods starting on January 1, 2025. The option for early adoption is permitted, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures in future years as a result of the adoption of ASU 2023-07.In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which enhances the transparency of income tax disclosures to provide information to investors to better assess how a companyâ€™s operations and related tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This requires public entities to disclose additional categories in the rate reconciliation regarding federal and state income taxes, and provide more details surrounding reconciling items if a quantitative threshold is met. The effective date for public companies is for annual periods starting on January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures will be in future years as a result of the adoption of ASU 2023-09. X - DefinitionDisclosure of accounting policy for unaudited interim financial information. + ReferencesNo definition available. + Details Name: srrk_UnauditedInterimFinancialInformationPolicyTextBlock Namespace Prefix: srrk_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Tables) 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Policies Â Reconciliation of cash, cash equivalents and restricted cash The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As of JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Cash and cash equivalentsâ€‹$ 93,372â€‹$ 108,064Restricted cashâ€‹Â 2,407â€‹Â 2,612â€‹â€‹$ 95,779â€‹$ 110,676 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cash and cash equivalents restricted as to withdrawal or usage. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 8 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value of Financial Assets and Liabilities (Tables) 6 Months Ended Jun. 30, 2024 Fair Value of Financial Assets and Liabilities Â Schedule of summary of the assets and liabilities measured at fair value on a recurring basis The following tables summarize the assets and liabilities measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

DOCUMENT v3.24.2.u1 Equity-Based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Equity-Based Compensation Â Summary of allocation of equity-based compensation The Company recorded equity-based compensation expense related to all equity-based awards, which was allocated as follows in the consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Six Months Ended â€‹â€‹JuneÂ 30,Â â€‹JuneÂ 30,Â â€‹Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Research and development expenseâ€‹$ 4,050â€‹$ 2,838â€‹$ 7,581â€‹$ 5,483General and administrative expenseâ€‹Â 5,261â€‹Â 3,980â€‹Â 9,895â€‹Â 7,505â€‹â€‹$ 9,311â€‹$ 6,818â€‹$ 17,476â€‹$ 12,988 Summary of unrecognized equity-based compensation expense â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of June 30, 2024â€‹â€‹Unrecognized Expense (in thousands)Â Â Â Â Weighted Average Remaining Period of Recognition (years)Restricted Stock Units$ 35,116â€‹ 2.8Stock Optionsâ€‹ 42,470â€‹ 2.6â€‹$ 77,586â€‹â€‹ Summary of stock activity â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weightedâ€‹â€‹â€‹â€‹AverageÂ Grantâ€‹Â Â Â Â NumberÂ ofÂ UnitsÂ Â Â Â Date Fair ValueRestricted stock units as of DecemberÂ 31,Â 2023Â 2,089,552â€‹$ 11.92GrantedÂ 1,647,159â€‹$ 14.98VestedÂ (601,170)â€‹$ 12.16ForfeitedÂ (150,878)â€‹$ 12.38Restricted stock units as of JuneÂ 30,Â 2024Â 2,984,663â€‹$ 13.54 Summary of stock option activity â€‹Weightedâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Weightedâ€‹Averageâ€‹â€‹â€‹â€‹â€‹NumberÂ ofÂ â€‹Averageâ€‹Remainingâ€‹Aggregateâ€‹Â Â Â Â PriceÂ Â Â Â Contractual TermÂ Â Â Â Intrinsic Valueâ€‹â€‹â€‹â€‹â€‹â€‹â€‹(inÂ years)â€‹(inÂ thousands)Outstanding as of DecemberÂ 31,Â 2023Â 7,300,953â€‹$ 15.00â€‹ 7.90â€‹$ 52,299GrantedÂ 2,196,217â€‹$ 14.98â€‹â€‹â€‹â€‹â€‹Exercisedâ€‹ (53,910)â€‹$ 6.09â€‹â€‹â€‹â€‹â€‹CancelledÂ (275,708)â€‹$ 17.91â€‹â€‹â€‹â€‹â€‹Outstanding as of JuneÂ 30,Â 2024Â 9,167,552â€‹$ 14.96â€‹ 7.86â€‹$ 3,529Options exercisable as of JuneÂ 30,Â 2024Â 4,473,458â€‹$ 16.82â€‹ 6.75â€‹$ 2,506 Schedule of weighted average assumptions in fair value â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended â€‹â€‹JuneÂ 30,Â â€‹â€‹2024Â Â Â Â 2023â€‹Risk-free interest rate4.18 %Â Â 3.84 %Expected dividend yield0.0%Â Â 0.0%Expected term (years to liquidity)5.98 â€‹6.13 â€‹Expected volatility91.35 %Â Â 90.51 %â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (i) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Tables) 6 Months Ended Jun. 30, 2024 Commitments and Contingencies. Â Summary of lease costs Other information related to the Lease is as follows (in thousands, except lease term and discount rate):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For Three Months Ended â€‹For Six Months Ended â€‹â€‹Â Â Â Â JuneÂ 30,Â Â Â Â Â JuneÂ 30,Â â€‹â€‹â€‹2024â€‹2024Â Â Â Â Â Â Lease Cost:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating lease costâ€‹$ 1,751â€‹$ 3,576â€‹Variable lease costâ€‹â€‹ 363â€‹â€‹ 723â€‹Total lease costâ€‹$ 2,114â€‹$ 4,299â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For Six Months Ended â€‹â€‹JuneÂ 30,Â â€‹â€‹2024Â Â Â Â Â Â Other information:â€‹â€‹â€‹Operating cash flows used for operating leases$ 3,963â€‹Weighted average remaining lease termâ€‹ 3.2â€‹Weighted average incremental borrowing rateâ€‹ 13.1% X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 47 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss per Share (Tables) 6 Months Ended Jun. 30, 2024 Net Loss per Share Â Summary of anti-dilutive securities â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Restricted stock unitsâ€‹ 2,984,663â€‹ 2,047,026Stock optionsâ€‹ 9,167,552â€‹ 7,835,195Warrantsâ€‹ 9,157,496â€‹ 10,459,181â€‹â€‹ 21,309,711â€‹ 20,341,402â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 48 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Nature of the Business (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Nature of the Business Â Â Â Â Â Â Â Net Income (Loss) $ (58,508) $ (56,853) $ (37,925) $ (39,379) $ (115,361) $ (77,304) Â Accumulated deficit $ (791,782) Â Â Â $ (791,782) Â $ (676,421) X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name

Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 49 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Cash (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Dec. 31, 2022 Cash and cash equivalents and restricted cash Â Â Â Â Cash and cash equivalents $ 93,372 $ 101,855 $ 108,064 Â Restricted cash 2,407 2,407 2,612 Â Total $ 95,779 $ 104,262 $ 110,676 $ 105,773 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RestrictedCashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 50 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value of Financial Assets and Liabilities - (Details) - USD ($) $ in Thousands 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Marketable securities: Â Â Transfer of assets between fair value measurement levels. $ 0 $ 0 Recurring Â Â Marketable securities: Â Â U.S. Treasury obligations and government agency securities 97,122 178,083 Total assets 186,141 270,612 Recurring | Money market funds Â Â Assets: Â Â Cash and cash equivalents 79,688 61,764 Recurring | U.S. Treasury obligations Â Â Assets: Â Â Cash and cash equivalents 9,331 30,765 Recurring | Level 1 Â Â Marketable securities: Â Â U.S. Treasury obligations and government agency securities 97,122 178,083 Total assets 186,141 270,612 Recurring | Level 1 | Money market funds Â Â Assets: Â Â Cash and cash equivalents 79,688 61,764 Recurring | Level 1 | U.S. Treasury obligations Â Â Assets: Â Â Cash and cash equivalents $ 9,331 $ 30,765 X - DefinitionTransfer Of Assets Between Fair Value Measurement Levels. + ReferencesNo definition available. + Details Name: srrk_TransferOfAssetsBetweenFairValueMeasurementLevels Namespace Prefix: srrk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Marketable Securities - Summary of Investments (Details) $ in Thousands Jun. 30, 2024 USD ($) security Dec. 31, 2023 USD ($) security Marketable securities available-for-sale Â Â Amortized Cost $ 97,176 $ 177,991 Gross Unrealized Gains 1 93 Gross Unrealized Losses (55) (1) Estimated Fair Value 97,122 178,083 Aggregate fair value of marketable securities with unrealized gains (losses) position for less than a year $ 81,300 $ 11,900 Number of investments in an unrealized loss position for less than a year | security 47 3 U.S. Treasury obligations Â Â Marketable securities available-for-sale Â Â Amortized Cost $ 97,176 $ 177,991 Gross Unrealized Gains 1 93 Gross Unrealized Losses (55) (1) Estimated Fair Value $ 97,122 $ 178,083 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Prepaid Expenses and Other Assets (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Prepaid expenses and other current assets Â Â Prepaid external research and development expense $ 3,392 $ 4,059 Prepaid other 2,906 2,486 Receivables 1,288 1,076 Prepaid insurance 1,057 635 Total prepaid expenses and other current assets 8,643 8,256 Other long-term assets Â Â Prepaid external research and development expense 3,399 4,074 Prepaid other 375 312 Prepaid insurance 23 31 Total other long-term assets $ 3,797 $ 4,417 X - DefinitionThe amount of prepaid external research and development expense as of the balance sheet date. Used to reflect the current portion of the asset (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent Namespace Prefix: srrk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of prepaid external research and development expense as of the balance sheet date. Used to reflect the noncurrent portion of the asset (due after one year or outside the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent Namespace Prefix: srrk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits after a future period of one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: srrk_PrepaidInsuranceNoncurrent Namespace Prefix: srrk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NontradeReceivablesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OtherAssetsNoncurrentDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseOtherNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 53 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Accrued Expenses Â Â Accrued external research and development expense $ 9,339 $ 6,825 Accrued payroll and related expenses 7,352 10,591 Accrued professional and consulting expense 4,254 2,267 Accrued other 941 766 Accrued expenses $ 21,886 $ 20,449 X - DefinitionThe amount of accrued external research and development expense as of the balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: srrk_AccruedExternalResearchAndDevelopmentExpense Namespace Prefix: srrk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 54 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock - (Details) - USD ($) $ / shares in Units, $ in Millions 6 Months Ended Jun. 30, 2024 May 31, 2024 Nov. 30, 2022 Jun. 30, 2022 Nov. 30, 2020 Equity Â Â Â Â Â Common stock, shares authorized 300,000,000 150,000,000 Â Â Â Pre-funded warrants Â Â Â Â Â Equity Â Â Â Â Â Warrant to purchase (in shares) Â Â Â 25,510,205 2,179,487 Exercise of pre-funded and common warrants (in shares) 2,526,833 Â Â Â Â Outstanding warrants (in shares) 17,008,164 Â Â Â Â Â Pre-funded warrants | Aggregate Â Â Â Â Â Equity Â Â Â Â Â Exercise of pre-funded and common warrants (in shares) 10,681,528 Â Â Â Â Warrants, non pre-funded Â Â Â Â Â Equity Â Â Â Â Â Warrant to purchase (in shares) Â Â Â 10,459,181 Â Exercise of pre-funded and common warrants (in shares) 830,660 Â Â Â Â Â Outstanding warrants (in shares) 9,157,496 Â Â Â Â Â Warrant exercise price (in dollars per share) Â Â Â $ 7.35 Â ATM Offering Â Â Â Â Â Equity Â Â Â Â Â Maximum aggregate offering price Â Â $ 100.0 Â Â Sale of common shares, net of issuance costs (in shares) 0 Â Â Â Â Â ATM Offering | Aggregate Â Â Â Â Â Equity Â Â Â Â Â Sale of shares $ 5.2 Â Â Â Â Â Sale of common shares, net of issuance costs (in shares) 619,290 Â Â Â Â X - DefinitionMaximum aggregate offering price. + ReferencesNo definition available. + Details Name: srrk_MaximumAggregateOfferingPrice Namespace Prefix: srrk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares issued during period on exercise of warrants. + ReferencesNo definition available. + Details Name: srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants Namespace Prefix: srrk_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=srrk_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srrk_AggregateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=srrk_CommonWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=srrk_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation - Expense (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Equity-based compensation Â Â Â Â Equity-based compensation expense $ 9,311 $ 6,818 $ 17,476 $ 12,988 Research and development expense Â Â Â Â Â Equity-based compensation Â Â Â Â Â Equity-based compensation expense 4,050 2,838 7,581 5,483 General and administrative expense Â Â Â Â Â Equity-based compensation Â Â Â Â Â Equity-based compensation expense $ 5,261 $ 3,980 $ 9,895 $ 7,505 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation - Unrecognized Expense (Details) $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Equity-based compensation Â Unrecognized Expense $ 77,586 Restricted stock units Â Equity-based compensation Â Unrecognized Expense $ 35,116 Weighted Average Remaining Period of Recognition 2 years 9 months 18 days Employee Stock Option Â Equity-based compensation Â Unrecognized Expense $ 42,470 Weighted Average Remaining Period of Recognition 2 years 7 months 6 days X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation - Restricted stock (Details) - Restricted stock units $ / shares in Units, $ in Millions 6 Months Ended Jun. 30, 2024 USD ($) $ / shares shares Number of Shares/Units Â Outstanding, beginning (in shares) | shares 2,089,552 Granted (in shares) | shares 1,647,159 Vested (in shares) | shares (601,170) Forfeited (in shares) | shares (150,878) Outstanding, end (in shares) | shares 2,984,663 Weighted Average Grant Date Fair Value Â Outstanding, beginning (in dollars per share) | $ / shares $ 11.92 Granted (in dollars per share) | $ / shares 14.98 Vested (in dollars per share) | $ / shares 12.16 Forfeited (in dollars per share) | $ / shares 12.38 Outstanding, end (in dollars per share) | $ / shares $ 13.54

Fair value of non-option awards vested | $ $ 8.2 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionFair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation - Stock Options (Details) - Employee Stock Option $ / shares in Units, $ in Thousands 6 Months Ended 12 Months Ended Jun. 30, 2024 USD ($) $ / shares shares Dec. 31, 2023 USD ($) $ / shares shares Number of Units Â Â Outstanding, beginning (in shares) | shares 7,300,953 Â Granted (in shares) | shares 2,196,217 Â Exercised (in shares) | shares (53,910) Â Cancelled (in shares) | shares (275,708) Â Outstanding, end (in shares) | shares 9,167,552 7,300,953 Options exercisable, end (in shares) | shares 4,473,458 Â Weighted Average Exercise Price Â Â Outstanding, beginning (in dollars per share) $ 15.00 Â Granted (in dollars per share) 14.98 Â Exercised (in dollars per share) 6.09 Â Cancelled (in dollars per share) 17.91 Â Outstanding, end (in dollars per share) 14.96 $ 15.00 Options exercisable, end (in dollars per share) $ 16.82 Â Stock options Â Â Weighted average remaining contractual term 7 years 10 months 9 days 7 years 10 months 24 days Weighted average remaining contractual term, exercisable 6 years 9 months Â Aggregate intrinsic value, beginning | $ $ 52,299 Â Aggregate intrinsic value, end | $ 3,529 $ 52,299 Aggregate intrinsic value, exercisable | $ $ 2,506 Â Weighted average grant date fair value (in dollars per share) $ 11.50 Â X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-

1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation - Assumptions (Details) - Employee Stock Option 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Assumptions used in determining the fair value of options Â Â Risk-free interest rate 4.18% 3.84% Expected dividend yield 0.00% 0.00% Expected term (years to liquidity) 5 years 11 months 23 days 6 years 1 month 17 days Expected volatility 91.35% 90.51% X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended May 31, 2024 Nov. 30, 2019 Jun. 30, 2024 Jun. 30, 2024 Lease Cost: Â Â Â Â Operating lease cost Â Â $ 1,751 $ 3,576 Variable lease cost Â Â 363 723 Total lease cost Â Â $ 2,114 4,299 Operating cash flows used for operating leases Â Â Â $ 3,963 Weighted average remaining lease term Â Â 3 years 2 months 12 days 3 years 2 months 12 days Weighted average incremental borrowing rate Â Â 13.10% 13.10% 301 Binney St, Cambridge MA Â Â Â Â Â Leased assets Â Â Â Â Option to extend the term true true Â Â Renewal term 2 years 2 years Â Â Base rent $ 6,200 $ 6,900 Â Â Annual upward adjustment (as a percent) 3.00% 3.50% Â Â Incentive to lease Â Â $ 14,100 Â Â Letter of credit Â $ 2,300 Â Â 301 Binney St, Cambridge MA | First extension Â Â Â Â Leased assets Â Â Â Â Renewal term 5 years Â Â Â Â X - DefinitionThe annual upward lease adjustment percentage. + ReferencesNo definition available. + Details Name: srrk_AnnualLeaseAdjustmentPercent Namespace Prefix: srrk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of base rent for initial period under the lease. + ReferencesNo definition available. + Details Name: srrk_LesseeOperatingLeaseBaseRent Namespace Prefix: srrk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of incentive granted by lessor to lessee. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481178/840-20-25-6Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481178/840-20-25-7Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 30 -Paragraph 5 -Subparagraph (a) -SubTopic 10 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479924/842-10-30-5 + Details Name: us-gaap_IncentiveToLessee Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeaseCostAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionThe total amount of the contingent obligation under letters of credit outstanding as of the reporting date. + ReferencesNo definition available. + Details Name: us-gaap_LettersOfCreditOutstandingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=srrk_BinneyStCambridgeMaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srrk_UponExpirationOfFirstExtensionTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt (Details) - Loan and Security Agreement - USD ($) $ in Millions 1 Months Ended May 17, 2024 Nov. 10, 2022 Oct. 16, 2020 Dec. 31, 2021 Debt Â Â Â Â Line of credit maximum Â $ 100.0 $ 50.0 Â Proceeds from credit facility Â Â $ 25.0 $ 25.0 Interest only period Â 24 months Â Â Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Â us-gaap:PrimeRateMember Â Â Final payment fee (as a percent) Â 2.00% Â Â Repayments of debt Â $ 0.9 Â Â Percentage of dollar value of company's consolidated cash Â Â 100.00% Â Amount of cash required in a lender's account as a percentage of outstanding obligation (as a percent) Â Â 105.00% Â Long-term portion of loan $ 50.0 Â Â Â Â Interest additional period 6 months Â Â Â Extension period 6 months Â Â Â Minimum Â Â Â Â Debt Â Â Â Â Variable rate (as a percent) Â 4.60% Â Â Prepayment penalty (as a percent) Â 0.00% Â Â Maximum Â Â Â Â Debt Â Â Â Â Variable rate (as a percent) Â 9.35% Â Â Prepayment penalty (as a percent) Â 3.00% Â Â Tranche One Â Â Â Â Debt Â Â Â Â Line of credit maximum Â $ 25.0 Â Â Tranche Two Â Â Â Â Debt Â Â Â Â Line of credit maximum Â $ 25.0 Â Â Tranche Three Â Â Â Â Debt Â Â Â Â Line of credit maximum $ 25.0 Â Â Â Â Tranche Four Â Â Â Â Debt Â Â Â Â Line of credit maximum $ 25.0 Â Â Â Â X - DefinitionRepresents the final payment fee, as a percent of the aggregate advances on the debt. + ReferencesNo definition available. + Details Name: srrk_DebtInstrumentFinalPaymentFee Namespace Prefix: srrk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe interest only period. + ReferencesNo definition available. + Details Name: srrk_InterestOnlyPeriod Namespace Prefix: srrk_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAdditional period of only interest payments in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod Namespace Prefix: srrk_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAdditional extension period for repayment of principal amounts in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: srrk_LineOfCreditFacilityRepaymentOfPrincipalExtensionPeriod Namespace Prefix: srrk_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDollar value of company's consolidated cash as a percent, as required by the agreement. + ReferencesNo definition available. + Details Name: srrk_PercentageOfDollarValueOfConsolidatedCash Namespace Prefix: srrk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of cash required in a lender's account as a percentage of outstanding obligation requirement as per the agreement. + ReferencesNo definition available. + Details Name: srrk_PercentageOfOutstandingObligation Namespace Prefix: srrk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPrepayment penalty as a percent + ReferencesNo definition available. + Details Name: srrk_PrepaymentPenaltyPercent Namespace Prefix: srrk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50

-Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates type of variable interest rate on debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=srrk_LoanAndSecurityAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srrk_TrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srrk_TrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srrk_TrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srrk_TrancheFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss per Share - Antidilutive (Details) - shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Anti-dilutive securities Â Â Anti-dilutive securities excluded from the calculation of net loss per share 21,309,711 20,341,402 Pre-funded warrants Â Â Anti-dilutive securities Â Â Exercise of pre-funded and common warrants (in shares) 2,526,833 Â Outstanding warrants (in shares) 17,008,164 Â Pre-funded warrants | Aggregate Â Â Anti-dilutive securities Â Â Exercise of pre-funded and common warrants (in shares) 10,681,528 Â Restricted stock units Â Â Anti-dilutive securities Â Â Anti-dilutive securities excluded from the calculation of net loss per share 2,984,663 2,047,026 Employee Stock Option Â Â Anti-dilutive securities Â Â Anti-dilutive securities excluded from the calculation of net loss per share 9,167,552 7,835,195 Warrants, non pre-funded Â Â Anti-dilutive securities Â Â Anti-dilutive securities excluded from the calculation of net loss per share 9,157,496 10,459,181 X - DefinitionNumber of shares issued during period on exercise of warrants. + ReferencesNo definition available. + Details Name: srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants Namespace Prefix: srrk_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=srrk_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srrk_AggregateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srrk_CommonWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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{) R[)"3PLXLIE&$;M-$_YS8>RWL4[5R LOJXI41AYP4 M<>YC)I?FJ?R@'=1*IX!X3;F]76'#RI4%6%<7M$PX! XH^W9<,=V.$!YL4XUW MCJ1#RJ)W!X)"R'V8/IG$=S+/U;?24*IU;N9E K<0_*,/LZB%WZV1N9J?E==AW M')=TB3MHO=H8R[1#X(RR9]3#J=2Q;LP#]H8^,7LS'EL>[:^/<*BNHQE]G'AI#+2@$$. M&5'K&'}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

MNFUZGMZV$^B^C-XM)]6BC%Z\K^KZ)0"?'P_+J]GDUD#@*@PR%7E=>U$4[WC MF^[XIAL\SYILD"9%99IN-?;-AFG+;* >,!(DE<^I4OAV5,65B9V9YB>V\
MQ/I[Z84>8_5ML2KKET=Y[+$*L>\Q(A,J$LQ-/R\=W+=OG: M+#ZWU7Q:KFJ]Q/VQGC5_0E1R1#^,,,'&F& Y)IA" K/H%CNZ17#^?EEJCN>S M_^H5]T;OKJ(7\W;ICO3E1F^?OI5-
\75>1G4Y6:_T1:0$+U[!"OI2C@DV%OZZ M(H2S?&)6J,(56@3)'4$R2-!EH0FHKJ/)XR;@<5G]-5KJK;3^=E;7Z\WZ.ZGJ M!F0GB-Z7'>GU+Z6)
<]'"K##'!%/AUEOL)#MV$C1V]B^+$%.)USR9RDPZE\!@ M> I.$$RP'!-,(8%9I*8[4M,@]?GW:88"K<>HN*;$=%]C0JND93YKL,$=%4\'FVYXW MD@@):R(?]>ZO2PE[&\;HS0*J,H**EA-?
WADRO6H[XH[JMK/Y,(H&"4;0^QI5 MN9RV+Q^*U4Z18B [O%O$V]KLMS=)THP3=_C[=D-&G=[GD)40<4R(ZR;?D-)4 MB@,[+6*4 !*6 APW.2)>M\N X)=D:<:$]^*%V]%[L&*BY:AH"@O-
9M1(!R2L M'3Q9PM[BAH>_'TZ#(C9@!ZC8D!4H8P.&(1V;F$B>A$-Y%"6;^$'\ 2D[W)K> MDP UDD=%4UAH-J\FF"?I@&)"P<(.C:X1IZ M,X^J-:'BY:AHBOC:2TH)O#Q3HR+0L(IPU*8ZC-
&7,E2T,2I:CHJFJ"^.L#). $ MQ?P :T8@H&+!P-]Z_[Y>ZDMH?'@?N46T]A[.H)#8WLOT^#H5 -@Y]WM,3^&%8*(+$3DUC^8L?,8%2U' M15-8:#:C1@*@3TB+.":*VN*<?\0!D,/ $[(/"$K,# $S ,!9[4Q.?
TZ/C\ MX,Z[VW%^6'P@_ RWIO4RT,87T!^FNJ:AY"QU5VCP9O8/BI2Z)"7>E8JX M*ZVOAG"6>9LT5.T"%4W!/3CD>Z-)T'"& 6;:"/6/W?7E6V3<)0-5>D!%RU'1
M%!::3:Z1'N@30$%I83\%))&!#+)RQFKM(0;E!O:E'3$%#1 M%!::3:W10%A8]F?H[]"X?5Z.=5;R&(Y_<'T0[%:%4MX,* NQM<)GV59.@N MC>$V]N8'5=' 0K/YV;O/(ZQH',]/Y]2#=(2,<7<7/0JWJ/?
&C^>X MXX,9 8:%!9@GI7&%,?ON7)@OW\B4I.[\1!5;4-%45P]L;HR(PL)90+8>0?3N,+ M>OO?S]YPY434"G-4-!5LONUY(V2PL)!QU(E3&*,W"ZA2!2I:SH ,#99DU-DQ
MJ6X[FP\C6+"C$S2./4MBOD;AG24Q/\0'SY(. \L"3("SY(P!]9$C/2 @M+ M"S]YEL0@-0$\2PJWH_=81=434-$4%IK-J-$36%A/.":+"^8R\T9_XNVQ_([MBPE/O,4?L*/NX/=MAC*1G+HG28
AI8(>NEAR$^CS<*#?-X<+=!OW@_Y$3X", MN\KE*-R:WC>HHL;]&@*"\WFU<3]&#SG21)'O>, %6V,BI:CHBDL-)MU(PGP ML"2 <)(4KJ$W\ZCI$QP0)
AW%U74.E57G3931AS@QXL#G9)W&*LW)X":D+JW M_Z!6F:.BJ8X.V(SL/<6A(Z1_JN3-_3"6)S1S)>]P];VG FI#??(E_NA MN"2Q*WJ'6]F(;=34!{@'!\[?N9$2>%A*P!.SN1_',R82[B^8J/=[H*+EJ&@*
M"\WFU@@@O./I#4\1L\.8O?8:"BJ:X>V-P8*8.'I8RC)-4P M1F\N4.^[0$7+.2"8")D*9^U0W7;VLY^,7B*.UDN .V,YQ,X6,$L9HXLPG!1B2E";)(2\9]4'TNHDAD)D,>PRZ62'A M7
KW>AUN1]^QBHJ6HZ(I+#2;4:,LB])_MB.H#0K@R8VNI"K\&!N45"$[- H' M;&!)%3 ,2:K"A/8"]P&/L-N .Q9@237OJ/BC9&1G_]QC[C/>\1]X".JV("%IH0OOPP)/Q#*"]L.B M("(0LA3!&;\Y0LQ10T7)4-"6 7
9"!),'CNF%42#$SR0SP/M(/YG!WWG[P]71Q4T4-%4N/TV'T:FD,^4QR"!=`SI[@1&X=I[SP%4X0$536&A MV3P:X4'^O](8I!]'4Q[K/8U++:JR@(J6HZ(I+#2;VKT?J.A(8WC*@6L8L_?2 MZ ILH_T M
_(#LD^X';W'*FIR "J:PD)[9/1D[V<4VY_5_%"L;F9Z3S8OKS5\ "K1OE\] M_E+EXX>FNMO\LN+7JFFJQ>;M;5GH2+%\:6QZ.SLR0CT8\7> " M\<]TB4OYRYRR @GYE=V/^)AE.E!13Z"CA.."D3*P?
A$/[MEXQ-;B9R4^)8! M7A4%8B_G.*=/IP-WL'[P@]POA'HP&I\LT3V>8O%S>EXE8FN]&,> %<#8'N WS/ 6PWP M=* U,AW6!1)H?,+H$V#*6GI3'W1N]&@9#2E5&:>"R5^)'"?
&DYOKZ&!"GOZPE+!,'\ MV)2VVJUO=JL6\S%?HA2?#N1JY9@]XL'X]]_,V?H-=%'F.OS';019LD 76VIQE?\L% M)7NOX$!0V8126J8DQxd!<059/U>=4%;'B.%.3?>*!H>LX(&<[>0IW.0IM%;P M
DNG*4%UGRTS@ K*!/E7/S!%7KL+MLKE.DG8]JG!:R]["AIMD$96I&=;P "= MR_X]$R C/*55*31T_81P7J$RQ2"E7!@G9M0%YP6M PV063&'V_PQU;\E_]4
M1+P,%0]E$EPAR9GW9CGNOC_RHW::#58PB6,SSF2#,]D[SR.4I@RO,T[*1UXO M*]-GJ#%0Q"SXS>=1J2<^PJB99#O:B;Q9QCF72 GU7* ML9'G X6&"=>"
[#!R@N#GG2[6ZSLVFED@*C19PK40[OM$@+>"\SFM#Z+2Q=8UO +^;.S?HX#-8)5M6NP ;KG:M%*< L@HW53<"# R<$G2*VI4:ND[@ACT0 M&YIT[3QYTVHF6ZO2B+;+@+
(%QIU\&LQ\U^]A2K>A2M?.E?5D? UCE^1DKOPV M1(-5#'L -ESHVLGP>A_E903=Y;QA$B=Q6U6:[*(@{).5;L..;O(FT5^3XAZ2 MT;72[IO[](&\[>
[#&I*%=I*]K5BZ0*!!2UVP9*IZXD4W:RQESE)I!%,.8)=! MAWY;>YF,^OHS;%@66IE+,@M-,-(;@7>!OV@-+ORMBM">T)LR!..^0I[; M12D0>\!"M?M7Q!HTL&88^W[2+HO!3K96Z/2T?]A0)
[13YQ42*WQO VX@RP & M3KO)FNQBQ^G%W? J?'WWJYN8G$6/))-:/9B[=&]%TJC7W:1.:P4QN!/R> M!@P;RH7V_7&[C[0Q>-"M[Z&\[6:A875H9W5S4Y";LT+N>/@"R7<> MZ5,"M?MY=6-
I?]F;4]/5!@&$?4VBD0;0+@UV0Y9 AO-*'<_I#KB*_ DQAJ34 MQL^8I:1'D,&N, C=[ORUHGEO@1N= >TZXT(="10T(W.2UB<'4@/WMGB#9NA(M-OL+WQM0(S^@??
>FK&"I@]2.^G([-7[IK;]L%.LKE'@)>89YS5:P;-K!2U& MC<>@UG%O/@HC;#0-!M
M!13RCQE.F=JM?!J1LOZDI+8*Z*@.2RF>1]GURM59@TRS8"05ZH1*_FZ,RB # M8C]NGY48S/S$Z2O(UHF[72I,]L9^!&;XGI2EJI,2>I@1FAD#,L@#QX=AIU F MNR"*^F)J9(1GEQ%OB0FKXQ!K-
%V]D$B0;3%G,'-E\XYZ]LE>HRL\NZZ85LME MCE6'1;D^GD*@L0/VAM?.ZCW!MW("R_:O_[I6F3*ME/?0LO0S(4_D$Q8Y># _M$!U>(SH\N^C0VEH?
8\J@9>@"JW5L#*ON7'YGN>6'*8K)VEO7T9;%,9O?Z MOIP#??17[%NGF[NY, T373K^;E[/*EOUALW]47_%6*RI7(YG^?2I?,YDG.1 MU7?G]1=!E_KZ>4:%H(7^N, HPTP9R-
_GE(KU%_6"S?]@&/\'4$L#!!0 (M .HY"%E?)%;Q"PX #8C 8 >&PO=V]R:W-H965T&UL MI5IM;]LX$OXK1'91= 'GQ4[:9OL2P&G2;GJ;-DAZ=\!^HR7:XD4B59*RXW^_ MSPPI67*'OJL4)7T M![96!G?
FUE4RX*M;'/K:*9GSIJH\G!P=O3ZLI#9[9^_YVHT[>V^;4&JC;ISP M355)MSY7I5U]V!OOM1=N]:((=.'P['TM%^I.A7_7-P[?#CLIN:Z4\=H:X=3\ MP]YT_/;\A-;S@O]HM?*]SX(LF5E[3U^N\@]
[1Z20*E462(+$?TOU494E"8(: M/Y+,O>Z1M+'_N97>B6V'+3/IU4=;_E?GH?BP=[HGH/E>QY1?(R M6WK^*U9Q[>1X3V2-#[9*FZ%!L4W\/5XD''H;3H>>V#!)&R:L=WP0:WDA&O@[M[^O*.%H-:?
2!3>7=4$X;-QWWOWQ\&R*85 MAUF2A4<(};CF4)&]]+3/U80]9X)5;JKVS%[^,7Q^]>T;+DT[+ MD^>D_P,MGYE0L(_M)'FY]IE=*K<>(666H((:B1U&0IH<%TI-MTA5;8Q=2DI44:E<9Z0S9#D6$L_Z
M@?;12B"Q>-)LD)6>FP5]T)GA2*I'Z861)9LW6HG8V^Q:P!&A$'.P@'5>U*5< MDRWSQN221$)U9TMU(*9T>5':&;Z48#GE2')PTGBB0!(5P'F%C@V^?.G %MG[_\?
O+Z70>9;VKEYK+2Y9K@*NT"&) U/6S',]YY <-5*:"/<@#7L%^2\RIH MEC7DM4IEA33:5Y[N#15A@HL^5$;.2J#/T&_PICV2(*F=AM: '#@$,JO#N'-4 M!A%$44 /?VQ,?Y G+>;"0C:O_%KU7G
M,\Z^C25DR$P19"D* .:8DVVI+D:.Q*P{2]^[*8(E!#SC73]!&K4UZ'D>,,#,B& M8MTE\-WUM$W=@1-(F\P:0IY4NIO>W/QQ=7LY(GWTTI(-_P6%V+'($*,<)<&1 MDL$*M91E T^Q.O
P[F8I56+H$,1]RXVH@1%4M)K!JZJ9E 8&*[%W6MQ(3W M\\=C :T/Q)6A6GD\C&GBXY)A4088$5(.+3*MQJTU4>6TLE0D@0U R:#) 0= MF!.JJH1,Q/=O-]. DLWJ(:2^K2::SEMF+NP*^Y-M
CTBU%.G%)340%#< M=!Z+,;F!)OKDT\44<87(A;!/$B'PW4E4LUPQ15#TC<2M1/&[00V!AY%7%XD! M>FL8P&\.!K) MT?AT1&E3MZP8K;AL$'H*#[_N*MUTH4RV"<,+33!V]MX 3Z<1,^VN;O7-
[=7U M9,>^;PPK&569C%DSLN7R8R:E)2&WS.I,LUHB3(F2WA2%"Y=50C(\WG2XF](&O/3+,? M\0OQ),RK8@C=W?YK_^3X=TI7KK,#/MS>N9,=R;J4QPF,)S4C:LO*)E;P&1 , M5/+M"NN'_*4-
JDW0"Q:)[P9#3$Z1V+KTZNM%KY&85=K[]'#@^ IA9/&9Z_>. M2M_9O(G1DP'RH*D0BU0_CR^OSV^G?UT2?G.^CW^@O4S5(;V*(4$;,)4YZBG MY.HONV2*=4ZYC'$&M)2Y6VKX!70C1 M2!
<0KQ"?H-Y1D-/:'169L!^?CD<[2G%,.W;731C8R2Z3G)7'=R9:AEE@DO= M"[$?I.;42@9"'M-\=E],Y%1/@0@BFK@1P@O\(%,6W5P_+P(R??ESW&7"9H]X MB0%..1=#(5A47]SJRWCYYV^[-
J*R)GPVMK4ELO/#_M8Q/,?BXG;Z^=O7Q]&Y M574?E="N08V,D9-YE+N<\YGP2&'8T52V15],$H=BF 9BOCG38MQLJ5KU&AG M)1YRZN28 QTF@88:Q5S(+N[94EAH1*MV/ 8>R+4}\
,9W^%6EU1^4$M2,9L)IB8\ZG]9SABR:Z50<8]$&E=,:R) M024V(74.CWO'*$0/R3*5)%,YL#'KWO&+0&CRJ@]\K4#.QH&3#4-*T M .,,1-; 08K&P4JAB/ U]$>5?2H 16=@%\Y>%),!?)1Y,2"39F@[&RZ
7$*0*!CN5(0R MCN"=-;#!!P4VC@&/8$>S3_G Y>$+]@D84)QKF)(5\P%V0&U2&AMO<D%L\ MO]C"> CT0E;UN^X;Z4*2T)155'14HKR2&]M)U"8U9)TZ@\Y,SYK.\P!SWP_3
M=NE6,Y@6WX$W8,B/NFX.2K[;VR*YBXTQ3B>"*\)_"V1 4"@(2NCQE^IE+,K M^UY#%TL)2UIX:J,2N1<:0R[<1!$L6W8[TK0QW7M,,T QH9;9#[\Y/)56IJ: MX(D=9-
ZO6:%=B!Z!";UUQK"Z%?W2U)0QQV(FM++D; MF4I]/,F+;G\K=V,764ES*FLABG23(?EUSIP=E)6+NV9R>F]H72\MHR5YZNQ?M]K?!=_ARYH[>6&*/U7FMZ>#HP'+9,[KPM^8_<^R\>
<5Z1.F<.&7[:/L M,#I@HG,>E,UF("B5CO \KN&AM^$H>6)#VFQ(^YH**\RST_[%FSRQ)0QM=_M!%?#;H!3FH*R\A9/%?;YLU4,!C,Y6ZF_5KD27'NV%,+4VBN]8=>F4$))=S+V ML$>[QJ+1?
1YUIT_HGK/W1ONM8Y.ZJ9C>N(H+>3I-M3A+W)P]L-WDWER_SR68=\ M]ISV_XC\6=V/(T]'[.MM_AO1=U0)7$^&'V2J5J9V,F*,\"IN.6AG*:%HNM M>9TIC?#"-(<-&:>;7&7K%RA
(%,6XE"M8)]J91'RFX,&7%]?T/WQVE MD\4QA+W>G2,07..QL4'7O>2624IV]E8*6:ZE9=-)2-?I,$B2E#8>/N'*2F^& M;+]58ANP*2V*.GL:VE+K&A!N9&6L9^" ^A*,)"]_'1&-T+#E.\G64FH809?P
MTA)F\>5Z0R9-4/M/,(/EG3*U*^Y9IIPHC/L62%]%RHB1IF1ZS"ZXVP[#+[O\ M5*L=+R+'X.Q&.F^5H#B$Y^T6RIS<%!@K!-_S=2$Q)A WH0JX(8)&^F7R,XWV
MH#$\KV2$NN8%P@R&PCALZ6HC3M$.XCE,.O8B4 *>H-'*#}.W_RY!.'$R MM+AVF5I=X"HZ3_"_*F5_9Z]G@GP3ZF,$F.ALE\UB=1]$E,A[_D2T;N;3{)O
MD$'MJ^%B\JO=I(,YXMYMW+,E>&5IJPKV;NN9*YT/#M0U5+,_KFRFMINDNU0#M9Y3C8/V0Y,AXE56U=30C=!LS6E0(SUIBZ"\4[O2HK:*J\.BD!PYER,']\N+<#4Y_C'4V;_J.0WV8+,B.DL*FH1V
M/FS)-60.70)YVA\4 OA+.:?* MLC")M'_0^[&$LY?K.HT-72@X%G,0=:U,YF+4VFPBEU4FK6-R%[/-/B3.;SEJ M70 6X[E_M#50P-FZ]J 4QF-TGQPY2*D:H)"9E34[F 9#2! 8@JRD!5)L)64I
MH@0Y(.W'>9JA9A5U\8C1,!+U*K^GUN[)@P#54BNP#[0V?1MT1M],ID 5?)T%?:(.0U(AYZ/@4/?!N: M=) 9&;%,%Y1==AX2S,_F^Q,%%>K(9B$<>^6W[*E\KEP374REB"6_*/L\4@9
M]U>=;:%N0%_)[Q'G'%X\3")>=L7*G9/-Z"@47ZOBT#Q"\"!]8#SL0)+14"40 M3VV.YD(F?G\> 8UIX;64,1^]1)B@12N&R@4"NUPD]6AG@[>A/'>$/_^0 ^] MS;C09'])AO:J\-
:!64'9>4?,0GZ2!3S<(24P\BKNJQZ!4.)LT9S.-*LR0V\ M)#JD(\WE&O, YH=05M0E'*2^A!XF/!T@VJ1"@RR(3,3#LMR:DD:LZT5PA$DF M !YINQ6P2=+9Z3&V'=KFZ;1%TH#NNKKY
_R55OYM=/W%XVJ@ M"PQ\G>?I]&6R&&*TAM}J#H0DVWB8'B7P\$]PD%MB81))$K9 A[^_ M1J&.*IEC:S);O!HPF&[\FQ!MOJO &OS;>FS)<;B5'19$ MGN<&KQ3-#1GH/NF< _0U02P,$% @ ZCD(6?
L?,#"\! &1 !@ !X M,"]W;W)K3.O$*WG\HA^X\7FES M9W, QQX*J>PDR)TK3[M=F^90<-O1)2A\,}>FX X?S:)K2P,\\TJ%[,:]WJ!; M<*&"Z=C+,LQTK"LGA8(;PVQ5%-
RL+T#JU22(@HW@@UCDC@3=Z;CD"[@%]ZF\ M,?C4W:)DH@!EA5;,P'P2G$>G%WU:[Q=\%K"RK3DC3V9:W]'#+]DDZ)%!("%U MA,!Q6,(E2$E .,9]@QELMR3%]GR#?
N5}1U]FW,*EEK^)S.638!2P#..\DNZ# M7OT,C3\GA)=]-J:7TO6]5K^\. I95UNFB4T8)"J'KD#PT/+851;X]"W"C$WNYZ M(V_E6^[X=&$TBAE:C6@T\:YZ;31.*#4]46V?PK4]-[WBPK#/7%;_])Q=*"<55
M*KADY]:"LXRKC+T72":D< +LN.MP3]+LI@W^18T?[\$?L&NM7&[9.Y5!]F?] M+MJZ-3C>$^P1'P3\M5(=EO1"%O?B_@&\9$M XO&2?XR&K__/#XEU:DM>0]3 M
+/&@EE",'W]*AKTS@Y8W]].WS^$_C=8?Q@_Z; OVX)]S('-M<1D%VK!"})) M%-8I+WX'YO UWVC*EF8!W%8&,L8=F].FRWI33%U,_[0RAA Q!86E)1@(L T$ M#_864BAF8%@2>6G"?A *=]25Q=?
VQU/\^M4H[B5WQOLC+7A=>3GWFG0&C8W" M1^O%XO>P!,FB9HR,,6FH_WIW,#5AC;>)N3JQ+/)7PZ=F0L\5S M###)N8!O:K0]M<^0X+L&Z.DGP]LG0>I?2P7++L?
<(R\USMCE:6O]GVE'6Q, M9J41*=@:.T]3;3)\+]?A/E-:FS5"Q$ZY@X6F@@*K!=ORETJ4(PJ##I4IB+.B M'Z715:[L'(S7;UB;@5L!J'8I4NRN&"9I3\NRREA1J7.24*;<8F%%}2:6^QI#)(&Y1<9
P>L"6S4/.C M<;%A5!WY_"VA]CLI#5NR=<4(.%?BU)#9[(#*$NC'P0V-[XR0T=WWAY;9(7(M 6KK!L#FVKB?')B"*>Z0K=KA2UV47*V152F0.>M]I%6>\;O=VR^NF&6_1!5*!T3A'U5YG>!
(P4S>B]8/3I6_^9MIA*^FG M.?;N8&@!OI]K3,SF@3;8_ALP-02P,$% @ ZCD(60},>RRC P &@P M !D !X,"]W;W)K&4(_[5=M;]LX#/XKA0%<,*Y#Z M-6V2 -@G0=B]WPP84Z[I]5FS&UE06D-M2
!/QBNE[TV!:.&A%),O,+.:Q7D0F+3 DAE?+5#2R5SIDEG:ZCPP"XTLJXU* M$<1A>!:4C$MO.JYE-WHZ5I457.*-!E.5)=/K*Q1J-?$B,ROXP//".D$P'2]8
MCK=H[Q8WFG9!BY+Q$J7A2H+&^<2[C,ZO^DZ_5OC$<64Z:W"9S)2Z=_LXD7 MNH!08&H= J//$J]1" =$8?R]P21:E\ZPN]ZBOZYSIUQFS."U$!J%9HN)_0@ MPSFKA/V@5G_@)I]3AYI?
6#6GZ<>Q!6AFKRHT015!RV7S9P^8>.@;#\"L& M\<8@KN-N'51OF263<=:K4 {;4)SBSK5VIJ"X]{5Y=9J.N5D9Z?OF,Y'RV8" MX1,32G/+T8P#2]!.(4@W,%<-3/P5F#.XKZ0M#+R2&6:
[]@&%U,85,^.ZB@\" MOJVD#TG8@SB,^P?PDC,/I,9+?C3/!J:_\\-R+E9L!0G'LV 0;U$;_K\6706 M7AP(LM\&V3^$_NU!'H,I^[7"3X6"',E:!"YS*$Y,J:1_T/'EHZO5,E@T MHX!VYHZM\S,B&3TQ4V"V%
M>2P%6S(NG/"$'M83PP0^W=W=^;<^6(K;5'H-:B9XSMP32%YE!KE-HI:NHD"O MKDS7W;"V$$S[,@=;P9/T\4M,L9RA MAB2]>SGYW-:3NW4Y9V N'R2_L\N]RT>USEN<: M*3?
J>%>'95T':M]R;RE6W!90/=99-"5<4=_(AXQE(16J8*IV!$Z4%TSGA4LDV("<:1=W^ MG(RX;MX'=\SMOK[N!N>TG#_#'Z!LR\Z\K-[B_X^6A!T^%J)%))CI00254G; M4+=6VA+?
RX;O/:HWK)DF,G>S*G!.IJ$ ./?H8FHFVFRL6M3L,Z8L<3"'1J8F>V ^S?[^Q "H4RM'W!$PGSDW+0'D]#86X/O&:S4SIR82&9"/!OA5=;V19 MWC'-QD,I5D0:.T0S$QNJ]49R&3=%>=
(25S/TT^.IA)]E";E?8YD5*)X0K[J M%"2Y40JT&GH:MS'&7KR'IG-20P1N0$?D07*>*W/,$DGU_#^DU'(,MQTEP$O!+_MQ5N$^BX) "\@4>;F*G%H^2%%;(-6)X'-'K]FIVT&K+3(D=1Q0XJ#D3,"68?
FNQ,HSN(H9BA'6U;+75)N0&# M0S!6@\4"+[+2!A'59"YR? \ROB#O,HX:42ET4>\'Y.JB%_CT^I_'FOUK,1/_M7A#;51OBCD",+,,%.@^0L)Z:\3,.IC3"!)3YK)3Y2^B7TK?\EH2[M!SMRZ/J= M?
@-9I^.JDHS'<,RN MTSW01K1SH+LD/3<*Z9X<=*)7:3_KT-0)R 5??,#D%O_[2>GOGY1N^(>30KN' MU:'MX(QJ! 2(XY%*4[?;[^ZQ"MN-?.QA\W8:40%R8=NMJ6C%==V3&FW3T6_J
M1O9B7O\/#"YP A(#G-T]5O=CD-DW6)K08O2MK69T-@D[33%OQ*0Q@#7YT+H MK6 V:/YSQK\4$L#!!0 (.HY"%DZ^0F\O (.@& 9 >&PO=V]R M:W-H965TS37!ITD:3^@7[SO<\?
NZ,S[,=XT\B!Y!H7Y54S)U< MRGKJ>2+)H2)BP&J@:B5CO")2F7SKB90#20VH*CWL^[%7D8(ZBXYQ2EBQAI9 M%A36'(FFJ@A_64')=G,C<#K'0[-I79XBUE-MO (\E>]YLKR+$M:5$!%P2CB
MD,V=93!=13K>!/PN8"=ZP4E 5M!W)_E"'F#L?P# !P VNMN-C,I,(LEBQMD.<1VM MV/3$I&K02EQ!]:$\2JY6"X63BV62\ 92=+=7QRQ S#RI6/6:EQP85BT#_H A
M1O>,RER@.Y!"<2A0*356$NXDK?!9PI\-':#0=Q'V<72&+[0IAH8O_$2*+4/T-M/H.^&%-1DP3FCOKS!?IGH&,2M!2{04S MFPM:$INH4$]@UP% ,&&[KJ9K18Z+)4Y=.2$T@@6?2FH\K!&
M*";Q=8JN+L;8#Z_/;9BC[U&-!O-W-K)J&>$M@:PE\ I*9$^**3W"2>PK-J M0;5J*+++U,(OT<0-PTG/CMTQ'EK&FKQP503#PZ$DLE^M8]DC-QSB$V_@N\-)
M\,K(609"MS;2TNJ.JTZBJWRLKALC%P^C$R]V<3RRO$P=&#^)F43!J[>[WN4P''?FAZK?Z*&RK816.]MX\NV>[V&MV_/>'; M@@I40]@_F
T=!!O^VIK2%;,7K9A4G5&,W54P1&ULI5=K;]LV%/TKA%L4&Z#8DOQ,DQA(T@UKT19%']MG6KJVB$BD_M2E)QLE^_3%Q6 M4"7=V-2D\69K;"4]IG8W<,4EF0>CJIRD<;R85%+IT?
H\K'VRZW/3^%)I^F2%:M:ZI*VOLK*LW^8I2,^H7/;E=X7IBLSVNYHR_DO]6?+&:3 TJN*M).&2TL;2]& ME\GKJQGO#QM^5[1W@[%@%3S;&W/#D;7XQBID0E91Y1!!XW-(UE24#@<;W#G-T M.)(-
A^,>_=?@.WS92$?7IOQ#Y;ZX&*U&(}>M,$K_V>Q_H\Z?.>-EIG3A6^S, MO5-UQF!0*=T^Y5VGP\!@%3]AD'8&:>#=\A18OI%>KL^MV0O+NX'& M@^'IJL
8YI3DH7[S%6P4[O{XV505QOGB3W9Q//!!Y?9)UUE>M=?J$}4)\, H7 M3ORB<\H?VT_+$ {>E4?VED,K5R^217SV#+G9@=SL.?1_U?YYZ^58# 'SJQ>K M-
)Z>B;=.:0$4*"D;"%R04"XF20'7E^'CAC3"-:12"NQP5 MY[STF&1DO=JJ#!-AMD+IS-C:6!FJ"H980#MP%,[23;4AR_MDXPMCU9] <(4$ M&B]F+>/ 2&RMJ40RCZ,X#A\&F\8/T['X"D0X64M]+PKI\
$WX60)-+FS1(&\ MTJ(N$221-U;IG;B55IG&"8_N(6K")' M.:;EIJ2@,1L'==&7RJA5(-#$R_"4<,<[X0P,!K-"T+]D9 MUSQ$5&GFS2E&F=$YNKKP5N8L3R=A3TZB53JUTR&C-
M;AIW%"*I\!!7$4@P6.3$>4![N5\G/9'1*+!$HR" H>\>VBZ M"..)$G3+Z?C.OBR"#.I.5&W+;BO}$?%_%EP7;L3G9-L$@[VT5FH/_I)/1F+P MLUOD<2VM[_-TJ[3465"6?WV55QS3*X.Z8S9'8$-
Q'"85A11'"'B"[%%="&U'Z MWBA_+{)2.M>VIO +#U-(BY)&APIM#'`AJ8WF_.'P#UHAEW2R/.O!N!L@C63> M'B1+>*+RSRQELE8HA/&PM:,AM&'.Q7^O^J!<.H_F21RE\3P8I%&R/(UF]^5Q
M2;MFA'M*>3\6;WXT;OB.YNDB6DVG[.2 1N>C.RIUR!NZ(YLI1_D/IG*R1&[}> M186\%BOQTBR=*:7"/+,Y]=1LDH&U+@UHQI[=@\U^'(YGL[% M?Q)GA>%B$3\ES?-3
\3GRVAVNCBNP,%KPF1P7:O([L*EQ)MZHWU[VG^(.U.H2A*VL(T$D-GA';BV@[\.8.E[^-\;A*AF&!NSM9WH#W M6V-V^$##O\&UG\!4$L#!!0 (.HY"%D#K!^P" 8 .02 9 >&PO M=V]R:W-
H965TU>/JLVDPBUK4R2D_9^_5&R8SMMDV7%;E]B2Z(>DN)#BO'Q2LA_0?0 MY*XL*G4RFFN].!J/53.'DBE'+*#"E:F0)=,XE+.Q6DA@N=U4%F/?=>-QR7@U
M.CVV$2R6FE1MIO1#(J)7S9/=M>1Q,!8Y6BO"*:%2>B4})@N=V M66E\8+YK1-248-F15BTB5(TA$N:F&BR!%$(9+&E!)%P"6"%[TC9*HQ;8?%9C@6+*VWBB$%[J"*B?MP#!#1->G4I3=*H&Z$J-
WIT @$,3O0D-)_%PPDMZU5FWE OMDK#-?/EAC#&2!;&+5 N MSN02)!>Y47/5P%CO#N^13+@16:4ES\S6:RVR6]3&,8L/2!!1S^L#X#M)*_!I MT:3V>B7T,5+N0'
8M8FA6KS5_2W.GQ%4V2,IBU0C4M,X8'R[@1/54IJ<,=[_M?\6CB\8/P]]&Z[UD:-1Z]!^ZO %I(M85]42]0UD M8+<''FU+"'63E$:1^PFSTG]1BVB>#0.)]2+TJ%$Z*0)^8JJ4. P=CWJ3=R7
M&PGI(#^POYH"MS)>Y-)DDCR0P<*ST]Y-[LD#VD,V0*EE&0&<HF<,1&K M*K+=(VT^@RR)!JPS+%AR=J4>Z[7IDRWE78X-,CO'D805$_^/!^27#:RN@ MD9]V*0^-
\S;5GX(A0(,:!AM]"^QD_3J8F<2#19],(IZ=5_4NC2=%RB[?76= MS46!^F\3Q(9.@1*D4 !K=QJG4NLS8# 4BA:NV=M^!^R^.'=$+G.@T+W2"53
M6/5:12N00&K##N1V#AHSJ,E#HW*W,>V_B3W; ^?7QY]ORKN&INO NSK#U>VK MJ>G_.?I@+!AXB38T')'6QA_R2!DX3X,)V:O8YRK/D7N.10Y<1T75YO?3L8< M6=N3F?]F!<>V-
,=;XB6)AFD:.UYO1K=Y*?!/'2 ,I9)Z3A A<.HZD8?/5O\:1 M/[;CP9>'$N3,?E]1V /7E6X^0G2SW2>?/_YR.0,JR4I8(I;723[MB,CFFTHST&)AOV/<"%*U%.5_GP'*01@#7IT+H]<[HZ#YLG?X'4$L#!!0 (M
.HY"%D!WT],"P8 (H/ 9 >&PO=V]R:W-H965T0)-UF(=FC5HNO8S+=$65XE422J.__W.O91D MN7&,K1L0Q.+CGGONDˆ3YRKIO/E,JB(N->_,%)+[_$V+\U(NU9T*?Y:W#J-
ABY+J0AFOK1%.+2YZ,\:G5S/.SQN^ M:+7RG6!!ELRM_4:#]^E%;T2$5*Z20 @2/_?J6N4Y 8'&]QJSUZHDP>YW@_Z. M;8$E]C<\W^QBGNGT)A4/MBB
M%L:XT";^RH?:#QV!UZ,G!":UP(1Y1T7,E<9Y.6YLROA:#?OZ(--96F0TX:" M]2Y?/!L?C<{VL)VU,*&#?IT/]]=/;"[29[,A![MU8B/I7*2QN*#OOZ+]T;\@5)5,5<.41F?]$7(%&&4TJP%0)13J= F6"%%SB)V
M@;,^%3A3#YW)N@6C=6C ,(0-"/!97VABU%F!,W4@;<2V+N=/!4O7%C?1>)EGE M50!)0,^5P"-5T@N-&8/Z3ZPK"5B)#.W1>R4=]'CQ"]%[\>SU9#(Z8POX>WSV-M**I43$-M"%LR#-
**BIAZ"P2$#@4(CY6H25%6LEG8]JJ96@JYD@*I2*XZV-IH[R@Z/\">H^_MSPD8@6"(/GKH_"_T-5(%O=*8"E*@XAIW3P>'S_M,L!L<0NR*B@5<_8I9 %M; MVNULMJSJBI5S'?
GM[ZHA_XZ/SY!+>6X3^#05/I.. M>2761Z'.79:2@& KW2HD))H;< B;P$NQVIN'?DXNB1RL=LDVB;==01F%2 MC0}(^-NY)J[M]Y^0
OOM$-2O8'NE/4_*L_-6E.HC9/C\H[R8O8EHO.@8;K*.]76;ZPELVQ; MO]2VN(:[ZB.UMP3.EX[/P&XYM ';5"Z8^(N0PUL6SW*=K*C;!>6\@K>0(9+
M,7W^8^4.Q&WE?"4C]L;DUB/;OI6YMYPL>WO/5D.#X@6*H/%-5=J8^YTN6._? MY8Q-O#]BBP/O>"V,-[2M@JC+SU.#CF:C$W.AV/)9NZS M#4C?GCIW>?
Y2R3_M]X]=$^DPL.'OYND&=QFY[MW;-G3SJ>^LIO 6K>]]BYI&Y![Z--G#C96Q^C53PIR9V!*A]NQJT)]T=*X4M.

**M>@Y99MK(I$Q&!@E/BW_VO2Q$+2&@9Q+\,L'_T82@3 ARH06S7-8M,RR:*+DG MRD8CFGW(:Y-GHQJ>VFF<&X5O,>:9Z'>F'L"PA0 RAV6FN.&@R169%]-*Y)I\ M3'>@#4Z=T>3B%H.YT)?D#>$I^1K+3+-TI2>N03(6TEV6]\4 _MG!OZ4I3T2 M>+\0W_/[Y'Y^2R[>7!)=<'ALP9MUX]W"$O%HCA<\@^=BD:I*^56E_'R X/E* MZ4.EV [+83NO<$M=.2:@K10%[4:[UE2Y@ZN!4UJ!TXT<_T:'W:UL= M7@GL_A!582@"SUZFTAE^-^P(C.I39O4(G^8Y]LS9!>-0QH.)^ZNKJ$91<-P M/*95V!&[? L6NW\GNO9):D_L4SS.1DWR/YUCKVBQP!O7Q3Q@V(\9!.[M!Q6[P M,G:?L0VM] :-P:\&@Q."+3%GRC>L' X[*?ZF#<>#$9F]8UR1;TQDK:MYV"Q-M2'W_A%\SBH8C;W2FB&'%,>Q>@)N-@@V2)&O+<6VYBDATJOK'M@5R(O/"79"LUS\T$]RX1@+-C8H;60AZ!J3;E86/9CFC@>2?*FU&4CFM11\)' ME?!1I_ _LF0!RDKEM?,8SV D7%-HI77K(O]TG;(WH\:T]<,3?>I:^$MB1:NH=O-?[WRREA'ZE.KP6 MVG$A:I<0^A]MI01XSE=:PKJ,A1[,GW;:Z@NLI03J\I:6D'/F0@_.3+NM^07V M4B)U^TM;T+DR'@R:=COTCUI,"3-\QF-:PEI-QJU=D.W7"6Z\C74" 6M,]HA MJE3%A;]H&+G-[\P+:? &GC_&^(3 =2@"64VJEAK^-1+ P04 M" #J.0A99'\OC2H# !9"P &0 'AL+W=O(DWO./??8OO9H0^@<RP X>BJ+BHV-C//ZTC19DD&)V06IH1)?%H26 MF(LA79JLIH!3!2H+T[&LP"QQ74F3D7HWHY,16?$BKV!&$5N5):9_KJ$@F[%A M&\\O;O-EQN4+2YB54+"<5HK 8&U?VY=1V)$!%_,QA MPWK/2)8R)^11#KZF8\.2BJ" A$L*+/[6,(6BD$Q"Q^^6U.AR2F#_^9G]LRI> M%#/'#*:D^)6G//!L;D8%26.!5P6_)Y@NT!? F2+R$%4[]HT\0&L8&2%>.D;,%" M09E7S3]^:HWH 6QO#\!I 87N,[)B(IR-3"Z42#XS:;->-UF=/5F_K:H+Y%H?D&,YG@8^ M/0R_@43 ;05WM^&FJ+\SP>E,GEKN MPDM6XP3&AMAF#.@:C,G[=W9@?=35 49D6RZXG0ON(?:>"QQHA0LD4V":9,J. M%-9BS]>E-*/U2>=&DR)0*60+64]<-W9&YKI?Y6Z09_EQ%[2EWNO4>T>15].F M4], _5Y2)[:"@3)-D!<%>F5^!\P_J.P6$LC7>%Z =OWX.REM)XH&NC1!5KA'M5]#I"HYR+*_8BN(JT\+%"JQ?LS'#'551 MX+D#Z9H@Q]]C;-1ICPZVDZ9]%J1:GHN=5!Z0&++UE[W@CLJV2XZ[D^/_WCGAG M+D3OB <3MAOD6:&GGS#;>CD%K==UCQ:_)2[T!]IT0;.S1UOOA+9?OT];CJW. M-5SKFAC7WJ/NY>BT#Y}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end XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 124 229 1 false 30 0 false 5 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 995210101 - Disclosure - Nature of the Business Sheet http://www.scholarrock.com/role/DisclosureNatureOfBusiness Nature of the Business Notes 7 false false R8.htm 995210201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 995210301 - Disclosure - Fair Value of Financial Assets and Liabilities Sheet http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities Fair Value of Financial Assets and Liabilities Notes 9 false false R10.htm 995210401 - Disclosure - Marketable Securities Sheet http://www.scholarrock.com/role/DisclosureMarketableSecurities Marketable Securities Notes 10 false false R11.htm 995210501 - Disclosure - Prepaid Expenses and Other Assets Sheet http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssets Prepaid Expenses and Other Assets Notes 11 false false R12.htm 995210601 - Disclosure - Accrued Expenses Sheet http://www.scholarrock.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 12 false false R13.htm 995210701 - Disclosure - Common Stock Sheet http://www.scholarrock.com/role/DisclosureCommonStock Common Stock Notes 13 false false R14.htm 995210801 - Disclosure - Equity-Based Compensation Sheet http://www.scholarrock.com/role/DisclosureEquityBasedCompensation Equity-Based Compensation Notes 14 false false R15.htm 995210901 - Disclosure - Commitments and Contingencies Sheet http://www.scholarrock.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 995211001 - Disclosure - Debt Sheet http://www.scholarrock.com/role/DisclosureDebt Debt Notes 16 false false R17.htm 995211101 - Disclosure - Net Loss per Share Sheet http://www.scholarrock.com/role/DisclosureNetLossPerShare Net Loss per Share Notes 17 false false R18.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 18 false false R19.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 19 false false R20.htm 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies 20 false false R21.htm 99930203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 99930303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) Sheet http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables Fair Value of Financial Assets and Liabilities (Tables) Tables http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities 22 false false R23.htm 99930403 - Disclosure - Marketable Securities (Tables) Sheet http://www.scholarrock.com/role/DisclosureMarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.scholarrock.com/role/DisclosureMarketableSecurities 23 false false R24.htm 99930503 - Disclosure - Prepaid Expenses and Other Assets (Tables) Sheet http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables Prepaid Expenses and Other Assets (Tables) Tables http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssets 24 false false R25.htm 99930603 - Disclosure - Accrued Expenses (Tables) Sheet http://www.scholarrock.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.scholarrock.com/role/DisclosureAccruedExpenses 25 false false R26.htm 99930803 - Disclosure - Equity-Based Compensation (Tables) Sheet http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables Equity-Based Compensation (Tables) Tables http://www.scholarrock.com/role/DisclosureEquityBasedCompensation 26 false false R27.htm 99930903 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.scholarrock.com/role/DisclosureCommitmentsAndContingencies 27 false false R28.htm 99931103 - Disclosure - Net Loss per Share (Tables) Sheet http://www.scholarrock.com/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.scholarrock.com/role/DisclosureNetLossPerShare 28 false false R29.htm 99940101 - Disclosure - Nature of the Business (Details) Sheet http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails Nature of the Business (Details) Details http://www.scholarrock.com/role/DisclosureNatureOfBusiness 29 false false R30.htm 99940201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details) Sheet http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails Summary of Significant Accounting Policies - Cash (Details) Details http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 30 false false R31.htm 99940301 - Disclosure - Fair Value of Financial Assets and Liabilities - (Details) Sheet http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails Fair Value of Financial Assets and Liabilities - (Details) Details http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables 31 false false R32.htm 99940401 - Disclosure - Marketable Securities - Summary of Investments (Details) Sheet http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails Marketable Securities - Summary of Investments (Details) Details 32 false false R33.htm 99940501 - Disclosure - Prepaid Expenses and Other Assets (Details) Sheet http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails Prepaid Expenses and Other Assets (Details) Details http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables 33 false false R34.htm 99940601 - Disclosure - Accrued Expenses (Details) Sheet http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://www.scholarrock.com/role/DisclosureAccruedExpensesTables 34 false false R35.htm 99940701 - Disclosure - Common Stock - (Details) Sheet http://www.scholarrock.com/role/DisclosureCommonStockDetails Common Stock - (Details) Details http://www.scholarrock.com/role/DisclosureCommonStock 35 false false R36.htm 99940801 - Disclosure - Equity-Based Compensation - Expense (Details) Sheet http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails Equity-Based Compensation - Expense (Details) Details 36 false false R37.htm 99940802 - Disclosure - Equity-Based Compensation - Unrecognized Expense (Details) Sheet http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails Equity-Based Compensation - Unrecognized Expense (Details) Details 37 false false R38.htm 99940803 - Disclosure - Equity-Based Compensation - Restricted stock (Details) Sheet http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails Equity-Based Compensation - Restricted stock (Details) Details 38 false false R39.htm 99940804 - Disclosure - Equity-Based Compensation - Stock Options (Details) Sheet http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails Equity-Based Compensation - Stock Options (Details) Details 39 false false R40.htm 99940805 - Disclosure - Equity-Based Compensation - Assumptions (Details) Sheet http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails Equity-Based Compensation - Assumptions (Details) Details 40 false false R41.htm 99940901 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesTables 41 false false R42.htm 99941001 - Disclosure - Debt (Details) Sheet http://www.scholarrock.com/role/DisclosureDebtDetails Debt (Details) Details http://www.scholarrock.com/role/DisclosureDebt 42 false false R43.htm 99941101 - Disclosure - Net Loss per Share - Antidilutive (Details) Sheet http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails Net Loss per Share - Antidilutive (Details) Details 43 false false All Reports Book All Reports srrk-20240630.xsd srrk-20240630_cal.xml srrk-20240630_def.xml srrk-20240630_lab.xml srrk-20240630_pre.xml srrk-20240630x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "srrk-20240630x10q.htm": { "nsprefix": "srrk", "nsuri": "http://www.scholarrock.com/20240630", "dts": { "schema": { "local": ["srrk-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["srrk-20240630_cal.xml"] }, "definitionLink": { "local": ["srrk-20240630_def.xml"] }, "labelLink": { "local": ["srrk-20240630_lab.xml"] }, "presentationLink": { "local": ["srrk-20240630_pre.xml"] }, "inline": { "local": ["srrk-20240630x10q.htm"] } }, "keyStandard": 209, "keyCustom": 20, "axisStandard": 15, "axisCustom": 0, "memberStandard": 14, "memberCustom": 12, "hidden": { "total": 14, "http://fasb.org/us-gaap/2024": 9, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 124, "entityCount": 1, "segmentCount": 30, "elementCount": 447, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 455, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 6 }, "report": { "R1": { "role": "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals", null, "ancestors", ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil":

```
"false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets", "longName": "995200100 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukgwaIEJ1qmg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukgwaIEJ1qmg", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "unique": true } }, "R3": { "role": "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukgwaIEJ1qmg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_aqyrxkDCCUqaQBa-Igj8XA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukgwaIEJ1qmg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_aqyrxkDCCUqaQBa-Igj8XA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_5akYDuMRXU-sbz9-qxhJ2g", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_5akYDuMRXU-sbz9-qxhJ2g", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "longName": "995200300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-NWu8pzw2UamuyEZzsryjQ", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UqSBgUvAwUaOYb_BK1F3Og", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "unique": true } }, "R6": { "role": "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.scholarrock.com/role/DisclosureNatureOfBusiness", "longName": "995210101 - Disclosure - Nature of the Business", "shortName": "Nature of the Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities", "longName": "995210301 - Disclosure - Fair Value of Financial Assets and Liabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.scholarrock.com/role/DisclosureMarketableSecurities", "longName": "995210401 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssets", "longName": "995210501 - Disclosure - Prepaid Expenses and Other Assets", "shortName": "Prepaid Expenses and Other Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.scholarrock.com/role/DisclosureAccruedExpenses", "longName": "995210601 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.scholarrock.com/role/DisclosureCommonStock", "longName": "995210701 - Disclosure - Common Stock", "shortName": "Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "srrk:CommonStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "srrk:CommonStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.scholarrock.com/role/DisclosureEquityBasedCompensation", "longName": "995210801 - Disclosure - Equity-Based Compensation", "shortName": "Equity-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210901 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.scholarrock.com/role/DisclosureDebt", "longName": "995211001 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.scholarrock.com/role/DisclosureNetLossPerShare", "longName": "995211101 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_5akYDuMRXU-sbz9-qxhJ2g", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role":
```

```
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables", "longName": "99930303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesTables", "longName": "99930403 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables", "longName": "99930503 - Disclosure - Prepaid Expenses and Other Assets (Tables)", "shortName": "Prepaid Expenses and Other Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.scholarrock.com/role/DisclosureAccruedExpensesTables", "longName": "99930603 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables", "longName": "99930803 - Disclosure - Equity-Based Compensation (Tables)", "shortName": "Equity-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesTables", "longName": "99930903 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.scholarrock.com/role/DisclosureNetLossPerShareTables", "longName": "99931103 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails", "longName": "99940101 - Disclosure - Nature of the Business (Details)", "shortName": "Nature of the Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_5akYDuMRXU-sbz9-qxhJ2g", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies - Cash (Details)", "shortName": "Summary of Significant Accounting Policies - Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukqwaIEJ1qmg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_30oU8easj0ueit_ddC1uTg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "unique": true } }, "R31": { "role": "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails", "longName": "99940301 - Disclosure - Fair Value of Financial Assets and Liabilities - (Details)", "shortName": "Fair Value of Financial Assets and Liabilities - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "srrk:TransferOfAssetsBetweenFairValueMeasurementLevels", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "srrk:TransferOfAssetsBetweenFairValueMeasurementLevels", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails", "longName": "99940401 - Disclosure - Marketable Securities - Summary of Investments (Details)", "shortName": "Marketable Securities - Summary of Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukqwaIEJ1qmg", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukqwaIEJ1qmg", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails", "longName": "99940501 - Disclosure - Prepaid Expenses and Other Assets (Details)", "shortName": "Prepaid Expenses and Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukqwaIEJ1qmg", "name": "srrk:PrepaidExternalResearchAndDevelopmentExpenseCurrent", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukqwaIEJ1qmg", "name": "srrk:PrepaidExternalResearchAndDevelopmentExpenseCurrent", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null,
```

```
"decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R34": { "role":
"http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails", "longName": "99940601 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef":
"As_Of_6_30_2024_ZwhIemgVcUukqwaIEJ1qmg", "name": "srrk:AccruedExternalResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukqwaIEJ1qmg", "name": "srrk:AccruedExternalResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.scholarrock.com/role/DisclosureCommonStockDetails", "longName": "99940701 - Disclosure - Common Stock - (Details)", "shortName": "Common Stock - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukqwaIEJ1qmg", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_DssL6QHPR0-9nquS0YV2ig", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_5_31_2024_kDV-xL4hLUi2vYZYpgvnUw", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_DssL6QHPR0-9nquS0YV2ig", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "srrk:CommonStockTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "unique": true } }, "R36": { "role":
"http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails", "longName": "99940801 - Disclosure - Equity-Based Compensation - Expense (Details)", "shortName": "Equity-Based Compensation - Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_5akYDuMRXU-sbz9-qxhJ2g", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_5akYDuMRXU-sbz9-qxhJ2g", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails", "longName": "99940802 - Disclosure - Equity-Based Compensation - Unrecognized Expense (Details)", "shortName": "Equity-Based Compensation - Unrecognized Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukqwaIEJ1qmg", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef":
"Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_ZwhIemgVcUukqwaIEJ1qmg", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R38": { "role":
"http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails", "longName": "99940803 - Disclosure - Equity-Based Compensation - Restricted stock (Details)", "shortName": "Equity-Based Compensation - Restricted stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nayPFWpZ_U6qI67dmrBx4Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef":
"Unit_Standard_shares_DssL6QHPR0-9nquS0YV2ig", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nayPFWpZ_U6qI67dmrBx4Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef":
"Unit_Standard_shares_DssL6QHPR0-9nquS0YV2ig", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R39": { "role":
"http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails", "longName": "99940804 - Disclosure - Equity-Based Compensation - Stock Options (Details)", "shortName": "Equity-Based Compensation - Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5zd2Nvto9UipAJB2kRalzw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_DssL6QHPR0-9nquS0YV2ig", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef":
"Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xdvIL5i-qUuaDk1QrbVLVQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_DssL6QHPR0-9nquS0YV2ig", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "unique": true } }, "R40": { "role":
"http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails", "longName": "99940805 - Disclosure - Equity-Based Compensation - Assumptions (Details)", "shortName": "Equity-Based Compensation - Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xdvIL5i-qUuaDk1QrbVLVQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef":
"Unit_Standard_pure_6ESQPCtfX0ORIpFTPTRe-g", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xdvIL5i-qUuaDk1QrbVLVQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef":
"Unit_Standard_pure_6ESQPCtfX0ORIpFTPTRe-g", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "99940901 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_5akYDuMRXU-sbz9-qxhJ2g", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_5akYDuMRXU-sbz9-qxhJ2g", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.scholarrock.com/role/DisclosureDebtDetails", "longName": "99941001 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_jr_MJRDV0kOIumHDFJESxA", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_11_10_2022_us-gaap_DebtInstrumentAxis_srrk_LoanAndSecurityAgreementMember_jr_MJRDV0kOIumHDFJESxA", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_USD_8mGKBXgdT0WlBEz5-Wks0Q", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } }, "R43": { "role":
"http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails", "longName": "99941101 - Disclosure - Net Loss per Share - Antidilutive (Details)", "shortName": "Net Loss per Share - Antidilutive (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_DssL6QHPR0-9nquS0YV2ig", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"Duration_1_1_2024_To_6_30_2024_1z_R10FRLEaLFxAdlWcAOQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef":
"Unit_Standard_shares_DssL6QHPR0-9nquS0YV2ig", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "srrk-20240630x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.scholarrock.com/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r32", "r35", "r39", "r707" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [
"http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r32", "r549" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": [
"http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization/accretion of investment securities", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r58" ] }, "srrk_AccruedExternalResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri":
```

{"http://www.scholarrock.com/20240630", "localname": "AccruedExternalResearchAndDevelopmentExpense", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of accrued external research and development expense as of the balance sheet date. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued External Research And Development Expense", "terseLabel": "Accrued external research and development expense" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails", "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r35"] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional and consulting expense", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r35"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r14", "r15", "r49", "r99", "r422", "r441", "r442"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r7", "r15", "r324", "r327", "r376", "r437", "r438", "r666", "r667", "r668", "r678", "r679", "r680", "r682"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r599"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r44", "r549", "r739"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r440", "r678", "r679", "r680", "r682", "r708", "r740"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r612"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r612"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r612"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r612"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Equity-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "srrk_AggregateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "AggregateMember", "presentation": ["http://www.scholarrock.com/role/DisclosureCommonStockDetails", "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"], "lang": { "en-us": { "role": { "documentation": "Information reported for the aggregate, since inception.", "label": "Aggregate [Member]", "terseLabel": "Aggregate" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r645"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r571", "r581", "r591", "r623"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r574", "r584", "r594", "r626"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r646"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r612"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r619"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r575", "r585", "r595", "r619", "r627", "r631", "r639"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r637"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Equity-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r299", "r304"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt discount and debt issuance costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": ["r53", "r250", "r674", "r719"] }, "srrk_AnnualLeaseAdjustmentPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "AnnualLeaseAdjustmentPercent", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "The annual upward lease adjustment percentage.", "label": "Annual Lease Adjustment Percent", "terseLabel": "Annual upward adjustment (as a percent)" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities excluded from the calculation of net loss per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r147"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r20"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Anti-dilutive securities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r20"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r73", "r81", "r97", "r122", "r151", "r153", "r154", "r155", "r189", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r317", "r321", "r355", "r418", "r472", "r519", "r520", "r549", "r562", "r703", "r704", "r723"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent",

```
"crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r93", "r100", "r122", "r189", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r317", "r321", "r355", "r549", "r703", "r704", "r723" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r334", "r335", "r537" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "auth_ref": [] }, "srrk_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "AtMarketOfferingMember", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to At the market offering.", "label": "At Market Offering [Member]", "terseLabel": "ATM Offering" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r163" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r164" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r160", "r197", "r417" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "terseLabel": "Estimated Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r161", "r197", "r334", "r411", "r537", "r540", "r688", "r712", "r713", "r714" ] }, "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract", "presentation": [ "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]", "terseLabel": "Marketable securities available-for-sale" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r634" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r635" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r630" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r630" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r630" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r630" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r630" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r630" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r633" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r632" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r631" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r631" ] }, "srrk_BinneyStCambridgeMaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "BinneyStCambridgeMaMember", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Related to property located on Binney Street in Cambridge, Massachusetts.", "label": "Binney St Cambridge MA [Member]", "terseLabel": "301 Binney St, Cambridge MA" } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.scholarrock.com/role/DisclosureNatureOfBusiness" ], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Nature of the Business", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r31", "r59", "r60" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails", "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r18", "r95", "r513" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r95" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "verboseLabel": "Cash and cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r710", "r711" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r19", "r72" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails", "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r18", "r56", "r119" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [
"http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and
Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease)/increase in cash, cash equivalents and restricted
cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from
exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general
characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts
of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r56" ] },
"ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer
Group, Footnote" } } }, "auth_ref": [ "r610" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair
Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r607" ] },
"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair
Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r605" ] }, "dei_CityAreaCode": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } }
}, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis",
"presentation": [ "http://www.scholarrock.com/role/DisclosureCommonStockDetails", "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails" ],
"lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r27" ] }, "us-
gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation":
[ "http://www.scholarrock.com/role/DisclosureCommonStockDetails", "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails" ], "lang": { "en-us": {
"role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative
securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a
new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the
company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a
typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [
"http://www.scholarrock.com/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
"terseLabel": "Warrant exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [
"r258" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommonStockDetails" ],
"lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Warrant to purchase (in shares)",
"documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into
1,000,000 shares." } } }, "auth_ref": [ "r258" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
"http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding",
"verboseLabel": "Outstanding warrants (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": {
"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r611" ] },
"ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } },
"auth_ref": [ "r611" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 9)", "documentation": "Represents the caption on the face of the balance
sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2)
is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and
(b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
} } }, "auth_ref": [ "r40", "r76", "r419", "r459" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "auth_ref": [] },
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": {
"role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for
commitments and contingencies." } } }, "auth_ref": [ "r62", "r211", "r212", "r507", "r697", "r702" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel":
"Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r552", "r553", "r554", "r556", "r557", "r558", "r559", "r678",
"r679", "r682", "r708", "r738", "r740" ] }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Common Stock." }
} }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": {
"role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of
common stock." } } }, "auth_ref": [ "r43" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesAuthorized", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommonStockDetails",
"http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized",
"terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } },
"auth_ref": [ "r43", "r460" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesIssued", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label":
"Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted
to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and
owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [
"r43" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesOutstanding", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": {
"label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding.
Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r43", "r460", "r478", "r740", "r741" ] }, "srrk_CommonStockTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "CommonStockTextBlock", "presentation": [
"http://www.scholarrock.com/role/DisclosureCommonStock" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of common stock.", "label": "Common
Stock [Text Block]", "terseLabel": "Common Stock" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us":
{ "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 300,000,000 shares authorized; 79,992,068 and 75,979,495 shares issued
and outstanding as of June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or
common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable
common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r43", "r421", "r549" ] },
"srrk_CommonWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "CommonWarrantMember", "presentation": [
"http://www.scholarrock.com/role/DisclosureCommonStockDetails", "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails" ], "lang": { "en-us": {
"role": { "documentation": "Represents the information pertaining to the common warrants.", "label": "Common Warrant [Member]", "terseLabel": "Warrants, non pre-funded"
} } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation
Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r616" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid
vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r615" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation
Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r617" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } },
"auth_ref": [ "r614" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after
tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity.
Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r16", "r106", "r108", "r112", "r412", "r430", "r431" ] }, "us-
gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ],
"lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "auth_ref": [] },
"dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and
Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-
gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": {
"label": "Debt" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtDisclosureTextBlock", "presentation": [ "http://www.scholarrock.com/role/DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]",
```

"terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r63", "r121", "r204", "r205", "r206", "r207", "r208", "r217", "r218", "r228", "r234", "r235", "r236", "r237", "r238", "r239", "r244", "r251", "r252", "r254", "r362"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r13", "r34", "r35", "r74", "r75", "r123", "r229", "r230", "r231", "r232", "r233", "r235", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r524", "r525", "r526", "r527", "r528", "r547", "r676", "r698", "r699", "r700", "r718", "r720"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate (as a percent)", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "srrk_DebtInstrumentFinalPaymentFee": { "xbrltype": "percentItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "DebtInstrumentFinalPaymentFee", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the final payment fee, as a percent of the aggregate advances on the debt.", "label": "Debt Instrument, Final Payment Fee", "terseLabel": "Final payment fee (as a percent)" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r123", "r229", "r230", "r231", "r232", "r233", "r235", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r253", "r524", "r525", "r526", "r527", "r528", "r547", "r676", "r718", "r720"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r13", "r123", "r229", "r230", "r231", "r232", "r233", "r235", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r524", "r525", "r526", "r527", "r528", "r547", "r676", "r698", "r699", "r700", "r718", "r720"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r13", "r25", "r26", "r30", "r64", "r65", "r123", "r229", "r230", "r231", "r232", "r233", "r235", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r253", "r524", "r525", "r526", "r527", "r528", "r547", "r676", "r718", "r720"] }, "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth_ref": ["r416"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Aggregate fair value of marketable securities with unrealized gains (losses) position for less than a year", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r82", "r199", "r522"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "presentation": ["http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "terseLabel": "Number of investments in an unrealized loss position for less than a year", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r695"] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": ["http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r5", "r24"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Equity-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r269", "r272", "r300", "r301", "r303", "r534"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Equity-Based Compensation" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r566"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r598"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r609"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss per Share" } } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r113", "r129", "r130", "r131", "r132", "r133", "r134", "r140", "r142", "r144", "r145", "r146", "r150", "r312", "r315", "r331", "r332", "r413", "r432", "r516"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r113", "r129", "r130", "r131", "r132", "r133", "r134", "r142", "r144", "r145", "r146", "r150", "r312", "r315", "r331", "r332", "r413", "r432", "r516"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureNetLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r139", "r147", "r148", "r149"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and related expenses", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r35"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Equity-based compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized Expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r302"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment
Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted Average Remaining Period of Recognition", "documentation":
"Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format,
for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r302"] }, "us-gaap_EmployeeStockOptionMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails",
"http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails",
"http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails",
"http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label":
"Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other
restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [
"http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation":
"Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"],
"lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code
for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressStateOrProvince", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": {
"label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype":
"centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique
10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r564"] },
"dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding",
"presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares
Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests,
if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A
[Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] },
"dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation":
"Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This
information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation":
"Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r564"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-
us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the
sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] },
"dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate
whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the
Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r564"] },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityIncorporationStateCountryCode", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label":
"Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] },
"dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation":
"Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r640"] }, "dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact
name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r564"] }, "dei_EntityShellCompany": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
"http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag
that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r564"] }, "dei_EntitySmallBusiness": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that
the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r564"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"],
"lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification
Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r564"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r603"] },
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity
Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation
Table" } } }, "auth_ref": ["r644"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]",
"terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r644"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
"en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant
Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r644"] }, "us-gaap_EquityComponentDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]",
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings,
etc." } } }, "auth_ref": ["r8", "r91", "r109", "r110", "r111", "r124", "r125", "r126", "r128", "r133", "r135", "r137", "r152", "r190", "r191", "r202", "r259", "r307", "r308", "r309",
"r310", "r311", "r313", "r314", "r315", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r356", "r357", "r358", "r359", "r360", "r361", "r363", "r364", "r376", "r428",
"r437", "r438", "r439", "r448", "r498"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity
Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r613"] },
"ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous
Compensation Analysis" } } }, "auth_ref": ["r571", "r581", "r591", "r623"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label":
"Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r568", "r578", "r588", "r620"] },
"ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category." } } }, "auth_ref": ["r619"]
}, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities
Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Financial assets and financial liabilities measured at fair value on a recurring basis:",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table." } } }, "auth_ref": ["r334", "r335", "r345", "r537"] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring
[Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r334", "r335",
"r345", "r537"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us":
{ "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per
share as practical expedient." } } }, "auth_ref": ["r242", "r261", "r262", "r263", "r264", "r265", "r266", "r333", "r335", "r336", "r337", "r338", "r344", "r345", "r347", "r380",
"r381", "r382", "r525", "r526", "r530", "r531", "r532", "r537", "r540"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]",
"documentation": "Information by measurement frequency." } } }, "auth_ref": ["r334", "r335", "r336", "r338", "r537", "r713", "r716"] }, "us-
gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": {
"role": { "label": "Fair Value of Financial Assets and Liabilities" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [
"http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]",
"terseLabel": "Fair Value of Financial Assets and Liabilities", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including

financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r340", "r342", "r343", "r344", "r347", "r348", "r349", "r350", "r351", "r410", "r537", "r541"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r242", "r261", "r266", "r335", "r345", "r380", "r530", "r531", "r532", "r537"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r334", "r335", "r336", "r338", "r537", "r713", "r716"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r242", "r261", "r262", "r263", "r264", "r265", "r266", "r333", "r335", "r336", "r337", "r338", "r344", "r345", "r347", "r380", "r381", "r382", "r525", "r526", "r530", "r531", "r532", "r537", "r540"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r537", "r710", "r711", "r712", "r713", "r714", "r716"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r192", "r193", "r194", "r195", "r196", "r198", "r200", "r201", "r253", "r257", "r329", "r352", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r429", "r522", "r537", "r538", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r550", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r690", "r691", "r692", "r693", "r709", "r712", "r713", "r714", "r715", "r716"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r575", "r585", "r595", "r627"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r575", "r585", "r595", "r627"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r575", "r585", "r595", "r627"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r575", "r585", "r595", "r627"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r575", "r585", "r595", "r627"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r608"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r51", "r482"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r51"] }, "us-gaap_IncentiveToLessee": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncentiveToLessee", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Incentive to Lessee", "terseLabel": "Incentive to lease", "documentation": "Amount of incentive granted by lessor to lessee." } } }, "auth_ref": ["r83", "r84", "r651"] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r203", "r209", "r210", "r339", "r341", "r346", "r434", "r436", "r483", "r512", "r539", "r737"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r209", "r210", "r339", "r341", "r346", "r434", "r436", "r483", "r512", "r539", "r737"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r653", "r673"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r673"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (decrease) in Stockholders' Equity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r575", "r585", "r595", "r619", "r627", "r631", "r639"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r637"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r567", "r643"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r567", "r643"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r567", "r643"] }, "srrk_InterestOnlyPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "InterestOnlyPeriod", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "The interest only period.", "label": "Interest Only, Period", "terseLabel": "Interest only period" } } }, "auth_ref": [] }, "us-

gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r114", "r117", "r118"] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Marketable Securities" } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure", "terseLabel": "U.S. Treasury obligations and government agency securities", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": ["r710", "r711", "r715"] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureMarketableSecurities"], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r79", "r90", "r157", "r158", "r353", "r354", "r732"] }, "srrk_JingMarantzMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "JingMarantzMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Jing Marantz.", "label": "Jing Marantz [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r369", "r548"] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost:" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of lease costs", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r722"] }, "srrk_LesseeOperatingLeaseBaseRent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "LesseeOperatingLeaseBaseRent", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of base rent for initial period under the lease.", "label": "Lessee Operating Lease Base Rent", "terseLabel": "Base rent" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Option to extend the term", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": ["r368"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r721"] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letter of credit", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r13", "r34", "r35", "r36", "r38", "r39", "r40", "r41", "r122", "r189", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r318", "r321", "r322", "r355", "r458", "r517", "r562", "r703", "r723", "r724"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r48", "r77", "r424", "r549", "r677", "r694", "r717"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r36", "r94", "r122", "r189", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r318", "r321", "r322", "r355", "r549", "r703", "r723", "r724"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "srrk_LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "LineOfCreditFacilityInterestOnlyPaymentsAdditionalPeriod", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Additional period of only interest payments in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Line of Credit Facility, Interest Only Payments, Additional Period", "terseLabel": "Interest additional period" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit maximum", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r33", "r37"] }, "srrk_LineOfCreditFacilityRepaymentOfPrincipalExtensionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "LineOfCreditFacilityRepaymentOfPrincipalExtensionPeriod", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Additional extension period for repayment of principal amounts in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Line of Credit Facility, Repayment Of Principal, Extension Period", "terseLabel": "Extension period" } } }, "auth_ref": [] }, "srrk_LoanAndSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "LoanAndSecurityAgreementMember", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the Loan and Security Agreement.", "label": "Loan and Security Agreement [Member]", "terseLabel": "Loan and Security Agreement" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "terseLabel": "Long-term portion of loan", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r13", "r75", "r241", "r255", "r525", "r526", "r547", "r735"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r98"] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesAbstract", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]", "terseLabel": "Marketable securities:" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r662"] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table Text Block]", "terseLabel": "Summary of investments", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "srrk_MaximumAggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "MaximumAggregateOfferingPrice", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum aggregate offering price.", "label": "Maximum Aggregate Offering Price", "terseLabel": "Maximum aggregate offering price" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "verboseLabel": "Maximum" } } }, "auth_ref": ["r213", "r214", "r215", "r216", "r267", "r305", "r338", "r408", "r433", "r435", "r443", "r450", "r451", "r501", "r502", "r503", "r504", "r505", "r510", "r511", "r521", "r529", "r533", "r540", "r541", "r545", "r551", "r705", "r725", "r726", "r727", "r728", "r729", "r730"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r611"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r611"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "verboseLabel": "Minimum" } } }, "auth_ref": ["r213", "r214", "r215", "r216", "r267", "r305", "r338", "r408", "r433", "r435", "r443", "r450", "r451", "r501", "r502", "r503", "r504", "r505", "r510", "r511", "r521", "r529", "r533", "r540", "r541", "r545", "r551", "r705", "r725", "r726", "r727", "r728", "r729", "r730"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r630"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money market funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r706"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel":

"Material Terms of Trading Arrangement" } } }, "auth_ref": ["r638"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r612"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r116"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r116"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r56", "r57", "r58"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails", "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r50", "r58", "r78", "r92", "r104", "r107", "r111", "r122", "r127", "r129", "r130", "r131", "r132", "r133", "r136", "r137", "r143", "r189", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r312", "r315", "r332", "r355", "r427", "r480", "r496", "r497", "r560", "r703"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted and Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r611"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r575", "r585", "r595", "r619", "r627"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r602"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r601"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r619"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r638"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r638"] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of non-cash items:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r52"] }, "us-gaap_NontradeReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NontradeReceivablesCurrent", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Nontrade Receivables, Current", "terseLabel": "Receivables", "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r663"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r80", "r518", "r683", "r684", "r685", "r686", "r687"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r370", "r548"] }, "srrk_OperatingLeaseLiabilityAdjustmentFromRentModification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "OperatingLeaseLiabilityAdjustmentFromRentModification", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Effect on cash flow during the period of non-cash operating lease liability, adjustment from rent modification.", "label": "Operating Lease Liability, Adjustment From Rent Modification", "terseLabel": "Operating lease liability, adjustment from rent modification" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r366"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term portion of operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r366"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows used for operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r367", "r372"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r365"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "verboseLabel": "Non-cash operating lease expense", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r674"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average incremental borrowing rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r374", "r548"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r373", "r548"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Nature of the Business" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r35"] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsDisclosureTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssets"], "lang": { "en-us": { "role": { "label": "Other Assets Disclosure [Text Block]", "terseLabel": "Prepaid Expenses and Other Assets", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails", "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets", "totalLabel": "Total other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r96"] }, "us-gaap_OtherAssetsNoncurrentDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrentDisclosureAbstract", "presentation": ["http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent Disclosure [Abstract]", "terseLabel": "Other long-term assets" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized gain (loss) on marketable securities", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r101", "r102", "r103", "r428"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss)", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r3", "r7", "r71", "r105", "r108", "r133"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r35", "r549"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r611"] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid other", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r664", "r696"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r573", "r583", "r593", "r625"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r576", "r586", "r596", "r628"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r576", "r586", "r596", "r628"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r600"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtRestructuringCosts", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Debt Restructuring Costs", "negatedLabel": "Debt modification payment", "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage." } } }, "auth_ref": ["r17"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r689"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r55"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r610"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r610"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r602"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r619"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r612"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r601"] }, "srrk_PercentageOfDollarValueOfConsolidatedCash": { "xbrltype": "percentItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "PercentageOfDollarValueOfConsolidatedCash", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Dollar value of company's consolidated cash as a percent, as required by the agreement.", "label": "Percentage Of Dollar Value of Consolidated Cash", "terseLabel": "Percentage of dollar value of company's consolidated cash" } } }, "auth_ref": [] }, "srrk_PercentageOfOutstandingObligation": { "xbrltype": "percentItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "PercentageOfOutstandingObligation", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of cash required in a lender's account as a percentage of outstanding obligation requirement as per the agreement.", "label": "Percentage of Outstanding Obligation", "terseLabel": "Amount of cash required in a lender's account as a percentage of outstanding obligation (as a percent)" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r603"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r647"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r602"] }, "srrk_PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "PreFundedWarrantMember", "presentation": ["http://www.scholarrock.com/role/DisclosureCommonStockDetails", "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the pre-funded warrants.", "label": "Pre Funded Warrant [Member]", "terseLabel": "Pre-funded warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r42", "r256"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r42", "r460"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r42", "r460", "r478", "r740", "r741"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r42", "r420", "r549"] }, "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails", "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal

```
operating cycle, if longer." } } }, "auth_ref": [ "r665" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "presentation": [
"http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current
[Abstract]", "terseLabel": "Prepaid expenses and other current assets" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseOtherNoncurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseOtherNoncurrent", "crdr": "debit", "presentation": [
"http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense Other, Noncurrent",
"terseLabel": "Prepaid other", "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods
after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r661" ] }, "srrk_PrepaidExternalResearchAndDevelopmentExpenseCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "PrepaidExternalResearchAndDevelopmentExpenseCurrent", "crdr": "debit",
"presentation": [ "http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of
prepaid external research and development expense as of the balance sheet date. Used to reflect the current portion of the asset (due within one year or within the normal
operating cycle if longer).", "label": "Prepaid External Research And Development Expense, Current", "terseLabel": "Prepaid external research and development expense" } } },
"auth_ref": [] }, "srrk_PrepaidExternalResearchAndDevelopmentExpenseNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scholarrock.com/20240630",
"localname": "PrepaidExternalResearchAndDevelopmentExpenseNoncurrent", "crdr": "debit", "presentation": [
"http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of prepaid external
research and development expense as of the balance sheet date. Used to reflect the noncurrent portion of the asset (due after one year or outside the normal operating cycle if
longer).", "label": "Prepaid External Research And Development Expense, Noncurrent", "terseLabel": "Prepaid external research and development expense" } } }, "auth_ref": [] },
"us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": [
"http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Insurance", "terseLabel": "Prepaid
insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the
normal operating cycle, if longer." } } }, "auth_ref": [ "r514", "r523", "r696" ] }, "srrk_PrepaidInsuranceNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.scholarrock.com/20240630", "localname": "PrepaidInsuranceNoncurrent", "crdr": "debit", "presentation": [
"http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to
consideration paid in advance for insurance that provides economic benefits after a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid
Insurance, Noncurrent", "terseLabel": "Prepaid insurance" } } }, "auth_ref": [] }, "srrk_PrepaymentPenaltyPercent": { "xbrltype": "percentItemType", "nsuri":
"http://www.scholarrock.com/20240630", "localname": "PrepaymentPenaltyPercent", "presentation": [ "http://www.scholarrock.com/role/DisclosureDebtDetails" ], "lang": {
"en-us": { "role": { "documentation": "Prepayment penalty as a percent", "label": "Prepayment Penalty, Percent", "terseLabel": "Prepayment penalty (as a percent)" } } },
"auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-
us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sale of common shares, net of issuance costs", "documentation": "The cash
inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/DisclosureDebtDetails" ],
"lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "verboseLabel": "Proceeds from credit facility", "documentation": "The cash inflow during the period
from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r671" ] }, "us-
gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role":
{ "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Sale of shares", "documentation": "The cash inflow associated with the amount received from entity's
raising of capital via private rather than public placement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "presentation": [
"http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from (Payments for) Other Financing
Activities", "terseLabel": "Other", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r652", "r669" ] }, "us-
gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" ],
"lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities", "documentation": "The
cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the
period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": [
"http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Property, Plant, and
Equipment", "terseLabel": "Proceeds from sale of property and equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the
normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r54" ] }, "us-gaap_ProceedsFromStockOptionsExercised": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [
"http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised",
"verboseLabel": "Proceeds from stock option exercises", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } },
"auth_ref": [ "r2", "r11" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": {
"role": { "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from pre-funded and common warrant exercises", "documentation": "The cash inflow associated
with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r670" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"
], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The
consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r92", "r104", "r107",
"r115", "r122", "r127", "r133", "r136", "r137", "r189", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r312", "r315", "r316", "r319", "r320", "r332",
"r355", "r414", "r426", "r447", "r480", "r496", "r497", "r535", "r536", "r561", "r668", "r703" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]",
"verboseLabel": "Leased assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r375" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property
and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to
produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture
and fixtures." } } }, "auth_ref": [ "r6", "r375", "r415", "r425", "r549" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs
Performance Disclosure" } } }, "auth_ref": [ "r600" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]",
"terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r600" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "RangeAxis", "presentation": [ "http://www.scholarrock.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" }
} }, "auth_ref": [ "r213", "r214", "r215", "r216", "r260", "r267", "r295", "r296", "r297", "r305", "r338", "r383", "r392", "r408", "r433", "r435", "r443", "r450", "r451", "r501",
"r502", "r503", "r504", "r505", "r510", "r511", "r521", "r529", "r533", "r540", "r541", "r545", "r546", "r551", "r554", "r701", "r705", "r713", "r726", "r727", "r728", "r729",
"r730" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.scholarrock.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r213", "r214", "r215",
"r216", "r260", "r267", "r295", "r296", "r297", "r305", "r338", "r383", "r392", "r408", "r433", "r450", "r451", "r501", "r502", "r503", "r504", "r505", "r510",
"r511", "r521", "r529", "r533", "r540", "r541", "r545", "r546", "r551", "r554", "r701", "r705", "r713", "r726", "r727", "r728", "r729", "r730" ] },
"srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails" ],
"lang": { "en-us": { "role": { "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r508", "r509", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749" ] },
"srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails" ],
"lang": { "en-us": { "role": { "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r508", "r509", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749" ] },
"ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems",
"lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation
Disclosure" } } }, "auth_ref": [ "r568", "r578", "r588", "r620" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label":
"Repayments of Debt", "terseLabel": "Repayments of debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease
obligation." } } }, "auth_ref": [ "r672" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and Development
Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer
software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint
venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and
development activity." } } }, "auth_ref": [ "r306", "r512", "r519", "r731" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense
[Member]", "terseLabel": "Research and development expense", "documentation": "Primary financial statement caption in which the reported facts about research and
development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination
Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r569", "r579", "r589", "r621" ] }, "ecd_RestatementDeterminationDate": { "xbrltype":
"dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ],
"lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r570", "r580", "r590", "r622" ] },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does
Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r577", "r587", "r597", "r629" ] }, "us-
gaap_RestrictedCashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedCashAndCashEquivalentsAbstract", "presentation": [ "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails" ], "lang": {
"en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and cash equivalents and restricted cash" } } }, "auth_ref": [] }, "us-
```

gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r95"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashDetails", "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r85", "r661", "r675"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails", "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.scholarrock.com/role/DisclosureNatureOfBusinessDetails", "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r45", "r66", "r423", "r440", "r442", "r446", "r461", "r549"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r91", "r124", "r125", "r126", "r128", "r133", "r135", "r137", "r190", "r191", "r202", "r307", "r308", "r309", "r310", "r311", "r313", "r314", "r315", "r323", "r325", "r326", "r328", "r330", "r363", "r364", "r437", "r439", "r448", "r740"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r638"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r638"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.scholarrock.com/role/DisclosureCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.scholarrock.com/role/DisclosureCommonStockDetails", "http://www.scholarrock.com/role/DisclosureDebtDetails", "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r138", "r268", "r649", "r681"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r20"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of anti-dilutive securities", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r20"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationExpenseDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "verboseLabel": "Summary of allocation of equity-based compensation", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of summary of the assets and liabilities measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r710", "r711"] }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "terseLabel": "Schedule of other long-term assets", "documentation": "Tabular disclosure of noncurrent assets." } } }, "auth_ref": ["r661"] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosurePrepaidExpensesAndOtherAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r6", "r375"] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": ["r12", "r72", "r736"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "verboseLabel": "Summary of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r9", "r10", "r67"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of weighted average assumptions in fair value", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r69"] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of stock activity", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted

stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]", "terseLabel": "Summary of unrecognized equity-based compensation expense", "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r70"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r563"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r565"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Equity-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r289"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r289"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r287"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r287"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding, end (in shares)", "periodStartLabel": "Outstanding, beginning (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r284", "r285"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares/Units", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding, end (in dollars per share)", "periodStartLabel": "Outstanding, beginning (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r284", "r285"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r288"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of non-option awards vested", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": ["r291"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r288"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Assumptions used in determining the fair value of options" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r296"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r295"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r297"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "verboseLabel": "Equity-Based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r270", "r271",

"r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Stock options" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable, end (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r278"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable, end (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r278"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Cancelled (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r280"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r290"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value, end", "periodStartLabel": "Aggregate intrinsic value, beginning", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r28"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end (in shares)", "periodStartLabel": "Outstanding, beginning (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r276", "r277"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Units", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end (in dollars per share)", "periodStartLabel": "Outstanding, beginning (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r276", "r277"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationRestrictedStockDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails", "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationUnrecognizedExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r281"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r280"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years to liquidity)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r294"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r28"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r28"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r28"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance at end (in shares)", "periodStartLabel": "Balance at beginning (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"ShortTermBorrowings", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt", "terseLabel": "Short-term debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r32", "r74", "r549", "r734" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r59", "r120" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r43", "r46", "r47", "r91", "r109", "r110", "r111", "r124", "r125", "r126", "r128", "r133", "r135", "r137", "r152", "r190", "r191", "r202", "r259", "r307", "r308", "r309", "r310", "r311", "r313", "r314", "r315", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r356", "r357", "r358", "r359", "r360", "r361", "r363", "r364", "r376", "r428", "r437", "r438", "r439", "r448", "r498" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r124", "r125", "r126", "r152", "r364", "r409", "r444", "r449", "r452", "r453", "r454", "r455", "r456", "r457", "r460", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r477", "r479", "r481", "r482", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r555" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENT OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.scholarrock.com/role/DisclosureCommonStockDetails", "http://www.scholarrock.com/role/DisclosureDebtDetails", "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r138", "r268", "r649", "r650", "r681" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r124", "r125", "r126", "r152", "r156", "r364", "r409", "r444", "r449", "r452", "r453", "r454", "r455", "r456", "r457", "r460", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r473", "r474", "r475", "r476", "r477", "r479", "r481", "r482", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r555" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r572", "r582", "r592", "r624" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "srrk_StockIssuedDuringPeriodSharesExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommonStockDetails", "http://www.scholarrock.com/role/DisclosureNetLossPerShareAntidilutiveDetails", "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during period on exercise of warrants.", "label": "Stock Issued During Period, Shares, Exercise Of Warrants", "terseLabel": "Exercise of pre-funded and common warrants (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommonStockDetails", "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Sale of common shares, net of issuance costs (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r42", "r43", "r66", "r445", "r498", "r506" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Issuance of common shares upon RSU vesting (in shares)", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r8", "r66" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.scholarrock.com/role/DisclosureEquityBasedCompensationStockOptionsDetails", "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "verboseLabel": "Exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r42", "r43", "r66", "r281" ] }, "srrk_StockIssuedDuringPeriodValueExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Equity impact of shares issued during period on exercise of warrants.", "label": "Stock Issued During Period, Value, Exercise Of Warrants", "terseLabel": "Exercise of pre-funded and common warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Sale of common shares, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r42", "r43", "r66", "r448", "r498", "r506", "r561" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Other", "terseLabel": "Other", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Issuance of common shares upon RSU vesting", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r8", "r42", "r43", "r66" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r8", "r43", "r46", "r47", "r66" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets", "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance at end", "periodStartLabel": "Balance at beginning", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r43", "r46", "r47", "r61", "r462", "r478", "r499", "r500", "r549", "r562", "r677", "r694", "r717", "r740" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://www.scholarrock.com/role/DisclosureCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Equity", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.scholarrock.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r618" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r610" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r617" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement." } } }, "auth_ref": [ "r637" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r639" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.scholarrock.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "srrk_TrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "TrancheFourMember", "presentation": [ "http://www.scholarrock.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents
```

information pertaining to tranche four.", "label": "Tranche Four [Member]", "terseLabel": "Tranche Four" } } }, "auth_ref": [] }, "srrk_TrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "TrancheOneMember", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Tranche one of the debt agreement", "label": "Tranche One [Member]", "terseLabel": "Tranche One" } } }, "auth_ref": [] }, "srrk_TrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "TrancheThreeMember", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to tranche three.", "label": "Tranche Three [Member]", "terseLabel": "Tranche Three" } } }, "auth_ref": [] }, "srrk_TrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "TrancheTwoMember", "presentation": ["http://www.scholarrock.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Tranche two of the debt agreement", "label": "Tranche Two [Member]", "terseLabel": "Tranche Two" } } }, "auth_ref": [] }, "srrk_TransferOfAssetsBetweenFairValueMeasurementLevels": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "TransferOfAssetsBetweenFairValueMeasurementLevels", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Transfer Of Assets Between Fair Value Measurement Levels.", "label": "Transfer Of Assets Between Fair Value Measurement Levels", "terseLabel": "Transfer of assets between fair value measurement levels." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r253", "r257", "r329", "r352", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r429", "r537", "r538", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r550", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r690", "r691", "r692", "r693", "r709", "r712", "r713", "r714", "r715", "r716"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r640"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r641"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r641"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r639"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r639"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r642"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r640"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://www.scholarrock.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails", "http://www.scholarrock.com/role/DisclosureMarketableSecuritiesSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury obligations", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r515", "r530", "r532", "r537", "r733"] }, "srrk_UnauditedInterimFinancialInformationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "UnauditedInterimFinancialInformationPolicyTextBlock", "presentation": ["http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for unaudited interim financial information.", "label": "Unaudited Interim Financial Information [Policy Text Block]", "terseLabel": "Unaudited Interim Financial Information" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r636"] }, "srrk_UponExpirationOfFirstExtensionTermMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scholarrock.com/20240630", "localname": "UponExpirationOfFirstExtensionTermMember", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the scenario after expiration of first extension term", "label": "Upon Expiration Of First Extension Term [Member]", "terseLabel": "First extension" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.scholarrock.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r21", "r22", "r23", "r86", "r87", "r88", "r89"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": ["http://www.scholarrock.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r371", "r548"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r606"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.scholarrock.com/role/DisclosureCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r552", "r553", "r556", "r557", "r558", "r559"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r141", "r146"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.scholarrock.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding, basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r140", "r146"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r604"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(i)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-6" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-7" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",

"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480139/470-20-50-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r306": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-
10-65-8" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r310": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r311": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-
323-65-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r315": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-
45-25" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r319": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r320": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r321": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-
65-6" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r325": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r326": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r327": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r328": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r329": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-
40-65-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r333": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r337": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r338": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r339": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r340": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r341": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

```
"Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r466": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r467": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r468": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r469": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r470": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r471": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r472": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r473": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r474": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r475": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r476": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r477": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r478": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r479": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-
50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r508": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r509": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r510": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r513": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r517": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r520": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r523": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name":
```

```
"Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef",
```

"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r649": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r650": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "5", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479924/842-10-30-5" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r747": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } } } ZIP 71 0001558370-24-011461-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-011461-xbrl.zip M4$L#!!0 (,HY'"%G;7#_'B P !-Y 1 ,;FYLL7@9F!&F8K0-CA+A":9;WGK846TET8\M9 M20:R?_VUY*\X_I"=#%79.K] L+1,W?!)K59;.3[!^.HZZ)EP03UVV>IW>BU$ MF.79E"TO6[Y>LU M9NB><$X=!UUQ:B\)0OU>YT.GU^FC=ONS%G&%!;!X#&E9)YU^U' =2O/8!?K8 M_=`JZ9VH*N:YZ!8*R17K;,,&;,>)S[!!8TR:$?TRT+3!_/S MKF[=ED1+M!,2,PLT$)BOB3R ;M$K+%%4CQ@E^=@SCWK6\?R7&U_[_U H>80 MADA."R+3=K(F*A"RSF6HFX2,A.:NZI9=7#2[@W:@WZB%_]6T=F-WR.8=IODE++$,3J++WG;M2:&@E?M+GGY(U:/Z#0D%:I=*[8R5S1/ICF.NCW@8.F.]-J3>;%4TLU MIJ>791?,+LO>)6P+2UY(K!H#AL_(*0W)LR0>]5#4H^BA^LU90LO> -/U+VQ MW4C-9Q!HL5J0!?G^Y*_,>]+LJ+,<3/B=3Fl_VYO:0V=>>?D)XI?*7BQG,Q9>%| MRUP=TSQG#J@&1$%P-=E M-\$^R,*NND"Z#X5\W L*ND$0:Z&MCH"A0=V(^CWFWV"0Y@Z9$CCWZY&+U_=-M>R9";K= <@'I===A/JIUG4DRY0TD?,"6QUU&!NQOR1DS6F]NAU#5$44>MS(E>$ M!\NH .A*/"9TS[+HAG)1)%BO8BTZ6M8-H$9 8>/C/HG!*8"P@,H$VOLL:*&D M!+0&(R-& <&XQ>:"TL@4:@4.$W;G6>RVI.JUEI+; +E_2N(1 M$0G!]U/%FJ!"L*N>K$#O4M(;2.L>7*<2Z(`1)ER,?O>IW%0\P>8P&]$= MU#G*3F>3ZW]!F8QO1D_3OZ'1Of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f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l%?,(<9I*[*!M;4YGI;;Y986M^= M%9BBD[:B]&@B4L)4,@=! <;?L!W&W*X$?=9+$@2MW(#R1[,P'|@8YAU^PRW7'>= M2)$M]_B05NKX[7,*FHI(!D"VX\ MZ#9Z-;]=ITR50V[E'SH,/(=ZROT0#=%B]&9,GUFt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{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`_%JNSUU!"WL MRFN1SQDK;@ BPE&79Y6 LTC+8U8(Y4QHCQ2MS9&"UV6(ROA@L.S.6-1G -/=&K\H<]_!EN08(8=6.X>9F#%_59.PJBZX"0C7F&\'7;M3C*[K0 MK7]+@S#\E!IU+@%%B6?&M(O)XY1>XNV!T>8]8DQ2+V+'S\ARY/#=-O#+, ,:D M&&EU5_(W@BJ\1((&ZU;P"YE"W"93<0;Z+LJ.6/37-XV$# J85C[Y>+CHORU^LJ:>8R:L2W.VLQ!710#=(RC1XRY 4=.H0%HG91>#MT MK${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|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|S3X9BZ7_V9B7.5H"D>BWD$V8.-HI.[+&LK"R MH&CUP7D=Q]$BN?I:6J];9:4:[+ K2!4H4"U#JY!;-=EJ0*^URI2V7@8*D;M M(UZO0V4C,+9J!F"ZQ!85S.00_(*2,IPY.L05,D48&2T=UL4P&0@%(PY?#5-$ ML50(4T7->&R>7 P07JQGE\)((G,&M# N\%#;0:LX&.?!Z]#;;>@M9CY4Q.1(MO,U$O11MBU V;B13D)0MW]%RA>)NZ>FZ^(O ;M0[$)Q'U>G",),$9E4'5'*Z M.T-[) THPVIPH|(AHWR@EH7^X)G|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

87N@)U2E·MKH:7:?,T43M*K:B0O071-<28X)3<|C<.(J_S@YB>]=0NG#Vl%\Z2[D>T_]$*·MH%$R GTUIS"()1?C%5'*;M=\@"[>W2 FQ-+T'[T=,8ZRJTPN'$0+W;=L4|L^ MKYM!3#R@TP[QTS6[ ]%S/'V.:%=U<3]*6'KAIT|FYE[LHPT!'QM5:=FSO)D% MQ0<#FJ-QZ[F=* BCDTZMGDU=K'HEP\/3^4?CDCZ2-+9E858TN)S2$)DF7 MURX_S\19 S214Y]/+7%B?'I-,0S_<.@%SX*#"4PP6W9P=5C-ℏ:\%9P%#L.3 M68;7!$WIL3!5"2 M^N(00\QC8 5ELI5&'\(6U@4>D@U5BJCOL!|W'"%P&=,5 MJM3%\2!MF? @5M*BXM<>D97_/=|8RJZRBJ9F6KNV1)/>NJCHL)BLR2 MZ&&1M21+W;6 _0+!1Y+,%UDDD:7'V!WM|5 2 $D\@7\Z[H|V43H&:=9F,1 M_,:=Z[?? (!S[21#&CW_\9I>O3]YFW_[T__ZAW_]QY.3 S]IO49!XN\V.,Z1 MGV(OQP'Z'.9/Z#[9;KT8O<=I&D81.DW#X!$C].[MZS^|?OOZ'3HY^1,C<>IE M!"6)$;/U_>MWY0|G!;4D_@G|\Y1_O/G^[?? A/|HW=O?WKW!W3SO@1[3QA; MAP:X*(Q_^XG^OP7] Y3WCCG81QEGNQC[_A6 V,+P|!5.+||*8D_TU)G_Y!-L*[*W_||0W] ME8!FX4\9&^DZ\;V<:5PV!D+4D+0_ZI8/]%_.GGW_(8C OWO#?_SF3_^ $-=QFD3X%]\1$^^^C?+_%?_PF"S?;B<)C?WM"&5^^G?FO@_TB|/^?^1\0_NIY3__UW\^=IIP-WB)^O+U22O)C@U:!]*;F M-*)_N2;_:O"*O^0X#G{0O9PGQR.5#EJ>>GY>4F Q__$;R^YL&/Q1LF3:9 M\E*_)$/^:9"S@'CC)|2NMOE)Q-7)T===ILI$R40R72'[\-7J(9%PV6$QOENQ2 M'_?Z&")G*OWPT8E|$P@:U"!\0'NFS^=EX',BP-T$>=AOD=7\3D)-\PS__5- M373]SUVRM8H!:84W!P1OZY2N^3S[%)2A'2 3OI.BZUDAH,UD;;?!@MA"+0 M&8FB@%D'FQ=7Z4V:/(>QK|YU5. .V(E"!*FQM&!A+4;*C-%L]DRFQ .SG9LD MR[WH_X9;;98L!W; ;J3L2ZVF 0EK,Q)6C!;#<1!!FCWKI3%NF6)/82'-GX%. MW"0L5@=NPF_SG[=U!N|\.3;%4)C9/RPI:X|NGD)8O7/6!8*YE"I6RX_<_GWV M#RUGH!,Q&1AB< #KCV+!?;Q_N^X?I,(]DWMP%@?G@*E;+#|[^??8/+]E>@\|'9 M;RA9HW?? OWKX#I588[RUELOS8C1]G_]*2T;N?-MF<,@#@3ATQ=?_"?"$5;L@LO!8'U;QG+;OT48,|_O,]ZMFC$A9H%_QLEZ8X MSODQ'+5:LM+89QXPP2]P4(6$.!,$^4F.Z:VP M\|F?> fE7,*,9UI>#PYZ8Z$1H'Y7(8,'.2-3,J]'*AQZ*<,K30GF|#'T|\W+\|-MF*1[|:FR 5]-M]AN'L(7X$ GL.W>% 9 P-%)>S\)G"W\,:+H=)>%,<[4LTT+-M"\M($I PW3: ! F0"$AY4)L! 40D|OPE<;'#Z2":QG+_YTEFRV7JR.!@H-M2)/0"M T#2DHD(EH>%&92HF", XJD #"QA..(I.I-(% @X;$W5,,$"'"'0D:' M!67$H)!P'Y\,O*$W0A+_ MJLGCRABMUUU|V0-C=/"K>EG|B'.59^9?Z6Q=_^)7=-MXJ*\K-;?8>S%?DBL->$/H11OU/NASF\A0T2CQM,';U:[ZL]8-T59?;A;?5^= M+^\OSM'T\GKYX>P"W?WYXN+^SA'[N_<>.HEE.,\R*5MR$ +%@&0O=]{H!H4\E&+3A]F#: M!8LM=C.L#+<#"VV_"N:[9MP"'+1F*2<*^UA4=VTFN[#^/$7+]JI$E)+7#AOZ"6TH.S MKN$1)%8*C/U#0%\@+T^AO.Z2*C+KHAOYIG MA0'G51;"B+ZD 0?Q("_*8.J,5"-TIO'4PX2)ZM08'WC)L5,+ZNDPOO MG&'B^^\0\":>-254AOA4FG*_T$$ST&0LT$-^QY]MC= 4F*E!9?&;(}?73 ;O3 MX1)BCIHQ$1,FHM_(^":6,,F[:!H)[REIM#U8SOF7<399NS/+-N-R#7Z99K<| M S9T>Y-VR6YOTF2+TWQ_0_C.B7?2|'=+|_$^8/4%@QC2-C&TDV1!0A!Y<@CL M,8=)%5$DE)9" [6CNJQ5|%L^YQ5F>AGZ.V1;+:IV*=VD1)#0[G+R811%=1P8)X MB9Z9CBG5X&S?CLPA%0:P8PP?A.|, 4|=]:+':/T*6,"I0L=\8XJ0 <),#6I. MNL&SL2_@C+GW%R%*XL<30G? COLJ_CP\|893T$V&A;UVS0>_E%>OX0$7[\,. MW>=2#TE44!"UU'Y7O#?0%!=#@#IBNB:.*V MN"!.T(^Y;L&OK&KU:U9.UL3-7$%8863R3P;2&L,PG=SM'A^"$?UG70X#:? fG#0|5ZUJ"IX4.O7"]$R?CDPE/WKN)%9 M#X5'LLD W@L&B5*>?D,OFZ9B^^#\IA1BKW=F$Y(K)S@J<=1',&T,!\YPY"R9 M#W$J/%?_$"Q^"E,F?4!+X3NGI(TO\? IYC1)T^0SX4_Y3$P&"?A.3,UXXZ%8 M%PSFI9B*C^YC*PIY0D'1.7Z MO6^?+,MW44'|WQ',M8YG1(;^%C&+H]3@,(=_MS5AG$/QDP\%,H@8?GE_7.A5MI6G9[68|L8? 78NP+,|ZUY;UYI=,:^M%6F8^0C>E=)>,|,G;?U:G"8%_4F?K[P4&?TXOXD_-G#B&E_$0:\^M)#E&/WX'?1>KYT4K-Z]6:M,Y=CU[=XWBCC0-BWS/_T?=O$%92@&|^M2R"] M!6M>C<(,!?@6R-TA@TEZQN]|Z8JV2'%/'\BK&&\]B& ^#03Y E_,A>P[.(_<7(N!C_Y^WKMV_?H:V7HF>*|R_HW=O%V[?L_U#&FP5X MN_PI2<,_X^!?4)R4?PV9Y/RY>-U-@):>^? ==C-$/;O>(VC4#,,<^ICU5T0_O MV%|_@,_5BF8*VH)('3#8K$S&Y*X9(S)1- Z48_O-7Z MT1|^?/SXX_>+M[__9^8@?_C=XD?RIW_Z\7[=+QT+O-5T(B" MHS\&!0+TI:ZA8M#")B=$#-\@QERW">;?>3EF)=HH>V=4OR$XXQXZ%7L)QM\ MG639!YROUO?>%Y4N^E(!O1$Y1.#6/8#0@_;-T:4O:@\UT\+Z2,J/?13^]P+8QQ<>&E,K^((K)_C==>B'MZD?W9D3(Y_>V8C4? XINP@)[DV[$E>=/,$5&)B5Z)IED@]RUP'I\;+)XD|=A M=L(M-[4<60CSV[#S3V-OD$;?-/;_)9U!K](@WX[>PH)3CWRGSZF>Q$XGG@] MR3F_R[TT'YOW!_P8QK&N1>,|9W'6O/,CN4RRG^K,_;+T+:WY#%^!Y111LU:D M/L^YH0^E-4Q9/M|VY]"ZCRR=DVPFD7MNU-QF)M/"*F5M20*V3W:#4]96- O7C786=.@09+&FQH5OM MY+KD>^8_S>-XE].\@V5T*\$3Q+';[K083KB235ZG 8=V'[7F MUU'8.YK.)17C Y2>5!SHWMY/8&EK=SL2L'W?^_#8M=W5A[O5]=7Y\O{B'-W= MD_]Y? _^A_@M=1W>7|% -#RPSDZ6[V_N;WX\\6'NZM?+M#UZNI.D=(+ M1>-B"#+8!/&;75U^D|$[RY&++#B'I<!:D#"HC36/4 ML;$"BYE8$\|1QSE<+*^|YUC;93NE.I5F6:57;J15UND4=#[?R MGI>IEX6^0BH%+)SM:ID7;5@*"|*P-9QT'X^5#R:K>T(+Q."| W4?&4HK1R2R M\W.L!7]@\.A5&*,@B2(O%7X$?HC PXX-ES10001Q*K201OX78?G%AHW-30YSN M^*|N>G$1]FQO0/6FXIPGFP2V\&45"9>\6<_CH?]LQK0[LN@6/BU.TTYXM>2; M3ED?R'")Q0H3]$]CK6"MFXTF- *@+CG9\R:X%V2N&%%9+Y/TSHOP'?:+]CC+X+]W&>M<@8*.1YY-X/-$!791IL^ MM)T+-_V9[[K.V=6"M6I^3))0TK")^LD/:&D%^AGC^3+90SRUL3E43T*NV<$ M7WUS8F5!C%/L1?3U'WIDVF#!!9'XN_'2WS'/OEE%U!V@8Q%RIPGDKH:8'@H9 M.8!Q+J!8\SQMW@)]J6<2#147W=RNYJM9W_5?$3JZ]=!SR\&UK89IMAB 7>Y0 M>>$08PCOIP:T\[+"=>(-9=\F7Q:(T.\E>W?(TKR2O+M?G?W'GU?7YQ>W=|^B MB__\>'7_5T<,DXM&_2:)60.]+Z'JAIL!QP%#U DC-4 9 JSAJ3E2E*)&-2SZ M1*'5NSKSW+AI"G">,,BB2'6I0@X+>-M&QWSCKHT,$:.FC9H3H\6@3QP3:44Y#@X$78-#Y$);> -]XJ#0>\1#>'>RCY?6L@TS MSO7T4EN\%L&E_EY:.VIU^3JHNWRYXA? C2N5\TR^]|CC.]WH2^-5MLBN-O?2 MV^7J[$IY6.F(NQTJ8I_.9=!E0IJ-D[2NIP)VIT>7VJGDD$[TXM+:4K?_EB-. MTDL*2H)26\J<)XR4A7J2 M /&M03QVS+6D@EZ5=+ZCO5|%4M\6_770)TH.%?2@G7)L\0.3^._;FY;7W9VZ MT&YU9=V-2^FV=Z]G+|MIUQS/DOME;SRK2^$C"F'ND]=?C*I-GCLWW%GPX!6& MSWV&2<^JU'- GIDOZK.(*US@[I>VPG4;8H0X7!DVG'6#0=L3Y$C(XZ-M-/|"MTZ@0|6:+4118L_^9!Z<3MX_A[B M!#_NPPI-3T:)9<>1E|S]3+&$1#/R"C

*!>)_;9/'(.D=.F)W8_*P>#OF^B<4SNJ_GMFC.$;;D6_NWM31C[F7.&\_M^3R5W@.PXNR%S1C]18>_/4"9=6.F %QFC/#AFM<.OIYYHCG%LB?=KBPIVLR\MQ'G 1OT0BX4F)R\LSIM%=6H9\!4$\ %?A&GEF=V"2-8H3N*3A-%"'BM.@?CQ MQ9&&[4(MPB'*A/>_#(.=8=BU4M\H854[TG&%30M1I@B+5> 3&]&]C.(+0S1: M%UDXYNH*7,.W1G%C!G#),$<9PI5R3!K$NQ68-%P)H[Z$MZ*]=7E&.T5&T4L*.M6$4G;]K.=]*EL6249E]^4"'&%1.M.[.+XZ.(5\)ZMW7$7N@(WZ2AS]Y@KN=3,H8889R_@/? C8G*&\:\B*,.^HZ\@_ +&W)<<:<!V+KB_KF& XK^* MI'C;.^KC7$]GO7:=1YB\GN3 X;EH?$7WFH_&&|[-.6EL^0;-2[5@!RK0V6,.MI9V"3?X"C?B=LTDZ -!(VY.) (PZV@]0]:KSMQ<%QAMP!(DX;=2N&OJK .\9G M*&%>;/25G%"Q-_>;!QQ!!ZH\E%C<$\>CC,*#Q)RVC@LO? '(D/W_.>YT,T M+TL<722V/Y$%V/*V'MWAN#NN@B>Z>7%\479,V>:]I7'D$752I6LO=;RTN+H, M-M-M93W8O.P\R/DHS.0N5!\D2?QS#F\<90*V6.&3FU QYEO+20:.(H68^/! 9> MS@6+0?K-$ |WQ) 9N_R]<$L_D/OX[U;O/%">EIWEL1,&3LONL? IYGO=AY$:%@0"%YX3L"N9\)AG(7^) 4%S>,=[QZ"48D37?39N&G;4>P<&>;9+01=C]_O MTD#5+\;24 ;.2&(65+EC1/K.3^M)N"A^]DNJFL /Q?SYLZF1&7+&SH O@&57 MJ'&B3+LUVK$GU%)QYLN;9YT$YLR-[?2]FP%>2L(+W.=M*:?'FOQ#|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|LD)CE>F'I\ MYKP,TRR_^)*3')/\-UU'JYW<'A?(Y_L*5X4 6T2XB-"/0TF (!-.AOGUM762 M;O@"BD:*XDD8"1WTXD#FX]A+PP1Y:V+G"%=#TGEG305 42^,'PUVL':9QG&*V)W1)CX\1J3!>P%R<,) MBQ 4F"2"(=Y2$R&/]5%NS@@ M"2^-NA$E'K44'B @1VD[-)8U+%SR.1U@#@BGY5>:PH^7<;SS(L;&,OCO7993 N0!1&.Y^Cu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n@L#Y.,J9BNO:0/ ^:FJ= 8WQGO&;3^N//=DG<$YX7'^V),.2I^\^)T;<$&%B?ZC#:]JD* -RG M6IPHQV[^.7'1IVS9)W N^50/MJ? T*0)DGJD:4,!^U66XXUDU"+QOM7D9^+J^ M=$%*#BJGM!:,LET*Z93/]6-]0K^[) (:W4X$@O6Z+KMMIZLAP'VNSH^],)?B:3=E,;ZO(LJV? @7!QK*XVO@)YCMK_5;YIQP8\LAXE5T2876LN73244(E92@ M'Y&.)S1_,(TV+DQ$-VGB8QODE\2$K)LYI%R=S1>*/2@0X#S.,,8HH>IH4'\ MR<1.QY!*!$25@$H4.EK:0#[U!C;2/(5]K LGFV+[MVPUN8/G;+)+ML^DT$1;M;0"K&;YV+I@<%O*EZD!:&J5K)@2Y*N4%M]5HS7G5CI9#L!CF!A=SK[<-Y MH&Z7%D.G7A9F=]L4>\$]+1_ZTFOQ$I=8]NBN++)?. (JK73VIN%4+;6F8"6?8C_F>S)Z4:.^<_'(1$\!4%OU' MH>B*FPY2A-IS>Y%SP)D'\&OV[!H)&NW,%X@21!]TDB@/U&^UU005<,"I8,FY]ND4 4(EQKJ.9(L#4IP$BL9/!(#)U":.%R(A[Z5>%(MGV+$24SAILV0=!F2<8MR!)>=DI\V"$.:R5&Y.5;.#C7M6#+!$9C39%0:49K M6LA>-*'R8[OW^)CB1YHF><$SW3[(;"Y87GF%6AP.D:\S 3*TJK?D)5BUU;$2 M7;8_H5.I[&T9HS+M+F87#"[I5+$L9I)M&)#T4,Z$S.4+L'EV)(WKMD%\!X<> ME:GRSJJ^.6$FB2*/_M=K<^2.$NB,*=_\Z|\$DZ8]LC0V6F?<6K4U5;3.#< MM1^+W3Q1:6BQ-X.(Y!0[7GU$(6/5]:O0'(@ MXFC%D48:*88;$4;#FKRQ1M4DAP60*EZ$,8DDs:.|<8O>3ZO?'&E\(NDWI ME%0CEH18ND>PMD6+';?B3QI=-9U1P$0UJBO!HH[C9?78HHJ4TEM_$? XW?Q^?W\9_)_]Q\B_C+N04KMH[>)MMA!?HVYMW M?_W=^W<_G']+YH'&#ASY3^(:M#BKY^=*(SVV$L)!=H+9Y/$^5.V8+4Z|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|<%/XY/1_;>BV3= [P1\_H?]YAE\;0?]"^*?NV/OYTTN2O/[T M]>N/'S^.^ #CZ$D8+V/U@_/6_O]T^.B]@:7_V@CBQ P=]RGI5>KP_1W[1Y^AK M,?RG8GSTB[8OC_.SKZF?UTWA0- YA*%+DXB]G^)T9K>A8R>IA*C=1M@6Z%]K M$C^C7WT>'WX^&G]YCU!D$<@TR,&3_[5&]HXS14>B#!S ?!33^E'R\@!\_Q=[R MU4<$I+|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fY=DN*FI)"8'GZ! MFR !B"QT4V\G=DX'P177UGP;)<9!22$QDH=@V)N&Z (>P19A|$&\;%BWVD,Y MT DH+E#U\ H\+FW?WV0 8\12:,6-8]$4(3B=/2W!A/+U1)$"VB0?XQ'"\D=N+ MBFFS [S6M+;>1C&Q$U*(BW3Z'TYJTC2O)TVBXE&1B%HDM=A*$%- MX93==- J^W;9[I/Q]NP1"GWHA!)90@[!^;!X"W\A*!&!I8A?F9?$-(3Q 4I# M6 \)?[Z8W3W.;F\NTI]?EZ/SZ>WT[N)I/CKU=738\\"^$E< &:#M_P7OZ]G5DH9Q@^S^%),L@)? UYY:TX6F/.69//MJHRHDCZU3 MZTR=-G61#5(T#M((*1!@#N ^Q+W-V(4E(Z4A 5$,TI8*!9WOFYCD76NKI=@9 MQ(>3.0MY$D0OTM7:,!0>H.@/*8(3_04F:,[8/4$YC<@%- ^P<\A*8U*3"X8.IK M,4Y81-Z&2w >]#81/6TF)LL>AA[&08675D+N5G^_]/?L=0%(M31'M3'(&2@_ M/:M,/+,%NMGC2T#3%>;"8EEVPH<%HB8#09FL;?Y@KG$'B:VKXG8[Z/P%43) MQ[UO9WGL<[E]1IOY.X W%/@N&H."VS1P4FG@8I+7EP\6M\".P8.W>('GN^_0 M4"%8M!![&,,//C)-'#-V%0!0KOSNS!PB,L'KKDYJ."B4-1JHA$@2MLG*AI: MVYH#!7;R"#G7VX]#HDP^81=IC]0)|!"RMK=UPUB]S0EW1[%]$2]I5]8A3'1&MCW8'" M(MF6Y8:=5C-A@4KW-KF(1T9[^RK#3BWK5 /GMPAP<)!KO,NBX,,\&23D3F8B MI0/- !GHP'E_"*'D"T?(\C*+P!V0'M32TM),8+ 2*M5]T3^&K;/[@GEIP.0V M$Q4A0!KHT& &Q:[@@0\%CE . LGW=I)ZZ<[4$2<:,ILQP5B/ W!^Y-<&& >]HE=++YE':6TF M)'B(E7HJ480,QUDM5SY*-4V]@f@$2@1>0!!;LpP#5Q%\"](K8'4AF\R?[^7\Q MQS.*H4@2P 2I?G@U"'M C\T%P+VRHP#=/Y38= GFGN/A(TQU'Z1\YI MU$"GR4KF(T^%1: <'$VM<#W'81F@PTBG54:\&"K138L<(12UA(L_/QLX#PN,V M_2%4%%Y674_C/A7%"T@\9f,99BJN,6$OKC'Z2^4S_[8OMB'!RP%9/(O2N;KI MP;YXJ9,;)8'KK*5QZ!VWC-D.XIV5!F0%0RB5X/-3B MA%'E;=#IP8^B AYLX7K%C(6MM-@X(<$JXE-4! _1-!?-%;^/00"-4 MD# B#43/8144"IP0ZU_&LWD>1 G_F@:XE*X,T&4!AU/BD%SQ\ $)_N?;U=W3 MXVAV/9K=7SU,GVY@@!'T[A*V_';_S1\4E0;/DCI#\M\R M.RS81E$9=9S7JJ+5#,6VU]TF\,BQ-;*8B6 S_!,/4%"0R:@\XB5X WZ8%BC* M&8"](B/TT1(3-VE%WB(@^C1+#)8*++V,A$L7 MF@U.4&BPD76A,1(4,%2*@D"K*+)3PH_" M=V$05@DF+QK8]J;"@8|@.[S<=R"A6H1*FRHO#JV)98CPJ41*2$I2(/ BM*SP MS)_;L>=@!_.;UE0 L!-KAI^Z3N^EYZ\2K)\.TW17P$ BUPR7[6\U;X%[O0- MKH +<+=;/H-H-F^X;$G/V.FL,4Z'3GPFB O"T!%2N2:S7(IRC[!BHN-B0PZKM MR;DM@E4+XXJT"HHKG.&GJ?#I2GH.F;8\K8(.B+...!4G.PJ1/ZSCKB2D!5+ M5]69!"RY6?=AE,HT22+O>94^0O049F'AT!537R6)Z_G.GI' ^T*;?-M+2 M(^!)YJH3]6-L,$IE+*^HQQ8>!F9$R%05}![MW#%A0G]=%;M'@)$<3*3*:V M4BY%H\%R)%*#\G/VNDM36;!M*[' #)2;$6R+]?1$1 *QC[&HX*?:C*Q@AFI. M9+2PIC<7.;TX8$9D5;V6$Q$R[8V-Q0<'N68D"==X=1DN(?VX4)NVME7>6-;D M^- @,*+!3BPV[4GE0N(4POH$_4D\'ZX0Z2[+3D8!,F]2D"C4G"+B$1>CABTN0 M_?2"V6 M7^>>]!@9- /H(U59/+$FAQK$@HH!"]?18V>/9 .HZ$A*X/D#B)/($/(QQ^I,:^I#M1)G2BH(B93!M(2B.-[#$1.B)3CT^V$ MR#B*_DAA=G!\=)!"#?V&R,_"_I_FO|E19 =)'5\=1M 25&+MFRBN2$B@'A1# MF=[T A%N"'*U0)$K>; CB8HE^9DA X%OA28R?0DQL5U"Y!*39?2"(4QB4MI8/ M_"IU|"7@$41OG@.RWCX)UP$Z8C8$+I!QIX5ON7N E5R5$(M 4T/T:D=2EWW M'0XK;|\=@F0W7DBH,J#:UO8L.6 T2.ATRTCG5EU[0%A@Q[$>;YVJ">PXKC[6 M+B:RXRIP=7&BB8GK,!LB3+07"'!$3V-&&$$W21B_L^.7:#W_PO!=A\62+7DP? M?QU=W\Y^4_PPQ)I0]M30EBYJ]@)HQ(O=1^.9!B9Q_? (?;\9M@77QXZB3>6Q;K M0:;,?R MS0*+3&O[!1%D&_@8 &3)W$I(6)Q- RV1{$BR3E%SQA"[7C!NY1|);>:AG? M!&\@EQ'.FG4;_ (1@4$45SL&X%_$ E V OD.VI)D3M>U2WR#X@*J;S^:0 M^=.X!DF99^0WBGB'V<.TEI,D@<^"(QKUBF=M.J_7O.KOUBG'9/8!]P"DI89S M<4VJ3*N:!;[)$;AXO-J>>YE3E*LG7%72;_94?7$+?+?!M 1I3Z2P0*\S;_J> MC2G+MH[!:,&(S;<0>NPBM)"L'S(:^V]U!C9T;?0S$%6[H8.,B)3C?+|_8' MH9@JM=^NXHF%#5)/P[K8"086T%*//O9\|,="0^4.EUW&$TLG)",+ZX+H*K' MHH(EN(@NYOZ|"BT>=DA-WU43+$K="70Q7/@AJFP|M28Z/&XJ;*QA&IQT@U MAHS]0KMW!)*6()-VH=^3+X,;Z%U*#)?MX"@~)) 6D)/4- ,+ZJ!+D&WH["TTR1 M\^3|<^5% /((ZEGR<>_;|~ <78,=4+88Z ;C9WCO8\"59:>6:=G]2@7 MDQ#7DR^B/&KZGS[7X:9]3Y^$@;2$GJ#3)R_9!H9:EJT[*G0 ^0%WKJ7WTQ@6 MS=9^6N)&$ {(BR0[.PPLRE-F1%Z0[*A0Q++ JG?9?10Q<4+]F5$1@/)#SFQ^ M"9Z3M-;>RDG2XBNDG!5:MQT#4A=N2#XDJK=')/6#]?UV#%"=V"'HT(<+1%;S M5E:9%86>78=1>AO;PF@&? #&,LKMHZ\HH|^2\.\X$G=9+SU MY(NHR J-'Z(\>C_T97%F^TC!=R4/4_F 9N!>EEEF1O&; BN.O4'V<]W?G MQ0X6X %N$ZIF9MNC\(@# ^RUTO;GGM)4%Z3Y0E7=C;S+1H-91/\EOD"28+09> M-#RN7E_]5"EMQU#*FV >1LM,W12BFFRH<08KS7]0ZO4NOBJTC+A,*!VHG<% MX,$?FX!2;.4G$'H(M@D3%HH'J3DJMP QJECCA_$J GKV M S%YP M>'P _V_T>,09"OXC&VT4SD?)"QBMQU10B29:V$%>Y6139#DK@'=?XMRZ6IGM M,^HO4\RFH+$5:'TAD$L0.Y'WFL YW(Z|& 7[;J;^|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

*Z\2$IB(^%J3/.5%4?Q^K1<`M.LE!0__-)"^A&_KAXD-626?G@Q7]<1P"Y=@&$`M7_(`SX-#Z$C;=ZL"G%B3@[,MU!">P)6L0LS\EZI 6Q:?WL;([_=7X"3`O?3>`M/!<$[E*U/;=O0(-IT#,_#?U6>$N5XHD1DH)!*-^<*\R=)49CO%2P](-6FS^`M'OIP&!^2-?1R4_WR7GN&7W-8)"`U=_=XX:MAR+JEEV074H&+8G\]R+W`\0#_`MO?#9P;A^+UP:?F0'Z&JX]&EM\$DPM<44/P;G&,HO=B|C\)7$"4?R'V;P-FB`M&_M7-'6V>UMR=RTM52<)MU^Y=-J!^V`NV.$I*<(#_VD_!_N/W!V#[5S'D/G+/@-M3QUGM5RE5].7,K%\5*I7(+8B;QTFAN"6VY=>X^G)5AZR7H=,Y>`G)XF<3<+2O*)P)-M 5A"IT,;NENHO8?L.1H56*(B+U+,C!)XX1\'T!\],@ZCPYRA$1__`!N!0'X M>9b+\'T$+D=+,\,UNO48E-ZY,_EAM61OA4B@+F)L+&E^04JS'(V(?LJ;/#@AL`M.++XP*TQK.ZT0(6'E8"=:D-O+'U;V.57?@Q@>MKRY!U4'MS1@VVJ% 3ZAU83- M1:$@C>\L<(RE__X:!O#H[$5VMJY=>U&<7*$S8@S_C5Q1>,,//VE<_B7-)KF;H`M>U&ML=WG.)1B[>0M)?'"%WE$KK A>(7IR07+%QU,E4+H%<0S #/+#1J?[6V#'`MX K;7ZA.#N1W%FGV%*;ZA2NHSS6&E@#KB(@FM/JSPL!*&U,>0`!^)$52.! M5:G7[N&(1KS4FlQ."<"8/4\;<>-<9@75';,6I$3#H1K9^5;,P)@&P0?2?M^:#:CI1/U!M8E34TIRB:FM7$LWVID.#Q9RJVY"\$0T MC79&R9^-.@-+%M+$;g:XF<3<+Q09)O#LHH>8J_:MJ[_!9.N+QEH"0-@.@(I'FM'IZG!EF!*O6XLJ[I'TE9+S#[!*B.G(C!]O9KH -A56BOD*G6[WAW4=9H?! MQLJ-8GM{(!5M0\6E7X+GA#<_??S0#$'\'XZBM.H8(80THQS56H.AH*CTK(*T%-KUZ^" M^KB"K'32,CQ4@A3T)LVE#YNJ@D]" M,+>J+.BT"-HZ5M.$AI*D_4Z69/GOVRY)*BV"=I!R)-G9!7I+R1'$M-9*VJ+= MVF0J#0RK1P07X<#7MI/6Z\H5XCR,HO`>L?6?H5_23YPL5$<0VP!>,@0: *H M-_D&1E/>1Z$#@!M?0S[?Q/"3I,>$9\Q&)W,! GG,1*67IV"*E?=^]S"BZJ M-,\"-R-I-Z[M&-QL99"0>2B4FJ>GPRWKN1U\2.DQG9G01%4Z\.@9G;S>[-S+50 ;9K5 F,#%-)6X(T3 M.30 IF>/V$({&SC67Q;OLV#=1^ U"W^^!W!NR0:!" MC7QFO^P%.F6%OF)G-F[XM.\!*YGK]" M5:"X$_W&S40 ,/P(C3]Z!=$H_0+\9?DC2K, K^P(\0MOJ"2G >*;*WU#HLS. M/)G# _'5N^.OH*#0Q1:ZB6F5Y*6-ZU2PO30CXB-:6A4:!MJ?GI'&#FU3WGI2 M?/[1/@ A"U+B%[5$X@#H:D)Z."9O&;ZIJ9VT;EHB;6BAL*.PC;I(:E<_EVX M3'CH;<+`!&ZMO@=>$C\|?F\-M^G[AVW$\F^?DS[('5*(L,/%OMC2#TKV!W%T.!KKX((FY `3VT1!&>0!D!-MO:!7TR>Z[B-PO4*-.IRT=YR>V1+D*$TS6(B54HWWAX,5(M%Z,N"WRL$;2M M$+P>#%[K1#52^(16$S87A9I:^^EB8%9 #>S-:>;Z"<_+CG4+#L+<1];!,'<MY+>4/$I1PVL%KVUV@),YJE^2)\9`I'(###4;*(?DE-]U03%-=ZABB%"?(<@TO==AEN MO7@D.6-4371^3\837P43,O8>KC(9*357MMA("8G@2K\;_^?+(GS[^APW^_!- M$'N0@J?(3H;0^J\ )7G1RC!6A/+FM1#M?)!1_FHH\JPBI_'*?Y\ZOLWT#R] M>>[*!N.V T0NU=KZ^A^0B&W\1G1_$CJH/C!63%E9TD05<]R-\<(OHV:'N'@F M, /9X';,9%,I%-)&3MR?^,N?9CL'?_6I02P.$% @ ZSD(6?^<0^?NP@(M9;L: !4 !S#$P<2YH=&WLO6EWXKJV+OS]_@J_M<^Y M>ZTQXI0;,#BU5MU!8_H>`!*^>+@1X&!L<$/WZU!)-FU(#XE)^8RS5P6096G]`MF:VFIOJ?XNQ0B6^>\_Z6OJOP0P54O3S<&__TVU,\?B?__?[__SS_]'`MDH1^EVY5",U2O3$P74*U@>P"C9CK[O"&Z%B3B6P256#;NF$0:5O7!B!XA*;N-M$}?4-4V09-!566;@DY9YLVZQ^X,FZ!C\G/R9^,E03(R(W=#4#14C&M5M0__9 MBJI8LKU<3^(&=D9=)WF&O;,CL1AWV+P-)FN )D*40Q>T.HC,+'35\)BQ(`MD+DHYRUX^1/!,#-,O0O,(P?A]#%Y(*DLMT;CR',CRY-\?0]>=W/S\V9<= MY=JR!S^#'_"8?P2-#=T<;5K.Y,/KA6(;N#5#4>Q/!+,"Z,%NOG#TO=9S=MV6 M_GE7K;35(1C+I&XZKFRJVZ=@GYJ]>7#W%?&?_H_KIOK")1V@[KT$?KX>6+,-? MN@F' Q"A?KJV;#!]RQ[++B0K{4B,DU229.EU/X[M/B8_`)O\OKBJ;G3I,I;_MULUMT"<25-Q/^,ON?/5GI'I(PWH^\19SQC^L#]@QXBO=.*YKOT6P0/'UHKF M>?[G N%EW2M0M>.OAS_LO=ZQ[7VP.,K0,F3;MM31M6J-<6.*8ZD-(1[!:V\0 MZ-&"A?O3IR1ZF133Y_]^R/XG727$_#CY^]_7-TUP.]_?]I_];M2+&WY^Q]- MGQ&.NS3 OS_&LCW03=*U)C$?4AM24)-M31+,62DYSI?3=P,M0W6- MM+`"*D]V10S4A99P,4S?@#&T/$AM/;.'WD7*D>E_B))-2T&I+O?FP"..,#6U7T M1M.Y7!1*Y0\^$&8\AB.-Q Y-QEK(-9=)}I=E*EE8!0AD-9K@/G!Z%# ^!7P MT*65<)>\5>;.B(DYM+>L,=3MIE^>(B,>?$\U(+(TFQ4KDT-*2>2;?'0'+=4J< MN7B8V.WW3FHN3KJCOB?,A':);<,`A?$RWQA\SJ3>NE -*,;@F@1:VX5,?2L, MJ-N=N7BM68^]ZJ9U42FDRF;N:.DQ4FKHP+E64+*>C06)1$NT3]B.M4-E>B6U:"K7[@AR);=(-4973=4W X/R+R;D?P\-NT)UOF;4;NRJ2+C"ELB) 7_G]fTL_EM-M0S]MIRE'LM3V%?XOZ\`KE_S<@\"SB#AN)6P0X2F.KNFRO6S+!JCW,3FVC)QR MJ[(} FZ]#[$(94Z A^1X-#>$;G4I=LE5>Y36[`PO'EX\/#7"[_1)&^.3_*< M.*"_&+@TL0@.[T4T?E0\)I=U79IE^@I(`=K'+=/+N?3Z(>_B;?&!?CPC8E,5N-MV$<1<6B0O0T"+>#*N@DT0;9-R#%.@((ZI-@H-JB;)BQ'JCPHB$([V4Y=. Z. MS_648/"#H>X1CE__\MGKF|(T'3%CS"U_F9Z?\S5=;5,VQ9Z#ML+H[!#9J9H,A(N0,&MRJ-0I,8"G5 M7LP+PWE,$:7LBZ/ID6A3L MN28E\|LGRW3=W7V5ZWO\$)7K]+W/5JN3&E-^E8;.B5YH8SN//!E_8>9'HK5 M?K5,]RQ6BA4O5$3'^+JY%ZM7#[#M2'K[*7PC4+I71;;P^'E=D'T:/>AK2Z3 MH,^?W=7ZTLGO!%%/HM',ZBS5 9VN*S)W@V=R(1N6 M(S\E5#/8>ZLGDNJ3')S4Q*68$6D:!:^6H$;.<^DQR$^6ZF>)1IQ6JO\+9-F MJG9=X P^DZM6VW5J&0GURUWM5\MT*DNUV&F?>1"FRX0^=VM=|2YQZ0S^]3+|-M+++&G$\ETU6UWAFZWR%% O&T+|5Y, MN/.ZA>QB=/'6VM?(\%"L]JMENDG%*+ZV]-9'C-W2JUVA^4!Q%Z_-OUZFGP<% MV?0BGR15G1&>$Y?:9"UH]RP:LMC3B2>_\569TVBT!=E1VXRW=;7N0I^;;$L: MY3ESZ8#_5(W&G"D8\=8%?EZE#=6J86ZH9JMB/5GNM<;=/I>H12KM@I?[UJ7W-7R8R9E:K5NZ=*/UJW7:B6%PNM38Y&@LTO/ MT@N7OMIG37T+7^,#XU6=#8IXE&Q>?X?2)JQJ*[,`R|KD MZM6I(JLP-R5TO?W*2H=N|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|)2X 9U\)[%B<$@;?]Q+.Q_PAQ.XC+69Y]&L U-MZ;O,:L'JFN(T68C5Z@.*[(0OC/M*P&W)$N'M^4WK,4GQ5XJXN74:O"UMU[+KMJCP<++>]KE72SQTX&X:M@_%H!MZ;*=X,,0)(T29\L.?-<*N;)]*GDQ3O8<P$4XJ&D@MP455P>;Y<(" M6NB,@G\13#07//[,CR-8GG:J_I.PI3% [_"'M_$CV_=PWTC$70HJ.1.+__0;!0C8/=`$A. OM&-|B#^/>`HX\IG!O)Y\'=#[(8B M@I%K=^MZX6C(:OEYT"?^Z%B>C3]AK_0F6#(\U"$$Z-]MT\4:3Z#[@:Q>M'3K5CN@"Q:L5ZPX92LW;HL@.2%M91&GR7GSQWHD !M"ZT^Z MAC[W=6 3F K@:_@@4RSOVT&'#Z^[<\ C=C_J,&7+2:&KNH!E@@-KI.)PTH;MX#P[RQ^ C_6>I&/ON+W>FR

*MU/%C1[.6<8"=64/[#5ZG>;R{@P_ZWB98FK)6"R$QS0#'Z[#M1C=PQW8%7DBL MV(=;5=-,3#/^FEE:,1)*8U)]S\O[.!$=MM9Q1H&>6YH[8GG!=PX"*EFB"=MN M\Z#5[)-MQ@DCMG_L+K6Y:5>J"D:,UM7@J:(X_W232.1>S,VEQ>ZUW>GZYTNRVCCMNN8D9KD9IF M.K97^.9Z2)?C//C@R=5.;],?+M(&9"*\=NALFH,NV[/1WW/S60#WC?3IV9]M4!F3LBT>(QU6,&+=<*!1GTE\<&9MW@^VDA8HS$;#QRHHVBS60,-$M-L)76] M=T,";_|_#VR5G+D9+4N$Y-C'-0$'AQWU[PNFUS^@~K{U%^M3L K*&<$O"Y1A;)!DI;#*!5<=2=T:S:W#_0-K.:1M! MW:UETV8;%B$DIMF@==FRU:7K'9}3G'EY)?1P-ES&OCVW-BJW6,_$EBLN4+UE M)%H+&=ZPB6DV9M2PZHZWT[!LUUF;,J4NCNR/)]ML) PZ5<*3!!P69RHSY42S MQ(E9$3N3(M1FO=EPTC5@:1TN-'P>+!=';$I,,_Z*ZA'JX&T;E?3NV$&ZXZ-! M'5+3,X7=<1DVK;;4A2%T#L>KD7]S(YYL,ZT5>RZVF8[++#QN**UHYIJK6B^V M/3/Q=U>'N#1*M:?!1[S!<>V#BM9I<@2]TG'7SB04UI[&?(62#M):MGK:M==P*:\PFIAGP;GUUNYV0LPI7=_QIN-HVVW4K-+4.S6/.TD"YW4%@64DBUFVXG*0G]IP:6FF8Z1O=%X5>\UAC#)A@NC/5IZ-MCAHEHF.A5.NS6%^.E`9N2>!(AMJ+JM(8M=1M1X$KT+. M3&TS'<.(VHCNXY[/M2%"C1O@5057D/$S2<)F)(8M)3 F"'IYE1Z#'([DV$Q, M,QVC*T=TUAZ.6(EW=B.OM2 5)=F(/),D--1C?]Q"MS-N',<^,#PO;4 & MD&H[V 4^S3+P.%CN.K/09%OKU/0,+PZT"3OW#,@>SR${(O:BW95%+3B7(V@S MQE%V^XXD#FDK9-2H%06I:<9;&ZN/R\[$)Z4QU3Q8!M>2A2;,F&:@T$1Z*K8+M%FW8\0#05&M;7[*$Q#0[ES;:U+X&&9.11))[:AX:1CB!T\=FY[*NW1)TH3F' M;6BPIAJ[ZI;4=Z?G/LZE# ^>7/VBM3LI7U5VME(VO?W[\X:G*(9$H/>@9$]6. M>A+X?"^$>]*,?5!"975F@?;XUD=Q?$A"\/Q;N ^RG1QXA.%/"?!?B(L>Q9 M-WZ@L7*C1^W1;UU+2O=B)?B3 M?_=,K>##^?YA3+_]E`&'B+S9B/OP&V$QBV]PHD;#LJ#QC1<69\/O*XW+[L M8%Q^.BXH&);\#0L9-PR,2_[&|<`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` M96#D'[+0P$6 BV!/1;>SCP$778Z+ODE"TF]+OA,:G>]^@#[RTZ)+<:M64VM*A M7ZMX"WJ*]>TKIT>U84OI58B#-?)Q7C7[4WM0VC*IZLJ&11P$N"D/`2FKO\ MZ'6>*/TK7Z0TF-/%$XD-")V:27-1RJ4-%E&2CV M9OR8,U1$S)>5C=M@9S;$5K#V3*IN=_N4BO"[+R1%WN-H-D>ZZ&89(*3|>RT7 MA'0ZE#A?A)2S)E:N!I=1^MC6W<#OT4Z^^7&$ZZ;S/1],M17*O,U?!_.X.&6 MWQ_]=2%A$.KN"XH2]RA"_R*C^8VMKYL$.X*FKY <3X^;==2UTLKU_5(D+&] MK3]<>*NKH18Z,R.FJ!)>'MKHP]+%PJ5QIPRIPRT+(B6K?."#8WNF]K'2K^/:[&V)5IC=*8JR?5KKB?& MJR'Q.\;/:LO0#Y)>]?2 -X;*_KG:R\%MD*ZAEPUX6SU23'V+;$:A*9-I&1C\ MLW7@OXL"04!*Q2*E*Y]V";A_|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`_RYG0C MN)QDD0)4G"=#3S[&>MPA/QY^4?=VEJ?,LJ:KKGDS|>D%3T#"0W*QX)(=* MW$%6%V^?5.+M4#7"!MZ@HCD_BF/B\5M R.R8 M6N:YZVFZ!YW^_6=DLR_Y!LK22G_!Z?_RQ2R7KFT6>!,0[/GE3?\V89%4[-UT M "0) D *3B NFG0D<) "DO#DISS[Y]1 RQT#*,#'?]_T-]$"Q'%WC%,^) MW>0_[R:<\2E:5R?P_5#AS?5B@XSR]^_U[RG!]^N\WKN2B'\T%HJMDY1<&7* M87.MRP4C*I*1N*OXW1>"O*>)[+>?%[NEK\ K(K\8@(Z MP@MJY!E8BX-$9]??=<<=3&693j>0D!M0:D^OG<^W1N>0N/N2UE9!0?!*D&I MJWCJXO_^0DCX'PRY/_V0#-___CU_"4**)%KJH#+59RA"F=:L+I,&QO?\'QG M-LDFO.|&(KHTMPGJ_/.;I;O0'Q\"F7>'#P$\Z%P_-F9,J1'T'[\=A"C"2T<4"/-M"^1=I0I(VAR5 7%W%,X?D2YS:)?H2;IR4'?[_[TW]$L/$H4#(GR;R(FSR MTDSB[:GDI8;VFUA M>W\@D8;$3F1(A_I\E+)??>%0Z^$-FY6_,H!E+LHR-]:?%YIE?K+Y$W59H1?5O0UG69MM MD_,$V7?>BE+Z5I6I=D>>P/&X@E/=UF+,?'[H>!W7R@,NT>I;$D%\ K@E:-U@?G\[^$6+&*I%!M0.Z\EPN#+]{YE0 MCYZ?ED22G1B$1N^ILS=H/1W_XHOP)=2W5XI?BL8WM9BXYRN]Y.MJ MZ,6+3QV(]-]4\)G8@ B?*#4NKE/BG'\+) T]_H "@Y"TH %"<5IPQDG7-M4\7A3U1QI(G$!URTB.Q/66D#;<8LC=Q!?EMI-N%YG?WM}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f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}+VZ5J&I%O+#WVIRIL\LO/RV6^).^ M8LO.T>;J#1V?E[`.BX)"=$DUZT19^]K 2P#6.,"+'-C^7FA6>8G>S_\IMEO M][&>QAUL53$;$B?2XEM1RG%/8]%Q)48V&@QQ:M+OZY4FFU(*GE15D'N*SLIN M .;-7KGL@BAO(OZ,+HAFT:*IK\V1*H7V-E*:7 O9KQ_P5.)?+6*.Y8W5KB^XZ*\.)#-ROZ46U!W7Q ,NR?17Q$\K49D[^=2[Q0\)&,^ ^AB@[#K>> M)/-')3G97SXA[UB7CGE9R",>7-2X"[#2Z5S0WO7%A>3A2U1QI(G

{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|*
f}$>=A*;ONX:30C0CCBP<"BB^PD2TS*5Q.]f4< MJR:>R_K8SN=2<=KEEB>2J0B>>L]?N,$MXUWBY6>9Y1]V^%T6O'J](27 LH M#C5
X!F=Z&*J0!;Z4TFWS')"6[W.C*MF5H25K0BJ?*W$DE8FT:>'V=&$'CO, M\1?/K(2 $!PKN50")H!#?5A ^'9&9938C":U0CO.9J.OFR2^FB_75LOAAK]D M1N4A
2+PQ23.FW@)X%"OG8")""N£$D1>J.!3-645[Q #RKD4&KSED8[A.^7 MS"0W$")"H$U%"],.(.W88O9%#&L>FDQ&5*37S^K$_$.*[%RNF6R^2^A0R#1*CN-M-JO;*[*_$!C3O4
W(TI/QX;TAC+C;B90-,P!L)DU=-/7FB?RE;$Z!&'C1C M"KJQ@BUY$_N?ZQ/ M&UU&H%\SWX!)U![7X}4H/=_9,H2D# MCPT\QY+4F6[PQOH)Z^XJE(W.Q5+>&<11H^14=$0S-
*Q"3!\V]ZG^[MI@,A2, M!\,7X*G0-5PR02NP@O)>OA.|VK2 2"8R&*K*KS%-MS =A#F&^VV@%DC]GBZU-MO@?(S?"$/90465]@&C$ D;[_WA;-K6D/7X'NP6E290T:'2; B98MS)#-*5 T
M$\V0:2M@'GQ%;3!1%M%LP-DS1 Q^)$Q E\%SH7HY#XDB+DLPCS+XDFPX\P[_M+/%NGKC;Z.P=;P?>9\@I3D35BDB:"1^TM$\Z_[2[Z6NX;;?=4H;MKZ]\ 04-NV(@E
MQ@4.3.3M#L.2%W92_.^\+4FEUQX1D_3+U\:XY^@LVU_]_3%+U!:XY^@LVU_]_3%+U!:F?!.6H&7\L*5HM 9R=K(XHD66QS\#-KD*(SZOBB*
M3)R7R#33F.W3@^*26%>5%FAY!,O*/U-9)<8"P5;&BL7]B_BTTAAS,0X_;"F; M,&\Q[]=>6)*P9U;..!47XR5H>?3V?#[^W"?C;(MM:-5A&R|^:,$(6OZ]O:/4 M977$R6F\4.N-
R4HOETI588GTH[?7$LOI"SLJ11D^FR^DFR_32CH)4S9'+=-K MNEFU1R-F:N,V2[5;))VNMKCD<.9##ML3U*PPM15AW%&]U:;_C"ID[JE,WK0]F<5Z3I&H#=]//!*5P91^I1.
M)6IY>SQ0[+3^QHDDRLF]W;^)1.&;Q9F[5)<5V:@37]ZRS+1.J53,VXN M_%*\62QDHP5'$N&$OZE$V3.I69DU'*4-9M MIC]K%)ES/5\61O0IG:*?
&?5Y)#-SAD^E,UWM6>%>9_0IG6(UM=T=BF*5[306 M0[]PLB9S:7E*ITSZ-3?.K'[=:46G=,HTAL0P+1>++-^HU6%.MF;F]LE"GCOK96*0*E)A1)E.>8)1R*K'D8^08M/3ZN8?
==>^YBSC;04@:FGG\M\ZIN<[.)#=A0;I@CN"V]PIH7GJB-,)-%6L8(S5K6-@QX& GUH0LIA>-YF\7PN1J/ M)06&GPSH451)2'B#OM!,O"UX&I7C^U0$.W.E+1U+FT/.2_H"4.YR7
M$,?"'>0EQ+.CSDGJ*A?9RN7GYXOV"G[SCZ\G@<T*X*(#'E C<G"F$"=H9$]6%I.d:S=(3' MV5(ZFZ4$3!++77D?)+O)_<]"-(SI M.]=H&==FVZ)T]H9VQFLNZ'NIF.?
N'/1X1/=2;5*U:?]P.*>6N>>!3T'#QM1 MQ ZA(E2:O.2%S-#'T\GTG<3N8YK^^>]9G=`VVY5!;++VL#20\4>[2\Q?[F>[E MX:' Q*]_8A$\?GP;XX;#0_'0>=<{L_1_T&(>]PQ?[2]?
C=0=78O9>_\XQ:Q M/L"D%QKGTJ/9]X%"'U%YV>&I8KSALO.2D32>N)P_\EAZ_8BV_-$6\]W8\N6N M=W_)F,O)7)O0,^'I:TZ<;S1'!1JW.V"7/)2.QU'O&?]YE;8D2/("'H]C(3)
MX\9)U_)+'C.]NIBK4@=0.GA1\AGNV'>V&QE\5^.R2UR>]U:-IU@\RN/IBV"MIE^MZ#YJ2V!>0>"G'9K'\'(+^3A?0H%YK,2V!+NE,(U-K5BHHIIM3UVZ.R(")X\ MNX\3A-?<&0FVP6N'"% 9?
8?#U-8!=6.2SX%C;I.;L?#W9C8 ZO^()N^Z)Z')?\Y7^83-9WIS8L!; M<0EO]#/K9R*M]'L=.// 0TE0\3O/P?%UH 0Y2*)&(7(20/$>+!`M$>+-O,W51QX A+BXL_1%B(BJS++.=FE[RK-
)JT2,@1"1@!!/QC_,\/P4 M)_$1%\\W+/IG^?40AP+ MYKRs.:,>0D)>$("GI")R3@"0EX;NWJ8& -)23@"0EX0@*>$U,>$O#<) X& M1=U# IYP+0P)>.[GD%)(P!.4)220%TM" IZ
G3GZ,@G':HO|O &#'+23-GM-R:=;PVI%*_,8K5)\?!U(%V1C|H?6'%\6'SL'SKOG7RMW%++]XMO!^6BC6 M7J1V:)>PPS;.VEXDK%[O$$6TO"$5TE"&[HKG8]&O^_>A:7\,%.Q6A-
RQA12N6QN ME!%>VCW:8>*ADN]=&PF-.33FD(?G)X\R?VS-W66V54W[E_/?6 S;0 %WB>"PQ?/+.UT/>?KUH^F5[_5=^-/,U;H^ M9UL%7.UJ[>IXP0T[*9>KA[RO.UXW<0_^X?'BDS?
'A(O+INP^1Q@3%.=XB8^ MF?<9;5R0^%%6K_3XED/K0Q'WE)&YU@7YOQJS"WO7OMJY0[M.UOYF $#LLG3* MAQA+A(G%HD1[IGVWI7T^UU=AMF$!O,>M&[\]X_*-
RKV"0R({&TM1YZ8-/P(O_LTK2WYM>AYF^FEK MM[^W]@G%@!'X$Q7_7\SW,Q3'D2SA'7&?Q/:NB;M?V[\IGWXP8T?=Y(L??:,; M!'
*%03Z@S0=1XL1CPEXQ>;]@.HI'8З)Q>FQC0TO^[V\B>U&7X,U |8-#^W_IS M:>Y'O_IHMOX^@C+ZNA:O;G58]Y_<]?"-(SI M,]=H&==FVZ)T]H9VQFLNZ'NIF.?
N'/1X1/=2;5*U:?]P.*>6N>>!3T'#QM1 MQ_ZA(E2:O.2%S-#'T\GTG<3N8YK^^>]9G=`VVY5!;++VL#20\4>[2\Q?[F>[E MX:' Q*]_8A$\?GP;XX;#0_'0>=<{L_1_T&(>]PQ?[2]?
C=0=78O9>_\XQ:Q M/L"D%QKGTJ/9]X%"'U%YV>&I8KSALO.2D32>N)P_\EAZ_8BV_-$6\]W8\N6N M=W_)F,O)7)O0,^'I:TZ<;S1'!1JW.V"7/)2.QU'O&?]YE;8D2/("'H]C(3)
MX\9)U_)+'C.]NIBK4@=0.GA1\AGNV'>V&QE\5^.R2UR>]U:-IU@\RN/IBV"MIE^MZ#YJ2V!>0>"G'9K'\'(+^3A?0H%YK,2V!+NE,(U-K5BHHIIM3UVZ.R(")X\ MNX\3A-?<&0FVP6N'"% 9?
8?#U-8!=6.2SX%C;I.;L?#W9C8 ZO^()N^Z)Z')?\Y7^83-9WIS8L!; M<0EO]#/K9R*M]'L=.// 0TE0\3O/P?%UH 0Y2*)&(7(20/$>+!

*MYUN+ZH;2]6&\WYC"*_>4Q6WM?0DTU4Z)9U+)T>=14$:-*K<_;T\4AF:](# MYW2V0[H3KI12D^)@"LWZV95R4E"G:SF?Z3AM-M5./?12DH:N/'M/HYU3Q9%=*

*MJ(.EIF&.P+\Z,H1%8^.I0F8C)(34AA%XS08):1X;"1.R)@8FXC1 M9#+Y^-[Q)-]CQKUJ31$R(IM)%1@NT4+21SV^,CR,Q9A-S1'(4H7-&@-RK*VJ*

M#2@I9U=&V\N"E8VF!V1ML38S^D"/C;M(4LZN["0?&HMXBZSSVU9&267R|>/3IM""U60;S_3@="F-79_K4<#)""*T(']P]6=,5 MO9\C4R+,T&<0W_*>M05 S-.G1!G ..,$V1ZKA B*

*MZ%L"NSCX%+1M$*AXE=!IZ0G$UD$F'J[+T.P3;,+8'# T)-MI8B4K*N@RW1 MLDT ,'2,..BUH8U.6IB!$5 3'+$LCM28;*]XMF 1,OQ$AVL1#7.:,@R(*

*M&1"DI2.8\%4LXF_T>L@WI,E ,67PW]2__T0(=" <,:l:R*_2$A'X+WQ7]P*4A M:B1@0.=%U@55W:)WXIRI8]GHZ'8,+T;61=5!!T:@0_ JQ7(UBTHBS8+_P*H%*

M_V69]](@)!)6W;/@64&\X470T!YIW(&7 PH2!(!Y!!JJ#>_(KS;IFP9DNKW% M0:MEFLK(I6'+WI.N(NPBUO B/1X+P"+3IW+@P/0U2QX8!&:9C37ND*

MU&5@60L90R3AX>/A:Z,"&H3-SAN&_P&?B =-0!HLLEA,,X;XTX)="H"]3"+ M5]\/)@^5.WU M:-X]7-Y:0H?C+*"_AI9- $78;45T1#UN\K',K0IKO,:<#<--DEMU)TONUO)[*

*M;1!X;_$QV5R91BEWPH2]2,!8 .HHHN5.C(!D^X46&>_L(^,'7AQUG(F](@^# MGG*1*R5T#,_8^>\(>BW9E8$!JW8G#R]NRE*C/GJ)9XM#.Q'E750("KXK;H$!V M(,Z%",L9SX%H(Q6*

*V""H,+Q7$9R8.\B\72K,;QCTMM(+S"T.TPLSB9/F$)*1 M=:X#4SSFUB[7A=FEMI*#P:S8C4)2"6*2KK35/K-&!87GV>& 0ACQHD#Z)AN3]R3!,;' D9+XB=[E0T0A/@O2!:HMNI\%L5*

MHL^N&XGABK6AXY]!FR^XB<6=N1L[LHHB=1<_7(C8FS;X![P4AIFXLVZ &H_@ MO+ C3]MP,>0B6J17)6/26$2MCC"4EDQ\.9"2G08>@7 AS[J#"X]]Z%T0[1%0 MH/XU:

XL^A1;2!W;.T+6%B;RR;!8X:0]CHQ\&\E8,E3E^-8RX3A[+_:(' M 5TZR!$=N/Q\I'TXCA#3D&.MFC8=D_9AWR3(JK<"4&]DQ>F8/Q M&*7MQX%"E(N1L1%953*=_]ZA+?*

>DH$Y28F]\AWSB41%#VBA>R.Q:$%[M4+&6$RO2C?*ZFSY M285==!?1CE/A*OF>LRGU18A9$QA#/&69G(7AA@)'^4J/+Y=,4>3S!N3/L1/[M?@#DZW?]:

[PG@;F1A@'T$ZTL'YBDHP^W);HC6-2R6:G6)J7RS5I9GHRP@2PT M(?*Y@H,X]RA^\X)Q"Z6Z77-E$7_CN-!P+&B1H-\--B)TM;WT E99%.U)LH5] M=!P6_I_?GR(1fQ<_;.;?

3"0CR>0U^F_&?FS_0;>Z)4+&#K44=VM'&&?KfZ=5 IP=\IM.!22I,G>2SE,F MWI0SO8(F9UVCWW]@OD(W6^DN$<== 0#(?SP=[K9HH<]\KL:Y,,#+Z)@S8@)*

M;O^,)Y^B03_&Z7$8ZVH\UVF)Y/. 4[2!\J,.!l,PPO,"?%:37;F)O)@_(M6I%*E!IAL\>YP\^94/(V98,^"PQN#TJ^@60/IWK8/4%3 >'+"U.TI4H39/UP M4@^-I0C\DZ_OG[P)\EZ<%'2*

J^%Z5@#:M"MV'&6Y%@I\D5\[TXL#>-"(G.?A M.2>-G"N,S9TLXB_1?!OJ#U=5<=.,H?A7B=7K5E&-!4UVODU?#$(5P1SF"*V M&\43.%5?WZDZ RL\> P9-$$EQH9I&FL$7&ANSK?

*PJ,Z&3[X"HZN/]WLMA+UM'&$K"WCS7$J0A%];@nH?!+=N:5YFG5*54K1{(,P-;*52AJ5]D!PHY@+(@X>_ MA2OVUQ%,(^1W+_%-3 !3W2CWS@\SP^?*

O&D93"$,UTT#&D4D.);/ M)Y?=X,W:A^F6(6)B&AIAPQ_CB7#P?T.$)FR),9HD;]I,]"E\1WGJS7AB>)2YO",W=1P5X'Q5M Q$,B8?G1O%$.O@'$R%<[?PRNGCC

MR809,+81FJN&!>W.^61"?;$;CC68& I@D,.6"\G+EV#9&L] BV.]<-T*7 M43>:8WBFQKNZOF,JG["$(B,$6O 5[>;8C?;J-4\>6=.)FF@;: HYQ6)9)$\& M.:Y7^V?

*@N\"!1#RB.@*J@]V1$K0E?WEK6YJ?RW*]MUF4C1% MCB@622PY\F1RA%A4T"TH+&A9AVFJ:.V<+NU6OE^X-T-5EY-+&525"9FKU+7A M*+$Q9?;M@Z#W-NN-%X]>?&/06GAX.?*

3$_6EF[S@#$=2$<(;_H1"X?IM' M!XPYL FBS/68!K2VE!UO#9.4.U:FLIR5[S?>#?3/+-M9:'1*EAHAC.,3HS> M[2*+.K PMZIEIC%^.95ELBL[:=<*TU]_Z-AS+$)V!N)@^(^--Q3W6XE,;-*

A,D M-!<:(1.Z"1?MV,1[=H\"G.(!H8@4Q_ET'BSR&[J=]VFT$5-Z[;R2WVL3C^+ M0X-TDLR-J93!LPV;;4. 4NO<^B4.0>]#1;KC^0H6C+0%6<4EYXAOYEYI: (&

*M$N+LF*7PMQD@XK4CN*9"Z!-(\+FCN_S",'L&T:[3XPW-=6%(T_FM<"- M+ ^FF7"EZ]D?PE>%|(=6AX4.'6(%>&85-3 S_Q@1+1_9,.!S0AEATV='4+O38W M=PY:%-*

*JMZ8RH&QO:NF0^S(+N)Y17B;W:W^Y.F@:6C<6\;T1FU"%/VX,\<3*L M_>A7]H9ZTF[O#(?!,=0F=']"A#;=01,,T"5"1KJG(8T/0O4L9X)6&6CD\+ M/3),-3:@F^TT66M!X0I?I7,W^1#*

(,!W%M48C]9P$-'=SF?2<% M8A^75__/217YWD4/>|>]O/*KHU5YU>LTSA=-0=@M4A8\OMK'X M35,1=%Q*@__T%A:E(O'8C5CU*!?&'!CS?P(Q.Y&F_]==2UILV<-I&1UID'H2*

*MSWD?_?K3QD8;BF_;/?!E[6-CX;BH_BE9/27U)0I"T?=B63>!\6SB+R#(&M ?.'&*7O 4B+]WD=#A5_0A2C;>BO-,. ^1T%NC?-XI]*621$.T^:JGFYJA2;&:ZI%(K M.%H^DRWRK(S((6Q*

MU\8MP]DSS:!,?!<;$[L%GO'!E(?[6Q(KJ8#CQ$?Y,.."HX=,6F,ETFFMP$.[M5RDUZ/RD N8&7 GV"QY'?<!]MJX M#]>V9'3FW\Q077BF_;/#M(K-*

B%DEMEXJ_EU%F& MXLCBA7"0?+A L"_:.TFVH#7$G-V%]L=!.@--&=J@$6RR7E;2TF'?",98KK5],.:+Y!KU-OZ-K%OKVLR-!.1.D< M*'"NMP876\?J.&#LJ MU*+=;*

*(A:,/O(G4ISU[UIXBQ46_7|W$0?S&]%WU7>B_JC#.-")/V7/-7%\! M(M.!7\)T^)>>N&G!TO\9)$%&^Z*G.B5<.(40%7X.*

M90[MA^^8T!-4E6C94!!MHF@X\M:!8TH@B0O+F(!+AMIY_#(C+N%01HM7-1J6 MK.P7^;FTC2GKB\?JKE!W\5R #Q>H ; 6S6,._A]BH3K6U6NF7L8 9$":@CX%

*MGMK;HXJL(P"^CL&HC0UK0 ;+ Z46K939:2YJ9.R3W93H&^S%Z4ND!$NV6@LH M(%)-W!7:1"5:U.7D2C2C=0VVXK25[:C'+//*95&[<@)@2C; 7DKXP%/.'UQ[*

*M>!UVT"*5(L%$[BKI%,@WF>4Z9HSOQ Y6VMC]2B%9[80IFV-FX42QD8;^8S+ "_M7$CV(A,(.1]\GPA1-\';,,K88]-D&]>70]N+S#:$$-61H.V&< +"NTLG .F= M/D6!'2[RN4V!XN?*

*I%K61+(7MU8>D.(AUVO;](/M=Z;KIQ2M0Q=2M;=/53EB MSAF=\K97G0M5OM1,9"NE="U0C')2T*WX7.U!29IFBE-NMH>TZV5AFPE'5M/ M6WR+ +P0RQ^KIX51L9*

*4>]W4ULL.2ZTR)//YD9Z_B+\]^WBPGUX^;PR0O"_0 M@V7IGQ!\ZP5PDQMH:W<&=.JGQQJE"=*C;7WX(7953WUT-HD*L@61\T:6^P %=)YO'6%7E!ER)=%F#<*

MBZJ;=]DQMXI2=NO\;>]/?*]"KINK++#PAKQTN;!8&"B0<[,662 !$_X,W@YM M.L+K+[#[0"#T MW BQIR<=W]/SR;M=('-M,I%%0!S5C=BF 7^W#V;3##ER4+FY#[D;#;L$X^]DG*

M[PE]W$*KM&Q@H= M;Y'(B)^6S4*FG19;'8@)HPNQ)2A7CZ(O,"UK..:)S_2:"H;C4N[#+ZM&A(@>U7 ? M/5;$(&BKJ';8NM&&26Q$Q=U3(A^-!1?R(%M[F+$=+3ZT4B- .U7E

*]O>ACY% MYZ.?!*E16 43!6HIX.;IXFSD)(8\UWBQOI80W15'4CH]"Q8,H6U3DC6&I<5 MH]UO+Z8[V6*UL4+?FENOW-V;P65<)(),OY.6H(E)ZM>IXE(3W-J6YJ.L\7Z/+:.^W_Y6*

M<2XYPT4Z+BDT5V6J.38WG?"OWF.5/!Z+'C'BN6U4495U=%CU=_.UL&^Z%RR(M+"Z<0X!Q1?(20GC;]RIN^$.X$ A>1[8:5+],R1L]O;-,Y/5VI0.MW-WK)@Q M,MKX85D(/_!"*

(TFIBWIQDM^\6K;.MD=WTH//(>[f\O_&@=XCL=I]^9Q@79"E M?VZP XNE[G<0?7UKK5)NO!IF#(?S5[9$69A_A@*<64;4$ K8K4G:RDRVT\+FW!

*M7I*ADVU9+_[G|FL]VZCMZ'5HD2;.AMSV^:HMFW,NZT +=3B?^N1.+7)%D"'\ M>I,6BY;[\B#;\Z'??:E-JGO*,.C&44N\!D;NO5MHJ&56TL^3,F,EFXAY4?5\M31,08J F]LI0T?*

E2@"K_83SO@3 MT!:#HP@45Y L" /=?@:ZNXU+/0:*(>#,@'8A]Y_[25VUH\;VD!#/7;3.DC, MH0+A>YRD*D/0P*!=2=S!!BH,%!U\8,B[WH,\=;V?5]\C-[4*ZS;^:V(9[@C X)\W=!P>A@?*

M4' MKV0)N%H'#3O.)9UT0@B]=B?*I>HH8UEEMI&O-\EP4E\Z+7+0I>4G]Z(NJOD+*

*MCB4WA<9C"K]^Y%,F5<&R:I.>2XB:V41RN6D@,"YCS&=QJPK4S6#$MW]MVW+_BH1TA>62) M%+(HQ>93*LN'&V;'F>OY7+&/CW""%V 05BM&<)<^?RDAS,H/Q@##Q/E-KT'NTf=*

M|=GYN+'0QQC27_>SE479K/# CE=M&(!H^X=#-F9@XMO<72D[B(3"A51R!57 M#V5>4^I-J9UK<$MC"ID0#Y%D(D2QYS,$+S+!'+8H_QK"O[TM8@!T+WLN%_'

M'6155<|EMM"]+91?DD$9;P>L=[_<+,3 ;5A$7;..82N7886HXB!3DJYR6I\ M,U1Z9KF>&DHOKPU'E7"P]*[ZZX9D;PP^F_KWXB,1Z<2 Q.)+[S1**P:Y_6*

*MRG##F#'1Q[PP&,>M)H9T#:'3.P0]VG[*Z7-0^G,A*&+%5S#Z VRTP[UG$ MGU\)QC6YWIBM4V2.SVX+R7H^&U;0E=\5)L>%HCZ8Q7DBIZ8-M$?*

GXRK&.3#?,QD)2!'.IRN%)=&L/IZ/H^97A9M&(.FR'YGNUPC+9<@;B)Kf& M8>?NRB=.8S[KN-](.HX\07M M$124T 'V$=R[f4/<$!5'QZQL L"0_H6?'OL V^%5O/96187(MQ>/J)X?

C|&4%@2YP!R5&AL\7! M9^|>W=H;-=ZC!VHK@HRQ8^-GUB8O1X_23!L-Z'0U3;8GN=9#2NN4|"EWHWCP M")R/.F\O@+-\3B?IRKF8Q&8HEKS-6D(\EGYWL%X^CN-

2:0H0.^^(\O%!5A M@&D&T/F0.5)AGA\L'?+F7P@1\ M=Z@>'8W$]>\T5.I(.I+DRL#?*=*B5>(L:!9@M>:Y]>Z,]I'XVVZAC*KYUP*

*M;RX8WTPJF&O@I,]&XC0/N^)N*A'M[%UCQIZ+B3Y;[1V&Q'CHZ/,A5I^_7[_; M[_U@IC6UO7P#O&.\>|9!R/%>.UJ2U6QU=DW5G%YY60^O4WQ-;E%4*]UG\R/N*

M_7O"UP1AW/UCS>8T0Z(E>W)VDBP>9;C\)7)JF(^;!LC!NV_T%D(AIB;S5X M$%FQ0)6I0(^1%3S68\9'>FR7^TS1.E 312@OKS*KL9%/D45 M>3:I5J12=],6AVC/,XKTF(S&0R3-*

/]/'7R\^PIPBC 5:R/5\BV^&/B^DV;\G MVMS1:,"UA6IL <#26\/"ZR&-MEH;J47+6I.L76X0%ZI3)(%-CU(H\AF2(8N.A6.R\U\57B'M]J:_3SOOZ L\K9WU*

*M07=]M*AP@<]Q6EL6]$86O2A'[#N.T5';2?83KI);ZBAS@05AX/:"?V >"C! MQ$)4\KPGUS?+/~RJFH.,P^TS#=@,OOD2O>[@6^ :.]C0NW3LM8-=*7+,&LM&:*

MDAZ;DKWHI:+\T(=)'"%UICU/AM, JO56NFN+K@V&+0\65KDL1BX>BR>>"ER) M<9,D1#:=W=,GE3M3C\S$>>%5IT7)&98KZ1U6@O[4+7MLII:#%/3*!^V!K-Z*

*M7V6E:G*53N*SQ%%8U"_$\^-T_YZB8G/U]\?G+HXQ2@&8I1D.*B0^*>"U"MK MU/V&$^N"#,9J(M'NU$86E[?,2E2,-^!"T#X$%6+(9"A./8<305KA0[OH@>8\ M-N_K36E:$U:-*

''|HS$\/CQ\)2)?DP'T>R]4ZG3,'Y+(SSX;3N%F2^OW/#V'3'+3"JZ\;GMX#Y^\+/6+'4-- M!,=0@V.H'S[&"E$[FABS (Q8fH'Q!L5,1D(B,1E)B;C)NF(,2%,@V,>!1MH

*MI*B2X;Q//[V/"GH!@HZX!7.508=BBQI/!'MS9&1++="QKU\]7TP5U:\G6:,]? M2%6WC1*<^]@DL1W4[|-867G<-ZR;`[*@Q_R=?D O9A@ @GAU;E4X7)APMS'!,*

MW$7:79QXLCCSL#ACOSC"FNVZ!.!%A=GH*,;.KK@P'OASBU"':@66,]05SSX34&]=X$X*=<_+XNX-)N2ZCIHXNK=&YW"S\ :0\.'2_GCL M%KX:X7;HVS=H8MQ>;0QJ*2_?*

*QC2]30)<'W0%T%K%2*5!$1#6\$B#0Z]JL,(\ M0&WH)!GUG4'SG."KX"X1^T/$%NWMXHI4Z4RQ,8PY$W*H"']?M%G;SP/PSZ. P MGM.^1:1#S:K#]F$HZ/D'YD>(^CJB[&*

*6;0W^/<_\]/6XU06:*3>%8@"?"]RV-MR\;'3[L_[K?[\AO>S#@GQ8E(AYI4 %5>.M"KM(\:3Q_/P_/:.1#5.I9MHG$J M^JRZ.NTf9+]'UF84B?PLR:~>*

fZ(+D1XC"H:U;"".2D%V=_OR%XL9]J,N099]T MT_]0"G'CW2TF(N+Y&'="@K%,Y? M]HOTSQ^7]Q5Y2 1Z"Q[Q"=]>0K,C^'1 M>54Y@MY=,R>7="]R?*

E@+H)@;YI&6O@H^70C$'0QFA@5U7;842$()!8]9R/L^ M\'7X,]=V%@HA AE3]U\4%R&:|=$UGVZ7TA]A"O(4@%@R1#]+]D"D-VM"I\'M

9LJ8[AP^_E!!E@.%.RGN;#KU&I!"Z40N.^EL&^QCXR<[)(':SQ,/`]$#J4 M0=;P_8TQY)^9Z[,.0XXC[M M*[X"YDH&ZRN^Q*5GOM3>O.?"M4 @GPO]#>]>-Y:-Q4R :"0"!R>*

[\,QM%Y%$ MQVM@F4<"C,ZR[H-'6,N:S@DR$#T%=('V1N% 9%;0YB-.F+N?2@;32Q_O>*Y[":?#.])T*-.< Z8UL:5C[3UX*B:[LC@&!CB(*R""(8K7S*(8G MKAD+4P:V *D%EV C2[*

GSY[&'E5/3+%FZ(:HXD;NR/$^&'%'5H!-71Q 03] MR@*LJ.ZT.A2_90KL72M!T3$MP\)ZB 0 .0\]_7P=T#M+!7[LV@=PQ!/\]!L5,1D(B,1E)B;C)NF(,2%,@V,>!1MH*

*MJ

M1TQ%C!T9E=DS]8!4!CHCG7=K+%A$%JUM R#C9/>G/$M6IT16Y+5=D-%CE&G) M^C.)+$38=#Z1A5FDEF>S.%%Q"7($6*JR5+6J:!F>E')>5*E\$$N[O#^(^1+$
MBVY6DL$)-7UI/$(D5HQ9@F."XQI:Y212&!;DK_!TL^DL\294@YB(3$%:J.B# M(=BHQ#1EY,KU/F-+>I;T6/TWHG^D\<\|0CAU;K#"CU!J%674!L5FRL60C&HE%1
MER)2#]^F@]+N.&AI8VNR M$2H#HW#ORJMVF>A#W("AXBA[3;F+ZY?^O\;E-YK0&-_|Y1=.R]'Y74Y@?HB" MPPTP?A@_38JB.02O-(0M2!A[!1'@O!P-%$"I2%^%GW-W),:Y@3]T?
E0I&8DK M#RE=479U=)U0W&"G5 ,BO]BSG]SCO54 MJ;V5K&!,=R!M["Z@?"L)M4.X3UMSZVA*1M$-Z8NQ:=KZ<;*("8H*IQATT'\ MENX@#"G?QR1* A$QZGI4VJ1;>89Z\]-
DS*U3%-;AW7SW%]Z9JQ%)MI<2V^:5 M"Z/)GC+G]TIF+/(PA!X&I7&H=GXE3]*$2]!8=1-L?%1D)ST4@,KEC%I*]8NG MTQ1>.UX6[U H';K@5[YF(L:9)L]2O]0Y)]]6J5UT(4'5Y)+,Z!N-
4D64?2#\ MI<\"B9AR" H [J;@+KU%4,$D2(O<["^@&0OG0TSM--ZMMM.@U<46@$^6"%;H M.9*E\CG2Z;_1%1$W>:4IK.^.XB>CO.2J) X3^&;%#E40_C5COP M6#3V,-
WTU8.SA'B:>"!+FP>U?Y^MAK*5U2Z456EBK5]Q6:+>JMHC2O5;:[(5 M)9FU>_F4P45K &:BT7^FHO<:>J'Q?'0/89J7JEM0G\]0U7[--ND=+,)66] P M-?2EWCB-
PSP33V$#MEOMP29I3O' MW9>F[_:?6G>OG1;'2O'&K@O5HXUA'O21^,*7?_YN\-UC_0_P2HS126V=!9?'>I'X]@$]STNWW"Q(4>I'M?CTW!>/71&,X+-
%KN_R'#LQ;VMI.6_W'TE9GT+KH/R?B>DLI+3LCGLU'YTXF M_^BIUO&)/8V:+S%VL.FK_ZY0O)8-WA>6RCD?5DL%,2&+8&H^=$ B]..O^_P=7S?+;\>ZLO/DA?-/O0^KX0
MI3ZT3Z]"7]UT_WR],_YMV%1+VO(3J<,893_Y9>#DG ,I.@R'F*'^R8>O"FO#) MDX?E$B/UPW*)/4LV9#]<_#)P8L')+X-E"L.6LB*SUI9Z+M1Q3'[Y3G;
%XF@;!6XONEWW=Y%;]=FCZ7@ MBHZ3@C=GI3.7@[KD[/+\XHC!G(REX6@O>88]O4 MK0=]=]>B:\]AEJT;__VSB:!(97\].HTU]/?VP@'+HV>_A
MH+MP.[V!C;%8_MDM_]2'5@X]^SWP3]?M>@C;(/_;\V1Q].30%/0G_K-VZ"KV M>W!VN:-.V]+/"'<1I'DD?[5;WF0=JOME .Y U1N#"?_E"_67CE;0VZS3Y%L7Q M%$XY:64]NR-M,'+[HZ&-
WU@V>(BQ].S8H#=RV\.=GMVG>!JT>X>GC:>T>9X= M&W3;:K]C[TDG&4G]MYV.6I#I6&&UZ]O*OM6QF5@<.N#>*YE!OL/$34W%7:= MF'K)!LLK&P2R'/"\ZV?6<@#;*COD 'L&-
+>(9O]AFB/D #93+ ?82,Q36C,- M(X[CC<3P*S;TF+)N!^N$/LU8S&BTP^0"&XAY[CSP+ ,Q';>S.]UO]G6Z]#<3L=CX?1>:$<6]#+T]=?] #P3Z) M<^REVH1#;'=5_TV<^3XB-T-
WT+:.1&\L^NV2?^Y3N/ _VZ5VXB M^] .KT/5+WS M#-GGGI4]SX-]NFUW.Q9]K$QH[4QHWYKAT!&1Q$S^B'S@*UW_^;JDO,OVD.# M5MSRH+9C1]LP/A9?@ZL_>E)_;PZ?
NH^_96CST;E^ML5Y@;')0;F;V'Z6>;9H< MSOPXC)/72J :LY*]XKI$'S?BC%O">5-X\6LOO/.6]1+?HY;V\]W6,AF7P>FT M42=TC+]Q.5;6GDQF3Q GMLG2-I MP$?6BUO-1U*]B7-
>BTZZ6@,>D@_^KV5[L"F0#P M[W2E7,&;NQGORFOK)M [IQF4H!-_*J 3G1V.9_WZK0-N5&6$SIV7.B_ZW5;? M@5>'L+UTY8ON>6NDOYG&B9/-!/P_-FN;Q]2L3>AF,4"SKH,-
=>A6]KB.HE(M%\)*@F7+GR/<7,0"BD1XXL.G,#ZZ?!PA 3ZON5\@?=,XS",[W#]2,X[:3Z' MV<%,4R?.$WSNYOD\>*S.RR""]^,\A6]2%Q[DBT7&[GX@)12?:(-+25Z]YP^2H
MI&QDI1/D8N@M4O%:_6'N#U*!%"/(4#XS8EEP&0>KE%]K!T.6]+<:G3F_N[=? MLM?]G6ACZ7HI**-V)9_8S?BZ423 MW8@F;(0530W9"*LU-68C.ALAL^U&/)EH&EB.:,)&6-'4D(VX:
(WL8=V$C=B6 MP&;]? !L]ZK$&[TE'7?[<%C^VYW@>4:W8097[*I'_$7 M7MS(MNQ'$VZGZS6DMB MY?OA67;-)]W^6\^,W<.DLDO@F\>8] MX[1#S[!!Y4//?-Y-
!$4\R$(TH(SN4(1_DO.VA'_R$K]S&##,@O/^X$3W^S3I M7)H;5M UH!;M6^;==)>NK@'C(I7+!6P#+/3<&O^# Z)G+HM?7P/D]P=?,?! M*UT?B+!VL=M6-T\--'A 6\$2Z%,0Z-
#M=4="%.U]'GUNSB1M+'UNSKML*'U> M#'8*%' "]+DMG;"1&]UI#U]=XX7B>_--V'L-#F:]<'LCX26ASE!*"20IC[PPC'TO$Q/.8;(.A.-L M[5*34O?
<^QD]5$GK=G9X/IU0E.'0A&")_/X>0K=[;D,5CS([GBF1#PY,FI(/ MCA_U=^AS.@D2AIHQT6_M5-IT@8['F=!=+KT@B]QYH6.*!4\6#M_WTU2GL]! M=*_&0D=_-
G6[]F"7_2)M2*1A]&+9XYOL$[#"+W9NH)PB>ZP)E1R:7O9]QC1O MNCMA\ 'VV+EQ[DV@0U/#$051X)GO(]/>>6T=#HVMG]BQ+G9] M)5DG%,^P9'D\9'DBTO+)BR5VK)H_^PTZ
2H'\>)! D^7.B/_3O\G+BIN1HB MDXS>S1=AO!0"=.4Y[FOS,M5Q;BPB,0ULO.#R??W?[_\,@N],W#[(UL"84L@ M3IT/VNZ@;3V7SZ0&8O^.R,C[]X[&K4M=5N_O"2"UOR,Y]8-
[>'.M;)G3@BVVN'(B+S; ML]4.1Q;(>%3Q?&NGVVR+'790[!!$MMC!%COLT*E[Z.GNVND[=[! CHT-1Q13$4;/8E(A9?X M,X]F3,2M".'%?%29([YB4I>P?7HC'QU9Z(+,G<3X.Q6'.J-
U!^!]\7KMV)7?= MWL4.0=1/-K)B2;RI)-X]=X?G.T?H?/8DOAHN>1XDOAHJ.7X2[PS<07N'#]F3 M(/"C#)=9<(+(3X27XA]; M#1'GSDN=11+ VDCI=E23#.:1F=+'8R>-
PT#L/X#C>29L"_R5E(V>?#)=XB M^%;.5'V]V,#TE48UOLGA!'VD,9Z&W(/L]33X*B:*!MMM)9#5OI7-17D9=E+_ MI(@?SAV\:<(53B$UAK!MX9;C"'__YI]'YQ>A-E0DK3&12X3<-
F3_B@V!DR=P+ M^9LI@7)%??7=7RZC$CG%>5*@EZVE+>JC'D^=%YUVJ^? ,,@CEP'E@.N+JC- MCZ,T2!$U.9Z^UERRPLW/@>(&_#%M#11@E"F/: M\=
(T]@,"U+X+,J"PHONF03^3G(24'P81KH\#LDO%F5UGX>&JY2'!=:,< VJ; MY'Z&='GU\?_^UR5B#N/HY@SH>4YD#>08XS+DDR6(O02>D05 T*DSA5<[0!TS
M>M*7JT^7_R"JO[\!.FO[S^_HWL"P7#@[S[\^/GR'^_X!9]F.+$N H;'TS/X M'PS#%R"OZ2TNS-2Y$V&(__4J*Z&F-4GR&R?-%PN8"&Q!/O7\#*@ENL')X_=Q
MDCEA,!7^T@=&@4N\&T&," _(8!6#6Y&^<2R#G12#M5OGFL$F8AN#R39<;Y" M+:&<%*%T6NU:21P;]0Y*ISN02# !T@$A"]>'.8]>0;M"2RQ)8R +R_+*? S* M5Z2Z?
F]4WT2AM9X.]Y:Y=-%=W01)?Z&89K1']0GGP.O6#WYWEPT.'5KN4BG MOVW6EI5R7#;')@D##=1-'?RX/*'=9$+%:.@;NS\=IYL%7
M7N@:FUF_>X707+6EJL:"WG$L01;BL<:J#EPX;<@7 H[4H0 M@5]>*;MZ$2P$/$VTG+\KDBKL:+Q :FCJ5?@$I=:Y>L^!L 2NBH@2.&&(@.!V M7%>>8\?
YZ?/E+UZ77E_QE+SH7K8Z6]GCQBT[7D/I(WKCFP$' MY'-X^RR%+9G QOPMCX"/VBZN5V4=3@EL.;D%Q,*8INE'YKI'\.S^ZW M6]WO6T]UU?QXU481$F<,R7*F;1]CPAY@.SZD
2\R1/D$RJFOU1FH?$P?A> M(/*I2%/B'P=V\3;P16]RQLWVG3(&4B,3"^Z#VP&!% MRJS QXYQ-(&E[27H$Y]5U+ >DI*A9>W#^>\+U"H4(7?[A@;+A-SM&Z,F?__# M"SAK4:5-
$Y>]U"5,:L9$9?Q'! *TS]_]ZM6\ G%_CIMG5!')30@XI$MB6JXM68"""R,Z%FP61'(3NG=G,$*TGOD M10GK;.3>1.4"*&&:PBM7C01]2XV(QN/IU]CCT^M:^&"?9TOG\@8.+-0:X @*
MTWCC$';N(I3V__'4\Q9.(UCG%.]&UG6N@Z_.!SYUWVTX=9^,9G0$9.@7R. ME/%O>-5J=K"F& M%A*) 5(\??7(!Y/$#%PH0GP6/651:<1]I9Q>/0JS1+U5/JTCO0_W2^@<
M;DGH-(2>\?P8GCF%'5#^&O69 N&O^6"[@T78>J 8GA9]J3=.XS#/Q%,<).U6 M>[!):M)]IW=1&>K!-\?^SS=FZME].=2^M"V_-'!?AJW!R.Y+_;%RK&F[HN5 M8TW4EQU9[2R
MYU+$X192]>(8V8.C<>Q^ORU<_;>>D;N/9>11Z_RPF-([YF,,2A^+Q&\("7 P MZ%F10,^2P$F3P(N3VO]O\;$\GSW_WBIOIO+6 "ANCBE=<[X\^& M3?40 $?MYNWX(?JCT"G6+!3-
!JR+Y1+)=58H^AZ8RK662QK()9G=K4 MO1\ ZOTO'O?JSG]#YYZ&O5"DMK\>'\B;^GOW?QVZ<IM#0H:[#Z$<>O:[EW:] MKMML?=*RKS/+/#OEGK=OXT+/?@Z;8=4?#D>4?RS^6?
Q[#/R.W?[YS5\')LTJC M(S6/(Y!^J[53^FA@]..;+;0#F6.$2RY1FN.5S#;K-OF6D^\4CKF#YUOO261U M.A?N]+/3IFZ6#YXQ'TAU[]GQP<7('8QV[ENP; X*C8H#=T>UT;T#_)8%)_
MN'OKY.A-E8:97K_&J>Q]4H ^6S?$L\ZBWG^4]+GIL.O$U$MILKRRGCC+ L=0 M'[-'%F!KQ7* Y8!3Y0 V5"P'V&C,D]HS#:/(XW&\"NNUK=#LIX'ZX [S7A, MUQT,K/_-
/41E^>.H>Z!U]\$N?8BK0))]CN2O^;./.]A&X&;N_<.JXM_^R,?^Y9?_\ M^.?BPNVU^Y9]+/M8]GE M4W48_(MV&N$5!QK9QM7BN_#OUT$&I.?S<\IPZ@5@]SM=UK3K\;Z\MFX"O7.;
M00GH]<*TMV^EV\=S)X]^7+NO-1Y,1RT!@Z\.@SBB*$\,3AOG>MOIG'B9#/A MI,%79QY3TRJAFU8YO;;K8/,2NA%;6+A.(M*%\!'>(URZ\#U&-Q/AP>OBJ?.B M.VR-
]+/AT8C>\GW+^0)OF,9A&-_AWA$S.FD^A[G!/%,GSA-\[N,9/""DSLL@ M@NOC/(5O4A<>XXM%Q@Y9H"($]O=N1/KJM4.;)X-
M$H!L%SCWOL*U40;/5*+N+!33S)1]9R2\Z9MRSJ\L46\UF@]^=V_G4;_5'JKF MAFOER<&:3G9;[8[=E^;M2Z?5'=A]:=Z^#&%@=E^:MR]6CC5S7ZP<:^:^@!S;
M"+%I]^5@!X_M\=QMM\X'SZGA[W7PU?G T8EW.CK!48=> MVU7YX,.=4=*!DU[W0$G];Z"D]K-J%_YVYD4WPQ:/M@?'$QT<.VG[KAFY^UA& M'K5ZG>?
$QQB5WIW$/Q42Z#XS$N@=RZ'?&!(8/:O3_,5)[?^W^%">SYY_;Y4W M4WEK6([HNZ^PN9$7@K!*L]09+YU%$M\DWOSUSD[JALWX$$4'&*4^^67@Y):&
M)8\W8%TLEU@N63G^+9?4]GPG3QZ<*7#RRS!L8KV-90HK,QNU+HVL2GOT,AR3 MLYP+HRX7L#&P]'-O? Q^SP9R]K8$W^.HO=Z6UM_4&MG>P.WU=MAWW%+P$5/P
MQL2NIE)P9^AVVSNL\VY8ML$3FAS'3\%/ 8ZV!P]^<#O=*8+$G2(%'ZOT&O5; M.^U4=\3P@ T?Gk!^?_WYO\]ZPX[U 5L?\/.E#Q.A)V[]?; QDHLGYR,W^^1
M;6G=_;=M@.PCF$;+6E M&0?R++ *+O$E;6 M[#;/P?*/Y9\U7LU#SWX/.N*%.^KUK5_\]2)(AZ:@IS2HFC?[OE62*]Q]6?HCC M8MRFU4:;>#?Q^9)MCN\
M.BV$/7Z^P8^NIN0'LYP&89FEX_Q;_MI>&3>+J^<;8)YPX]FZ^"..E$*#8 MS[$?HI>I?IYC$8EI8",OS[S&8/^1E>/S2_3;;K^[VR092_\-I7_KP/N6$$G;
M/;'F>6"QG'!P4[S9\@N[=V;/]=%&K:0 MYNBYX,(BJ1U[B.>1J]\%4FMF7*=41!-$MHCF25W9AY;PMHAFQZ&@D=L9VB(; MRS^[3T%KX.SW$"$:NN?G.U<1+?
_8(IHFSX/131M=]#=:,<,_RS_/*L34.I=% M-,T,;4-0RP1J? 2?T:!IHFX%6&\F(LH<\173+L3UN&^,X=[#\3^),['H6C$ MJ;>I=C<'G^8>G;@#M[IC."K+]^6!U:"!<^"!P;G[KGMJ+/[2-
SY('5-*S MX('NT!V>VVCJ24:2!IW6#@W8OLR$$T1^(KP4 M_]AI!CEW7NHLD@">""-QQ"Q@+@G%."ADL9/!XZ9Q&,9WN*,T_Y-SD)*1A\N M\1:>*W^>+.#Z2EY:WR3Q0OZ2&,X"
]UEG&>OI\%7,5'$V&XK<:WHKVR[RLN& M^-L/Y@_?-. *RQ#+PE@W,.UPA5'^\T^C\XO1FRHW5KC))+EO&C)_Q ?!R)*Y M%_(W=P/EC/KJN[]<1B5RBO.DP
E<2UL4^W3BJ?.B,VSU'!A@&,21Z\!RP-4% MM?EQE 8I[J7'T]>:2U;X^#E0W*"_F>+>PLH&(L$A]X6ZXH;1U8O.1.NC**-$ M8DP\7IK&?D H^G=!!8B16]"$V"&B2DY3RPR#"!7)
>*G0N^LL/%RV/"2,?A1D M0&Z3W,^0,*\^_M_ND3-81S=G %!SXFN@1YC7(=\L@2YE\ SL@ H.G6F\&H' MR&-&3_]R>GR'T3VUY>?/OWU_>=W=$\@N ? NP_?K[\QSM^P:
<93]R+70+B MZ1G\#X;A"Q#8_);7,/N; :SIT(0_RO M5UDM-76\TDGSQ0(F"_N43ST_Y*"Q\("X?=QDCEA,!7^T@=N@DN\&T'<"@_(M8*6*6#6Y&^<2P7GA87MBXT$T[$-B:4S0*=.?Q:
<%^);!=B/D[B,/AWCIP*3^]V MNSTI^.]$(IP\A:?!]\A&S!H=YZ?/E[]Q#,_<%YOTHO:S;5VJJULNZ U92:=3T]W^8@R__\A3 M5VBJAMQ-
H;=^N/.F*+7WOAG;=,Y2PO1]U>P0UJ4#W6%%N] MP?>.]RUO4]^13:*_C-_Z[E?)R(DB8)+/SU7 MLW.WT**D#\E!/K S$.]K15%6Y9RCQGC-+Q/3/W_WIR]7:.A;.6:I_=78-
JM02T;Z43F!\!,BPXSC*R219@G($"H[W59H*41R=^5XZ<\2_>&CH1 MX$=0N=20)LY,>!.?[(9LDY&0P;#CQ$N6VA"0S]S Z_6G=D?N,Y]H>W=FW2N2
M#],%O1(_^')YP,+*@HBUTS$(@WR<9AY\Y86NL;7U>UG(T%6/1E4?1O-"U]X MQ8TP>L'A;I1&XDUN/;#\Z"ZXC$S1>J%N&KO9#-3"FYEA2O8*H[-B^,)67W^X
MI,'OU\"M7PY)7#@#6ADOF03Q7 !!@4'#@JZ4Q)WH@YDGJ_I5N2Y4JTPK*?0] MZ#?(ZJE7()TPFV%,V]XH,<@;@H[4H0@=V,*=_6(E@(>)IH.7]7)%5XL_" M90+)5^$3E-
WDZCT'PA*X*B)"B<"@MNW6CPXB)^$#Q84* !H-[5VZ#(VQ2?L MQZ26[7IN.9I\!4LUBB;I; A$]B6O^610,@A7,,^W8B+[.*@P0V"]R"QF#(4
M79DCXV7P9+!6NM^WG)*_O>)+K["'DC=G2I S8=4>%_(PV?41 03F28X@B53U MO$5I'A+_XGN!Q*]F,Q>)'Y"X]V U MX,6.AWL!@Q7IDS/".G6&-9(CJ7 ?Z.Z@+Z/8/C">?
F.)_W*A=%D3QWT\6>= M=&,8$($^1%"9]BY'5%<0M, M,TWAE:M*E+ZEAFR187^/>;G:^&_9_MG":70^J1(@/&.8U#PR_3"0_#,MB&I#D,T!=B(A]) MYXS'7B#2?>*(C"YD+-
!0IH*'G,7^']+J#DCTXU-OZ>DA&&%STL3& DXNM53H MF@?%)A^C!@4<)V M,W1Q>K\$(3U8Z6,ER_A9&\6"0^Y7)<^5DLM:@V+PS8 '!^ MPG4H]^:L"+Q,0?
O_&,,T,^U7NY0;D@W.5]S 7\QXNL."%RCI-I@()(U>@Z6L/L=5SVSK\D M=WR-FJ.TI&++DV?7:%O3"^.EV>Q^H+=QO1-R;ML))#(:U;] M]UFB!B9?
V)&NE'ME]%_T6L/1H05P_(UGA_#,U&&*.>3^DQ9-;_9%W\'Z[35 M!VZXC?2EWCB-PSP3>_9]UZLT=.'I'6Q&"..;<\9Z/;L1#=B(SI.:#;L13[01 MHU;W;S>B 1MA15-#-L**IH9L!
(BFC6F^=B.>MA$/K*O68%QZI#GC..<7FV8"_A$/SNVN^YWCQ6#[7UGV0\W)33= M8S'0T.3I@I6Y9AWLKC\]UQN]Z^4[OQ5M(UD.:?= UV)O\."#?RK:R"
M_K=C$8A'2!S'3AN]71Q=#MSWL MJ>@X:@#$XJ("%O_0A!ZK,:Y>V3PXMM/3V5D'G^]NY<.H[?9'.P6QLLS1+(IY M.E/MX%/=;7-T+T;NJ+=<*!+_7@MY'4N\>AO&3Q#
]96O_CREJU!Z;6CKV0BOE4 M\=<$ZQQ>#$>MOBH2XMH@6991*2^5L#7X.L+#@ ^<<5JD2>BJ./0<-;_O@CO M4=+
]R+!.SBV6B<4RJ:75[5@F>V"Y*Q3@6!0$0@6+3?09,,@2F$Z0SAARZ&-] MJVMKNUA)QB5!]DQ4ELZD,R1:6T1S)(O[NYP0H-E->]@?$NT\/R!(EG8]Q!"R;-
Q3>.OD1RMO9*.)3N>6*VG!)AF;K4E/X/MN1] MJ02G0Y5>-+U!N^V"+-BTRJINR.,MT8=. !ME#AC+5]@\R1F+[S?R/E YPR^ MD 0^C1KW^A7[6?"[1/@"*'$"^],K ="55A>(
T41'#QXT.&RX @#"H;EPV0] MA$9*<9ITENR#OXK-[,B:(=K04M$5#)3HZ@X5)&0279M%Y7)_:WUJ.1_BY :N MNR[4]%]_?4O+^2D]<>YAC]#^.]_>O/%&V"-
%E6,)6*!.D24,4:=*]5/095 M54;_522I$WES0=5BB0@BEW4EB8&']\ .YJ2VF;5R%79V.EVWW\;>S!NIU,N< M%^>MX<#!@=-
U+>=3GN#S,_6Z^@6AM:,RUAM43GB\Y6EXP&QG$V\IM14394V* MEXX[/.^XO4Y?%W1CD38/EPOY0#?,4,5CN::7]+)#?*2Y+]SUEB:C-#)ZR31'^!,X)9.ZN>';2]!#5#37I=I
M#UY!WC-3%.*-H,A&*=;,HS0L%.?59Y(D]!9P_U?0R#,!&N6+4;?0W+E4&B6Y MN7^3(*4]>N9_,%KHWDFQ5DJ]!YB707_MAC',W)W+N[AS>H2%RPU C_YG#$DV7
M,VK,A])@X:@H;)06:&\5>!#RM]H'PL/Z VR"V-GPP),S2Q*G:8W]8W !$_H+ M&%%K+4$5^6\3,ZR4*A?_2NAOGXVA08/=N/R!UH3"L,N&,"6D6%G9E5,=7;U1"]0P?7A)Q(]MM.YV+D9N?
WBQD3+K MI%]%^VYSM7]]WKJ=00D1;PN];%-55W-$EV5Z+:5TY/*=O453*)7_+_?C2! MTE3]_*I-A<:4:?F0$X;N>]$=F-@**Z^ (7Y,X1#NB,U3U]"7?G^AKN]"W>;
M&$H=Y^4>"_R;MNMD\;#I TI-MPVVI+;>G"LW-_V,J12!I9512\D@]9#UUX> M;FPK]6/Y"FD4QT_/X2+R^]=SML?;TTP M#8/%%X;MHN"9%4*ZF)2]MB;&6LFCK
&:5@ZK2>#=1*!6P/YDB? R-GQ T @7 M]BD+;G@\,0&XW<*/4E@ #: ['6Z#O\CKE^)%.#"RQYLEF4"^#_?3@#E%U-$U/&7#$U3/ 4^W@:W<3V(M/4&6K8"L: F [S1T7S59>.3?
O"A'<!@4\RWGLX3ZD>(\OHF_">F7PJZE"2> M&+=U1EIBE82^]!NL"3PH+#/6CR7\R@1D6AAJO*$*)-469HY"]V+Q=FJ.?
M+_5P)=X*G)*Y4L&9%O7]\UM0B'0NWJ3*0%;VLYS^,SS&'F$U/B"^UW4'8.<- M>SUU4$F]U[G.K672$-[+N[EP)TXH'FWVT.W<]ZO?6:<9XA#BMR_RTU\Q.H]
MUZT>PJ_GY^UU&UTUNQ^UR6";#R[<_NA\Y7%[VM^3"R]>V/"B#2\>-+QHS.;A M$(M4!?.N2]6CC5S7TX7B>Y)]J7IQ=[W7H3A Q;AJ*IG]]D"&HUG\%@T
MGFZO=B>?O'7>:#B>FO7:A,YS#6;Q!S:+WVFS>"4G66AQK'0<,L"K$?U.S$MGJG#^*S*C0PRH$W62FR'MX'D7'6\Z#4TEV&9PM] MMGG#U44OQP-
W=&P\^I95=Q;XM\O\3V1Q'\Q<.;_57B/SYM7Q]M*O<) MTY0XW6Q/Q]LILO,AY]QC^+2#8U\]F%N'?;?=/C\B]62]9]+_M$_9$QA=] M]Z*_"O3WO PL\Q2:!I$7^=;(.BC0TR%1$?
=^EC5PJKN7&^=N?_2\(*HM^S2 M?>X#G?8>AI]L'A,W3]P[I.G9V6"9XGZR=1O&!(\["?ON]+T&@?NI M0$3+)4IT\9.6K-VK]*-WKL].JO_X308-
KW30\+)LS^YAU>X5L:3RVA>CD0FG M<*_Z#U=6Y4=ID#+N$=618%5_B% T6.O,Y0@I0LFE@/H"2.OW'DJ*@=5$' MX+OMM5S6CR!""'_2&NC5D/B_C$>0()QN 5PQCU,NE-
>EYB"^MX'FED#&OIW. MGY+,FB^U/QF>R/,\15>@HRY)@G#-Y9/$&&'$317SG MP^H]>%@*]JT6M G)_O++AYW]+OP1'_2(3NB?;O M#'CO9[1]&J,0%GTL".
(2+V$<(/"5HVF>Y0Q94P'@9P@H MGA#A]8/$]]B0+$\X&A(<$@1<,6_MN3L#)RSH;^H1Y,B-%N,4#\,\JG0-^,_MQ4$3Q]8!2*VD*OW=?'VQ6FHH/J@ZI3==?
_]O,X2XK"YOS'!1H+4!&Q%&QRR& M^^8>ZE\,FO.)83*=GSY?_G+UT=$813 :+ZR,Q'P[?)0M"F0!?#()XCF>$3%B MFVG4\ *BZ=V"S]?
N,=MXC@UW97(9#HO=6])\0R@]TN0)3T&W#R=ZHY5Q] M[-YP25MX!W)2CY)PM,KD18\,%@(>*218]U]8RUOB]_4$W@<1T=K7#8 M8,AF0;H!CY$+@43R.??1X(6>>]2*XU9(
7]7Q"@T),8G_I]GW-K$N_6"D)95 MS0:D^R <%QI'$<*V0V% @\+SD7>TY9S58C XFYCB6GA)@(W (,C3.TV#@6&Z>65K=CXSP H^7;%JCP@.MO<*^(V'$,9Z&WC//L]33X
M*B;F1BEBXR4MAUKE95B\\MT/Y@_?-."*GY]X$<:Z(: Q7">_^>?1N<7HS?5 M$$+%P[]"$3M0R=>34^WQB*>//.1!0H()V-Y]HX,93]OZ>^T0?DL5*9Z':*B M%1?
J5,^YOOSTZ:_O/[^KZ'%2>:877WW\O_\E'8O3&4(X6\X0.9'<91$BQ#H(M0[GDG^6->,AD9+D)_(KX!)\N?IT^0_&-58OUS"6]]#T*CJZFM!:?;)XY!]= ME9XH%6(^--=ME,1GQ4]Z-
PJM3TZ"3_W2&U+!]"E [M4TAU<;J=A;.N)50CY4@ M5H)(P@1JE"18-@W+=I!;T+6BOK+5LE:H6"JT5$A]$9E,/EA=+HM4ZHO(R.,*
M*%S2(^&'PT(LW76(U:XCX7OC9.EDROV!EQ*^1BC+A:P45T]%]5Q(]] SAT@ M;4NZEG0UZ6KG^"9(1].E]]H8N\? AZ&/BHSJ 0A1/:1\.6?C5< &M4LTSX
MLPB1SP,K."WU5:G/51HD.R4S'[14I,A$W.0AR\)$W ;P?N5AM*>Q):IZHB(? M'@?Q*6%!==B477R#*$-/O6_BY%,3MZEW"Q\IK@666\I'988]."UI6=+2\DJV MM%#A#MV\@H]
Q@#Z\A+G-*JMGAG(G?=&@P=W4OM,]8/$E*7PX:G;/PJO2W)^A>!66C"T9KRI]&.?%DW=A2L3:');\UY%=:]XV4HTL$A:?VXC\T$X!9P1I\"#77C%;KE ME&P35,,AEJ0M21>* 7<6C:;
(RU\0N.Q[OI8.72>=Q7DXV4*M MED M@3JDR%\D8N&OXV8*=I*4D4 QF[K7*IC](S%@M0.SW5U6Z,EI.4L&Q& MJ7I%-O'P570.?A-A*$ LS]H L'<6O:6 MB O+?
B:\";7@=&Z2^"Z;K?:MYNBNS"1326IC/ W 1DM5;I1JV;DV4;+0.=XX MEOXL_;W:39P"6*!DIGJI,12-H+GR^;4VW%;+ B]6TQ6Z:R?67I_DHF MZ#HRM:+1DN8].6[,AWV#-
-0@LFE;LFE<_D0 E.)SL<_$)]*YR:,QY@ZJ,=1 MJ"=B4MV.T75NGK"JSM&G<576)IDC#FY^-BY=Q,%63X1JONES'REL'B>8B*Q M-XYO16L]>=:G6/9X]3C]<#]YE$6EU/I-
ND1_%SSQKR*\%4@Q^'0O2L_D*^2(M=5>X]765J/6WQMAWXVY!+(>5N5WW3>Q*T AA YHS%)+\SE9$)R9CE8KWD)' M0"<4EZ&"HE0YRKT_1,HY6X%T'WHL +?EN]XW*5&EQ_)
<36 %< MI]HG]+&.A9$*#X_-B=4]'_,,S3 9.M,H3+:WCK+O5UNEXV+E$>W8-3:T]9)) MZORVP+7'IMO]L\] =7X"L1+&*>I3('!^4S1&Y1,@:')4P9QW\#DK&O!>%I'# MMVK-Z13])
<:7O<4\RR1R7E[G8Y \(F[[<%9O_V*VYT7%15<+ V$1 MJ-Q.R M)3SV_4280[0,]{0.:)#Y>9PO'$].[F5;FZP+282/ O6O,.B/[_#"$\,CFC
M2O33+\WA)N8$6)Z#+MD+4FPK#TM+RZ=*+F DB)%%5I6D#F)T^((B344-!M7F MX)"Q+AZK) (*@)%6C-1"?,)VVDKW8EPV[%GLT1[G\YPM_XF8!GZ0<4'O]%/4 M9[:Y[F4]PA
MO/:!@WM K5*I>&8LEC'5S0@'CX,: F:1(A7;]9?$"#(,.T])]!?24*,<&)6S MT<1E_IV]2C5:".0F!%:8R".+.!R.O&]G4 90]!W))*:=,KZH)&M#[+U08^L M#]]W*BQ!4BC>8@*6D-
8U#;EL$_1!.$4"G*H,68KI%'Y*5?DOGCF@CRHN9YW8 M@UNFTIE.EA7#M,@B? X>I377DK@V@5QT.2.?$2P%20M5HP*)<4\!\R3VQ6\P M@+!
(0R'5F"M)96DUT)E6W4VO]=1]&4^KEI"S9!1%K_"(D @4UH"6O88KK%#[R] M_7F08'.0-J'F@WP;X-@6LH_)@"7CA1FE$ M7V(]S4#A$]HIU$%
(8ZLIDU5#-7$3U"A) R// VXIC;0X0MT2O,(L#C%_*+Z# M-4QGP8*B*HB0F1*=@"(_";#WXZ0HW2'=O3@NC<,9[U!L$ 8PF(EJG4:BN* 8X21_'UVNO M%%030X-
B%U)\#=8=,3BB"2:XUBV576L0 GSM!"5EK"1G(H6L(MYP-I MM@Y0)*Q(*#E6%@Q)KY;<[#"-M^ZX1SX 35 >2QFP&B,2:F("%LI469AYI :R M(EC*>U:(DH]@,Y^L-

*V}8<7%58/T&+!NNN#0E64/!\E$(AD?2H/ MG)1QPL<>+WVQQ?(1AMVP-N\,O2.TN+3@=[@(+)76/ -=&F)/[NG1E9BMWJ)L M18^8X;9X)]$*G@9NY@L"),*

C/.9({>Z0GE>%A0@7A;LT()_=6-F$]_(&.\$ M@S((($*

,[61Z)!PBY);&T8Z[^R9KQUB2!Y#<.; M$%C5 @DP4BHR34PB>;"[E7).U!"I2"Y U5"|%6!ABT7E>?(5!M+9U()0%>\]DA/(T\S;2N9.(7O<3M[8=+0@AW+"LF12%XZ$@ML2?U: MQDCQ]K7Z3R1-T3;=G/TH?Z/5,@ YP;>BC3T(D?T?)/RD\IH9764%'+E!9C;1A!C)"-O8* M8"&\U97YG],SY=9-;4JFBDW&-'K-(S%1]22=3$D=$-H({B2$(]U K'R>:'1ARPP+J^B21XA8.'&"=9YI8O7E2<) M@4!YJ3K>F6,^QAB TLR_57I"'@DV%468BCMV'D>,9_4_.4@!D<#8F/GH3%W MN*"B*J^0/.]T8+ZM?1V: DQAA>,,9+)4/R[2X%22W">8/ -F[WR\&/7\X'OB_ M#\Z%@WO_8G+O^W#L3T[OG@O1;Q'\3^^NVO5]>_?98W/3E!DESMM3B+Y-N4R,M*VPQ>A M^EP$$3$XB)}\-/T^!^D?3T6WJ-EX3CH'BA6)U$09D4&0 0LI#0]_SO.Y@^GO"_F_]Z>]\>_> (1B=SH=C]K#7F_8ZZ_(P_[; MJX]?/E_]>@VR\-/GJ[?O?OKM\ [OKWX>CSO!\>%!!V)>"$%^,(UOHD;E*Y3:D-]R/-MTELF/75ZWEEG\%*\XH]X>V&]_"\[\$TPX1)7^-VIBE(HO MO2WH(9)OQGB1UI:E]IX8UW41M<`Z+>_C>? S@$PB33E)L:B4FAVCDQ?_>ME5 MBVMDGRA0TASSV"0<,".V*Y(.[K9#TK>*O*W4!$-YE]AA@35=4^:,WPN]C#/,*

MM$8L+R=%GC+'X\Y*9IHM148WO:#%"A/+QI36/>4&4,5;L8$%U;&<7(Z:HY$T$-MRZV\)51N7D^9TJ%\\R9P9OO!*&62DJBF@K2W7,7JG%(#=Q947G/G-A9X!:9-JMUE[$1EOQ.\C;,9>93WV:[5 M=":?V31("[)0PQREFF+ &76M_F'\(T*[^]!M8!:QIG"?.?"O_=9+=EAAKJJ MJE<5\X^QX0NNIPGDOCHJ<%[6Z$>.5(VF+'2D5@2?M#(B-7]G^]A,K>65@G"9 M/"+4"E"@)199RQ>@D"#P@$3DMO?]H-S,@*W=K77+G83NRU)+WFO3T>3PZ!-;(06(=#3OM44\%F MJ$"MA8^ZRv<*H[D8$,AGK"M2N2,P*@Z&2F<*FMIL= [!*%YEF+;$*-W@8CLN M]&!X(]5S!T% \!0/]3ZOJ/PK4)"]+9A5[DJYIFY;SS/=QGMMMS,I>334/K, ^ MB%0<>@(8I2QX/)Z2DG!!!+/7=<1]CCRN*EP4+AH531ISE\^5DXUD-VNC.XR& M,2)/-68E275/XA5%A&97UEA\-3"X$LY"K,.X4QXH(?!X\# K27? M@*3@16(##2|2)73E9<&89!YQ<3A!C;.SVGR=I2E: M-RV^A'V5""?E3067[@M,A? +\8@!H#\9I\444(]Q\^2L,@)+%+EOK,OS?6%"T ML@"T4Z:M880P89!0'O [{QPH"OZ"2F1QP16$BY&^)5]2$P6@A2L% ?#HQ M MSY &U21FM"KH 7GQ{T}C.I8P,J18(%4.E/ELZA*E@7KLY"CTG95#C)QXf,XJ MOU F!)3[^F 1MB-++LE4"JZS?G>1T&SK)L"!1A^LGH*<A$9=J=6_)]C*G4K"G MQ6CM5X"\F7 4I$(B!D%B8E{(9A>URM]4OD]KOV)+]]M6]^[XF2M]3O.O&0N M)I:A+4,KAB8/),/2ENAQ8BA[5/-KHKR.\R#D_/K4)S@HD^ZH7;R&Y]UNXA6. M)WIL$=8=L*UZ=.I%R1IQ78$YKCQ(OEX\?!!>3XR48@0;25;@N1(MXVI#.&04=6:7!6*IZSI'Q/&:!*E)D_' K3.VW&>YSS#B5D)\2V]H:N=U-$0 MGL9UWOUFQ$W^F2=!2M8&L9F|)P)6<2?1!(4U"JG/.2]4+S M4(.1&>==>$!GHI&O.N^V=[-=[=*S#6(8QCRO=INPJ62'XP4])?B-KG5C@:.GR7 MGW^Z9 %=4)]& T$@MDRU1[W^<*EQD-Z]9NLE#>3;+DP)PJ8;)}IQ/$>9B/?\\^OY99UK6993:S!)&99?:HV,M1 M\4.#SH=U1X"+(IT::SQ4K!+4C$2370TT(1B_#C51784&/C-@Z)7.Q)43_\!% MRIZ'8JS8Q%4[$TP/ GL&"(>.RX53LX4<)RK4GR.,[149NQFROPM I2U;2.%1%"4*(<._/6.N7259<<G\BQ'A*,+X+P*#6S;)6V)9YI LR O(=1{1RPC7]E-.CZ9M[.2J,,PD35V 0<-.,;G&2>!& ISS1E M2B0NJM?Y0RQ-KD%MA>XU(D1)'F1FDE)eL,;=9?-MFB=<(:W-I*"9\$(% M,2'PD22XQ70^(CS,W-/RRE;U$2!+$;Q#8"""S06#}Y^^.,+J^9. MSDMV)_@2BX3[1OG|;4")X\#'KG>'O0>)20W--GX.K*Z (MK0IKSNMSGJCH-14KY&VVV]/=DH-HBKX)'?Y;90?E+%0V'1:M%[Y#"60&%J6R MHGJ^D(Z_)7H(;V53.;XH*W6="U(";5VZ9;=B?0V<[#UG3]GU\8%U,!QO96/" MST:FMCV 3U90J80Q;I&*<0*0,V#&INQVP=CCDKM"@6(K,_3B'PM-4.BO),QI M471T1>4Z7KBRMGRHZF"AA(:FW1)6FIL@OM2$I'4-EJ.]35[I=4I4NSI*;I9X M3Y-A3Z_5$]P-856=#15B+VC.FS)')OJL!M$]Y;L+9PM#>F6(!3N0XD_!AHDVJO5Y' XZH|H7AL(A;"RTQ% M!(MT[@8H&>TR-X8NP+Y@LH""XHXHUYBY\^\$ .5 MG+]???*=3VKTQ>E5]G1H[6*K,4MDJ6)Y$>%4*XS Z>1.U 1DD$FNPIB)SJ9 M_%L9A&6C4V4C19PC4+Y0C""E11M7?3)ZU2)"TU. M$\1(=3%0ZH.28F9=\CI34;4[6.V'8,"K$$@+4;(&-X/I1")QBP#=FV>$(=NW MJ;,V=?21];-6]CYKV5NRNHSC6GI?/K?9]+H-R!.AR@56/2!9#)1!=:%E+56Y M5(H6S,HTU!VK)1,;/\D:-<*]#*=*MBI:$W(\L)TE,A++ MV;-VU2UOD288.O.ANU[(0\Y>3>/#(B4!*ZA:#L+*><*$=0{IU4>R4Z@21W M# %B++YSU|<;,;_(8V4 WU:MF5W&6G.\M,%EI@MIRJ1FB4E#G<10 @6LX4G@S MQE9C/R?_@]FWSQ+IJ1(IISRG65TJ^9H>K-*)=H.>K%I?G*6F4Z8F%8K6&,'K M*P=('E(RKD8I-HK,S2:.JY2YYHD*9,\,1G(>GX]:$X8"99H+([4<@X W&(>I MO.O2\f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{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{62=\(\+B4YX(%Y621DN_=[U'HW(XW;!,\'X8P, U=BRKNRWGV/ MB_1R,*_#ZHPI9;G8&=EVE+75)*$NJYGI>I.H_2KM3#42E>Y>O)DQG> MG'\&2BB:9XF8R5947+6AZS)*K^!0]$(DF)1-P_1-UR ^+XA4)];&$ 2B MCEEFE3:S]WLHD8FL=1E]:0%I,$\,H%M(O/ES8:I*IS5>I*3B!6\)O6H^QI" M%(5%=7C E*54$38[CE"6CD+"0I.U=/3J.A@?4##(*BF-7.J(IG5]ZX.'IF?!G M$=>=>@Q61@UJ"MQ#?(X*50!>V$3,$=RJ;JB,U3'7(P.=A%32BO M]3Q(N0TVR\(@TKIHD0XD/V(]DVF> MH@4>R!P#[-NF-0HL0Y(BFI0T:KBI5H4Z9Q>,2^M!6;VW|"P(;J-?!?NEV,F3 M*SXQPA1$:X,&524B LL67A|B>^Y8SO7=D"I*?R=T6&0EUF&LM9G^0+$A:8/= M=VQ4K[ZATZXL!/+]DK6-XB]CP?\M6 SI$5L5J)6!H.HT M-"+/9 2R'Q/%1%*T D="6$TS6E,6X*Y/;\#&V]>DZ9&7+0A"T?C[5TE?.MC@\'#HIA(*8IQ6B5=B:98 ,^S[&%+ "]LR-*&+!\9LK2B\)1$)Y?K3TOH(&:T MI]2VCRVB0)=ITGDN >U3F3X'BD\T68!!D:6;&CI90CLU0D//_0R!T4Z2E>], M(N\P+MINR!1^#:31-!0}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{62=\(\+B4YX(%Y621DN_=[U'HW(XW;!,\'X8P, U=BRKNRWGV/ MB_1R,*_#ZHPI9;G8&=EVE+75)*$NJYGI>I.H_2KM3#42E>Y>O)DQG> MG'\&2BB:9XF8R5947+6AZS)*K^!0]$(DF)1-P_1-UR ^+XA4)];&$ 2B MCEEFE3:S]WLHD8FL=1E]:0%I,$\,H%M(O/ES8:I*IS5>I*3B!6\)O6H^QI" M%(5%=7C E*54$38[CE"6CD+"0I.U=/3J.A@?4##(*BF-7.J(IG5]ZX.'IF?!G M$=>=>@Q61@UJ"MQ#?(X*50!>V$3,$=RJ;JB,U3'7(P.=A%32BO M]3Q(N0TVR\(@TKIHD0XD/V(]DVF> MH@4>R!P#[-NF-0HL0Y(BFI0T:KBI5H4Z9Q>,2^M!6;VW|"P(;J-?!?NEV,F3 M*SXQPA1$:X,&524B LL67A|B>^Y8SO7=D"I*?R=T6&0EUF&LM9G^0+$A:8/= M=VQ4K[ZATZXL!/+]DK6-XB]CP?\M6 SI$5L5J)6!H.HT M-"+/9 2R'Q/%1%*T D="6$TS6E,6X*Y/;\#&V]>DZ9&7+0A"T?C[5TE?.MC@\'#HIA(*8IQ6B5=B:98 ,^S[&%+ "]LR-*&+!\9LK2B\)1$)Y?K3TOH(&:T MI]2VCRVB0)=ITGDN >U3F3X'BD\T68!!D:6;&CI90CLU0D//_0R!T4Z2E>], M(N\P+MINR!1^#:31-!0}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

>N]0|KYC&$6/3)FDT^=2'"#)8#|\--[`@!CA2K-M_)24VB[6^,:^N5U&P*5TUH5CF4%+(TI,H\6(|%]M);<>SU$.[(!VX"'^N-A!;=-M=)VQ(NQ"^",&'5N@&-?)>#ZS[<%@+Y/9M"&B$|G?3C[T!,KO5^,\PD8)^%T-M^@RHX\$86R89Q.Q*=.X52$-MRK"/8D,KO.<1%3"&3AT5Q#'}S@B;T5I+VU!H]),>4W46)E_S>V7EG"OZ%M6F4C1_1L)%S=)))}Y}>MG(5.Z%BW01E"|_-M^X0O;EZ(.2G@+(&]WBON6;!9H-#=]O=,[,-[4C9<,7<9N19>=6>;DC%DKEB-MZ?;PP6UXP#[MCQ-F<|N5]TOW");['G2Y'6XT^9Q>E;YEO)K/[\@&DX2@Z#MR[M>-/B0!>ARMXWC6(N*F/RLS6'D;(1$"SL{)P?1^8#/E/20YM"3GXCEHW/B-"6"|-M3AQOSB;|-7CK78,R5Q^NRS#?%K!@4Y>H#'GZ2O4205H23[\UF62B4,#B MG&^(//&"ZSTFUJB_>06DM?_ZX&-?/$C!>@#;B.=#WS)IO6"O58_9V\!3P# MCFMB"HP'-H6<>OA,@Y1'S]#Q1T$-WA.U#*SFKMY&94'Z(K!0WH(U0+DT|)*9 MTK$-YNS<"(&;]VPP0[58)R?A-K@4\FYB_E8ZU&SAD_-7?BQOYMPG}]^LO,(M*_YVB!N3,_!Q-+>WN\%,6Q9W.VRN^D%N0_.;?)WK:W^R:6M?FFKO[N,"%E9-MZ;4509CQEA655G!Z/+I.34@CFA[I_*ML5HE(O)EB#,;4?LRLS6'D-?(1$"SL{)P?1^8#/E/20YM"3GXCEHW/B-"6"|-M3AQOSB;|-7CK78,R5Q^NRS#?%K!@4Y>H#'GZ2O4205H23[\UF62B4,#B-)1*Y=PTNJFMPO?:&(E"92*<5;D',X(:"'?SD=455(3H_-MU7ASBNJS)C*1AN2^>/X_;6H*)"P'FC#I*N7$^D6\PD[.+JSX>E@(8[+-<[*RE=1.S_]$>%@1V9S?*@@AZG6]GI(9!]DJ@+98L>N"'0'3?"73-AM8RT,20$-MHQ^-%##+QW_*&_74]E\6>,Z0GRRQR,]R>A9I+&GN1R6EW<6|=]2R^1*AWW8U-MZ8(ET+8VQ,\Z;"X1ZL[N-4-MVM![.5EDB0CAC56473S(<3]='OEZ_C#Y@2);7T=XNO;]{_Z=_,V;5.X.$N=7!7=X45Z<2'TOOHtY-M-(M{P1O}L;-K.(;KK%(^OUWB7!L@=OG;9_]*VV]77"??S"V)MID!!6?0W?_GZMA=']HT[WE6O"&%LGC+PTU=%7P..]*''/%U0FXMHDWQ)THHY=BQR:B-/CWS!%$<-M@%G/OK=S^&'>[F6K#Y=40]R,.5;%9-.]IEXO3GP#W_$&BSA/L,+]FRJT*ZD-MMA7L2L\Q(_3.6;\G9LW;?8M3G'VX=PWE[-MP'YKNU<;JBF',O'QA:S@<0ATE2G0OFU}>A+=T[LJX2KHKWOWK:7^8IO./-?-MQQ@ET56S-_[4M]1UA-#QZ<\P(U.9'21/Q3#C'IE7WU1AL-M+}^$7AJ3OH7UH;UWW&^KUG#BOM,&L,L7G5$.'88V+)M.S*-Y(S,"@-MTMBT)S2GB*OO,)>2L*P@/+I7?L]?!(/-MH!$?*-[9O(7FCS.4QG/HLXSWWNWYZ.1.,G=92)9\)H(QH])=:K5UL)1KB3M-M[]?<+TUW\K/5-Q(81K73A@GO-JA0@+BND(]>Z6XW-_V?WN6VW*>7MMRE+7>9-M=KV,W3QL3ZEC,3(&K,D9E-4:"T-Z.<#K!QLH.#>]!1:RR?0&11(+TZ$_(G(C$K4^&&3GHN%C3-MQ9K4U>W&/L/>E4WJD-,NETM(\]=7A6YEOW?[>]JZDKQ9[P,$_&#*VWXSC0\M+9N_&.C%0-E 3>VC[OID)&!T9IL2&S-7#.D)NT@=E3(=(#T2_-=263C>T_(-MVB[&]U]\TMF!!95-!"/2_QF:3M 1ID.%7FZY*"QYJ;S%+W]1WIZY?EJK.5PTPE0M>_^039!-{EG#GCGD:')S7VZB%B-?\IEI-M*BK20DHUDMC-M_0^PAHJK0IA+:-_M>)CNBUERXZFV]K@<3BOPZT[*W[UOO:T$9//FZY0\V2"C"]+S.];OP-MAFY!CMB4@YP5Z)G_4?=/Z]R;KJH95>KB+B,#.^]UKNWB=19,6X(<.9,5/3%-M.-6YH6+E;[U.-^70LKY7)-^"07?!TZCL.JK(B;3]*-M7M8Z1"$[^9W"\];M+*?=69*>DSA3YN*>@U4]MDQ6C=]4&_>A>%|M@M1X+M9O7_[MZn,.?,S_\=M/_[OEZ.(#.829*CWY?.FJ-G2'LW.:R10.KV=.!*]CV8\'3EO+&FI;A*^W)7TWM']&<@3R/^N!%XI]V\<]HRD]5JHBU%CK-M0GL';>AFW?-U0IXA0RIE$%(W+X3]*FD7_A\TL:P^RP>,N0I2)M(90F2'T.1CW-M2\)PN-;W-?;YPOOS-F;,*,/-F)U$X*-_92+_^=-^+-=C?"8XZYSFWT)"\A0#D\V)-MD0%&O*8NP49Y{7?'X"$D.7_/!?E!\F\+K8/PTI33!]L+SY;=.0\3%(^,Y-SEY*-M6Q=KSKSBX$!+PU19HS(AX[=AH'*(>1%W,O)S<5L7NQ*[8O8%84XBC""T3G=)-M@:1M+B?AQ:1>RU5),H/ZAAQ^,AREX$M'K(LB+<27&18C\$)1KL!?1\USNPNPXDU[\W-[RNP;H_NT%-MT'T=/[]>);>:<-_50);R:D.CM8D#Y9AANI0$<\&HR-XTH;8X)GU)A:4>"X0-MM77M1VHOTNKQAD5&TM]FO:&D-"!](0%1G:'4#I^*M$W[D-8/A,H@JAH^\489-M]1K6=7ND!FLX/D:<+P0A&7M*.^1^=1L^L#_Y.@DZ%!VO-=AES2A[-NV,\6Z9?X8^>PC.*3%-+W_OD4'H!-GD(+S1-MKS1#@1N7XI?.[<.],.LZY!][(!7)AU\+#91./Z[HH=0I4.4RVM5-V5-[-MJE@-U>;6Z[WT;+=C,"\ZF>'[-TSMV:-KUW)7T'74W.4<*X0C0N81OY5]2+8Q-MA[&T2"G2:7;PED]UJ^F84D5LLNE0)))ZXIR)?QU6F-R9M-_+S7^/=5\;I\[-MNQ!K0F2RTG:9W93J+N,X'XA_0?<;%W!=T3-MVH:BBP[CB#*SE5]fZ\%*.F>#-M/+!NKQKZ!K2V&U<>)4KN1MAGG!7Q9CB&H'ZD+X15[=K-"""R^-I$*8VUP%;'M*_E(*10@5V^D-}-E:ERTR408FG%=9Y9/#TB_6C@@VWF-47-A]!DPIW5W;&(S;V>,@G=IYFL\(>D)6>%^R&G>A"4+-M+V@21&5]2H5_+%XN(\$!JT$UKE(3]2D?F[_0P\,>VIVD,=5?S9KWLCP/MY?/A*M7#-S6(Z$VJP:*D>*-M,D?R!R^CU-EXA7N"-&Y77_WC\JZ#-A'C:D0P3^Z64:5%%@5IP>DZ89!!9;XD.-M]Y4"2-MQ-*C%1A%F.0GC%62T$L1[]H3-\BKSH"Z'.WS&X]'"^PC*7E5([M67_O+Q*4"M*V&6Q(Z8U*=H:IL*\VQ-MFIXUHE(5V6=H$=8AA&Z>NDM[SKQ4S$417[S0N1CCYFJ/](@))@(1[NZ*)@_&@-M+888TPB=!0=[])>1#-KM>3(D0GZ1$*]-M$-MAOO!\!*&@+!Z\IV-5B"_ZL19BF"-$

*M$H0]*C&!+13^*ZI9A3\/B>)PVI[,W1/PM(%Z??^]H3TCOJ'.4)?XI>>^VPK'-_M4/*'MHV@>*CD1?M,\==??"]<6(6P;'>5WX\X# ;.#\D-C+UKW-DGMSEK" KU MFWW9]Y$E1PHW8='YE@I%5/+'(,O/^/AR,*9287Y3KX'25PD)(1Q)FW (%IN MG>+$N82F"J1R.,G?KN39[>Z5_*A31O!8L&";M"H?5[\Yj% *_H #G.(8:G+*"A MZLS^=W:l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f[8H?3E?!9WW< `F+S&NC(ZGH%RTFOB<&-4?VH^O*)GHV%"!UI13, M7-#RU%YRIM2+FKAM.2HF9DZ,^EB(04L/-< M76BFR\1H NN0F24=SC">VCB[!/2)PI1:*GR':&HS?0=+G'[BLON"-OGLN#>- M@_GD@?S:!U LMZ@?T!QA>0/"L*H,S+Y17OC: IKH$HVXCW7/HF16+$W^,IW3D5UMLH="VJSG$0>G&I=1R2>YXZ@>V"*(FE;>4T\D BCD1OE$I.S=5X7'D* 5H] M'J5\H"?
@3%%>M3.S&R7(K65N)4@;M]I.WK>Q]#E!ZB&YWWCC#]$<7LD#FN> M>,'L*G8*]G'S#=U&*WD)KW-329XI.4N$K9QKRQ6"_C9D[*M$6]&."XK>RCJ MGS)A!9-<+P(]$;P"-KC[9,)%*,Z6RX!5 XS.)MM5<*[\ MGLHX)U1F>5,)+W>,^O#7_"L0HX:H#$5I.B?]f.8?,8+%\GJX7 :+2XSG-YI* MHX24H$-=3JU-Q@-($],-,FO;I3)35#\6RF:P UQLN6&$D_&8D5CL5T9FI)-MMUY+B3N1V958!-$2_S4U4N1YQ5EX?/B1B*;YR,Q',&^6'1>^?(GG50] M63N|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|SSB&-M*X;!$;@.(#B!CCI&-8SU;7<-.'!ZCXG-YK3<#>M=TAOF@3@U&C.%C-$IOOM\,!BA!%WP M,4.ZQ8S(L^,L8O$NM:\Z CM)PG4_UBP+,,#8RTD8.\,G2UGRUX["0Y,/#>\]f< MS!8TJE,/PRR++*[&^RLC+U=EIB5+%S_A#%XET;A=9%2]X2T<#DHK @N\+#MK4J\2=3_CW^H%@<";P5EC!RBN6"K$E2+1P5;Z2/SEVZ?MDL+]8ZB\}^{K}X_M],2[5?"XQ'A5N"R=(_M2@$4TX+FCT1]_RY(PK]W3? L/X*+45>9V#N38*NK=VH;3TO#^NNWM)P MTM=EV"';VY'26!%6#1Y>E*-E6%PIPF[?MEL23L4X]8_'D.C!../JTH\'XE(/ MIEAB/4U;-=@(F(+VJ^I8AYP04A"]HZP_+=M-S!/1;6G@>K#V&B^J','DQ>$ MZD9S("9'G8M7_A+Y\|&,/L[*J5PK)3P0(#P|_] BJT9QI-^#0=)2B=;R>B? MWM1.FAP"D88Y.PA\H>NHU,2)X*VG8],D?;4-*WI.K9M56[#1NL&F I+&V'8#W0+2G6WZ*==B-.*NY> M/W&'Y/U6[1>6&K5JK7C%ODO DT:?UJK9&Q@>^I[*^7/^61Y(8!511)<;)2 M=[RN#JE]U0[1~2M4=[RN#E]U0[1~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|Y>>O;+\[KGTD^C3 MT@+|*XI &PKW7I)0^F'U!ZG@)_$R^[HEO\A@R>LY?ZY;QA\SW'D 1Y%5IVU92'ZPX@QNO1,2/GK4RC=1>__UGZ;1M^JAE MM5K=1AX.D7 L2'V-I^SXDOR/&F>'L?'C$5;KEF+!U0?ZN6#R7XQ$)UE%/(L^?]W';C&1E4*.]5#4-I*A/[/@4);MU>2:QXP8W5;?Q&;.MU65]4.FGX8TT.S33[M_D+]H!ZA^\N(3 X^-02)0KQ&M&&R1:C8=)D?>F\MA'C!"\GX5 1.CNG[*6)Y M+\A;RWEI(7N9%F*YTNB(C? #&/]]8*,Z^,O]QF29\KXVAJ6K5M V7D62I03_" M,3F5^U]\MO#-XI!CY[R@X;.QJ9&:"_8\+QYER6.4PJ!1N+JW>O,CRB(AU4#8 M'S7O-0DZDVLDWTBP? *HG$D(O@4$KRF[,R919VSU;?=-4DZ1*=&SCL*#7[-2, M/7,+"/IA-F.U;<,;@RQ3$TM,G-5)"HO<"@ 7U8=(&-'9X2]M=&[WTP_+ M _.+,L^PDL_"@@+M.YNSG"&_MJ.B7'9PIK

+ZMEDZMASXC$!B+ /_+^&I9L^F$F)H!+L"V)XC#@$-Q4(A4;$ M0614PYJ0A^N;Z\N15/%W94&_#VYNAG^2B\'MKZHKTT6QI>33$P.4'>5I3@Y2

*MBD7)QS\9CNI=7QH>$QDMU;8F=^A"LfZA8/V'-E[\4)W0I!fC,!D5)Q9>9F*5 MJYP2MX_8/0'^BQH2\&K_C}(LY@R0'5]!FC0%G&"BH5!PKT M"L0)>;%)H>+C_?W0SNR?*

W=Y;\$S/_7M[^0R[O[KW?WW)_M""0))6,&UUG8C@:&\VP8^\I&2>%(+@QJ$?D^O;RL1F.9S]2(/;"D2C>>,1H M.E#&B;`^9YLL:G/S39KJGJ:(TE& U[CT"00N>$>F{V$[COVG*

MV2(7AF71ETC:[OSL^DDIGVON)YP\L;EXAJZ9@;;NV0L&$^1>-N8C<&9+1>-N@<4E]I\S/V1!^3+#3;K6Y[5VZ9F/VKW6AV=V+'C_EG-;Z3C..NM+F=BN M3>SDW+

*YIS+;QVPIN#"OP*G7ZXC3%(<(3SS.F M3/$S1\\M^]G18 <'C75&(>G=[S[^\7EX/QP\L!V.*0+*<4J5-1TH5PB.2'BP M^=1""A-0#S+3GB@)C$$$##5L5W:R=792-29H@0 JKCC5?*

0=TW#PS[N-F'$JP M>4"U, FG\\7#D9SBX?!9,0\,)H8&'>Z9X^!.!8-J-4 *AY(N]ENY@/3KMC> M:V#-SGF042@;YIO^*!A ?O*A# $D(&_%KX;K8B70S*4_HV#,>7;Q2.-6C*A M@#&]<"*

AVR015R,3(3VZ3)XDM_83G3.22AC%(XP@M;C9.[C/9/R29,:1G39C MQ=%F@XEDA4$K(34YI#8?E)L-#.(*Z,_E#$IH%T(]f)@X/LZR

*M0""D%XW)A>^XOI.3VU7MA#.54I^]CA,>F;2*7@QHK;F@]#!0%HH]9.05K,LX M9A@02]-6P8<@%"!,1K1<<-9HNFX[$@i1$*8T,#^P]_=P-!G37CLKBM\0/:4 M&T4C$Q,/ MYQZ%?*

_!S=]!1:NI/6KMR_SUP72_!6>O.$(2IP X+|R^:CA"G=T__U#;"'!7,!Y =U2ZM=%VVU(Q/]LFD 3K@ 2R": M@7"BY/+[PB3M\YN[EOQ:2*D*

MS3E$:N3J\MZR7S5BL;WYZ[LHM!$2@;2/ZV6\)\TQF-1R[LXUTSS6M86;17!K MR5;1(H)V.TIWP'+?;J['X+W"NZ6 MRRYBX.5B2BIO<6%IX60.2HX:2W?P,]N2<>)(+/AQ #/W&K*

'K"2W?,1A,9GO$4>WI(Q MDZJH\!=WS7=$IZ89)+.&GP,L\ ;Z\6(8QIY6MW#>?C'AlV+T&*XMCV/"M^ MOEP_3UKD)!CF?\S$$=OWS]Z=SD\RR+68:13H(#_C<)5R >$^+HS^^]2?*

RW MK79HE:)OEH@)^"P72,"A3(3>TVP"<'D6PUYCLG?)?ZPU=SYBiB,';9[CI;8P/+:A_THZ@]=0@Y$)A59"A='L5C S?K0|&B(NQOI#^5O:QV"\F++LRF%#&?A2,BC#NMR+HV/<=

M27$AOS%,I%IM2L.%TO1;,"[4WOBW13_=F69N-I]]+5RD>B[>%BK2/%)O"Q-S MJEEL)!4AH/L6PQ^-)UH9SKIO9 @S_AR,C-SN!4$RD35X;,=/VAD"<\lI4'E M_/P>;"GON?

*%E]_5@=F/BKY9EZXT:L(@/8M)6U:Z0+2L2L-R)6K+2VH*Q0 $ M#.QWY9W!'Q@*<-9[*2E9U"8=8NFI,74]BDVE&>CRE#HCNFV!$?S CH"PW%0(1 M4-%,(13M1BM'6.*

#),C9%FDWV@?C0W)P3O?:"VR$PW46_NS1@JD6>BFZ.3Z! MP.N9.WP;%\ 1A08;,N3"'"Z* P?^^ LRK9GP_1>1E-J4+9K]Z=C^XXR_;EE*8^55!EO\Q&!_,4PL(//(C?$R!

MR&32_F!N,W3\2P3!P'MS7"D1B,%"'^!H[ET?APM>A"Q?\D<#M"'^'>,WD@8?P MW^#FD/ $D>!6Q))$)CYLHB-B>QC=M2=D3+UG2M=/D]FD=8]H80>&, G%F,

(5H@QKSB$9:RVJR%] &?B#UB_!=K<)N%R!===$5!V$ MA[,)!$=.:P ,;8@"=3D5!",(s[VN)-K;B"05?:H5(!A{O)E+E LFT*_=H&A4L'D,BP?? 90!@<@<G>;AV$^7&-

,LA'#SG0DHK$O^V[5L,I9K0^D]/&^U^:"H-5.?F![GEP>9& M"BUVK/MR)X7PR^RM%##IA_D.P_&Z72W>[;]2@BC__4+K@E()0F#JG #SXQO79+*

*MVVPW!C]++,19OB)7KJ;>#"1&*AX)*B,M3WJB%R_;-E2#=DE0F17YTPG>?;T4(.M;'G2*'$0A-F]\,W/?=\(=Y3WX#6H6&KD3A*1VRN]!D*7 $UML;"]0_]BV[A*.M[)\T===77C[S#7C-*

C(M@EJ35YZ_S TC:#,.]PZAP.4T>TA MC9HIBTLGG1Y<,TV:<6=1\MFW-M)!#A/IK9O@N$[PI0XKCDX-^9PG34;#9=5?3AMJP<$T]OWHDN$W)"K%,N1&V M=HI[EMT2VUF

^L@["A(/S^_]E)("RM$T53V3AW27)\,1B'AG6&S2V$36S@V M>%6PI"',N_]D0_4IU$XNBQ)$-YH(&WID?YY!TC_H4@Q*IF.\QJRKD>"L@27U MDS%5MJ^0TY[73TX/>7 "#*&;*

{6R4OC=$B1'$"<41A&UV(#S-.(AJ0V<2%,J- M2+/#8/4'!BNX4#HRX@"A(&; @+25^LU&@ BJ Z=TC2=AZ+9E!>H:"DR&(O=) M0&C7G[BBRY#"&(X4C>[P$IJD@T_B[BWXK(0-*

*_M+\C0NF;-XA1#9)?1*KW* MMSI>U'E,]74$10Z?#>ZK;R(NQ6W:NZ#@Q_%;2>D>?E]0RZ7'1!F8(Y/ M]4PH6W&S;>*84!0R\K[^B KE')$9Z/;X"8], YEO^Z8!8*C;BHU*

*M0&8*XKHHD;Q"<[7D/0EHJE;-I(WI(??EPG>9[JYF4Y("^(*5/L'!5P;P9VN M*\]2!4FB&+C!&=.;5%"/ V8[E[P>&2K63Q:(7U;F1B!&RM1 Z#"'+;;FZ@Z3NW*

*M%DE]DC(PV.XZ_HJ;%RIHCAH!#!LW BH4H ,.D?N8073HXFAQ\O&%LI-G9Z#YW[=*H1'L] MS4>-RA!)B.Z4*P='HJZ?S4PHFR)U">17W"'"U<3&7@3@Q.*X98;DZ'A, C;E*

*M*8#_9K222(&+TZEA@C6'1Q&+^,6$!8W"1F@\;)H;_L(01W<&,0H\(#&TC@58 M6X[7L2T9&>U$@=2-UF?"F/3L&>]0B M[.1!XS6F=T/"BJ2&!K6:4 MCR0'FL$TRPKVZ58FV*

<3.IQ+#O8Y3DLV5D;[/&X7]9-PT94?]A,/A%9%_+ <=88!OK73X<3;ET.,@TTKRUQA>9&;D);8)>B3?+V*L!L3,Y6 M!2@=0.5M5H*

*XRS=G^":4E,;ORH6"4>"_KBS#4S]J6T:ESQ//FB)}MBO5Z3#5$ M!NK:?_Q;]!LB%1&OO=U$'Y_?&2|'X.ZWJ-7X%Q(SGZ!D(;?F1C-V\Z__ME15 ,4RVRTPM4*ZX]U]6#-(FLHI!!A>]9,*

*{G[2Q10Y(W3C%4LM.&IQ8S:KGS MN)51>K2211-$N^X_(T\R-(%P=DR-2$AQF.*42:0.1MO'#$%@0F MFR&K$Y:!W* 7IE*CK26T9ST;QEY<2@; O+*

M(^J$:!'N'A>^JFI242;0G<0IT_'@6!8G.YML*MI*O*KF$?B/QZ?)HWZ9,1 MNIA<$!+NH_|;YWD132)%BW6#C8LW1 M<(+&E:-2#QWXEJV?97CT'AG:1NXJC4#(FN!+U*8Z,3 Z-*

*BI!:9:D^V]G[&6WUB2[*47A*% Z3D2>1X6J0&E@ M^B\C0@ ' MG! SX+DOK8I==sYX:69&/)D2K,*C*U>,]'U38A,PR3CV=0E)%!*

M1LGWAT0P5VP05&T#BYFFCC!)0H7M4%WNCG2Y@W+..PIHWF2"WKPQZXQ,32' MT?((JAIHAY71\Y(ZWEDE^,Q0X2U-$R9!-O;[M!-#8NIV8;RAGL>>O8]CTF?5L9:*

*(X$[6J,9%0MZ Z,,G*EIDH&D:PK M2XLO*DH@Q4\N;-%?V3>#&SOOOX5OIXQOEC5?3 M;'UQTXILCN9$!,I_I8X+H;K<*L^EX5 NQYJZE)\)X7A,-%>);C+;MRAP@$U#6I M%P6LIDC#Q%,->G@'Z' J+8>X#-#YM0DPEJ*

*M2%JCK%8PB,/;"X8T'X#8YO 3X2N!'O7O#9#N9!] IN)OUU M$SD**JUE/ [K3P-O+0=Vf,%8 :,N7F!]MWTO6$1HE.%->L7\99,:+E%;5)!V M>:,^ZP&*^'@,KUMN\2@,;|28BH?)@;*

<,70*541PX7K$]_ZZ8/?;V56;5)^I2A M7&=R@+KFW$]]3K9_RK =N:\+'X2[%9[V7:DXH!-DD_0B@YZ1'$'G"]~H;@\X MV&?M43D 3A(+PX2+@98GVDE8'KRI@:ZD :9&9);Y.,&L2@*

*MCE]B7FI7L$Q#)'E_%>(!SR*G#LQ.%R:D OJ;GOX ;LV;67'K3'G;N#AYS:*, M'DX]FX?SEAIM@'.N%'-S.(A)I'X2>R*F]*.NNG!KTOLQ8 M$$#"J0P90!!%=(F$RCMS"XOD^KF(B<#?!K0*

*M@N&9W>BOCJU#^-;-S5=R,&8Z&6A$7LK D'*& ^]%#@42XQ+?TF68]TLDA$(II8 M/@(-+'=- %3_V:7F*1+JH8CPVI1W-D>@!Z)=D/=26@I\KT(I\,E>N>9*N-(O M=W=7?US?*

*XB37K_=WEZ/A/4Y8RV9%8F=V[TB)=NJDMQ8)O783)4=?.+8V><8F M4CWXAM*8F!S1:ZKFE7:1-IE#'S3&_7>/Y-3HN6"FR;[+G687M$AI,[!8%A/- MC\CE@)PUN\U6=C/1P/.L*

{3'5]+G2G4,Ul,7:@.$A.?_3C5>K3Y_#_',!9SG MWOKS/&3DVTS%1%L,<56L1XA"O\(Z_L^C8#.F]MS0![7EAM[7-I=M:)"I).KG*

M%XFVK42U/'NX4E2MSM:0\P$^N)3WJ*6[2U;UL%]QV:@DO1RR5:H8LQ"/N+4 MJ6!EC#L!\BT{ 47+658-M5('O?B_?8N2UA%I-[N]M6UWMTXO@S0M.^:L_]*]A "#S#-TI-*

*!JR55"9S110^Q*27+^Q)E\UXQP$*/UZW;12P M#+5AMBP4P#9;69%-[K@(1P,%Y N= "O'@0E/' H2.YTX*,JCG'S_?QOJP@A2 MDH'F.);W+]PRX(XC]QVW#O7%PK+D_I]+M:*

*[?!RAGSX6U5N*S^A8\| O6#.8.%9C*>)M!8CL@NV1+C?#IH M49&QWB>#@2$ZA#'>4\]@[8+0DPJW.*FIMM,9,K6URUD);B7?.TO<]B6$F M:ZA8A(3CKV(G"T;,%A/+H(K+L-*

*0=H(C,+V'>O*5R]9[2&)H&5L/K=P?' O$ M8B[3X>YM@;M]H@[U/#I<-LN)2@.:]>1;,O4V^?:BA7V\K'L9[!2\> Z8!&0 MB6 % 2Q@7()ZH2:W:WKV$8G<($<\B==A+-IZ)%.N[T!2 V-*

4['N>I7'$]X_B M5)W(QFKSX31(D.%=,*]LG>?%N!PT_ ^'9<"G,,:C$6D;"(FQ+4SW6&RKQ>OZ^-08S[V']3>84>P5$ H$Y5DMKA9"'6/X>^5E MAT%M="9 .;(_B+4SX>

(+X%Z1F1>58@(&Q#CR\' O>=H.JS1X%W$CX+'*0^&< M0A8.P8B.#]^(E374"S\B5KZ"P]JHA2>=LF8,OF$'(0U7FU'Y'S 'D*1&'$KP[M$!.,0^.RED5#_,:6&R\R]FDNFS$_#8ECQ%*

*JUG@V3 XV/HFJWD'4$L526Z)"^ M(LY,?%ZG2B3X1*U/HTTO)/RX7^$VISDDT.X6 BBW&5^1*W:2P4YBV!/)3A+L M(?N!G=(YVQ.XPF'70%[[+#!Q\!YC#@WV&;X)WTV9J**I9-*

*8F:6LM$17<=P! MG;],-<=DAQLGFF&SZ@^4Y@%I0$9KMS2]H[1W2P/;$79WUVQ1MHP@5X[>P.69 M1HY#[J&R*H2LBSUE]&V_W92"6N Y*S\NW6E0 43QCB9VER3Y7]`9'!*

*@>+@1 M@C]2+,XR:23CO:@!.:%%*K1,]27#]V2:Z;)>*ESI1D-_0^VTA(<@3*6E!R!/3 M0BF!3!H&2US;XMW)&=%F^K!0QM=I?@Z30XV%%W8(XX=HURJ"U#!W#+3%*V>>^ M%?*

*9F41A0$-B((.!.5US8')U0(/*(CNO[" + M6%G]>TA 0B-5P7.#NL6H 5 @*]-3IR6+.AS7C!2QFVJ,10RC;D(Q+'(P@YRV M74ON24L_C^$%FQ*0S]]0*L4#@R.?E H)LHQ-/6%T6P@S6*Q^.|*

*DD27@8(,'M10*AKI8WOV,B\>>@">(G8^J] +*

*4P?KVWNDH-_;_6:1TSZ@_|UFLU#;F/E M--=P79];T7B%=\VD8?HVM)-BKXH5?8>D90(66O90\&M0XPO,G|!4*N@+?V S MTNV/7?80S%\W;9?;#SE07AQ@XUN@L".X*9FNLF*

*8"@K<1*7R11L,7BK_H-,+ MBN9'5F2Q(C?ULP0:E3")\/$#[,TMI//!Y)$;]!LF2"5G@H.'&I2!?F.[+THU M;1QZ//4S!% FY_6L.1 5@5M,AC)MR0%!_"J22>)B.[!M*H.5SYA0AVQ|A2Q1 MA-*

*U)9!-2=?&49 WQ9=%8Y!8R(>X)=_O3 +1EAK(-F2@RBJ6UFQA+CXO*0L7^ MZ[OF.Z)3TPPTYNAS@!S^,30G"*5^=3XSN=Q/5P,:G0D.(Y[^'3<,+bL:[8WY_?>Y/XCUMMR8HN*

M!@3E.W3-##1YKO2Q!.S+\PMF=2J{3(#W8 %,/Y3GF7Q 4@>WFC[_$9N5,]=, M7&)A@6!3.$R9T[B0UUCJPMOJ6;@RK[(\)+0.IS$AH)?R M2.FH4>DEHP094)MP0CQ4C-*

GR5X=^\5%6GYOV<=BOYA(S4)^6XP7$R*KN2K(V#/-8.(]K>EGP%7MJB!BOP+7)HNQ5+&!:XKO0>=|SY7D MW==,C0A0D/DX@$Y(;TZ4,A60%YY2#(+404CBS

*M5AP51[KC]-EXX/A29)LGQWOU4AU?R8?O-2^U X[49VO&]*TQ,XVXM9*_9XP MSX8=PA%#YJIN2E+-D__UTT-9,)5DV"XLX/O\"&_]KL*1G1R0#/!H++,"&@J#?*

*M/69T|\@=75@CU.E$%_6U#ND2P2&'E9);YO3'"-Z>,Y8KX"YTZO$A_I]"5UJ:H M%48O>>]Y,*T:*\D@%!EVL2,XDSU1S)%\6M@0J M:]$1:4F\# QNR!A72DH=7K-*

"A96Y5\D144EUW#]^,DZE3BB7!MU]GS+^C[)[MU?IE\G"" M"B[8"['YI'SR1!M,0(7!6Y>IA4LZ0)99E#.@D+D2(ET,F9&A"I:6GL_=U/H1 M[\%1"K2KV27@'#=2,:I;/#N,I&2@J&PS\"X-

$D4TUXLGB>#PPS-*<$.")!/< MH, (A=OME<06',P,>1);YB%Z34[5LJD64'>#@]"TMHADR1EV+^T,2)^'KF* M*4(!PN;3Z;2JI.H$@D!]"&O-SEJ#3GB\U9GG22W(/^D-*

Q,NIC\H224:N0/ MK5U\$?#VTULY_E#L@BP70(1#[G\)-J&&Q&X>:AS<3=2"7FO"4Y6+!GJ6ZJ+=T M\F1N^U5[J&L'=;4=U)_LTOS3W4R"?DMF(FK"WN)W.Z89,YH2ZX:UU/,2*HQ*

*M4F4.$NPY/4%K@)?&###4E;I)N;GDCAIR M]F3.F4#?E@TY6SVA(69LR'D:RA&8AIQ,(M&W;\B9XN1(!?^[9IKT95OH*0[% M5.@7FO5MNV:RS!?S\3I2A@.3N*

*MDMC'0%F&\1>],2EY*6D@5&E6<1"!6A#1CAS@TGJ[K\ +J4311P'HP5$^[&'M:(73 <8@#3=ONU3,2.VPI%VX/HZ8VZN[10/*R7I^$I.A.&\W$YU&KR*

*MI7HLI[%&U2,)QKR_4=MC*Q491M[19V(Z6NXTVCL?E$>G M,,Z%;,P$6@"-30)IAPAAA%PXQN21$BXRD-O&H$$.F%8;T2) M'"%=92*!2+,:*Q4N$_;>2$:S5,4H7:9,^0=BDS_+8I-*

)A#!)@1S$.JG!]9@; M'B\ROK;:7W;#;:Q>82:QB$\FZ!F3VV2($C]77?\,EPB^232(D SZPH"WG3<@M!+F3>M USYM!MBL:Y7PO)U0/M .1 8O*QR;<|Z/#OY:^9G#/'=MTY@LI1MEW!+.2R>%-=?H,@9D-R^N76F(HK M=>F$H/B(:.Z'V")"HQ071]O1V[D+({][_+G3Y\G-_8ZW[^L':]6YK],3=H9D M8[Y.HSJ-^VZ,N>%MLO*4VL(NQ4I4* 8@G&//*]_'PK.0PG'A?4-*

;Z01Q]096 MP#2KB@Q022D$!)PJ&ZXU'R!P)6@[/,:.%?(3(9;M$<2;T\[A)A!P MML>;,0MXC#OJLT21&_9J6+&\S!+47MKAG,M.>\)[^\S_#G)&IK[G.Y1P31M^*

M9U^SN5!O@C$HZ^;+10V#X*"1(Q0L=%RO5ZEHN7PE1Vf)#:U;XI-.6.J %!AP_KT45 ZJ,N@Q+:E/\>G*GU^ LWGD9:-5R{$] M1>$"6LX$E.HE$V6Y<3R[_R8)'# *(+B!CNT5+"<$%.8.

(#2"U:\$50-.@ ,$G M;FG1&\)XWW@X;R ,))B^RXNL!A'!8(6?&D%(<%#O*Q@DY"DFJ4"5)/,_4Y]] M9*_515T^H2H5*RZ<[<8R72V;\XKUIG C="\25BHFA^ZO&*&*

[%3)"WR$@D3?..BDZ!],9Z/P(0U^U*B7;L:HE^OYG$Z@00PX/'EKM$?C MB9WDPY&%MLEB1|F0EVW8P',*1U/M+PQ.ZB-<7R:+T7,M1+H3,#0A<-*"?3">FK$RW6"E]-&8[' M,OS!

*+&LH5CC%']CH5#"\OO\$4D5U*A26@S\Q[M525FS'KV$IN1JUF*\$9 MA[><,(J7FU'+R"W-H'H.L?I_+!Q*[JN/@'$P+GX=5CZA K7MPZ?<4=HE:'XH MI>R*3C7?*

*+&$QLIQ7'H6QH/=E"02LA.M21M(!6)@-RV=#EPZ'-U<*OI.C%'RE M_"#9TEB6+D?-Y=Z'!?\$/@?>*=SW9K8#+=X]F!#O5/<|$;8\H29/[LKM),GG*

M(^\N/9LLJ#.UG3DQ/#>6Z>4&65I;U8+&"_%1+>A$PM?X3[.M5O*.YFDC7*5.VLFTU5 1W78>-2LH?I53\>*<[4FAUF//#\"$7%[QC5T$71$Y

MIAF""9&8GCT@"WR.H9ANCIOL5U&D]\QD(,$'\!6D,)@!:^X_I.3FD850*^_MA&)3KC!VZ?_Z>85[U*"PY_;GHO*Q"R^)F#.4@P8'EA"U]TQG6EF/JT+M9+B*

M0>1U&F%@;,4I4(LIH\Y<"5F16_(X9%]T+;L&N8<\P(,$ 1A!:I](7^ ?>|4$ M4? +9DD[X(]Y"4N#B8[HQS?$-ZY=;M:]K MA.#:S2RX"K41]F7$%*

*<74),BY9.W^HK'PD9QG(&FQQL!22,*4/XP>=F[5_YR MJ<1'9&+S6PI7SF%7UJ)%7*HLIS>Z>"VA9ZV>UP/CD%=+"=T?Q-2>!0UY]$U1 MK67,CA[$84(E&*

(=H0A)GG\.=/R(AOP6L73=1S63DR/'B%=G(5^IXR;?G'B9 M_#:>]WM$_NE/'OE19-.84)UM=EB:1K=]AW\M2M@\VNP\6_ H'TP6/CN4.AG;

MHA)-9$+A16R8.!GVKH2C"H$!1^MG!A5OC"<1$IK4_P#IU;!+BSSVDAH MI6AHI[S72T%S-U'9&0W$]6&0:ZC!-SW!$2;F_# 3EK=@$%PO'?M+,.()N-V5?

M'H57^U|!72N'L)^-25CEBE_A;L=UB/(7#I[(;_DG-P9CII9'BC[(GB\$ M#7SA,RB(L(@P.(YPTZ':X(7;?KF09X]%:+DHA#6AY(#]\6PPR8T)<2I_!M82 ML"H0 ?&P8(^N-*

4MT^R9& 8S$*$%BWLNLOW,{V";2!L2G&QAOD]T+@ULORB(,W'0DF M?ZS%;>SN\3@<V"83H^!O=]N/,/D-##'&]MLPOH*

*MSY>R@,O>:6H.R#4N$=W*V J9$I2099@P,3'84!<.9^OD0SY9%17% 0=$I)(P M'1"T30*D3E1P63B&I1M,]7.++8C>K^NAOIE2-&M+HOE-70Z]:R=6O9NK5LW5KV#*

<4J]!KXSK,Z"P[M'MMV)+IZI+=\#W_-+W=W5]N^J;?3&;&KN.V+-K/6'//Y?7#SV^#B9@A7_8%= MR'M^O57]H#.];,76!=/0* 24L7MHL#^8$I'@O7 MGS$*D+?Q7)4=C\7'-*

*)2Q0U0K(5%)5"IY'0CS& ,L82E!GDK>'B,H6$$F:64# M,)*9E'#4Z7YCV"P7";D^GADX=]M?$<0*PO&]4@a$1(9DY&>]'8GN%8] 7 ~A, !=O^$KX;:C\C4L>>B[410[%W-*

*0.L@!,ZAK>9AC#ZG7DY!(K,32B3"B=Y M(6$.QM!E4*R%@S)1FX>BTHXTKTR%K2LZ5W\DG3;+25YKH3<$_I 7ZO4G9(MSY^E7'[&&RJ?1O/S=G*J6G*CV!<@X81R#*

{3WL]!'Y!M3'H^(I4&K'"]KNX8 MB] I"@(M&\=D^^>9YKDV##QB?U/N,?G&%$S^F& Q/R' C'-RX6CTK>ACOF.'-MJMDP=FW3SUGFH&*1L2("CP?\%8\WQW#9L.+1YI?0JZR$0-*

*P2MC|GHCLJSL)-M785O.1.HK!*BB9>4J8R+:?5ZCCNM!=-'[:+BN+UK#6)X#43DN5&($WL;5#4*_&ZX7!/<$Q%"H:S3<.3X.EL5_M96]+.:1 6)?V'Y>Y2VO@B?*

*HIC_)2YU1N5NYBU)A5*S<58B*9P$H9$41?<6# M*F,Y^0/VRN!AUH0DP2IF8^_X1"7+X^E:0PEWQ$.6]YX=P1 M_^Z>ZH:GF2YWTGV$7^WP5M@!D_%6MA!+D.4/!"%:V!H:2NLK-*

PS!V@'THW(M1C"81!-$05KL-!\{/FB3N6%%HQW^MKR-2H5_Y"QHDKQ MQ?]X<%!>D1YG12BEEFT)Q5'.(&"C{!T2 M!6-B3*%L1.>TC6*

J$H#%N01ISU\N!W}JP[#.H.2\[F=@8+1AXRRBYQ91T M1F#RLF2-*9M\4%3M>$T3F#3;%;X,+W2C"CE9-!)-0/6^<+@IU M/&2S[Q8TU<K"\-

/B(44!K:\$;^6MIP3SAD@#++L6\04IIXA=Y087 ,E^M&5Q0 M@QZ4NLHKDJ!\Z?DD4@R(TAPZ[LSVS>(C I<5K7.:B,!C482X@AY%4,(5AY$D890T ~>!SXG PK:*\7R[IW9Y*

M,=G%1X:58%X# M\P?3L?(=@LI%;S%L?!-T5QCAGR@6^[(#BP!R*WUH@YR"<8BAZVD#$~>6"&T M\'GZ47,F)G5+, AEQ*'60L]Y^'%E\879_KG!V-*WRF9L8$,'BE>GRXAQ-K7G*

*M$DP/(KB7Y_@FLJEB <\-_#3RN!*(IH-MAPD(C]058IGA015:4?+9? &IBF$P4EP02.EXNUK= M60KGYR}_IS{(&;??L5WWEV[\" MS2@A*Q(RT6T?+%-*

*<=0C+Y9>B#!E0)HSK&QX80OHI?+1W!',P0URZ$#8J^-?+X*$.JAK'%8J6\IS^Y-X0=0,A4HH8R!:_M>8 90&3_J8MR8;,LA,2$$U\DZ^7"+BJUNXPPF1^DY&4)S*QR06R!AE2\@EW&*

M.>,^@L)1ECLY#^5Z+9<3)?LJZ5GNL C48'54CDSS)C!5F6@+ 6C"OA8.6UK4(+5XJJ6C)R5&)(:MT;B)&K2.+\O)1]1[U@%,*52#0M&TS![$\M$&H>ZKOE"7.I!+3)O%MA&C\3=*

ML,N^>/N^=T$UN:B_N+#)VO3!0=/5'"W-\O >>-.*><6C+R4#):R,:%?1*2Z M>M_8H> :0&60L5|[XK*7:0LA&Q9TQHH>A?#0F_I?9H%8R0U,C(-\92U/7SWQ@=K8ZTL>>3D>:G*

M>&.7!$JZ_IY!L5JGH^P*KO%#PJ5#EX7EB39FPIF(=-'/\3\AO4'&,^%& M=? M4,>E$TH6CF$[\9KQ(ETA*E"]'HD+=/"B'T2V-7$K^_!_0Z>V_!WA_I[B:G

MH7:0_,@.DL.4B&?!DTGJA?7??M.D@}QC2N[6JI#BJN\CST8$I*H;*34VWYB9-FC6 M5AETI<;!^/*'*/[#FNJ7]#?O@6-;$'A;XRQ.%2GQ(R L>>X]V](Y7O^UQ4 M2.#8-*

R7]9#@I?!OZX)<0T8J=;WC.\M\(4/HU>R"H>.+8;)O;8N23Q3RPX/2 MX3R#_2'H:|MN] X>#T-#$@_S6\8 'F@NX2YG-F;\(CP D3ITR%,:V_/D+] M(H^R1Z%, ;QK-#,<[X7]Q_9=\!%<*

=|S7'+P[YWF4;/9;#2;AU#N:$S!ON7 MZZGW3*F5"(V&]_-RPU!:2E1*8C\;3EAD*8Q@7QV;W&N>1A[@/= /EX${T]Y ML@4OHR0"&)=>B-8DIP*F8)4-1+'L02!2Z R;%B9E%LX&_Y?*

*GUV@E!(_;\R6 M6IT UWT?C6?"\(R4'KUOI&!4QR:T[X-1:WAK-RJ(&//7+8FH!$F4AJFOC%4 MB++0('E5!B-[ED4-5W=HE0*@]WU$>&1559"QYQ2UE+I(:TSJH Y:-!40TNI MQEDR*O:*

<|A]$ 1T8EF[ZO(BMX)LM'^0N.8/,443ZFF&:Q$8(W13=N%U^@S MJG\S#=>#PHA/QD0\H=N6%9B2 @--PD94E9#/W9>QC@=3AI0@*.=1!X,^R(&A*

MIQ4#+T4=5_!O5[*A5:#N M2*N41!C*-AK^?,Q=<-^&

MN1@.;\GP;YP4_C#X/R>C/K^R?SX,1_W0_.7Z870_N&4?[X>#T0-A MT+[>7_.1I[>W)Y=_M)S&MPTTA,B[_B#_;TW9?KT8C-*IHG@\R7(*9X=7?Y MVQ?V O+'-9O5@'R]&5P./]_=7WOXRN^^)//Y\O@_E<2Q"[JST_?3W(*BI M$;L#L?V,G7+YR*P[";MU-NS$ U#\"2/MQDERFDD3:=*.^C_K#9B"J!L>@Z&O M,[]>;"\:0IHT<)7U\CI*LJ@FE*&[8N2CCU51S^*"G?%OX3LW7Z)-P_.KU;BTA<@7'^W^Z&S"Q5!KB^~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l.[M$(DL|&NA|\O:MI5TZY7OQU%TBY4;8$W1,N0V<2U$;!* MVU'\2NI,S^R*,_S(YKRST+!%(_FP>.C0Q\UCY(#S31+MEGELLPUMS.-:0VUNU_-W(:MZUK]1I__WTGM,:C!\8|11TZTFQEE4D4S4>!=%W6IBO"MB?)}#%M=VE1UVB"F> M&/>VIL:5K.Y6D^0=DN1F39(K0)+;4FNXW!^_FXEC;0;>[MB%4:#?*M"\4 MNJV|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|>" 7P^$M&?]M\N:WM*.;KI_N[++V3T^?]!???Y^N)ZQ'Z_'/SV,"3L3_;MQ=WH,[F[&Q'VAN'!]>"& M#&ZOX(?1YR$9_?F5_?-Y.,*?[H>_7#^.[@>W!,/|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`GOU(O1F;I;/AS8@8>$08 M3M@=G_B:,;[PH5"V1'@=S98%9G\G<LNX Y<XWX8OE:] M^PZ3C)#^H$>'4O#(@IL'7J/-;>N1A),^(DO^2#C/.XH<0>+6N63JV'/BI=-:* M/%O\=Z$YW@L\XU#VU0$\G 53?"G1A_!?'P*$$5U;&!X[RG#]!#; 0TC&OD]J'OJP.C@U M.^LQ=WA4B+-+H7MG%(5C5]'<\V]MHS=Q2M+I)^G(*;_)$4L*&FMC G#"BU7 MIR)6.T58GAD>Y1L$,NVSHRT8G /M2*:V(IR:#'!V MA+!3SO8_$LK\#6\L4!-;PER+-YN1HZEI/X?G8-7&MXD1*^,3E/>%*A=C$D| KA <4A(>5N6YB#D.DE;H\)cIXG^IVRV(*1 # MA_ZO;S@4:"FC 9KEN81^CUD]K)H+Q 3(\"F7H?%ZC7514RWB]1>4MX3+XZ[OF M.\903#,0!:+/0GCGT/G2&J1KKQ$(NDGB;E)P+/ +TF\>M?4^$XG\2T5DPK= M0CS^-0K>"Q3C9D1.I."^K79%C@R$D\[# U<}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|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|,:/*E#8\]J)RI*^"ST3(>^,;)L3#F^DGF.]]Q79J>8C]*6N MN;F2DXL9PBV5E>]]]+,D M!O#PJ%N%KUOUVS&AGZN\ (%08.(*D^:T4!EDS7%X]<&*.@M4,/#'5I(2CTNY+ M=7>;D93-*]6TN1:ZJB1);D^64-S3PZAD8!:456KQZR_0EFWY.BF,> 5(G ,7 M!P7TG"?-W%1$3PDII7+&*MKR=>Y K2=O:U.4$"C-3"9:O@8X9;1:ZI2 ,=0Z MYE1S_;!H:@Y@V5LM;=+HDSV^Y?IFP;_5$7)1#K%V8$'M\&.<7:$3,_CO(5+|-M\$D.9T)UV^$]5J1";_*O,,US7EH9_EKY61C(7-LTH%KP$LA:LYW-<#XU[>=0M$%DMK+6I_0S_ZAAN9O+[Y&$.<.L@)."^@8\6INX LDIF%[_"Z0D$DI+2K-D MK%/I'LO9;>"[JX'154CAP+NIVY-5XRX[Z]H3XS7;F3)0I:*-3-WJ%SVG--):MVW!$>&CBQJAN=FM4DO=G,D8EAV#CD)#6*$G2BG<##=X 77)FHI,MEXS+:@,3 MKU'16NS0R=2/2BOOV_T!N-9W*D4%_916ZQL4R8)@^HV9=(`WNP$-0+$;]0-ME,<:5>4K>'E,>'XM5M)-SH32"M.D.GS;RCZOM]#OPA?&7::WT$|[T:M$A40H1*I^+&@^5.MZ(^VHD0E;AM/1T] M.BP(&1UK">;-AP?*X9EB<]HORYC7#]!E&S3!JA!$F@"T%@=2,&XT*QOJH!OR1NA;]DD17PS*!E)N@1H,(42)\'D5'B!TJ?#S*\7#RM F74!YIHWU+RAY@U9>$,W\J17E#<$;8B1IG]%6%X'>FJ[SZVFO$X@_@*$LW M)=G#U\'GNPXBD#S\$RC3@ 2AY'+)R%-#&3B!-[%Y.\/Q7BK*%3>=^,U!7Z=A M*&KMR;X]V>6?1CD,4Z+(K\&5FA<+;Z#X=#/J5'SMR4[0]@TE6UY5T+RD.T511/=+$PRMU"0Z>V?;-])-F/<#*IR)*7ETQ(2K]BNKZ23SPE9UP;KU^_)I#SDMALA=53K2IN,)7M*_RUPOJZ$<#YYGN>_1MFW^V6Y*\.O|0HEZC8=:.+]945FU8PSHV]DL%V_Y:V@ MOJA&+&W.?KFB7!?ZWV9_ O% ==]A:A%U_S'0=7!NNJ!!:)&6D;16K234W9),]=7R.#'K%?$S#3CPO=`V,UA_=^@-P9I=4YSD9*40SL M5FU[*BD^=_+Y%\TYW-M0R)Q%@Q?6ZYG>#X<3IQ$$=]SI"0B;M,M4QXT#BZ4YJO=ON1!J+4&B)O!"_-`MYER3P.:M/Q]3!f.J?C\^[C)?O*L6$<54#(C/ 79C MDHG)6-9_%:-@=!K-+)P@!]V/5;-+Q).?!2%XA%OTP-(^]< 3!+:N<(H;PA] MF]DM7'H>_A%?!#AV P/;?/O.GK4|=ERDV/6E7?#8B1RZH]@>NZZV[YUKOF<'`M-_6LTVB?<:"ONC#,?F:/%-MO=/2/7OQ)N8)"U8CI\/,XUH.,92N?=)MM\D M-CY+UXQ&]U&>;5 ;-[*?^&NU\QSYQCTS:^UER>CIVB 14MZ6<^W!6:.X?!VM2M,?,YS5>/P<:.^%)U*4Z"8=X1)/&<[HD#MF@)E1?.KI4"IB?@R8$!EXI!4K+!]0 M4%.@^-6(EV;8B@)U:@J4%/==P,CWXP!#O4;K_Y=U M^1'V(]Y>T4+_+]XKL/W\^,S=KO3.6DW._U^L]-J]7KM)BPB%7+:W^GW5G/2;C9;C7\N'L%;Y_WUW2^- MMI@9^KNUDY!>&Z\!9DL"R]GL283)EA*EYO'27M9QZF]=&J%$67_ M&-OV-S;@6S,(`D\):TX-`$Z_LE \LQ]@Y,NXJ Q(+?:H;"&G)DO#5!%6V. M%>' 339OK(C4>3<:4L"M" MX-03.,C$-;Y[+R0X:>2@W_S+(6%KA0F(C2-\,^ [-AFX/4/$ &X8G),-]A/+6H44B OOI0$QCGPM=%%R,<5EN$O6&!!E3O%TL=YAETEY$>RZU6^>GO9.V+^-_MJYA6JBQ8["!JQ$ MXW),UAUN9D=?7#Z<19K^6-._/3JV;TVD(%W=)H#"';^S#\D?0NND)'DU159F MG>42A&_XI-&/S_.!<_BTT8R2:GC#LXZ0J1^9?LVNS+=C?FO.-?.9W=% WCWM M-CIL4,"Q%M_)LOI2&^!9Q D7M9A&TDDMYK$JN.MO3 MS95*\P_"T,CP?C2XOB775\/,T?6GZ^$5N,[]=-'?_93"ZOKLEGP_';%?OUT?_>%C#Y?/["O/E!?7(_8[Y>#WQZ&A(WN)OKVX&WTFMWW)#![17\,/H\)*_.O\)_/@\&_-/|\)?KA]'IX)9]O!\.1@^$0?MZ?_T[M&TGN[LGEW>TG.;_!32.Q+?Z*/|C3=U^N1R,VJVB>##)?@ICBU=WE;U_@"\@?MUVQ6_+U9G Y_QW67A%L M6%'!3V?+C/|FKYSXIU97B/85C'I]-SIG&^*?SC"EAD[!"E>9R)RM&Q:=-*I3 M.'A>9^BSIM;/5VH&.<@A8TI5U@~)4[60G8=TIM8|*DU&LCT'-2>V+4R(RU!) M0)|.:V -8.@"#!E.:TDCLIOFL%9K6:B9S51 M7!%>H].I'A(|%!^R#Q81"UPX;72[KY1%M)$L_L\ADK57,S"(E:K8*@Z1A. YMFN5.F13XWM5,ZKZ'C;'9G^Y[AWI&CM8.V*KAER!^L4>0|&VA5^N1"%44|_PO4[.M6WO]JJ+1KD0:J 26I'9JT6>:<0ULE*,AN=@NV"K<&W=2,.4I)5DY+|'Y'+E*/M5W<=EG9'YOG;"O$HV98:ATI,29TN>+DMTP@>>$WE8F..$L&1C/^LC4)!9L.M)ZH_(GMX"KBNRI+M>PGFP36U-R.BNI4T-9O-1K-Y6%$I"2E0!RSQ.:L J1(*C=[=<7VNN!R3*OGU%VM2_E^O+ZG#SO%Z7'U*WC5$4N_LM=)M]?Y!L+,&\ M*MQ.=C6/^R3R@H9KS9^1@%#I^S&EY{&UCY-.+#U8=UB>@NLB(E:.@,9 F!) MYF %-#23!#XKB%"$8#Q=6_ J2?_B+FPB[E\LFI#8#A^OA06M<7TRU%*RK!/A MI.J[!07GNU*ED.-D=;_PM624Q).#U(H+4KUK;;,$ XFA>*3I?Z6-3 Z[5@84MJS?]A;I'87POT>I%@\;#9MDQ=7U|%CNK<'K# P\|QO"E&Y+$G(8-9'\K MSCZK6+\ZXKXF^B%*F2Q6C#RKF71I/=^+M>-W0GVL&M(93HCI"U_'3N287F7E MF%CT9ZL=-_9T8>MA/W56D&F024P;*ZDORDMJPB.6^2QZD-J]*,3(.=#[51 M$FE.E181.FMP4!.:^X_J:TG.M[XHR'RWQ^//.T)6I=24(7)+L@96X(I'HA1@B M_2786$HT-TPBFI#Q"Z3%,F^!FJ^3/21AJ4XWT?CU2M=5^4&FH-K;?Z#D.;0=*[\))4D##+3_S M7]Z< .&6<,/EY_O;@;WJ)C?^]O+ M7W%N?4AYO+[|\76NLZ4?W-U_O;OG29D%>]Y#?>*Q<5PN'TD[/=TT;S)%$(MJ-4XZV0H!-O^8C;5]HTSUI?]A0"F@)/.ZLRU(+* "JK@4SE(-Z*2WLIPB M*P(U5Z]!-HWAX]5(F@%A-VRWDA.#[@^I/%AJN5*W^L[8ZKO58B@7ALNBFGV3-MD>&9BMWCFD*]@7DV*31.RMT_UZQ@')610%EK5Z934#IKDHH*G$_3S#F]>UE MHY8SULH9K6Z[6\L9&23N"H@:]IU:U*A%C7H#:U&C#%M(]24-B3!'PL;5YM%S M4E^,S!>CW>1"RP]U;U"U:]*F>025XI{]3HG=7H-09%NAK=7PWN4=RW>W^^W MAV'NL3F;6=[=WOQ9C,^MW>A4NLKS.B6=1;B\YIJE%UJ"$E(9>+!E>3\FE9E MIE6.BI>+157*%P6C.V%671 9#6RGEKQWO^?=']M=U?BCV5*09($W5#I:7KK_W MNCQ-9VD]8!CN]&+6VW,#I#O">M:OW%R&M.X^X+;;;(@G/3ZIP58$/HAC569 M$+IH$\+RU7$;0@F6!":Q=C(9$_A#O\,K#3K)8.F2 ^FCXGY7_=\:I/C5]/5 MKVE@30-_8]Z^S2_YE+[,%**XF[^,!GN]B;UBGU=BNI5-&,+TH\)0#)QE[M^?HKRM>3]B?U)B;5K5LGU*T3EDNH6R=L<;7JU@E5:)VPNRR\M5+DOF7;5&MS M[!M,#8PLSOOI?S#\SHN7XCL@+{IM@'!9G4#D[6X[RW]S9BE.#.#+O/@[F-E-H M12D,O%LAFS^":5'ZC$Y\D[!H$)V,$*8VOC]'YNF/J#//Z7-1OW00V)NAW*E[M5#&TM+*^_:PL\+Q4MC;H>Q:43M:Z$&\+,JD;)H2+\=;$_X 1?B2:>SS&&, MR/B!2XOH(;'Q#"8Z.2Q:K5((U+6B52M:M;+U>A2MM$O=:E?1.K>W666,GMG# M)%N*^TE:IR>-<.ZMTRBB1A(&EC-?(W;R^5J1*6546EHOYCWO/GXRK/^_MO?-M3EO7UOA7\?1W|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|-2VBZMC6;*?:;@:OUFR6;*93YD)@,VF9+.P-".FZAB&9C#?'EA])\LEFYF560#8 M;$DV"TLSZ3=+-DLV\RFS ;#9EFP6EF;2;Y9LEFSF4\;N 8C'9D>R65B;2;]9 MLEFRF4 ^9"X#-KF0S/)K!4B/9+-G,GK?!?'L$A#/2)9V%Y9F.;D@Z2SIS@@U$ M.]#.#1279])WEG26=,;=O{"G65VH+@\D[ZSI+.D,R?8(*0'9]XSLX2SA+.G""&D")H2C@+BS,Y(2CA+,';"6<(.M.8*6A+.P.)>LX2SA#.GG"$D"=H2SL+B3'K.$LX2SIP+'2-D'3H2SL+B3'K. M$LX2SIQPAICZ$HXP\,9+1~#425A+../' &D2*H2SH+RS,9UY'1EG3FI#.(%$&9 M-(R@N5Z3O+.DLZSF"ID7"6<&;G&H0D04/"65B=-N_CX]N';;^S#Z-IK5^TD\//T93:-^%$>SA_HH M&@[#,?W&7W\X6#=.WY^DG_Z0E?=5RX4T-+\/\QJO2HF>K3W68@RCZ5TK!@$?/6EO\>31:GZ@>#[]\FR8_QL#9(XF12-M_T//_CL=Q&$PH;=B-CI=/S O(:977BOQO+PU^159'76=W6+&?1M3VN3[#N.IJ/E6[1+YU^Z"[Z%M?XD#+[7@J^T9]6#^YXF.[!NT.I3+_43R;#-M<%++W]/3"]+"%])N@U_S(TC7_UP 8;48B[=6RW&73*-9E(SKDS .9M'/\.E9MU\MY2U_.Q5\AFO2=E6:"C3G7M=OM-I^J^CU_=9%RVLJK?9%WO+\%N=MG+9 MZ"EGGM=6O`:>7WUJ!J,7WO2MRI99RZ?'SQN?>I\" Z3OGE7\2Z7=-M\15Z:[_;.EPIC78S/>!?>HK_Y8;^NFSXV:NN]I'5\[N--GW9]11^3Z%7N^FV M/M-O*VN=U7QV9>L/->-.[C^4M.5C_?1?[!JZ'W?V-SK55MK_-MROU<:>&/&\RFEG 03N=Y\N(C&P7@0 M'NOR?*

P6W=Z?'NGCO\YG2N$VHJ_J?(6)XJ>>7G:6 S4?@VBZ.6\^AJFY$(VG M-Q@E<3#9M0819PUVD\'W7:^MLEL1+CTR7/?EKK=<7 W#>N+/U9+

M;=&3S)W/U'D9T".4!:\]4.UU;R=TMO3TYY]&N<9BP4'38!E9KVA>N5A"+_ U M3NX7U;5X7;N?!'?UW,^_IXI?]+^7QX/^-(E_S,+3U!77G_C=JP.=PE$$0l.= MJF@E%;JO%=-*I%;1552MC#-3;!WW,#-3C!.@K%;E<'L+L\],B7S#C#FE"PMF4=3<2B^HJ%E!+E$-W=1,]VJ M67VX7[645]JL6, ^)V!6&>E$[*L.'#,RGIS*!V@XF;%4'47:V;EX&IB2R78 MU-RG3BMPV94V*^9;5 *>66'TB84T*RXT*YQ:&XMV.Q^VM|(**VQ4JVG$U!U6,,#8=GF)#0V:5E%?: MKNC PV".FR^.:5#<>-[?2"RIJ5G37577UMS*!8.(@56"D6;(Z94*:3>@+P:# MD/2-X9B5BBX&TQU=Q=2LZ)5+72'(4"VL:T;ET%HLP)],1B$=`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|>!8:,WO)ILJ9Y[45[Y_G5Y^:I.A% MMW.M^)>M'GWKLG76\NGQ\|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{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f/>X&?]UNG[OU2M?VV-#W]+_T7[*]73+FF7F[YO7RRI>/74- M:3JQ3-VAQ%W= 6>1T)S/G+W9\/7"0*?=VC%9MOU;I8:5BR7T E_CY'Y1@XO7 MM?M) <%?/]QRZI[7RXEY R^-!?YK$/N;A:,HM4%]N]3V 5C==8MCB#.']:#6W M @V>5]-";;A*6I%5':TP^BOCOL!LQNL6PL/K[8:_K6*'ZH@M2U17BLW97)!Q?Z\TD&@^BNY5M MI0!W6&\|?-),:Q.Z39W?CIQ/=%X1!*LBN#<[2GO!K"]XBR(TPTCN6K# -=# M=G:!Q*N,';=.YXV!,9I066<20?%RSI?7,-;I&/3852+<@U56;+@(]5.@R2"< M/NT3[I-]1!!ZV(8P2.)\131^>44T=C2QJJ FWB\1%YI_D@]%VZC(X)LX5 A M6 \JT"RV/=&F_&%&!""&F#VUV0 0<-CMP4D"AL,>FA91=6QKME-M-0*&\O@>_MK5R>3E-^-C.I@*R&4LVPZ,9+=#62S9+-S.J8@0FPW)9F%#IKLJ(40CI-IJ M))LEFYF5L,P>@'AL M=B2;A:69)]FF7%Y0?

0001727196 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001727196 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001727196 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001727196 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001727196 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001727196 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001727196 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001727196 2023-06-30 0001727196 us-gaap:USTreasurySecuritiesMember 2024-06-30 0001727196 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001727196 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001727196 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001727196 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001727196 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001727196 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-30 0001727196 us-gaap:EmployeeStockOptionMember 2024-01-012024-06-30 0001727196 srrk:CommonWarrantMember 2024-01-012024-06-30 0001727196 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-06-30 0001727196 us-gaap:EmployeeStockOptionMember 2023-01-012023-06-30 0001727196 srrk:CommonWarrantMember 2023-01-012023-06-30 0001727196 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0001727196 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-06-30 0001727196 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-06-30 0001727196 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-06-30 0001727196 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-012023-06-30 0001727196 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-012023-06-30 0001727196 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-06-30 0001727196 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-06-30 0001727196 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001727196 2024-04-012024-06-30 0001727196 2023-04-012023-06-30 0001727196 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001727196 2023-01-012023-03-31 0001727196 2023-01-012023-06-30 0001727196 2023-01-012023-12-31 0001727196 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001727196 2024-01-012024-03-31 0001727196 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001727196 srrk:AggregateMembersrrk:PreFundedWarrantMember 2024-01-012024-06-30 0001727196 srrk:PreFundedWarrantMember 2024-01-012024-06-30 0001727196 srrk:CommonWarrantMember 2024-01-012024-06-30 0001727196 us-gaap:CommonStockMember 2024-01-012024-03-31 0001727196 us-gaap:CommonStockMember 2023-04-012023-06-30 0001727196 srt:MinimumMembersrrk:LoanAndSecurityAgreementMember 2022-11-10 0001727196 srt:MaximumMembersrrk:LoanAndSecurityAgreementMember 2022-11-10 0001727196 srrk:LoanAndSecurityAgreementMember 2020-10-162020-10-16 0001727196 srrk:AtMarketOfferingMember 2022-11-30 0001727196 srrk:LoanAndSecurityAgreementMember 2024-05-172024-05-17 0001727196 srrk:BinneyStCambridgeMaMember 2024-05-31 0001727196 srrk:BinneyStCambridgeMaMember 2019-11-30 0001727196 srrk:LoanAndSecurityAgreementMember 2022-11-102022-11-10 0001727196 srrk:BinneyStCambridgeMaMember 2024-05-012024-05-31 0001727196 srrk:BinneyStCambridgeMaMember 2019-11-012019-11-30 0001727196 2024-06-30 0001727196 2023-12-31 0001727196 srrk:JingMarantzMember 2024-06-30 0001727196 srrk:JingMarantzMember 2024-04-012024-06-30 0001727196 2024-08-02 0001727196 2024-01-012024-06-30 shares iso4217:USD pure iso4217:USD shares srrk:security 0001727196--12-312024Q2false00799920687597949 5http://fasb.org/us-gaap/2024#PrimeRateMember10-Qtrue2024-06-302024-06-30false001-38501SCHOLAR ROCK HOLDING CORPDE82-3750435301 Binney Street, 3rd FloorCambridgeMA02142857259 3860Common StockSRRKNASDAQYesYesNon-accelerated Filertruefalsefalse8003262393372000101855000971220001780830008643000825600019913700028819400035490004600000179750001141700024070002407000379700044154400920000-791782000-67642100013362000022521800022686500031103500042373000268670008546600056602000171250001221500032451000229890005949800039082000117917000795910000990000115700025560002287000-58508000-37925000-115361000-77304000-0.60-0.60-0.47-0.47-1.20-1.20-0.97-0.979681311696813116801179838011798396352858963528587986542479865424-58508000-37925000-115361000-77304000-4000266000-146000821000-4000266000-146000821000-58512000-37659000-115507000-76483000759794957600090147100092000-67642100022521800-142000-142000472932800002800003603733357493400061020006106000816400008164000-56853000-56853000797446548000091601700050000-733274000182773000-4000-400066174700047000240797931200093120000-58508000-58508000799920688000092537600054000-791782000133620000516725795200077169900088400051063200026023500055500055500068696827000827000287062430002430002193786170000617000020002000-39379000-39379000519893595200077894100032900055001100022865300026600026600055059410004395000439600053333292000292000273035229346620002000681800068180001000100037925000-37925000055159787550007904450000-63000-587936000202501000-115361000-773040001096000146400013500015700017476000129880003236000256300028930003658000526000-1571000-620000-117000-150000-9500001456000-10516000-3280000-4144000-104000-82000-98981000-756040004500071000130006844900010520000015250000018000000084006000747420005223000610600080000466000539000300064920005765000-84830004903000104262000105773000957790001106760009451000333000030900000 1. Nature of the Business Scholar Rock Holding Corporation (the "Company") is a late-stage biopharmaceutical company focused on the discovery, development, and delivery of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. As a global leader in transforming growth factor beta ("TGFβ") superfamily biology, the Company's novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. By targeting the signaling proteins at the cellular level and acting in the disease microenvironment, the Company believes that it may avoid the historical dose-limiting safety challenges associated with inhibiting growth factors for therapeutic effect. The Company's first product candidate, apitegromab, is a highly selective, fully human, monoclonal antibody, with a unique mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of spinal muscular atrophy ("SMA"). The Company is conducting SAPPHIRE, a pivotal Phase 3 clinical trial to evaluate the efficacy and safety of apitegromab in patients with nonambulatory Type 2 and Type 3 SMA. In 2023, the Company completed enrollment for the Phase 3 SAPPHIRE trial. In 2024, the Company announced data from the Phase 2 TOPAZ trial extension period which showed patient outcomes at 48 months of treatment with apitegromab. The FDA granted Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation to apitegromab for the treatment of SMA in May 2021, August 2020 and March 2018, respectively. The European Medicines Agency ("EMA") granted Priority Medicine ("PRIME") designation in March 2021 and the EC granted Orphan Medicinal Product designation in December 2018 to apitegromab for the treatment of SMA. In October 2023, the Company announced plans to expand into cardiometabolic disorders and advance its anti-myostatin program with SRK-439, a novel, fully human anti-myostatin monoclonal antibody, for evaluation in cardiometabolic disorders, including obesity, towards a potential investigational new drug ("IND") submission in 2025. To inform the development of SRK-439, in May 2024 the Company initiated the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab to preserve muscle mass in individuals living with obesity and on background therapy of a GLP-1 receptor agonist ("GLP-1 RA"), with data expected in the second quarter of 2025. The Company's second product candidate, SRK-181, a highly selective inhibitor of the activation of latent TGFβ is being developed for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies (referred to together as anti-PD-(L)1 antibody therapies). SRK-181 is being evaluated in the Company's Phase 1 DRAGON proof-of-concept clinical trial in patients with locally advanced or metastatic solid tumors that exhibit resistance to anti-PD-(L)1 antibody therapies. The Phase 1 DRAGON trial completed enrollment in December 2023 and continues to treat patients who remain on study. This two-part clinical trial consists of a dose escalation portion (Part A) and a dose expansion evaluating SRK-181 in combination with an approved anti-PD- (L)1 antibody therapy (Part B). Part B includes the following active cohorts: urothelial carcinoma, cutaneous melanoma, non-small cell lung cancer, clear cell renal cell carcinoma, and head and neck squamous cell carcinoma. Safety, efficacy and biomarker data were presented in November 2023 at the Society for Immunotherapy of Cancer 38th Annual Meeting and in June 2024 at the American Society of Clinical Oncology ("ASCO") annual meeting. Additionally, the Company continues to create a pipeline of product candidates to deliver novel therapies to underserved patients suffering from a wide range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. The Company was originally formed in May 2012. Its principal offices are in Cambridge, Massachusetts. Since its inception, the Company's operations have focused on research and development of monoclonal antibodies that selectively inhibit activation of growth factors for therapeutic effect, as well as establishing the Company's intellectual property portfolio and performing research and development activities. The Company has primarily financed its operations through various equity financings, as well as research and development collaboration agreements and the Company's debt facility (Note 10). Revenue generation activities have been limited to two collaborations, both containing research services and the issuance of a license. The first agreement, executed in 2013, was with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson and was terminated in July 2022. The second agreement (the "Gilead Collaboration Agreement"), with Gilead Sciences, Inc. ("Gilead"), was in effect between December 2018 and January 2022. No revenues have been recorded from the sale of any commercial product. The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company's product candidates. The Company has incurred recurring losses since its inception, including net losses of $115.4 million and $77.3 million for the six months ended June 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of $791.8 million as of June 30, 2024. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. The Company has evaluated whether there are certain events, considered in the aggregate, which raise substantial doubt about the Company's ability to continue as a going concern beyond one year after the date that the consolidated financial statements are issued. Based on current operating plans, the Company does not expect to have sufficient cash, cash equivalents and marketable securities to fund its operating expenses and capital requirements beyond one year from the issuance of these consolidated financial statements without receiving additional external financing, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern. The Company will require additional funding through a combination of contribution from revenues, equity offerings, debt financings or other capital sources, such as collaborations with other companies, strategic alliances or licensing arrangements to finance its future operations. The Company may not be able to obtain such funding on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any such funding may adversely affect the holdings or rights of the Company's stockholders. If the Company is unable to obtain sufficient capital, the Company may be forced to delay or reduce the scale of some of its operations. -115400000-77300000-791800000 2. Summary of Significant Accounting Policies Summary of Significant Accounting Policies The significant accounting policies used in preparation of the unaudited consolidated financial statements are described in the Company's audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company's Annual Report on Form 10-K. There have been no material changes to the significant accounting policies previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Cash, Cash Equivalents and Restricted Cash The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of June 30, </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 108,064 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,407 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,612 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,779</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 110,676 </td></tr></table> Unaudited Interim Financial Information The consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). The unaudited consolidated financial statements include the accounts of Scholar Rock Holding Corporation and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates. Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under previous GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. In November 2019, the FASB deferred the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. Therefore, the new standard was effective for the Company on January 1, 2023. The Company established processes and internal controls to comply with the new credit loss standard and related disclosure requirements. The Company's investment policy has primary objectives of preservation of capital and maintenance of liquidity. As a result, the Company typically invests in money market funds, U.S. treasury obligations and government agency securities. The Company believes that such funds are subject to minimal credit risk. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these investments. The adoption of this standard did not have a material impact on the Company's consolidated financial position and results of operations. Recently Issued Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2017-07"). The standard requires disclosure of incremental segment information on an annual and interim basis and allows for multiple measures of a segment's profit or loss provided that one of those measures is consistent with GAAP. The amendments in this update do not change how a public company identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments, but rather requires public entities to provide in interim periods all disclosures about a reporting segment's profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for interim periods starting on January 1, 2025. The option for early adoption is permitted, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures in future years as a result of the adoption of ASU 2023-07. In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which enhances the transparency of income tax disclosures to provide information to investors to better assess how a company's operations and related tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This requires public entities to disclose additional categories in the rate reconciliation regarding federal and state income taxes, and provide more details surrounding reconciling items if a quantitative threshold is met. The effective date for public companies is for annual periods starting on January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures will be in future years as a result of the adoption of ASU 2023-09. Cash, Cash Equivalents and Restricted Cash The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of June 30, </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 108,064 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,407 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,612 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,779</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 110,676 </td></tr></table> The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statement of cash flows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of June 30, </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 108,064 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,407 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,612 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,779</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 110,676 </td></tr></table>933720001080640002407000261200095779000110676000 Unaudited Interim Financial Information The consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). The unaudited consolidated financial statements include the accounts of Scholar Rock Holding Corporation and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates. Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under previous GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. In November 2019, the FASB deferred the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. Therefore, the new standard was effective for the Company on January 1, 2023. The Company established processes and internal controls to comply with the new credit loss standard and related disclosure requirements. The Company's investment policy has primary objectives of preservation of capital and maintenance of liquidity. As a result, the Company typically invests in money market funds, U.S. treasury obligations and government agency securities. The Company believes that such funds are subject to minimal credit risk. The Company has not experienced any credit losses and does not believe it is exposed to any significant credit risk on these investments. The adoption of this standard did not have a material impact on the Company's consolidated financial position and results of operations. Recently Issued Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2017-07"). The standard requires disclosure of incremental segment information on an annual and interim basis and allows for multiple measures of a segment's profit or loss provided that one of those measures is consistent with GAAP. The amendments in this update do not change how a public company identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments, but rather requires public entities to provide in interim periods all disclosures about a reporting segment's profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for interim periods starting on January 1, 2025. The option for early adoption is permitted, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures in future years as a result of the adoption of ASU 2023-07. In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which enhances the transparency of income tax disclosures to provide information to investors to better assess how a company's operations and related tax risks, tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This requires public entities to disclose additional categories in the rate reconciliation regarding federal and state income taxes, and provide more details surrounding reconciling items if a quantitative threshold is met. The effective date for public companies is for annual periods starting on January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance, however, the Company has decided not to early adopt, does not anticipate a material impact to its net financial position, and is still evaluating the impact on its disclosures will be in future years as a result of the adoption of ASU 2023-09. 3. Fair Value of Financial Assets and Liabilities The following tables summarize the assets and liabilities measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurements at June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> Money market funds, included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> 79,688 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury obligations, included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> 9,331 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> 9,331 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.49%;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury obligations and government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 97,122 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 97,122 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurements at December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> Money market funds, included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 61,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury obligations, included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> 30,765 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> 30,765 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury obligations and government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 178,083 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 178,083 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> Total assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 270,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 270,612 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> . Cash, cash equivalents and marketable securities are Level 1 assets and include investments in money market funds and U.S. treasury obligations and government agency securities that are valued using quoted market prices. Accordingly, money market funds and government funds are categorized as Level 1 as of June 30, 2024 and December 31, 2023. There were no transfers of assets between fair value measurement levels during the six months ended June 30, 2024 or 2023. The carrying amounts reflected in the balance sheets for prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values at June 30, 2024 and December 31, 2023, due to their short-term nature. The Company believes the terms of its debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company's debt approximates its fair value based on Level 3 of the fair value hierarchy. The following tables summarize the assets and liabilities measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurements at June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> Money market funds, included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> 79,688 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury obligations, included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> 9,331 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> 9,331 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.49%;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury obligations and government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 97,122 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 97,122 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> Total assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 186,141 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurements at December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> Money market funds, included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 61,764 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury obligations, included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> 30,765 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"> 30,765 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. treasury obligations and government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 270,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 270,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr>
</table>796880000796880000933100093310009712200097122000186141000186141000617640006176400030765000307650001780830001780830002706120002706120000 4. Marketable Securities The following table summarizes the Company's investments as of June 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> $</p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> $</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> $</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</p></td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable securities available-for-sale: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"> U.S. treasury obligations and government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 97,122 </td></tr><tr><td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"> Total available-for-sale securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (55) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 97,122 </td></tr></table> . The following table summarizes the Company's investments as of December 31, 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"> Estimated </td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable securities available-for-sale: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"> U.S. treasury obligations and government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 93 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 178,083 </td></tr><tr><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"> Total available-for-sale securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 93 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 178,083 </td></tr></table> The aggregate fair value of marketable securities with unrealized losses was $81.3 million and $11.9 million at June 30, 2024 and December 31, 2023, respectively. At June 30, 2024 and December 31, 2023, 47 investments and three investments, respectively, were in an unrealized loss position. All such investments have been in an unrealized loss position for less than a year and these losses are considered temporary. The Company has the ability and intent to hold these investments until a recovery of their amortized cost, which may not occur until maturity. The Company believes that U.S. treasury obligations and government agency securities are subject to minimal credit risk. As a result, the Company did not record any charges for credit-related impairments for its available-for-sale securities for the six months ended June 30, 2024. The following table summarizes the Company's investments as of June 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"> Estimated </td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable securities available-for-sale: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:61.91%;margin:0pt;padding:0pt;"> U.S. treasury obligations and government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 97,122 </td></tr><tr><td style="vertical-align:bottom;width:61.91%;background:#cceeff;margin:0pt;padding:0pt;"> Total available-for-sale securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (55) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97,122</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company's investments as of December 31, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">)</p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities available-for-sale:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">)</p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">U.S. treasury obligations and government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 177,991 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td></tr><tr><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total available-for-sale securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 177,991 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 178,083</p></td></tr></table>971760001000550009712200097176000100055000971220001779910009300010001780830001779910009300010001780830008130000011900000473<p style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">5. Prepaid Expenses and other Assets</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of June 30, 2024 and December 31, 2023, prepaid expenses and other assets consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"> 3,392 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"> 4,059 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> Prepaid other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> 2,906 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"> 2,486 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"> Receivables </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"> 1,288 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"> 1,076 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> Prepaid insurance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,057 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 635 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,256 </td></tr></table>) As of June 30, 2024 and December 31, 2023, other long-term assets consist of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">) </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">) </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid external research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"> 4,074 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> Prepaid other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> 375 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"> 312 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid insurance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 23 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 31 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,417 </td></tr></table>) As of June 30, 2024 and December 31, 2023, prepaid expenses and other assets consist of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;">) </td></tr></table>

align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid external research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,392</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"> 4,059 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> Prepaid other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"> 2,906 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"> 2,486 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"> Receivables </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"> 1,288 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"> 1,076 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> Prepaid insurance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,057 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 635 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,256 </td></tr>
</table>339200040590002906000248600012880001076000105700063500086430008256000 As of June 30, 2024 and December 31, 2023, other long-term assets consist of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid external research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"> 4,074 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> Prepaid other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"> 375 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"> 312 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid insurance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 23 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 31 </td></tr><tr><td style="vertical-align:bottom;width:73.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,417 </td></tr></table> . 339900040740003750003120002300031000379700044170000 6. Accrued Expenses As of June 30, 2024 and December 31, 2023, accrued expenses consist of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.43%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued external research and development expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"> 6,825 </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> Accrued payroll and related expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 7,352 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;">

10,591 </td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued professional and consulting expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"> 4,254 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"> 2,267 </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> Accrued other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 941 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 766 </td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 20,449 </td></tr></table> . As of June 30, 2024 and December 31, 2023, accrued expenses consist of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.43%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued external research and development expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"> 6,825 </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> Accrued payroll and related expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> 7,352 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"> 10,591 </td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued professional and consulting expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"> 4,254 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;margin:0pt;padding:0pt;"> 2,267 </td></tr><tr><td style="vertical-align:bottom;width:73.33%;margin:0pt;padding:0pt;"> Accrued other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 941 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (766) </td></tr><tr><td style="vertical-align:bottom;width:73.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">21,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 20,449 </td></tr></table>
93390006825000735200010591000425400022670009410006760002188600020449000 7. Common Stock In June 2024, the stockholders approved an amendment to our amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000. The Company has had a sales agreement in place during various time periods with Jefferies LLC with respect to an at-the-market ("ATM") offering program. Under this program, the Company is able to offer and sell, from time to time at its sole discretion, shares of its common stock through Jefferies as its sales agent. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. The current ATM agreement, established in November 2022, allows for the sale of shares of common stock having an aggregate offering price of up to $100 million. As of June 30, 2024, the Company has sold 619,290 shares, generating net proceeds of $5.2 million, under the ATM program. No sales were made under the ATM program during the six months ended June 30, 2024. The Company has issued pre-funded warrants, as well as warrants as part of its financing activities. Both the pre-funded warrants and warrants meet the conditions for equity classification and are recorded as a component of stockholders' equity within additional paid-in capital. In June 2022 and November 2020, the Company issued 25,510,205 and 2,179,487 pre-funded warrants, respectively. During the six months ended June 30, 2024, 2,526,833 of the Company's pre-funded warrants were exercised. As of June 30, 2024, the Company has 17,008,164 pre-funded warrants outstanding. In June 2022, the Company also issued 10,459,181 warrants with an exercise price of $7.35. During the six months ended June 30, 2024, 830,660 of the Company's warrants were exercised. As of June 30, 2024, the Company has 9,157,496 warrants outstanding.
150000000030000000010000000061929052000000255102052179487252683317008164104591817.358306609157496 8. Equity-Based Compensation The Company recorded equity-based compensation expense related to all equity-based awards, which was allocated as follows in the consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.38%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;margin:0pt;padding:0pt;"> Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,050 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"> 7,581 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,483</p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,505</p></td></tr><tr><td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,311 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,818</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 17,476 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,988</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes the Company's unrecognized equity-based compensation expense as of June 30, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;width:20.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;width:16.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of June 30, 2024</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrecognized Expense (in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td style="vertical-align:bottom;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average Remaining Period of Recognition (years)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted Stock Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;margin:0pt;padding:0pt;"> 35,116 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"> 2.8 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"> Stock Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 42,470 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"> 2.6 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 77,586 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> Restricted Stock Units The following table summarizes the Company's restricted stock unit activity for the current year: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"> Average Grant </td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Date Fair Value </td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock units as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"> 2,089,552 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.92</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,647,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"> 14.98 </td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"> (601,170) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.16</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (150,878)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"> 12.38 </td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock units as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,984,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"> 13.54 </td></tr></table> x The total fair value of restricted stock units vested during the six months ended June 30, 2024 was $8.2 million. Stock Options The following table summarizes the Company's stock option activity for the current year: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Contractual Term </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Intrinsic Value </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 7,300,953 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"> 52,299 </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> 2,196,217 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> 14.98 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> <span

style="color:#ff0000;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> (53,910) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(275,708)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> 17.91 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,167,552 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">14.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">7.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,529 </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> Options exercisable as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> 4,473,458 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">16.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> 2,506 </td></tr></table> Using the Black-Scholes option pricing model, the weighted average fair value of options granted during the six months ended June 30, 2024 was $11.50. The following weighted average assumptions were used in determining the fair value of options granted in the six months ended June 30, 2024 and 2023. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;margin:0pt;padding:0pt;"> Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"> 4.18 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"> 3.84 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> 0.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;">% </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> 0.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term (years to liquidity) </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"> 5.98 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"> 6.13 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> 91.35 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> 90.51 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> % </td></tr></table> . The Company recorded equity-based compensation expense related to all equity-based awards, which was allocated as follows in the consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.38%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;margin:0pt;padding:0pt;"> Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"> 2,838 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,581</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"> 5,483 </td></tr><tr><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"> General and administrative expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,261 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,980 </td><td

style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,895 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,505 </td></tr><tr><td style="vertical-align:bottom;width:47.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,818 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,988 </td></tr></table>405000028380007581000548300052610003980000989500075050009311000681800017476000129880000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"> . </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"> . </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrecognized Expense (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:16.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Weighted Average Remaining Period of Recognition (years) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted Stock Units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.8</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.6</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:20.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 77,586 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.43%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table>35116000P2Y9M18D42470000P2Y7M6D77586000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"> Average Grant </td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Date Fair Value </td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock units as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"> 2,089,552 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.92</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,647,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"> 14.98 </td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"> (601,170) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.16</p></td></tr><tr><td style="vertical-align:bottom;width:71.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (150,878)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"> 12.38 </td></tr><tr><td style="vertical-align:bottom;width:71.79%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock units as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,984,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"> 13.54 </td></tr></table>
208955211.921647159 14.9860117012.1615087812.382984663 13.548200000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> <span style="font-size:8pt;font-

weight:bold;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Contractual Term </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Intrinsic Value </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"> 7,300,953 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"> 52,299 </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> 2,196,217 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (53,910)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"> 6.09 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> Cancelled </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (275,708) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> 17.91 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:46.21%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,167,552 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,529 </td></tr><tr><td style="vertical-align:bottom;width:46.21%;margin:0pt;padding:0pt;"> Options exercisable as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"> 4,473,458 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> 2,506 </td></tr>
</table>730095315.00P7Y10M24D522990002196217l4.98539106.0927570817.919167552l4.96P7Y10M9D352900044734581 6.82P6Y9M250600011.50 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:17.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;margin:0pt;padding:0pt;"> Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:38.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"> 4.18 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"> 3.84 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> 0.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> 0.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"> Expected term (years to liquidity) </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"> 5.98 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;background:#cceeff;margin:0pt;padding:0pt;"> 6.13 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> 91.35 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:17.74%;margin:0pt;padding:0pt;"> 90.51 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> % </td></tr></table> 0.04180.03840.0000.000P5Y11M23DP6Y1M17D0.91350.9051 9. Commitments and Contingencies Operating Lease In November 2019, the Company entered into a lease of office and laboratory space at 301 Binney Street in Cambridge, Massachusetts to be used as its new corporate headquarters (the “Lease”). The expiration date of the Lease was originally in August 2025 and included an option to extend the term by two years. The base rent under the original Lease was $6.9 million per year, subject to an annual increase of 3.5%, and the Company was subject to a free-rent period through mid-August 2020. Variable lease payments include the Company’s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The Lease included incentives of $14.1 million in the form of an allowance for tenant improvements related to the design and build out of the space. In connection with the Lease, the Company has secured a letter of credit for $2.3 million which renews automatically each year. The Lease commencement date, for accounting purposes, was reached in September 2020. In May 2024, the Company entered into the First Amendment (the “Lease Amendment”) to the Lease to extend the term for approximately two years, commencing on August 19, 2025 (the “First Extension Term”) with the base rent to start at approximately $6.2 million per year, followed by a 3% annual increase. Pursuant to the Lease Amendment, the Company also has an option to extend the term of the Lease by five years, upon the expiration of the First Extension Term. Other information related to the Lease is as follows (in thousands, except lease term and discount rate): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-

left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"> For Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;margin:0pt;padding:0pt;"> For Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;background:#cceeff;margin:0pt;padding:0pt;"> Lease Cost: </td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> 3,576 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;background:#cceeff;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 363 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 723 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> Total lease cost </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,299 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> <span style="font-

size:8pt;font-weight:bold;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;margin:0pt;padding:0pt;"> For Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;background:#cceeff;margin:0pt;padding:0pt;"> Other information: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> Operating cash flows used for operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"> 3,963 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average remaining lease term </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"> 3.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> Weighted average incremental borrowing rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"> 13.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> % </td></tr></table> Legal Proceedings The Company, from time to time, may be party to litigation arising in the ordinary course of its business. The Company was not subject to any material legal proceedings during the six months ended June 30, 2024 and 2023. trueP2Y69000000.0351410000023000000P2Y62000000.03truePT5Y Other information related to the Lease is as follows (in thousands, except lease term and discount rate): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"> For Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;margin:0pt;padding:0pt;"> For Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;background:#cceeff;margin:0pt;padding:0pt;"> Lease Cost. </td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> 3,576 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;background:#cceeff;margin:0pt;padding:0pt;"> Variable lease cost </td><td style="vertical-align:bottom;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 363 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 723 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.82%;margin:0pt;padding:0pt;"> Total lease cost </td><td style="vertical-align:bottom;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,299 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;margin:0pt;padding:0pt;"> For Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;background:#cceeff;margin:0pt;padding:0pt;"> Other information: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> Operating cash flows used for operating leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"> 3,963 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average remaining lease term </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"> 3.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.48%;margin:0pt;padding:0pt;"> Weighted average incremental borrowing rate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"> 13.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> % </td></tr></table>17510003576000363000723000211400042990003963000P3Y2M12D0.131 10. Debt On October 16, 2020 (the “Closing Date”) the Company entered into a Loan and Security Agreement with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) for $50.0 million (the “Loan and Security Agreement”). Tranche 1 of $25.0 million was funded on the Closing Date. The Company had an additional $25.0 million in loan proceeds available under Tranche 2 which was funded in December 2021, in conjunction with the Company entering into the First Amendment to Loan and Security Agreement with Oxford and SVB. The Loan and Security Agreement was to mature on May 1, 2025 and required interest-only payments through November 2022, with principal payments to commence in December 2022. Pursuant to the Loan and Security Agreement, the Company was required to maintain cash in an SVB account equal to the lesser of 100% of the Company’s consolidated cash or 105% of the dollar amount of the outstanding debt. On November 10, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (“Amendment 2”) to increase the Company’s borrowing capacity under the Loan and Security Agreement to an amount up to $100.0 million, comprised of the original $50.0 million loan which remains outstanding and two additional $25.0 million tranches. The first $25.0 million tranche available under Amendment 2, was available at the Company’s discretion through December 2023 upon achievement of certain development and business performance milestones. The Company did not exercise this tranche. The second $25.0 million tranche available under Amendment 2, may be available upon the Company’s request, at Oxford and SVB’s discretion. Amendment 2 also extended the interest-only payment period for an additional 24 months through November 2024, with principal payments to commence in December 2024. The maturity of the loan was extended to November 2027. Effective upon Amendment 2, the interest rate on the unpaid principal is the greater of the Wall Street Journal prime rate plus 4.60% or 9.35% per annum. Prepayment is permitted and may include a pre-payment fee ranging from 0% - 3% (of the principal amount being prepaid), depending on when the prepayment is made. The Company is also required to make a final payment equal to 2% of the original principal amount. In conjunction with Amendment 2, the Company was required to pay $0.9 million for the accrued portion of the final payment on the previous outstanding balance. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. Afterward, the FDIC transferred all deposits of the former Silicon Valley Bank to Silicon Valley Bridge Bank, N.A., as operated by the FDIC. On March 27, 2023, Silicon Valley Bridge Bank was closed by the Office of the Comptroller of the Currency, and the FDIC was appointed as receiver. First Citizens Bank then entered into an agreement with the FDIC to purchase out of FDIC receivership substantially all loans and certain other assets and assume all customer deposits and certain other liabilities of Silicon Valley Bridge Bank. On March 27, 2023, Silicon Valley Bridge Bank and its U.S. branches

began operating as Silicon Valley Bank, a division of First Citizens Bank. On April 18, 2023, the Company entered into the Third Amendment to the Loan and Security Agreement to amend certain provisions relating to the Company's operating accounts. On May 17, 2024, the Company entered into the Fourth Amendment to the Loan and Security Agreement ("Loan Amendment No. 4"). The Company currently has $50.0 million outstanding under the Loan and Security Agreement, which was drawn down in two equal tranches. The third $25.0 million tranche is available at the Company's discretion through December 2024, upon achievement of certain clinical and business milestones, which were amended under Loan Amendment No. 4. The fourth $25.0 million tranche may be available through June 1, 2025 (or through December 1, 2025 upon achievement of certain business milestones) upon the Company's request, at Oxford and SVB's discretion. Amendment No. 4 also extends the interest-only payment period for an additional six months through May 2025, with principal payments to commence in June 2025, or for an additional six months through November 2025 upon achievement of certain business performance milestones, with principal payments to commence in December 2025. 50000000.025000000.025000000.011.05100000000.050000000.025000000.025000000.025000000.0P24M0.04600.093500.030.029000005000000.025000000.025000000.style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">11. Net Loss per Share The Company calculates basic net loss per share by dividing net loss by the weighted average number of common shares outstanding, excluding restricted common stock. The weighted average number of common shares used in the basic and diluted net loss per share calculation includes the pre-funded warrants issued in connection with the Company's November 2020 and June 2022 follow-on offerings as the pre-funded warrants are exercisable at any time for nominal cash consideration. As of June 30, 2024, 10,681,528 pre-funded warrants have been exercised and 17,008,164 pre-funded warrants remain outstanding. The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive. The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:72.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.96%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 2,984,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"> 2,047,026 </td></tr><tr><td style="vertical-align:bottom;width:72.96%;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 9,167,552 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"> 7,835,195 </td></tr><tr><td style="vertical-align:bottom;width:72.96%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,157,496 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,459,181 </td></tr><tr><td style="vertical-align:bottom;width:72.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21,309,711 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 20,341,402 </td></tr></table> 1068152817008164 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:72.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.96%;background:#cceeff;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 2,984,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"> 2,047,026 </td></tr><tr><td style="vertical-align:bottom;width:72.96%;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 9,167,552 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"> 7,835,195 </td></tr><tr><td style="vertical-align:bottom;width:72.96%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,157,496 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,459,181 </td></tr><tr><td style="vertical-align:bottom;width:72.96%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 21,309,711 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 20,341,402 </td></tr></table> 29846632047026916755278351959157496104591821309711203414402 Trading Plans During the three months ended June 30, 2024, certain of our officers adopted contracts, instructions or written plans for the purchase or sale of our securities as noted below: <table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"> </td><td style="vertical-align:top;width:20.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"> </td><td style="vertical-align:top;width:13.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"> </td><td style="vertical-align:top;width:11.12%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"> </td><td style="vertical-align:top;width:12.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"> </td><td style="vertical-align:top;width:26.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"> </td></tr><tr style="height:60.75pt;"><td style="vertical-align:middle;width:14.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> Name and Title </td><td style="vertical-align:middle;width:20.37%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> Type of Trading Arrangement </td><td style="vertical-align:middle;width:13.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> Action Taken (Date of Action) </td><td style="vertical-align:middle;width:11.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> Duration or End Date </td><td style="vertical-align:middle;width:12.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> Aggregate Number of Securities to be Sold </td><td style="vertical-align:middle;width:26.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> Description of Trading Arrangement </td></tr><tr style="height:75.75pt;"><td style="vertical-align:middle;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> Jing Marantz, Chief Medical Officer </td><td style="vertical-align:middle;width:20.37%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) </td><td style="vertical-align:middle;width:13.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> Adoption (April 19, 2024) </td><td style="vertical-align:middle;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> August 11, 2025 </td><td style="vertical-align:middle;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> 120,000 </td><td style="vertical-align:middle;width:26.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"> Sale of the Company's common stock pursuant to the terms of the plan </td></tr></table> Other than as disclosed above, no other officer or director adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended June 30, 2024. Jing MarantzChief Medical OfficertrueApril 19, 20241200000'

*[]QV2S)XPBO__W+4{]1^6&6;,DBAMS38=9KDVF>YK-, MFOA@FB$M-IN9L \S#G5>F:4K-27.\2]{?'C(3WM!>F;[XX#G2*]EVU-+1\E,;)C64#JB.> ^|KYXV;@1&$|;L;#TF)7BK[/C)O\X^SNEZ+ M1-2@074!O;I378Z=A2"<@S U/) M]P=4^I>.8'Y&FQZT:B#0+L2/0#H)15I5Y0H@!1[D.B%%BQED5HW?$?'.OUHZ M>Y/*R$*98 S9)G>;G]"*N(':W!O?!R8$MI6L08PF986UI-4E3A)1+&]@_Q_?=$F"0SB+.UOB'X7Z-*)\{J>XDS+N0YZ3#SQZ*-;DAW=DY@JU;AMO5'GPJ#B*!)QY.#_^DL1ZM'H-^I;2Z1 M7*7 Q2/ Z0FL!XA(?(&*90PT]\;%82Y'JC-)Q1FZY$8?+>F5MN+93#BSBFI" MF-;F3@S.K,9H/G!,G&$M)^C",E,[F"SQ5%#?G-YNLW(:>QMSV/ED3I8DKOS M)_D? B>'3TA]+*E5Z3%S*N;JR2X; F]#/^)ZTFZWMV26W#&{1 M!^#[DY 0LY7IFA$3E:YHS)BGB+U#:\I)>RJTZ)@JSOC^\@MT=F[\KYXSV0P M6C;^[US%$18->H]Z6@^"3V .%5#)*5SXGH&$C8N39V[3D+F# @-:*L"97/|- M^15_MD(+[Y<0%Z"=X/0E1M5XPDD./UA0L0PE,YA?J/=,H-46/Q.^$?=" MLZ] YY<%"IFMN,K,(Y7D#G)]1M8?8G.#*AFW 5F",,_U]'MUX7C(K*!>$$+B M^)Q%)Q2C*UJP*,"H\V'-;?T*#O@90?P<36P]=,Y$K_"GDCKD 8'T0F6@8=@ M 7P)WKE=R\;KJVSJ$\$@B!\2/ IQ)Q!Z07ZP\)?1E*>"37Z83F.AN5_FS1#3] M>DIT4+O8P4K<3K,QW =^OI4,%P*P&B1YA,!$;+_ _I*^)0(24MG@:W8\?WG] M\LT+]CF_(<@:^_5RU0QG7+#0C&A+U:P/OODX(_%-_0E@K08+2>| 5Y8-(SD M!H'@9GPW8? W"F'K'-R="#8OR@9R.6Z,5/[.8Z94XK 6G^=> M5A:'V\KBMK+XIU86^QWN[!!+DZ]D7IACGMQHB*%8SSM5N_'/2T]U.IM#PJ%P M06P)@6,- A/!0EBJM\3#.!I1T'RG@FZZ':3LP!NY(4$#D/&,ISA0%"-QIB5H M4%-9X(T(7/RP<=#H\"5]#W86J84)% M2C!!6UA9FV-,*BFJ49W?,?,,IZ'N+#\U;71&C-Q M5.R80(@%'#38K#S3 Z.VN5L:(/$[^3#E5+G;B)-LGH_K*-747J/TNP@HM"R4 M91ST70,Y)#PBRRH^>G%D,L$=UD2N/P/N5PPEK)IKF*B?9.ED!D M=(;,P"'_ M0=,P/$R\!'B!XA[*X*,'N5J.=SG)DE1C\|JYRE\UD M#U49^#$^)YTD)94R-8"U*(97Y?)&2.E\[P\"/SK"G/)UH K05 MA) ^8LFM%Y!=Y=P'3,3GKB%-/?4';IEW"HQ[0H(S?L&]$B90D((Y ,S-5])Q4 MU\1CYJ2Z@.WNC"Q25_]\DB'R#C:BBM;,\FH/((%K"3K,,J(183RYF2?4XAW M6)-&;$BX#*[*0'K>A 4@[QO.PETP[*[+%L$\X@%01&_#3+ WV[%4!Y.YR(5 M_<(2(_4)]:?V,-P,6^K",LRV9?O!KJ=5)OD7+9{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|%=G&YHEW6L1V)7,RU$\Y,DXM?TPCCV MW CE9ODE2"\B6O#Z@G&8UUKT>-^.1;|QCHEG*=@'O03$/3-Q]|>+SH$T)@M] MJQ+B6,*>#NY6.<>OC:9. G4=-F\;]) T5$+&N$#R(VAWZ*;Z#\@O5[T,>=03 M!Y^+$"2ZB6"U^DY&(67"1$,!H51N16SM]NL^EY&GB/@8Y=E!W1Y@_?Y15F|_707+Y!?.V7G M'_GQ(0S/@#_WKN_\)TS'2$1OJ-19@1#4*&M6L,27/DCRBX(*N_UGH^%]3-O' MGCE;MR0$#RPIH64D/EHQ",A8 \Z>|T:K,+1VU:.+*&CKYY1# >&E;C7]X*VMU MF>'Z$('(6)PC5'X3YX7.#3PK8U\$QP>1V#\|>T@+0TV=_PX=BKQ^M^ORP;Y+ M9>PAH8F1V#9QAM6PV5XM&[Z0633@@/>A=IVPNM.7^8+2_MQ%JE 7&Q*6(2^_M6PP#U#E0-F]8:9KU\$1\TO.Q^!74& >@EBH0O26QXW4;1* =#!Q"E'$UZ706 MF]Y01KAOT+Z#+-:1O"^W[2&C?'0S[GD^5B)\R 1NB;$&N^;R.*%V@>EJ;5W%*.M3+5Z;*(N$;5_HO. 7:*7/L)02, ^EFH)M9N'8]P8AT1;K" M*BV(?.E>6=*36GH_P@_0VI 8M5 T[<&_.P.4K]SOF5>1$ZTH8LZ=/-AO'.'0 M.FMLQ'5*7-RP7OBPZT&P\;!Bf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|<[K^>PW,Z=K70W<*XG M*2"=N_WP-7R9!?$Z/A=YO$0OB T-PX/$;.^1Y^5Z0K:E<*M*--P-*.)YR+|7_.;5Y5-3RT#6) M3 -7!Q*!=&T;^XW9)KM'Q8F[EQI A]L2V[;$]J>6V/K/>._IV,X (IY)0:T7 M3%ZEZV[K7_F# L(^%R%F+NJR6M!X>HL3#AO?/:][Z6:'.F:][WN_B+V%)NE M6 I:\Y-B#^!N7'^C8Q=&5? A_N5VG0+7=<4" YJP>W-5BE!4T-4%= T0Y%X5(-MI(Q48(<-D]RB3U[4RU$-65@(((SEZAYC4J%>CH-^PLP. MG&Z8GO&> >5#E]"H@-'-.B/4ZF12404G:$_RTRV'N""
!50];&9N(*BD:0LB+ M2LE#G#+0BEC6D/X#[R@OZ#$H2YE!!$^M#AF!P2EA+#E:S G"8@!->NW1ZID& M\L$;;. *9X?EYEQV>1 3=*2H??X3"7%|"XS/YG+'%>$4^)Q[KY<+<%F<]0,! M\6KI@MX+7G"8+%!=A0 BVZ$3;&FZ-,>(3'*PH22X7KE3+ROX4406D'IHW$&N-ZS/"+_^<@T\+|PYZ6S3 A"
M0D1PZW;8BBG1=QPTPNX'R=41]=CO#LXIZ^.6V&|+:G+]$,*PF,:'FON*_=% /1DD*@UIEPL69)#"1$(6SP36-"I]T !4,7P.$WIO0W MN*:<"\+OT0[NV5?

H#WC>$A3F1,N*W_>%ZU;WE4DW(2B5KQ>12 6-4OP9)C:_MYRY(<@9BO#MX[VR:BW&F.8W!,QZFQV"*W&QCS9@\(G>W&8]I0%;23=?O>)(U MT'<(F0/H+92Z/B;IW
#64YH/J,E,4#)WP>&6AG^XFL4&TE:=N(^D13]%D&Y9 M4S]LDX_*B9:(D7.XG&7H[TSQ3#UDE@WTA$5G1C<55AJL5=K":M:?]J,4)7
M#0YMTH,CMU0?._]I>'SRW7"XCS3A#!LFITO>&E,\.DQEFW:(MMW]R X>D]"8O:0BDUL./ZW=_I_N;.G28?NZT"Z\2D$L(CT"^0: ;=$SWY M^=R9"[P)>[HB<%A/I1L_ZG=>
[R'!@!K)1_-[VKN*.2,3VNWRY9N[7R1$2#W M&)%%)-T;G#J&!LVI'/&O$#!EK7[)V&=*&R^/+;(;%,5W)4<_E9\3[&12!E9N M 1@0T+A5Y]@!T?I>_GX"YQ9)+B/Q4N
SK"Y1Y#I'7GH\74&Y9"W^^1(_,[MSM8F*\3WE7FT614L)!2U"&V3D_B>MS;?V;;IW=6,^!M3OO%4X|WE@:#M$!:7 M-5,BP"$HSD!T4"(T=@R&R$!*^)83W2[
(V4\:ZWH!QXP>'lEBQG+J] MA(X@L9*0)P.'1!\1"V++M6C53:HAC!<|O"9"B6%|4CCT' Q42L(BH4:FL.OF MR)>!(>7B_'"&/#Y>K^[%-/%8*TIM,3I-_F6"]IN ?$NFU@E,4O M-
!6,QA44\B^@QOL#H;\/?MR^ D.159S,)FTDPT).SA@3,1KW^0Y(@)]X1%* M?HP,),Y>("_Z&&@\W"S[.0%$Q2A1Q.-@4+! C.)&'HS62TV &=8#7>+8LXV M-__/H#P@]K!_C8KV?.?
R5&@4E44W=VW_O'0[#/J+M9@F8Q,%,+A\^OEHI*2- M5)ZKHH,%+R%O43W W!W+M>\$7PF)!N[>B(,L*!R?US==W3"=\ 7,#965Z6W' MO4B2K!2_UN\T/5%OG 58*!=$W4>
&6N,C=GE-$V@R>9IL]@,7F(N)=<^/TH? M#RB!AH$QU\RH%IVF(LB# MVR2XNADE$(ZMLSNP[^NZ?PTE+9(D?OW..?2?3R/V O%'!5(J&Q@S:!N1E"N! MCP)-
AID*ZE(V2R1!W1)87,+-T)3?;COA'T'K7F"-KG(@>"6B+4FB>B.D>9O$ MG) EGI/V:&H!(_((SP:,P7[3G(88]R1[NU2>B#%$Z9-PV5*XC9"[P_XYSCP M^(*
(^X^VI<=MZ7%+W+\UUAT+R,:$DW0.@M@8)P%Y \FE*BI&HP M!S41'Y;#T] -BGA]-TH]\(:HOO.^[SD#-YE@!Z-L_8MV"?B6:\(%,T,8\0
M'$60Q03XRW0Y(XXLD2G$Y41)&WBGILI@S<#;23:#6_N7^2AO*%8B%\-'FC95O/\4"ENH;CDW:5,H 4_N-[2!AR=D3GD
MX=&9BC:2X4QL:KV'Q__ZZ,Z'B+8_9U)NE_B#7>)H\@7F#WE%+=LSE-(LM%;O M!MA7>^00#2NRKK>T66,*8M-[90AB^B6 M3.9A+V& I2&&H-?
AIK==4G)GZ@5M/S4JD9,9_E^_#MFI^7!9EJ:G/,&X2< M25![O\CI7QNTAVT+C;1RZV6MS5^$MH+R-D'MM7+H4]O4GV0ZY*4)B3IB5/.9 M[8H97/?=5@M3!(J#&F:(
>OH(F1B4&%*9VV]@(/:/.]-"INF<%2E:6/2IMB= M[UN=&*^#5%!%6Z-)OZ.-]&^:6=NW?:M&LUS(M&\6W3E MFDMH>8_OM-:2&_.8_,[MI'\3("TBG*AP)>WS:F#\[>D5-'YYPE7;3Y37
H(+_MF")?I]-L\$-:C;#,[9Z:YL,9HPR9YQOH0$<(A+O(XUU&00SV3X;8SXE(N4OH MZ5TX:WWAUG4Z2@:O7_WOSO!TF!!\@,FN"U_R;]M!..!152'@?TA">(-U+6'8 M&[BQ-'P)?
==3=KJ@$?)T<=-NRKA""(J(U0[T+S+,%6>!*Q9K'"T@]M1E\+ MH?YXY?['QXSVBVR4F8(9X+]HL[0[\WK'QG80Y\6XK ">0U.;0]5PEF=3'.E5 M0'LC-
A$'%1UL:1O7:\+PE%R(;)XS&$7SVB-_6E9\6L)6)P%;&U>*NZY%>]# MPT#MA"ZZ73;PUA!/C.XWKTC!"N"?D@'E$#[J7 M ;$J4Y7E5 K//#YVA1CIEJ
29Z'<-+E6*0A[B&G>P%893I6 ><,4D2QU!#B M#1P,GEB00IE&"'*J*=]D[X[$(J>3HT,-\0-@ (16KUVHT>^*4Q<5'+R;[M) M=,,[&#,YU)A#.Z]67E4YE/W50HC')G,3O)66
F(L\7Y+#W#N+ C7SJFGGB*O M;\+6:=VY))#QPD/+*)9F5R'#T;$%=#HF#=.W#ZG%>=NT>Z%ZT%12E?2@K&7- MU4(4CIF[?S!,M/-IM2H??2'6X ,F)
[1].KW&PO_(X81.J^9/%\+5[=#&0Y+'PP%F*AFBVUG^$;(K10H#N$U<=9 M$W Q7LYPNP<@LKQO_C]Z^E/R3V2R0^/@W?AIO,GC*O154W6MF=I,WG;#6>N:
M%YX67+5Y_=$SXNQ EA-L)857YX-3[FQ/+(WPT=*>3>KA!+/ M>%_74H!T+8H;W#/Y&/4*/<*Q!9OPZHA5 XR&A7R#*5Q6A46?S]9=_$:&=.=/ M)=KQ9IYSY%"VFS1(
N,L7U9<$*V;Z<%@XI:)D*!>)<^"[=$"5<*7DPYX=SQ! M1ZCG6,#8RK"SN'?$\WUI>2,22^D3SIXP+9H^YS^9__!:0<^(!P85DS1?U96K4MJMKJ15
M%U;=]XCSR:DL2CK!>IJ0T<8(B7^5-UW?N^H$V!T\H\4]1^5 8E"C59".;@QL M IRK3K*T&O+P6^-QWS >QUN,QQ;C\>4P.&^P?M3!_![9D%""P%#;.?-0KFZ2 MP[D-/LPNTD.U_D\
(AQ:6>U:>CQ*GYD$#'3#7!KYF[Q8(!TN.F\LUL RT M<@*#[1<^6@OW%SE3#U840K/EG"813U5U[$RA@D>L:[#H*$D_>
("'I8.O.>OW],4+H<_Q#]FI=4K\#%K0H=W2#E@(=BCX*IHF4 M:A)),/_/TOFS^WO!![M_$NYIW_\)?()MD?TVB^QOB$R LWB2.8-6VQR3[QC\
M2J%VD@'U+.7A3.NP6T2!VQXQ)2"3VV*6%LH+YV;5G9G9[N .@3OVMJOPSUV% MY:+9@5INGE;46#V\M$3YO2F MG<9=D]??
>,S.4%Z,D4O2)R680+U&9QS'/&QC]:>]\3]HX*%6$9O9Y'YX4Y0, MQ)\2YIQI4T5;9DY#Q6Q09H3I:7.0]^Z!_O_ZX^=;%!#3C1LA0);P#DG6NO)G<7,B@(@E8+,7D=UF(2
MCQ:;+LGOK]UVQ7$5MQ7\3H/Z18/5 :5G!D?*]=BJL!!R$8+-5TW-1=R+"R6' M;1N?$?K-=TAZC8*81.0&ZP('.5E$#$V9Z$2W1L%ZW\$K#KRL=5=$9" W+1F' M*_B)0(I=D53>M$?
(+)/TU0YV%LN-RR)M:$S=GT<9-;(SS1&44K!ZUUXF*A(+ M)'9(?<0",N:6?4QE_GXX$C7R=]^W_/ZM6+X@GQPU(7>S*'@N"S5<'22"W2!E MZ^(VG]!MR37 16[4QAG8]>A?
9!28V33&27;E@XEH0 M22K,LR_&Q=JY\<>]H1U>"(R>%UL9]*%)H/J_SB"T)6I M2X0S$PF1Z/R-*D48A_(.!87BC;FOC570D=+U#*_ER#6JY MKD'K>4F3;8,!]?
H8UK^78836G*:9<3>9D(*:A^,45=)QYSFJ M"L8GGX8E$E<0CQ8?0+83 S!GVK;G@8],L!FC.K(/H%1"&+G+C(EZ1EFS HY. M!)%V]M(182E-FC!XRI<1O@E?
&KECVOG&0)$%Q<#P@>&%A$//U"*G]!#77A\1 M%]S-E[3,9#P%G_)0^4-ED$@O\7F(\<,#9D//@MJ(GWL@_[ ]M.\,A]3"+0R MS&!W$$CQ7(V&!RO[
141Y17DOI#,!8GY,%K@7656E<*&_4AO D9.25LK;HP0=BW) " FYFR K,' MB1%NCS$6(+0P6I05PPAY@38[4BVM3#6!?"4[P\1I$;L;IGGK)8.# M$,Z-29CJZ2=R&WR=
[5XX6]M=^OPFX]I\^O+@X/AT[_@,;_7TY?]Q?Z?!T?S_J M@3"\R-V7Y3'87'FF(\FG+]O+EF--7:3.EYO,,Z\8:E#_#=>I6LIQ"#H&,Q* MYS54G$':(-(JI1@W8@#*0)IE/)%IT5%H.
(U.G_;BPUR9(1/>'?RSFRZ;KB$) M+.P0\4.^4IS:*#-=2_1;%&\7I:&9QE"&%0L2VZB2V.P*"AU-HL9(FB!@:QB M1MAG[&69:
(0DK/+4"6$.:/P^9I8S\,U1OSH>M/:8/>K8LY0]4ORUCP".JNW$ M+?(41<#:F6R#49E!:.0&RIG2NL%=E# U7W69+F]&70></- MN5;2_NWFKDI?D6G1Q6X&@7NIT*!O92V]CI\?4KPQ
>_3,))WPI1)_C;F%!1 MJF.91?+K:V#!:^YA<"F8RT/X6A#0Y.[R,O';YRA19ZWT.C!-9KU NJ&,\I' M8(X(I?HCL-3P(TVE^Z[X#X1+A=%@>]&.P!L>DC8)(I?+T:Z;-15F(&1.PI M-
V@!/_0LO7"_O6!(6F,TB'T,2@)@ M/@B->K.$?(#[O$(62XRZJ#T54CN &C,!0*KA+UL'%7Y2C:HHC;\[>-'1BXTO
MBB_I,3=A:Q=\F'2.0%?,@NU3F\2OPU$3QX".&N4R%:C(-4&KVW8ADEXCG M:CLL;O1]0V0:936$DX772$A?'GQ1QYSY^V7UA)AV)O5L,JUV>0I=XU% @^[O!>/9H;ZLN)\ =V M<
VM,2>/I)-BCDT05&VEU6C1Q!^A=.#^F MG;\:3,J,2LDD#;VL;:?@E4T2/P9ER]I9#Z$LJ6H+J.?%4X@7R%C*?L.23Z(K M=B YB@FI2*3CF*
[3X&&D.NAALJV&>L97IS.NNI)8:9B(G^:Q,L M/DB#NXEU>E!RH<$2 -S2/M1C$MD_J_2JL>56-;= C&57/[!?= AU??GO)G'4HK<#H3S+P];\$791!C$-;
MQK$[YQ/#\)1L\2KS09[VU[=S#:9OGW N[MT#'%\B_3ETG$&G0-68Q$I'LR4N MTZRJX_'IX2 /U'X&X$NG[U@M06'HKP$%6H(%85B77=?:A"*+:"V<"?X,U$_[
M1XKW(*56!TA^+94!M8\3FW%LY*T$]1#)S+:-^E9GMT0)YH\)8U&01((C5 ML$3>AWQN5"S,5WD^T5NF?69%*HVX8.C\7,79[M=L]#3LWQBD[;VL(9YN:XC; M&N(=E6H>Y66D.F-
/J4(FF6 NIU3K>NK-5#U[Y M*O/JY4EMJPL+R M2S=Q:.544MR]V]6AKKVJ%O@:,CUQQ5&[ISNDZ,@!0CP!]$^]<)P;0[*(;+RX MNBXRJ/\H.5OG$R?^IL&VH(0^=;BA-
X9H#],E3E=):".Z6>;L.=^#.WNYM@VM M%Z$>,UPY(%SC,F_T>^H,EN[Q7UX^ENYO54YS?Z,\O^\'E1>S]7>W#<<99-P4 MBHK?Q0$6G6X:
(J\AVB+CA<*R5Y3FO*_O[,,ES$+W26LRXR$ECEPZWY:JK=8Y M*.X=24=PSEJV+E KI!LZHE.$+ZN?OLL#R?:&+F#X^GKO!A1899,)\?'IY0R. M2ZGO#V"\9OC5G5$*=0\#_K"'(W3TY-
,@8RN$9V*U;76_E>J__"F?-UN23G6 ME1S%R\>=$'(ZZESB-DA%]KN0**:MZ72[^D;BN#L7!=""TNKB-T^F. Z9PQ:.0' (%+V#6!0C\U)BX:S*G,8SM[N ?K(1H MIH>.?
AW,7CKY=5DW<\FO/$+4DOQ"M<\4]T^]>E39G6:AD5<8DE]BP*&,KW)NX@JBGW;#*P:AG2CG MG:)"O!U-=Z9BK(R/V2R_T(8#662=6\M8XR?5\L+YZ- H)'E)>1&V &_@IZ^P
M5XE>\EQ-]_#LJ# AQ.2[E*,W*7P0]JXI?'/[(,;\<&YH/(X*=3S(2"PYC#! M'G8$^3/? ME5R=KJ&#R0 D HL3)8S)9UJ[-L_&'K\C!2 M=J4VGNLU&"BL\?&>N_.:]@1?U_E3/FYM-/2PPT-
KZ()QYLTFCY 0:SALL)#SAF[-X!S\#OG" M"@ID 8NKH3R(X+KCJE+#C[@*=10ZRN]I.PTRQOW3DN"XL7CEQ/,E"^ES-" MB$ZYT X1UP>(A6J
;+K_<7^^P!]YI8I@QJG%95HS=6+/'@DN3//-\VM8F"=9 M.IG!*=OQ;8*AXE/9 ZO*9MG[5!$-A"/SU0AS&=CI]71M[\=H!S8Q7@^8YT:^
MACN"MS%O/\ZB=*$UE5)#P0RL/$7*'R8^/IQ22#S2SG7U))E@[%Y""M #P$UZQR]G MC!*%R2.)8'XQQ@^J;NYZ>6FQ%(_,(5*R,4X@:I"$BW>O4X]E5[ME5AGY4Y&.%W+S4-;L@
Q8S*L07$I M:<.U957!L:^-#JL0$O59PX\0>$T(RL]>;:ID?_E#,[+@:]&M_9B%;2$$N1\;NO]@@(2H56#I_*VF5R.\-78(6IC+^A!.=B84S+7NUX)NZ>0 M&ZJQ%:'B4,!M,(\+
(+/@CED,*'6GL8L1B2=/GTEB"^VYV!(>0P&%:MA4TP M*44MENS[LG=-)9H/ MI"'2I!40IZA_4*7/3QUYNUJ7""SN?>%P35GW/G#$OBU'[&Y09;3H(>SD8]VH M
!&*90]W>!\4M+=R6<2*]M]M',A49;G9+XHR=A"&4N0$F%OM2%],^NB-<6; MVD\$TZ>UZ$Z69(_4\I19_;TG@_,9B!I>7*K1])ML4:TMX:-],Y95RX49[!S1/+8\5UH<_ M9/ A[&YD=BC
$7&A9C#.J_%R#CM1Y'6M V<6!F;@-HRG@;?C".9&9M0/ Y=# MB<2B,OU89=#[2!/0-" M/;R@1^?#;M!K]1[SJ6P8T?I2$$WDLHA5YEU@_'Y 1J1+SA5I&?$&GC@F BZ6 M0#HLCF)?
(U0G+?VZ!;'#=#L5:*&?D(Q'P0,$Z2^;$L-.?F<-QE2C&T'IE9LP2(,NSK:&-NR.6>F(W6NS7'%X M8@;!!!?&5] .0&8<)"L3OXF3+O^;^AIZ+5CY^0=O(Y@KKX5QD>/!45[&Y PA
M\-49B&7=:*<_#98Q&X1,04\;W'>HQH/30&,*0$< 6R']J,AGT<9K0VQA=X=_MT7X!ZP/%*7(4#U'TBO_
.&)%V:$(%Q+!ZS.YQ]:\)M@$#8QH!8&!Y%*=Y6LVN#%1[%5;@TTY2X2#JJ^G_F,I[R MG0&@*@U&X, M.2CRAU9ZI1RUSEV52?CF<&G5?G)"^)^6]C_R)0 M5%0U4-;.]+.
(R(GL^F'>09N]C8VW1\MD^D^\%X(6'H@V5;P]9SR&0 K,PT MS*>&2#ZCF**>2P-/W%^L9:^W9+G%T!Z%D'PGVDDLFS6%2S^1,(DB3)-X,RQIVOQSD/
.VYK!B;N*PVAU>]>0^14)I M\[4)T62E/J5,2]DTRU.=5]$(B]2*?V,CK?2+0FJ)-DTB)0,"U]X+/E;32 M0DZ<(6 'F%.0"A@:0FHZ0$QP9&(^"[(@DR;T7H1CJL$:#2F_EB=U3K1MS_TG
M96L@T2+BYDSO@\!,Y[+@WR+Q>-//#L8<+3G>NY]]H4L.AWR/#:N!J.F0M-H= M11/-J"O]3LU?392$D71[XR^R:)+FPJ@#MHV+N@,0O=6LI0]$/@,]"PXTVZD'.5%X6
M7#"F6Y.8&+NMV(G*?$P37KI1=KZJ;I[^29LF[W7K--9)MU"^H"$N"?P,\)7 M,UAE3&%#SP&_TR&G'JW6:K01=N_X&X(N#L+C_'Q97)1XCNA41Y!/-KF,4ICF MI-
(%PXWGMET*5!'$C2Y8]<1X3("EO,/0D%*\3I\SS82Z#7\Q#OP4V?8-D! M78I(!=F',M_&0Z/=@\'MU'ILNY6[RRZ6M##<$)!?T>.<.S R MMUGGZ2@9O'[UOSO#TR']Q^'!&0\DF!EB,
[T5'M^K3.CQ32JV)77H9J:)U.P& MD;1!KAI3[U)?A]\]J+12EXG5$T<0RQ+3 2$KLMH9PE";Q4)^DKD37,?S+T(R M"-AY*/7#^FV63'$4YP[=OD]1@,VKD& B4?,U-
E\+]I=,\.296LJZ64ZTR!2; M3^@BSI$HM*.)%IV+Z^@NR2QO\0E2Q@1 VFOO#=*O9Z4:^NX(UZ FC DH8NL M_ZK83^&N-?8SX1#1\^5VHR^74S"."F]VXF7DD-!SP-BD0H$XK&+
MWRUB8 K"LPDR8.-+ B?R8L1C3ESE2<_G?2ZO)+TP4\E&)/@AD9ZJP-!9XHH2 M_FE10.K(.=MY34 \2),O!2#5OVDD$9SQC1IBBE\&V3D85I\TAAJ_O(I33]IN M,":?-5&2]MICT;
[I:A,G4!LSCC9HHNV<..7=?O"=LT M]'5]#Q=?("K3D+E1MA\M6*J"YUVG@VP[9?X"EEDZ& M37E"X8IXQ!;;A\D;A M+ MD618$[!#G$G<<%GJ[N8->BZ_Z]"Q<3?1-8X:5OI5Y:!U-
^;")HMU$+FLG$DU< OBAK(=-'Z/60TS)I3RN3RG74%. A ML'Y O9$U@UD07<&R$ +*X"UXQ[R=L 8G(-FX?'S8U?NLAT!80^(+P3Z;BY? M1U0C)%NG(ZE],BYFOTOD0RX+?,_0S30-
_Y$6)!]5Q1PP7^T,D^-:'?$ZIY+\, MS_9VCS1:@Z/)S49"<^(!H[4Y&7#K^'+J[N![F]93;UMKD@ RP[M+VX:'7GS(MJ8'TIO?LB0&5DL=R9.:&P]TNL.EB8\R1&'B8GD'6W;_$()LZ\MU-
CW8'/Z& M#+N!S<$CEPPNHW03%(;[R0Q&PA=3\6WJY8*(4\,M"F?B>S!O(>,29BQ6G#*C MC:BA*5Z,W6+"YF^PM^AQ@(H.#L9"Z1>ZQWMW)<%L]W%8/[W3\U";I938M4TU
MHN N=5TSH$@IO9 +$V89F9P_;8U:%"T1 ,M^\1-0=G(MF]4+4IT?BURY'O& M5"#C3E9)C,9#;%_^7 TI\+RT0VC#SK(8%H8GH1SX0< M(R;I0G)*YF,':@-/QPZ1KSHL.?
4TZA^<'9^4E0$1^S2Q0*F(A8_\+%X3\W1< ME7"6E7,8%ELX1K4 4"3X=>51+E=="X(SU8_J:SPSX!AE< M@!RS;8!+-@SE5 6K*RUI?=H3-!G 3G4+,ZV(ZT HT!
(,W@T030C>&@61QEDD M,B@((2\]"F_M8<9NQE\%]#AWL$,X.+.OI7_^.X36 $'TXDUWW)HHE\VW MT_Q#-K&F5XX/,@A-Y?
YG(D_(7SN%SQ]9#_[0$P)X%-8!'ZEXNKJ3XCOGK#39 MCANL,9CA594NOC,/P.<0/^A__-O9\N*$^=6@$>]$N/&=KED8WD>P*!IA*MJNX >P@G7IV',+8BP\ MW3SZHC_JW*Z?
A]Q^BB5J4Z(5NDP!\>VNZ!PFXA/LK+LS]S.VP4S7-AVS74H/ M>2D1=RL"KZ42LWZB/6X =S-LNA;2WQG-?4">%Y>K*XAT?T#1GNYIO,<"G ME$R ^-
DNQ(>\$)GC0APYCM5J0CME4C4V!'4F+ZK\2&O1EEYTI:>71*T]DU8K2#B^L.QV*SK!"A MAK=+;:O4IE>J;4WR>K%L0]Q0AW8U7&CG15B0#YF],AN&9$7E M%H91D,Q%V
8/3R;@:8%RB<0\$'7W*S9#5]E4(_C?VKO,-6#6@W)@*?,YICA MJ92NF?OO+S/@R!B,H9;#[66V.J14S&YCN*ML]\8#WAOB;&K$# L,&V-B #AR M2>2C)7%]I8M4*"&H8-
*M2M(+$N^ .,'^<7 . SE>GR4*053&2ZT%IE2NBMW^ MQ7PW6\9BN6%XR[R!.B;PT5< X*'3C<"I4.]6RR! (JD*=""O@=6@R6="CZ#@ M5@.GDED#FK!R[0R'[Y9"X112$T+\
6"YPNIM,+>$L6?0O<<,VDLHF I:2;-L MXCO D(ISE!>>3H%L&?8]0*]:)F#8TCFC3!\RR49*7X%_"!*6=5?&$]E9-%]9 M81^&!W/Y)E\6]*S"=6]_(/A_0L8;Q!5-
D[S8==XC2+Q26X,!QC%%>K+WS,+1 M@#$!=85"Y4K(#VCS/[G+GPQY1MV!\]$V)M<:PH+V6"UBLJB)=?$]%T
M*4%U+!T*"D[^3=S)@^8403W(!H=0^'E*8/?)H.U""%4R.6GF 0!!4[RV1*U MG).&MA&X<(@(4,F9Z*6'#Q8@#F(3G$W11<&@ Q2+052,R&]@%<"W+O*/=&: M08T3DZAP
W+$[6GJ] \.5YP?0WA&,+(6U1V"^+51'<$Z0.GE/NM?=_&D;+#? MP<+7=72-W1/E^^UE$/(34>^S92!%0>#.=#Z16\"U2M]Y7B;?,_7*6&U[A,Q M)6*K:A#XG8=LAPI2<7\DF236TL
C@S:<]B,PB-RW=;DG88U49/=3DB/53Q& M<-AP%L$'.O#D?%SV80& E0U(M%%G#7%#)%%8&-HOE88:89'5.CXLOKL,;4A!T MG,QE%8RG9R]+[H%0:+I)@M9;/HF=I7F?U=W4
;VK%$5Y]112Z'CEIP9X:1>- MGXO6<@]1L@C"2C@]!&B6*(I9CU]XA>Y9K= /B$K7F!"P*G4W<(C^!4< MPW/"^U$[M3-##-T2P]C@C3L$5U1 I5-[)8:^1'T7'N?7RV]%2P%"F[_A_[YA
MAO>WF.$M9OB.ZFG<7)5(NS6Z.S5"]I68_NW&C1HW;, (JK(LN@?6$[E"/+%: M72\I!#O%U]52E%+]X8,,;02>N1]]85F=SR&CPY'U ; Y&OD*H_;ST?!A M@;!;@DDSL?
6MLL&^#MNP/"&&4BK8EF73%4G3MKX)L4O9V>[>[83RJ17@UL/)(#3FV^(43]3Y1OU M7G7T-)G>]@>S6V^Z60%WS_HL-JX.XCG9N,I^B3XB]LX;OQ$<2=+11+;U6])>
MO)8C'*8))"E0Q4D-R(45F"P!(C-/-FS#$ INO+_?T?K=2\##9$SH7GKGGU(*M_=P_!$^4^K 5&U89.W M>;'(NU="D,C)OQUQ066'@)4J,I'M. CW593LJ\/>YM@&1*W@P1:7ZH-Q[>.=
M+%TD'[&/Y72YT:EY-_BZH@[UQ[Y]TD_0%_.)N[50*RQ(["ZZ^1DP*90+8'N M:I*ER.."V1H4!.(>I83F.>$^'&*71V(1-S[<'U31&FDH_"1!<%;&!=9!Y)&& M(7U?SMX3*08UC5WD-
;G/H@F,-V%DWO."U_XK3N6\SBJ4.Y#N6GS*-Q7*.*P' M3S+(+L%RW!W()&(&[@,U5WW-ZJ3\D>8+JJRIRI24M5GA%U[JF[YI)S0,YTN[MJ9Z?
60DW&HW7+*8V/#F4?:XG+#"FQM'V#"D,SURHU*@(@2)W3YQ1R.BN ^& MZ"@,$W[(4U*W,M[?=).J!X\[CIOD2ME6D!H<=*/,RZ]!?TD27P>JEZ "G8[I
MK%RA6P9'>='0RR34GD4$Z#SPGL(.%488FXX?P9O,\G=(WAQR"I3C,9*#!>[I M,S;CK1TK61&F[18IVI']TD2?9'N) D-;3M'@GI +#_^PM,+=->@V?$RH^PY M'-4XU7CB =T?7
RW&OXEU':O]3T2J8=I*L9M5F*[9H'O(B5N6+=_G"M^D3*/ M*=AP/X4T&MPKB'WAOC6/B]-<*]HOW1Q$M0!\F%PYB"IM]+0#CVS3J R',\G5 M'QIC+.@Q=\>S.
[1_ITP9<6)3B2N:@>&; M2/715KB?HFY2AN7RB[32XGUN2&JPN.0U*3I656#=7;_?7.XD?"VXNP M/K'DYDP(M4)6)F>;>@[VKMENK*#1> 'YR:A_$8PR)OHB^UY2[0/TMO_R2\UN%'
MX6UL7P\TQ+UR4,#82BP>[^R%7XN'>OH^4 M0[)$V;MX'%C(?48DH0?[B6A/:>L7%.SW]X8G^D17/CX\U,'1_NZ)/A3=DEU3 MN]%0 ;]'"5US3 ?X<*MO==QTM/S(T& =[PX_9]B4R?
(P9J,,>[B1\O$F)[$; M:JH<0(B1BWFZ[E >G>_^NLHC\/#Q(3.G!X8M]-M6*CG6S?CX'1?'J7E1H'? 1\,STZ/48 [G5.]Y&OX.EC]_;WOX$@XG\/OODFL M,0Q+KRBC
H].A0DLULC#7\NF]*X6(S#]3,JRR<5%*8BC$9R"Z;3F"#8:$AJO MA.4_F8#1VR(.._GU !<#OV\MYQ@QI]"Z#>>WX&"F(<-1T+>/J/*0;K?BV/,(MS2*
<1I@Y5'"/L8:TVC<8G&.41)CWAM=>Z MWU\R'_%U(V((1%.E12W(<9PC=++0/Z/L8Q>3]Q=YAT^>OWR1X+LV57YQ04R. MX*R:D>71=A8!8E$\2CJ6-BS2SI%,Q/6"6WJ1&9DP?(#
[7*4ZV%:IME6J.\UL M/%KNKY$#I0D<0 MN@Z?@ZCT4]8%S_G5;$L&YS;:82@"$;=^6^=3Y3"X&'BO2B+'3> *"@'9X:;"WJ/Z#O*FZ6*@)EC!T-RI"%5--&&
M!)V44HB@H_R5R#D]UVP(=$!7XB;PB-M5@@Q&VXXP^8Z=(QT/L\).T]XU0 DE M&K[NV4@VSH7%C+$*I&9M^A?40-C6-WQ%G;4D6&>0CEC.(0N0C]"0I)1W!C+Y
M+@_AL0R*KT"4(Y]*0L&7,-E!O!:D_MMW1^PDS<<$^"IM?_^![5YUF5D7.=C]U.=5-4Y*G)8\(;>)&0EZSFRLOQ>5&4 M]I790?G?Q:+,"]%
<>/;D^6/8H@RL=A'":WIO'$%]KGU]+N=YI/BFWZ?%.R*W MR6?NAYB?$4V2QV6UV"7=4-09]%>D?XP8/KH1^&]P.UAL#>:]VJ6Z>?C'$!6 ML\H!K3K1.6(V:]]=/G.
(1\2DZ[ZW4\$)F;'L*+R+WC,PY?7V6P,]T:*4$NF=/").H(%7OA0"-H(>I9+Q?PK[_L'PU& M',R#_&&9%K7'@+?6 [XE[0Y).HD 8/=87&:SR883!-..G&K$<,!M_3#=QY$X
MLT0+9!GO"%=R-D;0)9.L=C.40F;=K2+.:XB$$D[*I$I70/3D]3W53A"V'O% M.Q\4KI7/YRY20U(X_1W2;W] 1G'LSD@7Z9C3?B,//!Q3H-D.%WL6Y#"M0NE M,N9D_:-
SC_4#F>0410PP-"URU-R= M0'A:T"NL.92?E(.Z))0&$! "/VKJ#,)ME73/C?0P"%77%.C"FU!'HU>>KUD8 M1 AR/7UU&>B:$\FL'UAAR5-U3\]408%]@+F&D6#DK&C)!2T7E:G[;/"3>-JZ
MW"5-S80)"Q(H*T;4+NS4T%A.^9+DNC,#S8"UT;@7#_<1.GUO?UG#(PQ;T*PHKPA<-CT2O[^&U9; M(("K&R'8T<0UR4'(#.T0->7(PWI7O36$-W)];\FJ>1,J,G=$=R2/PH,?H=Z;
M_HWCK#,LZ(P.+A]H%Q]\>0K3XE;"-UY5T?:&Z31H%[^;9Y-5SIR7!0V:6R;1 M+[\;%I%FX-WJ43S),+%F'#R_Z.#T]!O:>T."8]WZMUMJC(>TDA1IO$K+B'4
M!=89.=OHQKU"&V1UWLEG"-*B!!IUP0*<\]^YZVQ7UP-=73[6!<^04HE0]1E? M4G-NT53\5^N&XDDO@!_K&V$JC+6>)$8WIFP\YNBC\>VOW5[:9V_WY3',4T$ M@B?R7DX(%
<)@N22"MHK:T8.$5KVNFVQ>M\!6$?#9\-1XW#K#T3VQ"!#?,QF< MR>[@PPE3=0/3&YX?Q<24@K57&:T'/9V;!%\D54P\G6H25A4FD>QAQYA)&*VE M+=E]$?T]U?Q"AYY-J-
,Q\^WKZW5@[RWT_AP;LS4IYNV9Q+RE#805<1@^J1=3 MP0D(8C1)]?H*@6&L-W$8T$?V]$-81*#='X@FGTTA&8(_Q-N9+R1F)=!N\Z6H M8.8>L>Q=UR94X"%"B 0XL%82&
%7<&8+85; &$-]HYZ#SN1=F.F'62_M.V*307>77?E)5H^K? 2N$#:@F@;6F>.?=Z6?@,>=/2[H-S6*K9%_K^);F_M-Q'!(RP:7A44W+2>=:%AM.@%]#DL[YM$;#[_)VB9&+OX'N1\:7O
MN.I,M.+AA#T.MU..N3D@Y8796 9?CV)'SF24XR57YQ855]&4DT-43[TVWRK3 M$1R7;K1_STQQ+RX9,J UN&753-UM7="-F_;GW$+-'*"DD3?NU8VD@L *2UQV M]71ZQM9EMPL-
ZNS@)JH&/3 MH];Z<,SU%1T+F"C9(<8V(Y0YYOY8A+6AH?<09].4(:+?-+PTL'1G;"F.EKD[

*M.C);5S95#9,NAYN%=C\92&,]3<"D7!4753K)U*2;1^">*H;YR|!B6FR&"O/^EHDL0>PQFW25P_A8X4I-0,$#]&E] M9PT+'339>.,N_Q\QP7=()U72654VH:$%PC1X-9/&"#;(3?DD>$BT6OID"09 M.^ISQH9-1CK;Z]?=C["L"3O/^9S;A^^)K\HWOVZG%PP)% K=Z+5I@=G@"F; MVBD032M,&388G9H9L+,8](5QW9S+A*/4-U08<@ 6SI8@V=D-]S0+SGWHPF7Z M-@_GX/O=$AB@Z;',^,N>,8"H7-VXD8DFN/,VBTNN9$=-_@["%,Q!Q8,0N\% M.^TT4PA]*Z"9;A8M1-\+ECN,J'MP8*"4PXI7_N[@GY?YC' $%R4X56C5 (S+ M*#&9[R623LX!9;.."99IH&P?YB% M*<-&O1@YU1ZH2^Q2GP"?+TF$8)\%?!3^{NDV++>PO)_)>>;?=P>ML-@LM#=W. MG031*IZXK<]-2H$E&/4UX"/%S9S;N\{_8B"A??F,3HVSBL,4EYQ-LF- M*GB%CPFO_1KPVG>TI_)-3(Q&X'*W"]YCJF[&S?/KTAG8Z=V%&S@+<&J>4+VK!6W1H!:Y.S MY3P+:(B\(\?ITKQY44LM= ?NB;FU#I:YN*#<8@?60C=I-JLSXCF6' Y]Z=8(M'*IN `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|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|SZSG?^H(S;.W]Y+U\>O//"[:_3HO8R%YDA7F8Q+(@<4,M)^2D9%Z"4B\X*.B6^&5 M2&5X>$YNHICTG*U;,"4D)%.QC'737^=5]LTR.]=%QU#VE1J.>=$TR3HK=VBR(1&;(9KQ2=&X B$ M;_^\#D8V16^-M6U M+\BWH$$EM)\+R)!B6!2CR>[&AFM53;%OJ3?R:5]P!J/L'3V6T4_D]-1J%Q S-MOGN!'=1JF!7S,VVEP|#WDQ&?+$>MW_?:O[^#\B80.\CS#_=4?JJ]&;VX7"2V-UU6@(A'JX^>'3?4FM5<%C?S&FD[M@$P&Z-K#%2I0 X-@>"+;UEBB:5[-O>Y=_'CXQI!.,AH(I3ES]/NW,%75Z[NUM7=H#&X>_'1U;4",3@SK"!A7H!:^R@_6F"=R:R'SH=7. M(UUQ/6=:-@-]C$HDKC55 C\R.$0M?4"^/AI3-5GCR*RX<*MG0JR=TMT$[@!G M2"C@@PJ'R#E>>_*TP;I>0#%.CQKC3EWM;C -?B< =84L!EQ17 Z[W-5^GA; ME=Y6I;^5;(DX2VEV,P>7+.F:DOC0@=:"#RE>6DXR.!M8M-^8T\@U)DE@M\N M@P?\RFF5SME/O9D?X)[=1P*IB5R=$V3./*XF=$@M2HL>T$781[%K=#G%M+A" M&LLIP%2Y)=Q;3*$\.I8N3K>C<|-#&W8%>N7>SQ%&^\HB*HDE]P[8)QS/_*3 M0MQF-]R:1DK=+"20M*^'H\> >6SAP!H@B-2.WL)835,GS2;F@/&9;-]UZX\YU,+7P[)D*S[):(R(*%/EL#YPR.P$!:ROW1P$N91\VE'%ELM*X)PH\Y=2%&4S1@+>5>+V#P./ER7@231&M&A%L^Q7*3C@=RF7&CDE;>9^Z"]OIGF'-? MAUL2I$7;4-&^R[[>W':'#'\=%A:!E&IM*>M-AIO.02I3X!A1)8-X94AHYUV MB$G\"GM0P$RY\C0)BYK7<&>%"^M+Y-N5]\>;ADNLL.NA@NZ"\_]DB+UB3LU M2+%%CPHLT/+2-V @^,NZ[W]XX'8'WW/%G[=AL425:&Q6@AYG'X4%)(MHP(3) MB<++FOGED,K'PB1)V L%\A&V&OX8)?`]^L*D@@.1H2D_GFE0$?$QP=>&Z X2L: M/=W.+(^\O6>"\87<(+VA/)FI,H6HI9C5U!(FNQ&-N%QG@?,&8<+8<)(,S*U1= MEBA"NG,K-]K>YVZ:=@"!A 80XY;.B#AP72)?H6'0^+P\EFZ0K.>O=_U'K/-MTK6-3U.14Q:6=O<66P?/RW=?U:6F%L+):?5DB@E\.2?+PS;JHV!4:YXC@:0A??2S?-=,<9>5$<5TIF=IL,L0H&985FTRRD5(05AZ$SI_-5I#PZA"M\LWD&R;6:TU]K$9>Q;+M(P2C6_RM/\N#V:*|C_2,"+,2\OK=P6OFS;$-:\YV MRSKSX)}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|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|LZ3F'NY<.]-N9A"^O?'=G%BH51Z M;VZRBVZX2G/[%PY)>*;9!.]"&_?! $F+>#N; MUKV&%U&^:.&-K8V0ED8ZB$D2KL':\B/%B5HXEP?XXG8^[?'+ACN#@ 1BLWA40 M(0<(U#!8PU9&;2(O,Y9W=_LCRB;VZZLC(S)CH"Z+50|OL^+RQ86$;LJQ"4G^B T_]!7*\,2T]-JP5',&?, &TOI>_.1X\(@M|\PM/FZ[:=]UJ;UXZ*K4O:EG1UTE5M1XQA M'P%U5 PQ2,T;-(,O]>E?DL[+2CP&'B5]YKIJ51,AP^-*&!@J-EL:BH:A;GU) MD23L 9T0BEU&F=)391/,H-G9WCB|WJ}-X<-2&C!ZUN!&Q14)Y/,, 1"(9F|F= M_]Z13NOB-[*?>Y%8C03]9/-]WT2PW.<4NZ3+RQXV7]16+EHK+PIWHMQX?]CE M*"US1"1I7\'&,]BL6%C9ALWFS9.\6UPD#DIM?&>D(2"L$?.)S*.ON$K';BAB[G-O9J4&"S!9HF.-!6F?.X+UO&>W=PKD\%00Z/!+DL^X[*\ M +X9!>>I?0"?;/&A^:BR00L&$5%H3M%+@U3(M8G@/R)D9^I2"=QMG=24O7!;M1;0O'"#PY<=%U=<.,JGF!P;D/7F#0;_R>XC# M(MCK7?L-?`E4W^ MC-WNO.V1#%Z+L;9,R.E.IM#$)T( QB2B9_6HXA4*[7#N%8X\.&S<'V$=8X81 M6FCIS\ W5AOU>1!N&>)M\@@'F9VW-9]?5+^@."!T%6YCWQ<66?=PZHVH-T#E>NLW^( ONET@2I"_Y9F+@ >O=*THV\ZD*3E$1-2%/.$V+]>B?5PV.AQW-`;9U6&;Q &6LR MP\XHJF@%\Z-P%06O)W.>V,"JT-X3HH6@?70C'I0/+W38&7@,>_1E43Y!FD@ M_!&RJ*&E(I9\KY8NJ?NR'KLD\ ??MO4_Q_?=L5H$V)D$K.3Q)IO9.D^'QMX:;MCSAQ.)MV9B[&8Z1R]3F<<./<<1)M2%UVKUJZ/N"2.)&*SV:T> "6@5KGK)QIL. M-VV/2]%WX;6# ^U14H395E9/(M=+&Z#XTAYI[H4U@4,RA+?Z)ML_&Y+(CD8TWL<"\Y/ATF1_NGLG+W3]Q?SI+C< ML_W.1>QK]WIXW7$$RQM=)N9$Z!Y.GE_< R4%LN!C\#JR L^.$A+]U]/+TS M99:D"_^27?1194)9YX)\/AH__OAX\#4GX_2OG(?I)@DJMS M666L4 G])('68>)=&#|=VK6'%55T,X:7)H+0I_MA,)\T1&T"V2 I;_[60T]\U8#M]7 .UH-G&0SP')1\A!YI*#G<]F-Q-D8=YU<]%6.?;\GYQU#2_B-&?X)'N;VA^H*8%_M/,38SRXE-;CVZ3?@G0C<0:@P<1]K0T))TU]A+H'$9H16<%T&=HJB 7'1_R ML^G:/8-,R_^DQ1*06D/R/C76:(?]H@.&8X$EBFYWRD8K?NW$Q^U=TG)+|_GD MO[/Z>[P_/3<@1]^$Y/IF\)/GD;;W>/AV-#VD3H?9WM!9/H5&5+ZQ?,F MF^ _4OB\%&Z@O>/*;KWO 9]O(_YM>+5WXPM9K\F>85Z%%-=?93 M=VALC@3ZG_T521+1@X:/_SD>M_]9?BZQ)>!NM*[$O3Y@NZO!2P*]]$[J[06# M?K!X6PW/AD=I>C!Z.YH>NVUU9-,4 MRL"_+,KB=5;D9>5?Y^W\R?!D.+S5;77:L:L.0 F%'G, SSF@![V5Y7G:/^#1 MZ3A-G3%[ZPS=WMO#_?3@[>AD.GU[EAT<#L=')X>'|\>M 3_*2^RU^DT:J9/ MO"COVI.]L^:>P9\^TH>[WB^_3W@P#SAGS+"\.]D^SX^/CMV?#L^.WA\ MV!'P?L;|<'AZ.!TIW0TS":M$3YZ 3H<[0]PV0;FMX?!U%PNL"A^7L[=O<;4+_]A>04!RI-EQ>_@_C^X^%_?E&^/WQ[LT3^&OH]I M=Q[[NK'I^F/SSZ<3V;_')^_^/M7@R*=NS?,QI-O?VJfV1MH8'\Q?5--SJQ] MC;OT]S/G0'R%(_9F]/;#OY[]^N;=Z.G3I_/1NW32_/U_GC2_G\UR.IQNG"7 M:.IE=@L!R7_EF^SO&^XA>PEE]OZE-^.D7WB8P1BWG3N5W,)TB&0&(Q\-R:,MCEW>BFQ@;!QVT*;C!C53:S>]'@(DY(E4A!,D(",L,7LG_CD6$PS#. 8]D%,# M_OQO!S=EB:5!@*"< W((3<<4TD9!>5/))?FK0R:K4-Z'F%*B5.J(P]W3@W^WM#]2AB!@<[4KJ!/\K2A^8FP'Z?@JOR4ZF_'L'6"]^I=3(RKWNE2D)_3P=N3AR MV63?07:BG3(RF9N8XZ+W7??W=@].'LB[#@]VS_8?RKL.=^\%(WV\\IPG6389Z[AYYEH6VFH\.3]>)^SZ&%VM_Y#L3PR.=BB& TF?.Z;-C.NKB-. *V\|9YW> /%;?ST. MO'U>H-.),IV=!^!CKMW55O7O[/^ZE?DH!?_7[3XBR>?NOM6SQ_-=G?RM_R;_?]9J?OOB_@_&;E!3XZGSQY^?O+JY]>3\Z_^"O<8\$W^ZU'P"G]-\G?LG=#/-"]UV10__/U? MP^737^;3M\<7IZ_2#"\;__VKOSY&1O>?4-=]-GA!R:CXI;:^ZA]=\6)^4.Y>MY=^@E.U61CTEG@@ HF.^]SUT'4]1+5%;=.KH,'GZ@4GWH'_SSUQ\E*/^[Z_R M#V!]RUGF?@.I8+,J7RUGV7!O=#1T;_.O]|?7^[^^G7]X^>Z'|\XPGR^]?#88GE&&/5XI-UDEO4?XM-OR(%\R8EDW@R&!58X^Q1AO8XUN-^E9Q>V?I'(&&_(7]QJ7T/33%I-WA+P MY^V3NOJQ^._O'RUMW-6_+9\O??__6_,=S;6]N3S^NV+Z4=MW?KBA\>_K_Y1M9T_73_XV35_\5]]>%>=?,#I^GZ>S^K^_>O[SL_P*);S2=GP%]J:W)IE+FPZ MAVZ!\WGSU:!V*\9]|:_L^^,S=V=O'__?ZM6[G=.GO[S[Q_+)V>-_N7T_W-]+ MW,3)AI=QVD96?WCEO38P_<=$"_K_UB&N+&8%(_ISZ>UQ;DX46GU:5O$_##+[M'\A_+-]C*$):JZ3]! AS2#%0%CM7?>WKM&;M1YPOP.@Z5U;\W@&$,#C/)<;?"[_Z\==\U6&)D;O!D]ZRKMX71OV6P[6KXF^K&,T+.]SZ2AR:H5WIPO++=_G\+R-CT/B; M3=.3@\.SO;VCTZP%]3I^->@&U&>]WP\/AR=Z?C_ ZWAW((WV>5F=WMZ?_^N'Y M/]_?T V?__SDZ\;^*>@GV"'&<>'M@=:,"2MFDRZ9L(86NZZ"Y[=V+,XC$;C:& M_]O'O9";&USF\'1WKQ>F)-=Q0PE;XK^_.OSJ2FS!X=[N6?_U/L'],/N#N?3G M5EIEM\:NP32K@~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|+7P]/[?8|>?(*Y-MY^CV'.T1T\.#N@';/$BQ6-64@^VINCU5O^A3=?@1X<_].%<# M2V%A/T':B,?"K_XZ&,#12XQXG!R=[M^X=[>'1'N_/)"U ZB*CO>/[DP_9AX/)B2^HQ;O=.=_ O|!SV"W+G8/3H[T; MGU7WYAC^0@0]AQ&7MGPHT^CX?K(?;@W5[L'ZN-/'AGYHF_GZ]@[)"#^[$W,:N M]_G0O+E%OA^'YA>2$1[N[0[_/9A NA V/%&:SP91UFS @6-U^/+$H1B7R&#M LO=_'C MW]ZM?.JO #:O->-NUX#R@CVK.Q9/OLX\(,/7":WXD2IW9US3X[BVQV4^W%\ MW_)"N1\G_Z<:E'OI+.S_Y14222@V<_C1JV#K7'S\SL6M0:V>@;,O9>1=E"G) M3"%?\;K'TSB)/(UT7G)7HX^ZDPZ_(OF\^#M]\G@&O!]6KS;>B);3^1.#,K6$]EZ(O?.$SD87B|M88B(IX1;<>U.)M/Y]T"R M];&S<#"\O4R$+U%S3?IEE1<@0#4;//W@? 6DVV+B,Q!N458+H%*@.1T>1#O# MPZ_3;^B?964_.YH5^GU$&OX^HRWTV/#LXO%E.WZ^?NW'NWZ]Q#KC5[\01_V>] M_QTYS?^TZ;\C!_?VF)9C>G]|3'_IQ_2MQ?0;CFF*N'//3[H|IN^TG=X>T]MC M^@M]_WMX3.^[:'I[3G_9Y_3^'0VG(3[^W7-\>#KX9??U[N-=.)7AXG*H'^TE M0*C(Q-'!;X)OGNT="X#N=5]-TB*K=U\'@)P|'^G[>WO[VR-]>Z1OC_3MD7Z?MC_3AWG#W^<^O[^&9?HMK|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|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|YL--NHT;[0&A<-#7V[M0Z=_/%]_8 _?/%P_^O;D$/|IL?GVZ_7Z.3L_/R?K>OS\YOG&_Y%NP[CGEUL M>Z9O.C:VSL^'|R?H9.K[\XO5\|?7U_IK[^ZXD_/GQ_.I//;YY;C>*1N^,;) MIX_T$_B;8./3QQGQ,=*GV/6(_^O)"\|?SOKPA&_Z%OGT\3SZES\[O,,VIGKZ;A3P'=QE\NY[@P3'MR M9I&Q?T%7JKG\S#4G4_^B6V|TX#.'XW;A$@OIY@NA+T^\5K<(=B|&CC^|S&)8 M&3F#.4X)?WE?JS?.:*J)MX7?]KOU)OV23:[3J&O:7Q)O;P_]_4'B_7CD.5;@ MDTN*?V?0KO=A*'^TUZNW]_#;GV>F;9'WBV9'ZW;ZS79C"[AT(;,5 ?Q\9)8_M6DSK#0I>,,XFR'/U7I\U_U^.IJFLT6TUWLB;UC(@:9KU_)PG)PA;L-&_N7@^ M-?63#1-9>37?5OI/W/:HT=FS_;{OGIK6X^.NS.2,>NB>OZ-&98?NO-?X)_.L1 MUQS_]9(]I9E_D@NM"2]EO[YRL"//.BY[\N:?8M>@\F@3KU-M?@?^:?_=$X8V7@&TQB^3*L46^RE]++#]WT\\|%KYOO5)MG\0@10!K05R>-R)>OCT_/_[ZZ&|[?P)_G M?S\__/MV>/4TY$AEL,E9R9-/[$T,C:T'K:X(GQT2>|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|=2)-83(@ 1" (;L <>LN4N0MGE2JL*QESDPPM[9.R)F'>24N;K+!9(VC@3V.%CETK8<*7A)1#*%_:L81:-4>YZL^-4?9UA[E M0F&32=K<:&#G&;+,>-\P'RUE'*\8XF@!69PJ[@.Y@#3;TU:P*M_[T>MW|C'MEHE'1F7ZBSSM\4<$$MZUIW9'-M"0T[+U'UO03C RPRJ^M8BW;>6/]T,[Z'B M10"]I^O?'VZO'H5 /#Y<_Z-@4FD@7^^OZT(#L,C#,;O+QR%#".X\W-(4.QL> MA]=?GZ]NGT+6OKY6S9E=3!TAMPOR!@DG6=B8VXS,37QB+CJ^4]DB\M6DS.8.C.V MEOX?ZGA$S=Z*(TO$3:5X82.JB(C*WA

*'K0RB46+JC$>++F>G(E'G2*,X)H:SM2@J1*5X*7(\<3\94? H4U56 MHZ@,7BE7:G*\IS_7?=K\ M@!8$NQX+%_M3T_4)L=&IUOJ #+R@,>S9C-@4%^38Z"J8P(N1-JBA9J/925_% M+Z,N&G/4H-CV1Y%Q@DJ!?LT7@T1%B?.J?)7LRRE!,5U6"DL>J94DL4'J^#T7 MYO9DRG^R'14:D;!WA,8QO(1&Y->37GT^E)A"8Z+ ,/Z@M%*47X-Z%<9($&]^ Ml,7&M+3<0G^K X"A!'));PVM /->9 RMT#);) ,R1UQ:A7&D=IT#) X5H_L.C MKA-,IFR(#9R6/,:D*/X0#W;,,#8.CYG2E{4HI\=#56&"<>PJ9Q&;*PN8# &5 M,OUHNALB33SK@R\Y6^\P/X1O#0.R+DT$WA+I9#SDM)X$ZC|&BM,>* =MG>+4 M.F2*T|,|=EBM*&PE9CHQ\=VY# 1*AY.P-D3+BLADB0L1,WHBKFUX)D&3:()2U8D(+%@= %4.*>+-B,$Q4[(4%'$!^ M/=!DLVT$V"$GV6YN,;]0F*75JQ+%[CAP67I*&X=GDB45+(Y/28SE:*48% A MCS2@B@;2%P4X FHJ_&]4"-]J>;P4^RGC8M4;\# (DM@\YTTWF3Z,SMUZS_;JB+RKHIO>_TBPY:\- M)(C<,-ST]K$##9B*K#JX*@M8X;[3/FZVU6QE99[9CBZ8B)MN:-/)W=C/Y-;8G MOQ4C-]$X- $*#.:@S69&LGVFB<>B@ONR+J:UV*DF|ZHQFM;_UD^]%!O]YO;FH_VFUVZ[WNITNXV6IO4Z MW7[1!+9N1!H59\G 7O]ZBOEJ*Y?ENS)6?/3N$Q5-W.!H]Y({$D<2$@P%:7F4 M. (C9YUF,E!!E[K^)S J"VYPH;:>)3|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|,).%H]@]'_8[^CF MA,_J<%)O(+)R,E.=2R0\Q",M&l,+M^S)LU?;:'/ -L/*2[*#VH>\@?$YJH^W M?510\8P.%A1\7+G?^=,NQ4W@FF&/:X'%>*_1XDUUXGY&RACF%&#[*8DC+I25 M:Y4HSJ2_HT:/; G<$BSYPI:G:2!V@.6"]")K9MJ>#WH?O8$F66]7R#&O''!\[MR1&58:S9 -6VOKF$MR0P&#O??$%ZZ8STD$?8"_QI=#,WK-1*+.=5I3F=3C'= M6VIF0G-,)2GVN*Z-F*.Q .A\R MF37L+M.\D^5D<> [8?;E0*MW^BP5VH|S2$,(W5Z8BIXHS)HM]^I$95VU0;W9 MC[,XPYQ1;?Z&&.-"$>|+O^>)FYN^Y;/> ^#73UU> ^3"399JK'[B=M>:LDWN;V ME/(3S&K[$U:Z#!-1]W1W&S97=N$DF7L ^VC!G]NM!&]W0TA%>W.0F4T9Y\VGM MUGNM]WQ:TQRQOG[+D^9RN%,)RNW%<%.'"G]ATJK]3D68MS.>;W7JK^YIY?/4U MC1TE$9<_K1"W07RQKPJ'I8I9SF#CO1$#<7?F^SIWZ,7TY2J'LKCP)46/159K#UH9 WUH<'=)MA2.S]Z#U)(V8ND,93\2]B"RB+,.5EJ]I9+$\|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j;9(6AW0,YO]>O]HD;Q+0MF?0=(>$S//%728R UB1#YP4ALQ!R(U"G]QY%=+M>9"6$>6D%"0+2B?B?IFK\LBN0[MB(-"6K^&Z$J. M;Y_)1(N?V|CVF>&50<44,]#3%+NO[!P#'],6(L.W,;$]XM7"6M<.?.,OT!VV\830 MJM|H"R$UI#O>LKYW1J9&5&(]=EC5>6M*9605>@P;|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{5Q3 M;N7Y.7;_PQ="RT3$EI7U-15XWB7>G.BY9EQV2'Z7/8F-Z^R^TLJ[CMHU4H-G66K\P#VFN&D&I/8=5LDBQ@0VW1|B'YWB M#\(CTD>E1V@*Q)/(UPLE3.H3/QX%E+1"C&1.[G$0I$>D1%,=BV!@#=F.3Q_U M?/B-6GS SOPI_8&>#0SKF"9FY25L@+%(@1!I? B7;,;TA-H2NGXO=A615)*%F M7A.72HAWL37X>PDT)KG_(C-\/"N!R$Q;_9:8DJW;1%8K9E+JT0G[L6/U2)E1 MAW3ED$I-1K*YGA-UEW$N#>RK!S(E+G'&)7#^1#? J6Q#@H!T9L5_7)7-LNDP] MF($@]ZEJ,:KKTG_L@=XZ!|W? !UAK>K*8RRGHP_QR\.HQ12_$- <,KYH, $J MM0BN__#FIQ7T#7@]?"A2]+Z!XV(9'S1D4(NUP&S*{)TC}X'70%(MU;I5CH[l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|P@>@^4!MPL$_,+1"S')1;R*)? 7+6S.0(2,%HS;9X)TM66PSUXOHN22 MJGHBYN%L;CD+2?-0!%)R0[$GL"ZJD=E),<%1$#LP*!+|*0(.2#8&3 E SHB M;R8I!D1 T%1]>0EJT@?S_T[.??5R?'I'";IW_(')][1S! ^E[CHS=DC -+ M34V0DJP5L>!8E)@EIW8),,*CM"_E6,EZK(34?-UY87M40KR7&OPE[(^L35E& M%KM8B$DRB5T(DQ*"\[G[*+XR*D<++1F?HW)7;'G>9?6+AEW),(-89H8D)D*N M'_5X&)&DE0 D%+^0/*AB1"RG)HO D$5#D#N;2%8C"J>N"Z MDDX&(4CR"JX0&.ET$!$JD!5PA3"98_#$TE ZH6.6$4(4[*0@A 429]<*65' MA+9^8KZ4POC+V'K094V]A#4[=5Q$RZ]]0*],8+'4!A"??D 3.E"HB-* %3%9 M<"K.HXCOK]/T!Y*

"